# Merlintrader Trading Pub > Biotech catalyst news and analysis. FDA PDUFA tracker ## Posts - [Weekly Market Analysis Nov 24](https://www.merlintrader.com/weekly-market-analysis-nov-24/): The major US stock indices closed the week of November 22 with significant losses, despite a Friday rebound. - [ALT Altimmune, Inc.](https://www.merlintrader.com/alt-altimmune-inc/): Altimmune, Inc. (NASDAQ: ALT) is a late-stage clinical biotech company headquartered in Gaithersburg, Maryland, developing pemvidutide (ALT-801), a dual GLP-1/glucagon receptor agonist with a balanced 1:1 mechanism designed for metabolic diseases. - [PLX Protalix Biotherapeutics](https://www.merlintrader.com/plx-protalix-biotherapeutics/): Protalix Biotherapeutics (NASDAQ: PLX) is an Israeli biotech company specializing in plant cell-expressed recombinant proteins using its proprietary ProCellEx platform. - [OTLK Outlook Therapeutics, Inc.](https://www.merlintrader.com/outlook-therapeutics/): Binary Event Analysis: Outlook Therapeutics (OLTK) faces a critical PDUFA decision on December 31, 2025, for ONS-5010 (LYTENAVA™), a bevacizumab biosimilar for wet age-related macular degeneration (wet AMD). - [Palatin Technologies Inc.](https://www.merlintrader.com/palatin-tecnologies/): Palatin Technologies (NYSE American: PTN) is a micro-cap biotech specializing in obesity treatment through melanocortin-4 receptor (MC4R) agonists. - [BCRX BioCryst Pharmaceuticals nov 21](https://www.merlintrader.com/bcrx-biocryst/): Positive Pediatric Catalyst: FDA approval on December 12 could represent a doubling of TAM (Total Addressable Market) by adding the completely underserved pediatric segment (zero approved oral therapies). - [RGNX REGENXBIO ](https://www.merlintrader.com/regenxbio/): Currently at channel support , technically a good entry point . REGENXBIO Inc. (RGNX) is facing a landmark FDA decision on February 8, 2026 regarding approval of RGX-121 (clemidsogene lanparvovec), a one-shot AAV gene therapy for MPS II (Hunter Syndrome). - [Aldeyra Therapeutics dec 16 PDUFA](https://www.merlintrader.com/aldeyra-therapeutics-aldx-fda-pdufa-december/): Aldeyra Therapeutics (ALDX) – Comprehensive PDUFA Report ?? ?? Aldeyra Therapeutics Ticker ALDX PDUFA Date December 16, 2025 Current Price ~$5.16 Report Date November 21, 2025 ? Executive Summary Aldeyra Therapeutics (ALDX) is approaching a pivotal catalyst: a binary FDA decision on December 16, 2025 regarding approval of Reproxalap for dry eye disease (DED) and […] - [NVRI Enviri Corporation](https://www.merlintrader.com/nvri-enviri/): Enviri Corporation Announces Sale of Clean Earth to Veolia for $3.04 Billion and Taxable Spin-Off of Harsco Environmental and Rail Businesses ("New Enviri") to Shareholders - [MNDR Mobile-health Network Solutions](https://www.merlintrader.com/mndr-mobile/): Mobile-health Network Solutions (MNDR) announced a non-binding MOU on November 19, 2025, to acquire two AI-optimized data centers in Malaysia valued up to $120 million. - [Top 10 Healthcare Small-Caps Stocks](https://www.merlintrader.com/top-10-healthcare-small-caps-stocks/): Top 10 Healthcare Small-Caps Stocks Nov '25 - [NUVB Oncology Breakout](https://www.merlintrader.com/nuvb-oncology-breakout/): ?? EN ?? IT ✅ NUVB — Oncology Breakout & Commercial Growth Story IBTROZI FDA Approval Success | Q3 Revenue +100% Beat | TRUST-IV Phase 3 Catalyst | $549M Cash | +111% YTD Performance Nuvation Bio — Approved PK activator + oncology pipeline | Commercialization ramp underway | Growth inflection point ? TODAY’S MOVEMENT: November […] - [AGIO](https://www.merlintrader.com/agio-4/): AGIO "From Crisis to Recovery: How Dec 7 + Jan 22 PDUFA Decisions Could Drive +80–120% Upside" - [STEC E-Commerce Revolution](https://www.merlintrader.com/stec-e-commerce-revolution/): Intraday Move premarket gainer - [KZIA](https://www.merlintrader.com/kzia/): KZIA Stock Analysis: Biotech Breakthrough in Triple-Negative Breast Cancer | Kazia Therapeutics ?? EN ?? IT ⚡ KZIA — The Breakthrough Moment Immune-Complete Response (iCR) Achieved | Stage IV Metastatic TNBC | +51% Surge on iCR Announcement Kazia Therapeutics — Oncology-focused biotech | Lead candidate: Paxalisib (PI3K/AKT/mTOR inhibitor) ? Current Situation: The Game-Changer Catalyst On […] - [⚡ “OMER — The Biotech Force Awakens”](https://www.merlintrader.com/omer-awakens-biotech-stock-analysis/): ⚡ “OMER — The Biotech Force Awakens” - [Weekly report nov 17-24 2025](https://www.merlintrader.com/weekly-report-nov-17-24-2025/): Weekly report nov 17-24 2025 - [Comparative Catalysts and Trade Ideas](https://www.merlintrader.com/comparative-catalysts-and-trade-ideas/): Discover comparative catalyst analysis for biotech stocks. This guide provides real-time trading insights comparing FDA PDUFA timelines, pipeline catalysts, and price targets across multiple small-cap pharmaceutical companies. Comparative Catalyst Report – EBS, RIGL, BNBX, DFDV Comparative Catalyst Report EBS | RIGL | BNBX | DFDV — Strong Catalysts Analysis (November 2025) Executive Summary Analisi comparativa […] - [Biotech Fury](https://www.merlintrader.com/biotech-fury/): Titoli biotech rischiosi ma potenzialmente esplosivi nei prossimi 6 mesi. Per duri e puri :) - [Cruises Report](https://www.merlintrader.com/cruises-report/): Comparative Cruise Lines report - [Airlines Report](https://www.merlintrader.com/airlines-report/): Comparative report Major Airlines - [QH stock](https://www.merlintrader.com/qh/): QH | QUHUO LIMITED +26% WEEKLY SPIKE - EXTREME MICRO-CA - [$SPRU stock](https://www.merlintrader.com/spru/): Intraday move - [ABEO stock](https://www.merlintrader.com/abeo/): ABEO Daily Catalyst Report | Merlintrader ?? ?? Daily Catalyst Analysis ABEO | ABEONA THERAPEUTICS +28-33% SPIKE – GENE THERAPY COMMERCIAL LAUNCH INFLECTION November 12, 2025 | Q3 Earnings + FDA J-Code Catalyst Analysis Daily Catalyst Analysis ABEO | ABEONA THERAPEUTICS +28-33% SPIKE – GENE THERAPY COMMERCIAL LAUNCH INFLECTION 12 Novembre 2025 | Q3 Earnings […] - [LPTX stock](https://www.merlintrader.com/lptx/): LPTX → CYPH | CYPHERPUNK TECHNOLOGIES BIOTECH TO CRYPTO PIVOT - TICKER CHANGES TOMORROW - [$ONDS stock](https://www.merlintrader.com/onds/): BULLISH CASE: +426% revenue growth YoY (Wasp drone orders), strategic acquisitions (Sentrycs Nov 4, Safe Pro Nov 6), defense sector tailwinds, 500 units Wasp scalable a 20,000/month, analyst consensus Strong Buy, PT $7.25 - [$SWAG stock](https://www.merlintrader.com/swag/): Earnings tomorrow Nov 13 - [$VCIG stock](https://www.merlintrader.com/vcig/): Intraday move - [$BKYI stock](https://www.merlintrader.com/bkyi/): Intraday move - [$CMCT stock](https://www.merlintrader.com/cmct/): Intraday Move - [$LUCY stock](https://www.merlintrader.com/lucy/): Innovative Eyewear Inc. - Smart Glasses Company - Earnings Release Today - [$FUFU stock](https://www.merlintrader.com/fufu/): Intraday Move - [$AMZE stock](https://www.merlintrader.com/amze/): Intraday move - [$SLRX stock](https://www.merlintrader.com/slrx/): Intraday alert - [PDUFA dates jan 2026](https://www.merlintrader.com/pdufa-jan-2026/): Comprehensive Biotech Approval Timeline - January 2026 - [BIOTECH e non solo](https://www.merlintrader.com/biotech-e-non-solo/): ⚡ CATALIZZATORI 60 GIORNI | "La Finestra si Apre" Novembre - Dicembre 2025 è il mese critico. Decisioni FDA per AUTL (domani), AGIO (7 dic), MIST (13 dic). Approvazioni SEC Solana/XRP dicembre. Earnings tech late dicembre. Tre mesi di volatilità esplosiva. Report strategico con allocazione, stop-loss, profit-taking. Griglie complete: prezzi attuali vs target long/bear. - [$AUTL](https://www.merlintrader.com/autl/): AUTL Rischio alto ricompensa alta; da prendere a piccole dosi potrebbe essere una sorpresa. - [$AGIO](https://www.merlintrader.com/agio-3/): Agios Pharmaceuticals è un biotech specializzato nel trattamento di rare malattie ematologiche attraverso l'attivazione della piruvato chinasi. Il suo principale asset PYRUKYND (mitapivat) rappresenta una breakthrough therapy per thalassemia e sickle cell disease, con catalizzatori critici imminenti nel Q4 2025. - [$MIST Pdufa dec 13](https://www.merlintrader.com/mist-pdufa-dec-13/): Pdufa dec 13 il tempo corre in fretta ed il 13 dec è alle porte. Ha 84M di azioni, che non sono poi tante ed un Mkt cap 156 M. Mi risulta difficile credere che noin farà un pò di strada da qui verso il 13 dec. Cmq rischiosa è. Ma chi non risika non rosika :) - [$Omer a sleeping giant...](https://www.merlintrader.com/omer-a-sleeping-giant/): Omer è un gigante che aspetta di svegliarsi. Assopito ma fino a quando? considerando le più che buone notizie avute poco tempo fà con l'accordo con Novo, non ci metterà molto a reagire al declino di questi ultimi giorni senza grossi volumi. - [$BCRX BioCryst Pharmaceuticals](https://www.merlintrader.com/bcrx-biocryst-pharmaceuticals/): Report Approfondito BCRX BioCryst Pharmaceuticals in vista del Pdufa di dicembre. E ci metto la faccia :) - [Catalyst FDA report Nov 11 2025](https://www.merlintrader.com/catalyst-fda-report-nov-11-2025/): FDA PDUFA Catalyst Report | November – December 2025 ? FDA PDUFA Catalyst Report Comprehensive Biotech Approval Timeline with Price Targets ? Report Date: November 11, 2025 ⏰ Report Time: 3:12 AM CET ? Data Updated: Real-time ⚠️ Disclaimer: This report contains analyst price targets and projections based on market data as of November 11, […] - [Weekly Report 10 al 17 nov '25](https://www.merlintrader.com/weekly-report-10-al-17-nov-25/): Merlintrader Weekly Report — 10 → 17 Novembre 2025 Merlintrader Weekly Report — 10 → 17 Novembre 2025 ? Outlook Macro & Geopolitico La settimana si apre con l’attenzione sui dati d’inflazione USA e sugli ultimi commenti della Fed. Il rendimento del Treasury 10Y resta sotto 4,6 %, segno di mercato più equilibrato, mentre l’azionario […] - [$AAL](https://www.merlintrader.com/aal-2/): AAL sembrerebbe che il peggio è passato ; ora si va verso le vacanze d'inverno, un buon momento per le compagnie di solito. Io son osempre bullish anche se ci mette un pò a dare soddisfazione il rischio è molto minore di quello delle biotech. - [$MIST](https://www.merlintrader.com/mist/): Un altro titolo che si avvicina al suo PDUFA il 13 dicembre. Ad oggi come si vede nel grafico si trova in un punto di supporto intorno al quale ruota da due anni. Potrebbe essere la base per una posizione in vista di un RunUp Da valutare. Essendo una ripresentazione dopo crl, a meno che non siano incapaci, dovrebbero aver risolto. - [$OMER](https://www.merlintrader.com/omer-2/): OMER si trova in un punto perfetto per un possibile assestamento dopo il rintracciamento degli tultimi giorni a seguito dello spike fini a 13 il giorno delle news dell'accordo con Novo. Se tiene il supporto da qui la ripartenza verso fine dicembre , 26 dicembre Pdufa. - [$AGIO](https://www.merlintrader.com/agio-2/): AGIO anche questa continua ad essere interessante in vista del PDUFA di dicembre; non ha un prezzo basso , ma ha solo 58M di azioni. Può fare una bella strada nel prossimo mese. - [$BCRX](https://www.merlintrader.com/bcrx/): BCRX ho sempre avuto un debole per questo titolo, sarà che in passato mi ha datto tante soddisfazioni :) cmq a dicembre ha un espansione della prescrizione per Orl. che aumenterebbe la popolazione a cui si può somministrare il loro farmaco principale. Da grafico proprio ora è nel supporto della trendline, posizione che è più che invitante per un eventuale ingresso in vista del PDFUFA di dicembre. fatevi i conti :) - [$FSM](https://www.merlintrader.com/fsm/): FSM non è una Bio ma non ho resistito al grafico, molto interessante; si trova al supporto di qusto lungo canale e probabilmente formando un cup and handle di 3 anni.. Se tiene il supporto può dare soddisfazioni. IMPORTANTE confermare che regge/rimbalza al supporto e non va sotto! - [Weekly Report 03-10 nov 2025](https://www.merlintrader.com/weekly-report-03-10-nov-2025/): ? Biotech Weekly Settimana intensa per il comparto biotech e healthcare, con numerosi eventi scientifici e aggiornamenti clinici di rilievo. I riflettori restano su obesità, immunoterapia e malattie metaboliche, temi che continuano ad attirare forti volumi sulle small e mid-cap del settore. VKTX — Poster su VK2735 (GLP-1/GIP) con analisi estesa del trial VENTURE e […] - [Weekly Report 27/10 al 03/11](https://www.merlintrader.com/weekly-report-27-10-al-03-11/): Report valido per la settimana dal 27 ottobre al 3 novembre - [$PROK 20 oct](https://www.merlintrader.com/prok-20-oct/): Ripropongo anche PROK alla vostra attenzione. Il trend del grafico è evidente, lento ma ben incamminato. Catalyst la prima settimana di novembre. presentazione completa dati clinici (con l'anticipo mesi fà ha superato i 7). Salvo sorprese i dati dovrebbero confermare. Difficle che scenda prima. Come sempre regolde del runup per on rischiare è quella di uscire prima. E come con tutte le azioni , uno stop ponderato è necessario. La manipolazione è sempre in agguato. Poichè il seguente catalyst è lontano, meglio che non dormite e pronti allo scarico. - [$Aspi 20 oct](https://www.merlintrader.com/aspi-20-oct/): Anche Aspi nonostrante la discesa causa diluzione degli ultimi giorni (dopo la mega volata annunciata in anticipo) è ancora in gioco mentre si mantienga dentro il canale. Da aspettare alla base con doveroso stop in caso lo sfondasse. basta vedere il grafico da marzo fà violenti su e giù ma sempre con trend rialzista. Chiaro che aspettarla alla base è la scelta più conservativa e di minor rischio, ma no è detto che ci arrivi. - [$FMST 20 oct](https://www.merlintrader.com/fmst-2/): La ripropongo perchè è ancora valida mentre stà nel canale. Solo 12M di azioni. Potenzialmente esplosiva. - [Weekly report 20-27 ottobre 2025](https://www.merlintrader.com/weekly-report-20-27-ottobre-2025/): Riassunto eventi importante settimana dal 20 ottobre al 27 ottobre 2025 - [$MIST-Milestone Pharmaceuticals](https://www.merlintrader.com/mist-milestone-pharmaceuticals/): Messo in evidenza da Airfive, estreno il nuovo format di schede per questo titolo che graficamente è interessante e vale la pena di aprirlo ed esaminarlo per bene. Oggi nel punto più basso ha toccato la MM e la trendline che ho tracciato. Da li è rimbalzata.Potrebbe essere un buon punto per conisderare un azione. Ovviamente ragionando con le vostre teste . Nelle tessere manano ancora dei dati , ma arriveranno presto e saranno autoaggiornabili. - [$OMER](https://www.merlintrader.com/omer/): Oggi Omer ha siglato una partership con Novo Nordisk molto buona, con upfront che dovrebbe evitare diluzoni prima dell'eventuale approvazione. Giustificando il salto nel prezzo. Ora da qui a dicembre un runup è verosimile. Le prossime resitenze stanno nel grafico. Sicuramente una possibilità da considerare il runup qui, stando attenti a scegliere bene ingresso ed uscita. - [$QNCX](https://www.merlintrader.com/qncx/): QNCX Titolo suggerito da un utente del FOL. Ha un unico prodotto in pipeline , ma molto interessante. Non molto cash quindi a rischio diluzione. Tuttavia andando verso il catalyst potrebbe farsi una cors. Sitratta di un trial di stadio 3, quindi molto importante. Fosse positivo volerebbe. Cmq qui il rischio è elevato. Ciascuno valuti con la propria testa :) come sempre :) - [$FMST](https://www.merlintrader.com/fmst/): Questa non la conoscevo, ma oggi mi è arrivato un articolo interessante da Zero Hedge www.zerohedge.com ed incuriosito ci ho messo su le mani. Molto molto interessante. Leggetevi il report e valutate . Da quello che ho visto io, se brekka 4,20 può andare verso i prossimi target di 4,90 5,70 e 7. Cmq essendo una low float (12M azioni e 9 M di float) a buone news potrebbe andare parabolica. - [$AGIO](https://www.merlintrader.com/agio/): Come sempre , la prudenza è d'obbligo. leggete bene la storia, rispettate il grafico ed il trend (salvo eventi macro imprevedibili tipo Trump che spara sciocchezze) . Anche se non è una small cap ha buone potenzialità. - [$VRDN](https://www.merlintrader.com/vrdn/): Grafico è interessante, bel canale rialzista. Incamminata verso i suoi catalyst; non male se si riesce a prendere alla base del canale. Ha pochi volumi giornalieri il chè non mi piace tanto. Cmq interessante. Viridian Therapeutics (VRDN) — Merlintrader Report Viridian Therapeutics (VRDN) — Company & Catalyst Report Updated: October 2025 — Merlintrader Biotech Coverage […] - [$GUTS](https://www.merlintrader.com/guts/): $Guts e le sfide nel mercato Altro titolo super speculativo messo in evidenza da Thomass del Fol. Ha un evento binario questo trimestre e binario vuol dire “bere o affogare” . Perciò è un altra roulette russa. Ha 131 M di azioni, ciò limiterà una eventuale salita. Però si trova poco sopra i minimi , […] - [$TENX](https://www.merlintrader.com/tenx/): Segnalata da Lazy del Fol., questa si è “risvegliata” già un mese fà… i volumi lo mostrano(oltre al prezzo). Ha un float bassisimo (circa 6M) percui si muove con poco. Catalyst vicini importantissimi non ne vedo, salvo la possibile approvazione di un brevetto (che cmq hanno già anticipato tempo fà, non è sicuro ma probabile). […] - [$TRAW](https://www.merlintrader.com/traw/): Questo titolo segnalato da un utente del Fol ha un catalyst binario molto interessante e considerando il bassisimo flottanteed il potenziale del catalyst potrebbe avere , in caso di risultati positivi nel loro trial, un effetto imponente sul prezzo, che cmq stà già scalando velocemente.considerando che no c’è una data precisa ma solo stimata, forse […] - [$AAL](https://www.merlintrader.com/aal/): Anche AAL l’avevo postata ieri, ma persa col resto del lavoro. Cmq oggi in pre addirittura 5%, in questo momento un 2,20% ma ha spazio ancora, se presenta buona trimestrale, come ha fatto oggi Delta. Le prospettive di crescita per $AAL sembrano positive. ✈️ American Airlines Group (AAL) Compagnia aerea leader globale con vasto network […] - [$ASPI](https://www.merlintrader.com/aspi/): Ricarico $ASPI con il grafico che avevo messo ieri. Purtroppo ho avuto problemi ed ho dovuto usare un backup di 2 giorni fà perdendo tutto il lavoro di ieri. Cmq, stà rimbalzando dal supporto del canale già oggi. Il focus di oggi è su $ASPI, con un onesto 4% al momento di rimbalzo dal supporto […] - [$ARQT](https://www.merlintrader.com/arqt/): Questo è un catalyst ravvicinato (13 oct) quindi va valutato con le pinze, in quanto ha già fatto un “runup” e quindi un vero spike lo avrebbe con un’approvazione dell’espansione. Cmq è interessante, sia da grafico con diversi obiettivi, sia per il fatto che già si stà vendendo il prodotto, $ARQT. Ricordate cmq sempre, riducete […] - [$NRXP](https://www.merlintrader.com/nrxp/): Il grafico è interessante ma non vedo grossi catalyst vicino. Ma mentre si mantiene in trend è buona. Questa è una fase critica per il grafico, vediam se brekka 3,82 intanto. Catalyst attuali / imminenti Non Altri contenuti su NRXP su Merlintrader trading Blog: NRXP – Approfondimento 1 | NRXP – Approfondimento 2 | NRXP […] - [$FBIO](https://www.merlintrader.com/fbio/): Fortress Biotech (FBIO) – Catalyst Overview Diversified biotech with focus on innovative therapies and specialized controlled subsidiaries Company Profile Fortress Biotech is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biological products. It currently counts eight approved products and an expanding portfolio in oncology, dermatology, rare diseases and gene therapies. The business model […] - [$ADGM](https://www.merlintrader.com/adgm/) - [$PROK](https://www.merlintrader.com/prok/): Kidney Week 2025 (5–9 novembre 2025, Houston) → attesa presentazione dei dati completi della fase 2 REGEN-007. Questo è il prossimo grande catalyst pubblico, con visibilità elevata perché l’ASN Kidney Week è il congresso nefrologico più importante. Inoltre, il nostro focus sarà su $PROK, che rappresenta un punto di riferimento nella ricerca. - [Weekly report 06/10/2025](https://www.merlintrader.com/weekly-report-06-10-2025/) - [MBIO Mustang Bio Inc](https://www.merlintrader.com/mbio-mustang-bio-inc/): Mustang Bio is a clinical-stage biotech focused on CAR-T and oncolytic virus approaches for hard-to-treat cancers and rare diseases. The science is interesting (especially around MB-106 and MB-101), but cash is tight, dilution is heavy and the going-concern risk is real. Here we lay out numbers, pipeline, sentiment and risk without any promotional angle. - [SLS SELLAS Life Sciences Group Inc](https://www.merlintrader.com/sls-sellas-life-sciences/): SELLAS Life Sciences is a late-stage oncology biotech whose near-term equity story is dominated by a single survival-driven Phase 3 trial (REGAL with GPS in AML maintenance) and a rapidly de-risking CDK9 program (SLS009 in AML-MR). - [BEAM Beam Therapeutics](https://www.merlintrader.com/beam-therapeutics/): Beam Therapeutics is one of the purest listed plays on base editing. Its pipeline spans ex vivo and in vivo programs: risto-cel (BEAM-101) for sickle cell disease, BEAM-201 for aggressive T-cell malignancies, BEAM-301 for glycogen storage disease type Ia (GSD1a) and BEAM-302 for severe alpha-1 antitrypsin deficiency, plus an engineered stem-cell antibody-paired evasion (ESCAPE) platform aimed at non-genotoxic conditioning. - [MREO Mereo BioPharma](https://www.merlintrader.com/mreo-mereo-biopharma-2/): Mereo BioPharma is now a concentrated bet on setrusumab (UX143), an anti-sclerostin monoclonal antibody partnered with Ultragenyx for osteogenesis imperfecta (OI), plus a back-up program in respiratory alpha-1 antitrypsin deficiency (alvelestat) and an earlier-stage bone asset (vantictumab) licensed to āshibio for autosomal dominant osteopetrosis type 2, where Mereo retains European commercial rights. - [ABVX Abivax  ](https://www.merlintrader.com/abvx-abivax/): Abivax SA is a French biotech now focused almost entirely on chronic inflammatory diseases, with obefazimod as its lead – and effectively only late-stage – asset. Originally developed for HIV, obefazimod was repositioned in ulcerative colitis after mid-stage virology data underwhelmed but immune-modulation readouts looked promising. Over time, the company abandoned its older infectious disease and oncology projects and concentrated resources on inflammatory bowel disease. - [CYTK Cytokinetics](https://www.merlintrader.com/cytk-cytokinetics-2/): Cytokinetics enters 2026 in a very different position from just a year ago. After years as a development-stage muscle biology company – including the high-profile failure of omecamtiv mecarbil in chronic heart failure – the company now has its first approved product: MYQORZO (aficamten) for symptomatic obstructive HCM. - [CRSP Crispr Therapeutics](https://www.merlintrader.com/crsp-crispr-therapeutics/): CRISPR Therapeutics enters 2026 as a hybrid story: part royalty-like partner on a first-in-class commercial gene therapy (Casgevy for SCD/TDT), part high-risk platform company pushing CRISPR into autoimmune disease, oncology, cardiovascular disease and regenerative medicine. - [ALT Altimmune Inc 22 Dec Update](https://www.merlintrader.com/alt-altimmune-2decupdate/): On December 18, 2025, Altimmune announced 48-week data from the IMPACT Phase 2b trial of pemvidutide for MASH (metabolic dysfunction-associated steatohepatitis). While the company highlighted “key measures of success” including improvements in non-invasive fibrosis markers (ELF, LSM, cT1), sustained weight loss, and favorable safety, the stock fell by more than 20% in the following sessions. - [CGTX Cognition Therapeutics](https://www.merlintrader.com/cgtx-cognition/): Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company (no products on the market yet) headquartered in Purchase, New York (USA). The company develops orally available therapies for age-related neurodegenerative disorders, primarily Alzheimer’s disease and Dementia with Lewy bodies (DLB). - [RVPH Reviva Pharmaceuticals Holdings Inc Dec 22](https://www.merlintrader.com/rvph-reviva-dec22/): Reviva Pharmaceuticals is a small late-stage clinical company built almost entirely around one asset: brilaroxazine (RP5063), a serotonin-dopamine modulator for schizophrenia and other CNS / inflammatory indications. The company has successfully completed one large global Phase 3 trial (RECOVER-1) and a 1-year open-label extension and is now preparing for a pre-NDA meeting with the FDA in Q4 2025, targeting a full NDA submission in Q2 2026 for schizophrenia. - [Premarket Update dec 22 – Tech Strength, Positive Futures and a Focus on Biotech Catalysts](https://www.merlintrader.com/premarket-update-dec-22/): Christmas week: lower liquidity, but often faster and more technical moves. Below you’ll find market movers, Europe/commodities, and a “Biotech Special” built on calendar catalysts (RVPH, ARGX, AARD, plus technical notes on ZLAB and HALO). - [FBIO Pdufa Jan 14 2026](https://www.merlintrader.com/fbio-pdufa-jan-14-2026/): CUTX-101 (copper histidinate) – Copper replacement therapy for Menkes disease, an ultra-rare pediatric condition. Developed by Cyprium Therapeutics (a Fortress subsidiary), it is the flagship program right now: clinical data showed meaningful survival benefits when treatment is initiated early in life. The NDA has been filed with the FDA and granted Priority Review, now in the final regulatory phase. - [Weekly Biotech & Market Recap Dec 22](https://www.merlintrader.com/weeklyr22/): The week’s backdrop for biotech and small caps sits at the intersection of interest rates, portfolio positioning, US politics and geopolitics. None of these elements decides a trade alone, but together they define the risk corridor in which individual catalysts play out. - [CTM Castellum Inc](https://www.merlintrader.com/ctm-castellum/): In early December 2025 Castellum’s CEO Glen Ives released a year-end shareholder letter summarizing a step-change year: record Q3 revenue, the company’s first GAAP net profit, significant debt reduction, and a contract backlog that more than doubled year-on-year. The letter also highlights a 103.3 million dollar NAVAIR Special Missions contract (via GTMR), a 66.2 million dollar NAWCAD Lakehurst prime contract for the SSI subsidiary, and fresh awards under the Missile Defense Agency’s SHIELD IDIQ program. - [UNCY Unicycive Therapeutics Inc](https://www.merlintrader.com/uncy-unicycive/): On 18 December 2025, law firm Bragar Eagel & Squire announced a new investigation into certain officers and directors of Unicycive Therapeutics. The investigation follows the securities class action already filed in August 2025 over the company’s public statements around the OLC New Drug Application and the June 2025 FDA Complete Response Letter. In practical terms this does not change day-to-day operations, but it reinforces a clear message: the OLC NDA path and related communication are now under legal as well as regulatory scrutiny. - [VNDA Vanda Pharmaceuticals Inc](https://www.merlintrader.com/vnda-vanda-pharmaceuticals-inc/): Tradipitant (motion sickness) is under NDA review with an unchanged PDUFA action date on December 30, 2025. FDA has started formal labeling discussions. The FDA has lifted the partial clinical hold on long-term tradipitant studies, accepting that motion sickness is acute, so a 6-month dog tox study is no longer required. - [SGMO Sangamo Therapeutics Inc](https://www.merlintrader.com/sgmo-sangamo/): Full dossier on Sangamo Therapeutics (NASDAQ: SGMO) as of 18 December 2025: Fabry gene therapy ST-920, neurology pivot, cash and dilution, Nasdaq listing risk, analyst and retail sentiment, and scenario analysis including a hypothetical bullish path if the Fabry BLA is accepted for review. - [RunUp Biotech 2026](https://www.merlintrader.com/runup-biotech-26/): This guide is the core pillar of the Run-Up Biotech 2026 framework. It is designed as a reference map for event-driven traders who want to follow biotech catalysts in a more structured way: from calendar building and candidate selection to timing, risk management and post-event review. - [NRXP NRX Pharmaceuticals Inc](https://www.merlintrader.com/nrxp-nrx-pharmaceuticals-inc/): NRx has announced the conversion of the remaining 5.4M USD owed to Anson Funds into common equity, with no additional warrants or repricing features disclosed. Management states that, following this transaction, the year-end 2025 balance sheet is expected to show no remaining convertible debt and a “debt-free” capital structure. - [OMER Omeros Corp Yartemlya (narsoplimab)](https://www.merlintrader.com/omer-scenarios/): This article is built around one simple idea: before the label is public, you can only discuss “expectations” seriously if you anchor them to official sources, peer-reviewed evidence, and observable regulatory patterns. This is not a “tip.” It is a disciplined reading exercise. - [OMER Omeros: The Finish Line Approaches](https://www.merlintrader.com/omer-omeros-corporation/): Omeros Corporation is approaching a binary regulatory event: the U.S. Food and Drug Administration (FDA) is scheduled to decide on the Biologics License Application (BLA) for narsoplimab (to be marketed as Yartemlya) in hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) on December 26, 2025. This is the company’s most important near-term catalyst and one of the most closely watched PDUFAs into year-end. - [RXRX Recursion Pharmaceuticals Inc](https://www.merlintrader.com/rxrx-recursion/): J.P. Morgan upgraded Recursion Pharmaceuticals (RXRX) from Neutral to Overweight and increased its price target from 10 to 11 USD after reviewing new Phase 1b/2 data for REC-4881 in familial adenomatous polyposis (FAP). At a spot price around 4.20 USD, the new target implies more than 160 percent upside versus the current quote - [PMGC's  subsidiary NorthStrive Biosciences](https://www.merlintrader.com/pmgc-elab/): On December 17, 2025, PMGC’s subsidiary NorthStrive Biosciences announced the initiation of Phase III of its AI-driven drug discovery program in partnership with Yuva Biosciences:contentReference[oaicite:5]{index=5}. This stage is intended to experimentally validate multiple candidate compounds prioritized by YuvaBio’s MitoNova™ AI platform during Phase II, focusing on enhancing mitochondrial function and preserving muscle mass in obese patients - [ADTX Sparked Aditxt ](https://www.merlintrader.com/adtx-sparked/): Deep dive on Aditxt Inc. (ADTX), a highly distressed micro-cap trying to build an ecosystem around immune tolerance, precision diagnostics and women’s health, while struggling with going concern warnings, heavy dilution and a very fragile balance sheet. - [ALDX Aldeyra Therapeutics Inc Update dec 16](https://www.merlintrader.com/aldx-aldeyra-therapeutics-inc-update-dec-16/): On December 16, 2025, the FDA formally extended the PDUFA target action date for reproxalap in dry eye disease from December 16, 2025 to March 16, 2026, after Aldeyra submitted the Clinical Study Report (CSR) for its dry-eye field trial to the NDA at the FDA’s request. - [CUE Emergency Deep Dive](https://www.merlintrader.com/cue-emergency-deep-dive/): Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively engage and modulate disease-specific T cells using its Immuno-STAT platform, targeting both autoimmune disease and cancer. - [FBIO Fortress Biotech](https://www.merlintrader.com/fbio-fortress-biotech/): Fortress Biotech has evolved into a hybrid model: part commercial dermatology company (via Journey Medical), part royalty/affiliate platform with exposure to multiple late-stage assets developed by partners and subsidiaries. - [RCKT Rocket Pharmaceuticals Inc](https://www.merlintrader.com/rckt-rocket/): Rocket Pharmaceuticals is a gene therapy-focused company with disclosed programs across lentiviral (hematology) and AAV (cardiovascular) platforms, as described in SEC-filed materials. - [GRCE Grace Therapeutics](https://www.merlintrader.com/grce-grace/): Grace Therapeutics has disclosed that it submitted an NDA for GTx-104 (intravenous nimodipine) on June 25, 2025, and that the FDA accepted the application for review with a PDUFA target date of April 23, 2026. - [Biotech Weekly Recap](https://www.merlintrader.com/biotech-weekly/): This week delivered a clear “biotech reality check” mix: multiple FDA decisions (including a first-in-class gene therapy), two new oral options for gonorrhea, and several high-visibility clinical readouts across obesity/metabolic and rare disease. The flow of headlines was “event-driven”, with market attention concentrating on hard endpoints, safety/tolerability, and execution quality. - [MARKET REPORT – WEEK 15–19 DECEMBER 2025](https://www.merlintrader.com/market-report-1519-december-2025/): The coming week looks like a genuine pivot week for global markets, with three macro catalysts in sequence that will reshape expectations on rates, growth and inflation. The backdrop is a rotation into small caps and cyclicals, supported by a Fed that has shifted into a less aggressive “pause” mode and by a potential divergence between central banks: the BoE is expected to cut (18 Dec), the ECB is likely to stay on hold, and US CPI (18 Dec) together with labour data will refine the timing of 2026 rate cuts. - [TENX Tenax Therapeutics](https://www.merlintrader.com/tenx-tenax/): Tenax Therapeutics is advancing oral levosimendan for pulmonary hypertension associated with HFpEF (PH-HFpEF), with a registrational path built around the LEVEL Phase 3 program and a planned second global Phase 3 study (LEVEL-2) accepted by FDA in 2025. - [SANA Biotechnology](https://www.merlintrader.com/sana-bio/): SANA Biotechnology is often framed as a high-risk / high-reward cellular engineering story. The core thesis revolves around its proprietary hypoimmune (HIP) platform: engineered cells designed to evade immune rejection, with the long-term goal of enabling allogeneic cell therapies without chronic immunosuppression. - [VKTX Viking Therapeutics Inc](https://www.merlintrader.com/vktx-viking-therapeutics-inc/): Viking Therapeutics is one of the most watched “metabolic” biotechs because it is trying to build a two-lane story: (1) obesity with VK2735 (the same molecule in injectable and oral tablet forms), and (2) MASH/NASH with VK2809 (thyroid receptor beta agonist with histology data). - [BCRX BioCryst](https://www.merlintrader.com/bcrx-bioc/): (BCRX) Update: FDA Expands ORLADEYO Approval to Younger Children | Merlintrader trading Blog - [ALT Altimmune Update dec 12](https://www.merlintrader.com/alt-updatedec12/): Altimmune announced a succession plan under which Jerry Durso will assume the role of President & CEO on January 1, 2026, while outgoing CEO Vipin Garg remains an advisor through June 30, 2026. - [CYTK Cytokinetics](https://www.merlintrader.com/cytk-cytokinetics/): Cytokinetics is a late-stage cardiovascular biotech whose investment case now turns almost entirely around aficamten, a next-generation cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM). The clinical package in oHCM is strong: the pivotal SEQUOIA-HCM trial versus placebo and the active-control MAPLE-HCM trial versus metoprolol both met their primary endpoints with clinically meaningful gains in peak oxygen uptake (pVO₂), improved symptoms and a safety profile that appears manageable so far. - [ACIU AC Immune](https://www.merlintrader.com/aciu-ac-immune/): AC Immune’s ACI-7104.056 is an active peptide vaccine designed to raise antibodies against misfolded α-synuclein in early Parkinson’s disease (PD). The ongoing Phase 2 VacSYn trial is the first randomized, double-blind study to show that such an approach can consistently drive very high antibody titers that reach the CNS and are associated with stabilization of multiple disease-relevant biomarkers. - [DNLI Denali Therapeutics](https://www.merlintrader.com/dnli/): Denali Therapeutics is a late-stage biotech focused on neurodegenerative and lysosomal storage diseases, with a proprietary Transport Vehicle (TV) platform to move biologics across the blood–brain barrier. The investment case in the next 12–18 months is dominated by the accelerated approval decision for DNL310 (tividenofusp alfa) in Hunter syndrome (MPS II), alongside the company’s ability to fund and execute a first commercial launch while advancing a broader pipeline. - [FDA PDUFA Catalyst Report-January 2026](https://www.merlintrader.com/fda-pdufa-dates-jan-2026/): FDA PDUFA Catalyst Report January 2026 | Merlintrader trading Blog English Italiano FDA PDUFA Catalyst Report – January 2026 Report Catalysts FDA PDUFA – Gennaio 2026 Key biotech approval events with price scenarios and qualitative sentiment for active traders. Principali eventi di approvazione biotech con scenari di prezzo e sentiment qualitativo per trader attivi. Report […] - [ATRA Atara Biotherapeutics Inc JAN 2 Update](https://www.merlintrader.com/atra-atara/): Atara Biotherapeutics is a small-cap cell therapy company whose equity story is now essentially a single binary catalyst: the U.S. FDA decision on tab-cel (tabelecleucel) for EBV-positive PTLD, with a Priority Review PDUFA action date on 10 January 2026. The company has already divested or discontinued its other programs and has transferred most tab-cel operational responsibilities to Pierre Fabre Laboratories. What remains for shareholders is a high-volatility, high-uncertainty exposure to the outcome of that regulatory event and its knock-on impact on liquidity and solvency. - [DAL Delta Air Lines](https://www.merlintrader.com/dal-delta/): Delta today looks like the carrier you used to book for demanding but pragmatic business clients. Strong hub positioning in Atlanta, a wide global network and a product built around a rich mix of premium cabins and corporate traffic. - [ALDX Aldeyra Therapeutics  Update dec 12](https://www.merlintrader.com/aldx-aldeyra-update-dec-12/): Aldeyra Therapeutics is a clinical-stage biotech focused on inflammation, oxidative stress and ocular / metabolic diseases via its RASP platform. The lead asset, Reproxalap, is currently under FDA review for dry eye disease with a target action date of December 16, 2025 — a highly binary event coming after previous Complete Response Letters (CRLs) in 2023 and 2025. - [OMER The Path of the Force Update dec 9](https://www.merlintrader.com/omer-path-o-the-force/): Omeros Corporation is a US-based biotechnology company focused on complement-related diseases. Its lead asset, narsoplimab (OMS721), targets transplant-associated thrombotic microangiopathy (TA-TMA), with a PDUFA target action date of December 26, 2025 for its resubmitted BLA. This is the core binary catalyst currently driving the stock. - [SNTI Senti Biosciences Inc](https://www.merlintrader.com/snti-senti/): Senti Biosciences is a micro-cap cell therapy company built around programmable gene-circuit technology. The lead asset, SENTI-202, is an off-the-shelf, logic-gated CAR-NK therapy in Phase 1 for relapsed / refractory acute myeloid leukemia (R/R AML). - [VOR BIOPHARMA](https://www.merlintrader.com/vor-biopharma/): VOR transformed from a dying cell therapy company into a focused autoimmune player with a globally licensed, China-approved dual BAFF/APRIL inhibitor (telitacicept). The stock has crashed/rallied 5 times in 2025 alone. - [XCUR Exicure Inc](https://www.merlintrader.com/xcur-exicure/): Exicure has repositioned itself around burixafor, a CXCR4 antagonist designed to mobilize hematopoietic progenitor cells (HPCs) for autologous stem-cell transplant in multiple myeloma and potentially other settings. At the ASH 2025 annual meeting, the company presented Phase 2 data showing high rates of successful HPC collection, including in daratumumab-exposed patients who are traditionally harder to mobilize. - [PHAR Pharming Group (Updated dec 19)](https://www.merlintrader.com/phar-pharming-group/): Pharming Group has quietly moved into an unusual position in the biotech universe: it is a profitable, cash-generating rare-disease company, yet still trades in the small/mid-cap bracket and continues to carry several meaningful catalysts. - [AQST Aquestive Therapeutics](https://www.merlintrader.com/aqst-aquestive/): Aquestive Therapeutics is a small-cap specialty pharma player built around its PharmFilm oral film technology and a mix of manufacturing revenue and proprietary pipeline assets. The stock is now tightly linked to a single binary catalyst: the FDA decision on Anaphylm, its epinephrine sublingual film for severe allergic reactions. - [TVTX Travere Therapeutics](https://www.merlintrader.com/tvtx-travere-therapeutics/): Travere Therapeutics is a commercial-stage rare-disease biotech focused on kidney and metabolic disorders. Its lead product, FILSPARI (sparsentan), is approved in the United States for IgA nephropathy (IgAN) and is under FDA review for focal segmental glomerulosclerosis (FSGS). A supplemental NDA for FSGS has an FDA target action date in early 2026, turning TVTX into a classic binary catalyst name with an already meaningful revenue base from IgAN. - [FULC Fulcrum Therapeutics](https://www.merlintrader.com/fulc-fulcrum-therapeutics/): Fulcrum Therapeutics (FULC) – Pociredir SCD Deep Dive | Merlintrader trading Blog EN IT Fulcrum Therapeutics (FULC) – Pociredir in Sickle Cell Disease Deep Dive (December 2025) Last updated: December 8, 2025 – Authors: Merlintrader and Jane – Educational, non-promotional research note. 0. Executive Summary and Quick Profile 0.1 High-level takeaway Fulcrum Therapeutics, Inc. (NASDAQ: […] - [INVA Innoviva Inc](https://www.merlintrader.com/inva-innoviva/): Innoviva Inc (NASDAQ: INVA) is a diversified holding company with a core royalty portfolio derived from respiratory assets in partnership with GlaxoSmithKline (GSK) and a growing commercial platform focused on critical care and infectious disease therapies through Innoviva Specialty Therapeutics (IST). - [Wall Street Weekly Report Dec 9–15](https://www.merlintrader.com/wall-street-weekly-report-dec-915/): Economic Events: The Week Ahead KEY CATALYST FACT Federal Reserve FOMC Meeting (Dec 17–18) – markets are currently pricing an approximate probability of a 25 bp rate cut to 3.50%–3.75%, which would be the third cut of 2025. This decision is likely to be the single most important event affecting equity valuations in the following week. - [QNTM Quantum BioPharma Ltd](https://www.merlintrader.com/qntm-quantum/): QNTM Quantum BioPharma – Comprehensive Report EN IT QNTM – Quantum BioPharma Ltd NASDAQ: QNTM | CSE: QNTM | FSE: 0K91 Sector: Biotech / Pharmaceuticals Report Date: December 5, 2025 ⚠️ SPECULATIVE – HIGH RISK Current Price (Dec 5) $9.755 USD Market Cap $37.2M USD [SEC-EDGAR] 52-Week Range $1.35 – $19.82 Shares Outstanding ~3.82M [SEC […] - [QCLS Q/C Technologies ](https://www.merlintrader.com/qcls/): Q/C Technologies (QCLS) – Photonic Hype, Shkreli Factor and a Very Thin Runway | Q/C Technologies (QCLS) – Photonics, Shkreli factor e runway molto corta English Italiano Q/C Technologies (QCLS) NASDAQ: QCLS – Photonic computing pivot and Shkreli-fueled squeeze story Report generated: Data snapshot mainly based on Finviz / SEC as of Dec 5, 2025 […] - [AKBA Akebia Therapeutics Inc](https://www.merlintrader.com/akba-akebia/): Akebia Therapeutics is a Cambridge, MA-based biopharmaceutical company focused on kidney disease treatment. Leading the market with innovative therapies for anemia and renal dysfunction. - [PDUFA dates december 2025](https://www.merlintrader.com/pdufa-dec25/): December 2025 is the densest FDA decision month of the year. In only 26 days the agency is expected to rule on fourteen key dossiers across oncology (Breyanzi), cardiology (Aficamten), ophthalmology (EYLEA HD, LYTENAVA), rare diseases (Narsoplimab, Mitapivat), endocrine disorders (Relacorilant), infectious diseases (Zoliflodacin) and more. - [PDSB PDS Biotechnology Corporation](https://www.merlintrader.com/pdsb/): On December 3, 2025, PDS Biotech announced via an official 8-K filing that the FDA has granted a Type C Meeting to discuss a potential accelerated approval pathway based on PFS for PDS0101 + pembrolizumab in first-line HPV16+ HNSCC. The market reaction was immediate: the stock gained roughly +18% on Dec 3 and closed at $0.899 on Dec 4, about +12% across 48 hours. - [HOTH Hoth Therapeutics Inc](https://www.merlintrader.com/hoth-therapeutics/): Hoth Therapeutics is a micro-cap, clinical-stage biotech focused on oncology-supportive care, mast-cell–driven diseases, neurodegeneration and metabolic/obesity indications. The company just issued a comprehensive pipeline update covering four core programs: HT-001 (topical therapy for EGFR-inhibitor rash), HT-KIT (KIT-driven mast-cell diseases, Orphan Drug Designation), HT-ALZ (Alzheimer’s / CNS inflammation) and a newly launched GDNF-based metabolic program in collaboration with the Atlanta VA Medical Cente - [ONDS Ondas Holdings Update dec 3](https://www.merlintrader.com/onds-ondas/): 2025, Ondas Holdings transformed from a marginal wireless communications company into an emerging leader in autonomous defense, driven by strategic acquisitions, record government contracts, and a rapidly expanding global customer pipeline. With Q3 2025 revenue of $10.1 million, a record backlog of $23.3 million, and an ultra-strong cash position of $840 million, Ondas is exceptionally positioned to capitalize on the boom in the counter-UAS market. - [PLRZ Polyrizon Ltd](https://www.merlintrader.com/plrz-polyrizon/): Polyrizon Ltd is an early-stage biotech leveraging proprietary Capture & Contain (C&C) hydrogel technology for nasal barriers against allergens/viruses and Trap & Target (T&T) for enhanced intranasal drug delivery - [MREO Mereo BioPharma](https://www.merlintrader.com/mreo-mereo-biopharma/): LONDON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2025, and provided recent corporate highlights. - [ALT Altimmune Update dec 3](https://www.merlintrader.com/alt-altimmune/): Altimmune is entering a pivotal phase with several bullish drivers converging through Q4 2025 and into 2026 - [ADCT ADC Therapeutics](https://www.merlintrader.com/adct-adc-therapeutics/): ADC Therapeutics announced updated LOTIS-7 Phase 1b trial results on December 3, 2025, showing highly encouraging efficacy and manageable safety for ZYNLONTA + glofitamab combination in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) - [JANX](https://www.merlintrader.com/janx/): Janux Therapeutics has gone from market darling to high-risk story stock in 2025: 52-Week High (early 2025): around US$71–72 per share (after strong early JANX007 data and sector momentum). Price after December 2–3, 2025 update: mid-teens (≈US$16–17), following a two-day collapse of ~50% after the latest Phase 1 JANX007 update. - [CAPR Capricor Therapeutics (CAPR)](https://www.merlintrader.com/capr-capricor-2/): Positive Phase 3 HOPE-3 topline results in Duchenne muscular dystrophy cardiomyopathy with statistically significant skeletal and cardiac benefit, reopening the regulatory path after the 2025 CRL. - [GUTS Fractyl Health Inc](https://www.merlintrader.com/guts-fractyl-health-inc/): Fractyl Health (NASDAQ: GUTS) is emerging as one of the most interesting names in the metabolic space thanks to its flagship device Revita®, a duodenal mucosal resurfacing (DMR) procedure designed to maintain weight loss after stopping GLP-1 drugs. - [VVera Therapeutics (Nasdaq: $VERA): Atacicept’s July 7 FDA Decision, the New eGFR Timeline, and the Real IgAN Competitive Test](https://www.merlintrader.com/vera-vera-therapeutics/): VERA Therapeutics is a biopharmaceutical company in advanced clinical stage focused on serious immunological diseases. The company achieved its most important milestone in November 2025 with the submission of a Biologics License Application (BLA) to the FDA for atacicept, its lead candidate for the treatment of IgA Nephropathy (IgAN). - [Verastem Oncology ($VSTM) Stock Hub: Q2 2026, VS-7375 & Catalysts](https://www.merlintrader.com/vstm-verastem-inc/): Complete Verastem Oncology VSTM Stock Hub updated through Q2 2026 earnings: AVMAPKI FAKZYNJA launch, VS-7375, RAMP 301, RAMP 205, cash, dilution, risks and future catalysts. - [VERI Veritone](https://www.merlintrader.com/veri-veritone/): Veritone is a small-cap AI/software company that has struggled for several years with dilution, weak fundamentals, and high volatility. Today’s ~12% move appears more like a speculative rebound than a structural change - [PMCB PharmaCyte Biotech](https://www.merlintrader.com/pmcb/): PharmaCyte has successfully monetized its equity stake in Femasys Inc. (FEMY), increasing its cash and marketable securities to roughly ~20 million USD, up from about 13.3 M USD as of July 31, 2025, according to the company’s press release and BusinessWire distribution. - [CTOR Citius Oncology Inc (ctxr)](https://www.merlintrader.com/ctor-citius-oncology-inc-ctxr/): FDA approval secured June 2024 with orphan drug exclusivity through 2031 $8.27M inventory ready for immediate commercialization Strong clinical efficacy: 36.2% ORR, 84.4% tumor burden reduction - [HOLO MicroCloud Hologram Inc.](https://www.merlintrader.com/holo-microcloud-hologram-inc/): MicroCloud Hologram Inc. (HOLO) is a Chinese technology company specializing in holographic LiDAR technology, autonomous driving ADAS systems, and holographic digital twin solutions. The company represents a **recovery play** from a post-reverse-split penny stock to a **profitable, cash-rich operation** with significant exposure to the autonomous vehicle and advanced driver assistance systems (ADAS) market - [RVPH Reviva Pharmaceuticals](https://www.merlintrader.com/rvph-reviva-pharmaceuticals/): FDA Pre-NDA Meeting (Schizophrenia) TIMEFRAME: Q4 2025 (IMMINENT) The Event: Reviva has a scheduled meeting with the FDA in Q4 2025 to discuss submitting a New Drug Application (NDA) for Brilaroxazine based solely on existing data (RECOVER-1 Phase 3 + OLE Long-term data). - [AGIO BCRX MIST December 7-13, 2025: Three Biotech PDUFA Catalysts – Complete Analysis](https://www.merlintrader.com/agio-bcrx-mist-december-7-13-2025-three-biotech-pdufa-catalysts-complete-analysis/): AGIO, BCRX, MIST: December 2025 PDUFA Deep Dive | Analyst Targets & Timeline - [Weekly Market Analysis & Trading Outlook](https://www.merlintrader.com/weekly-market-analysis-trading-outlook/): The week of November 24-29 closed with continued volatility as investors digested stretched AI valuations, mixed macro signals, and elevated geopolitical tensions. Major indexes ended modestly lower: S&P 500 [finance:S&P 500] -1.9%, Nasdaq [finance:Nasdaq Composite] -2.7%, Dow [finance:Dow Jones Industrial Average] -1.9%. - [CODX Co-Diagnostics](https://www.merlintrader.com/codx-co-diagnostics/): Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company specializing in the development, manufacturing, and commercialization of rapid PCR diagnostic tests. Core focus: affordable, rapid tuberculosis (TB) detection tests for global markets (MENA, Africa, Asia). Company historically revenue-focused but currently in severe financial distress with strategic pivots toward AI and international partnerships. - [LXRX Lexicon Pharmaceuticals Inc](https://www.merlintrader.com/lxrx-lexicon-pharmaceuticals-inc/): Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products using its proprietary gene science approach. The company operates in two segments: Product (INPEFA® commercialization) and Licensing (Novo Nordisk partnership for LX9851 obesity program). - [ONMD OneMedNet Corporation](https://www.merlintrader.com/onmd-onemednet-corporation/): OneMedNet Corporation (NASDAQ: ONMD) is a healthcare technology company specializing in curating and providing regulatory-grade Real-World Data (RWD) through its proprietary iRWD™ platform. The company connects life sciences organizations, medical device companies, and AI researchers with de-identified medical imaging, electronic health records, and clinical data from over 2,130 healthcare provider sites spanning 47+ million unique patient lives and 186+ million clinical exams. - [MBOT Microbot Medical Inc.](https://www.merlintrader.com/mbot-microbot-medical/): Microbot Medical is a commercial-stage medical device company specializing in endovascular robotic systems. The company achieved a transformational milestone in September 2025 with FDA 510(k) clearance for its flagship LIBERTY® Endovascular Robotic System - the world's first FDA-cleared single-use, remotely operated robotic platform for peripheral endovascular procedures. - [VRCA Verrica Pharmaceuticals Inc](https://www.merlintrader.com/vrca-verrica-pharmaceuticals-inc/): Verrica Pharmaceuticals [finance:Verrica Pharmaceuticals Inc.] (NASDAQ: VRCA) is a commercial-stage dermatology biopharmaceutical company focused on developing and commercializing innovative medical aesthetic solutions for skin conditions including molluscum contagiosum, basal cell carcinoma, and aesthetic dermatology indications. The company operates through a partnership model, leveraging strategic alliances with larger pharmaceutical companies (Torii Pharmaceutical [finance:Torii Pharmaceutical Co., Ltd.]) for commercialization and geographic expansion. - [ACRS Aclaris Therapeutics Inc](https://www.merlintrader.com/acrs-aclaris-therapeutics-inc/): Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage dermatology-focused biopharmaceutical company developing innovative immunological therapies for inflammatory and immune-mediated skin diseases. The company transitioned from a commercial-stage company with FDA-approved products to a clinical-stage organization, strategically acquiring promising pipeline assets to build a competitive portfolio in atopic dermatitis and related indications. - [FLGT Fulgent Genetics, Inc. ](https://www.merlintrader.com/flgt-fulgent-genetics-inc/): Diagnostics + Therapeutics | Genetic Testing & Cancer Drug Development | Q3 2025 Report - [XLO Xilio Therapeutics Inc Report](https://www.merlintrader.com/xlo-xilio-therapeutics-inc-report/): Xilio Therapeutics, Inc. (NASDAQ: XLO) is a clinical-stage biopharmaceutical company pioneering the development of masked tumor-activated immunotherapies - [AMRN Amarin Corp](https://www.merlintrader.com/amrn/): ? Amarin Corporation (AMRN) – Company History & Analysis ⚠️ IMPORTANT NOTICE / AVVISO IMPORTANTE: This document is a company analysis and financial summary compiled from publicly available sources (SEC filings, press releases, clinical publications). It is NOT investment advice, NOT a recommendation to buy or sell, and does NOT constitute a solicitation. The author […] - [AVXL Anavex Life Sciences](https://www.merlintrader.com/avxl/): What happened: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed Anavex of a negative trend vote on the Marketing Authorisation Application (MAA) for blarcamesine following its oral explanation on November 11, 2025. - [NRXP](https://www.merlintrader.com/nrxp-2/): NRx Pharmaceuticals (NRXP) | Investment Research Report ⚠️ IMPORTANT NOTICE / AVVISO IMPORTANTE: This document is a news digest and company profile compiled from publicly available sources (SEC filings, press releases, official company announcements). It is NOT investment advice, NOT a recommendation to buy or sell, and does NOT constitute a solicitation of any kind. […] - [CUE Biopharma](https://www.merlintrader.com/cue/): Cue Biopharma (CUE) | Investment Research Report ?? English Version ? Cue Biopharma (CUE) Investment Research Report — Platform Play: Immuno-STAT T-Cell Modulators Update: November 26, 2025 ⚠️ GOING CONCERN WARNING ? STRATEGIC PIVOT TO AUTOIMMUNE NASDAQ: CUE | Price: ~$0.61 | Market Cap: ~$47M | 52-Week Range: $0.45 – $5.12 Table of Contents 1. […] - [KALA Bio Caution risk 100%](https://www.merlintrader.com/kala/): KALA Bio was a clinical-stage biotech developing KPI-012, a mesenchymal stem cell secretome (MSC-S) therapy for Persistent Corneal Epithelial Defect (PCED), an orphan eye disease with ~100,000 US patients and no FDA-approved treatments. - [CAPR Capricor](https://www.merlintrader.com/capr-capricor/): Capricor Therapeutics [finance:Capricor Therapeutics, Inc.] is a clinical‑stage biotech focused on cell and exosome‑based therapeutics for rare diseases, with lead asset Deramiocel (CAP‑1002) targeting cardiomyopathy in Duchenne muscular dystrophy - [PLRX Will PLRX have a merry Christmas?](https://www.merlintrader.com/plrx/): "Will PLRX have a merry Christmas? Very speculative play . - [SMMT Summit Therapeutics](https://www.merlintrader.com/smmt/): ummit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical company focused on developing innovative oncology therapies. The primary pipeline is built around ivonescimab, a first-in-class bispecific antibody developed in partnership with Akeso Biopharma (China). - [Anti-obesity drugs and weight-loss therapies](https://www.merlintrader.com/anti-obesity/): Scientific Comparison of Anti-Obesity Drug Efficacy 2025 – Complete Report Scientific Comparison of Anti-Obesity Drug Efficacy Semaglutide, Tirzepatide, Liraglutide, and Pemvidutide Complete Scientific Report – Updated: November 25, 2025 Table of Contents 1. Introduction 2. Mechanisms of Action and Pharmacological Rationale 3. Clinical Efficacy: Results from Major Trials 4. Comparative Analysis of Efficacy Endpoints 5. […] - [SYM Symbotic Inc](https://www.merlintrader.com/sym/): Symbotic surges +35% post-earnings; valuation tightens as growth investors price in upside - [ADMA BIOLOGICS](https://www.merlintrader.com/adma-biologics/): ADMA Biologics is a rare biotech company that combines clinical success with financial profitability. Unlike pre-revenue biotech plays, ADMA operates a functioning immunoglobulin (plasma-derived therapy) business generating $426.5M in FY2024 revenue (+65% YoY) with actual net income of $197.7M. The company is well-managed, debt-reducing, and positioned in a high-growth market ($53.5B global plasma therapy market projected by 2033). - [TNXP Tonix Pharmaceuticals ](https://www.merlintrader.com/tnxp/): FDA APPROVED BUT HIGH DILUTION RISK - [GME THE REDDIT REVOLUTION CONTINUES](https://www.merlintrader.com/gme/): GameStop [finance:GameStop Corp.] is not a typical stock—it is a cultural movement, a symbol of retail trader empowerment, and a battleground between Wall Street and Main Street. S - [RIGL Rigel Pharmaceuticals Update Feb 2026](https://www.merlintrader.com/rigl/): Rigel Pharmaceuticals [finance:Rigel Pharmaceuticals, Inc.] is a rare breed in biotech: profitable, cash-generative, and growth-oriented. - [OSCR Oscar Health](https://www.merlintrader.com/oscr/): oscr-aca-catalyst-report-nov24-2025.html OSCR Breaking News | Oscar Health | Merlintrader ?? ?? OSCR BREAKING CATALYST ACA SUBSIDY EXTENSION November 24, 2025 | Political Healthcare Policy Breakthrough OSCR CATALYST ACUTO ESTENSIONE SUSSIDI ACA 24 Novembre 2025 | Breakthrough Politica Healthcare Executive Summary On November 23-24, 2025, reports emerged that the Trump White House is planning a healthcare […] - [ENLV Enlivex Therapeutics ](https://www.merlintrader.com/enlv/): Enlivex Therapeutics [finance:Enlivex Therapeutics Ltd.] announced two simultaneous catalysts on November 23-24, 2025, triggering a 74% intraday spike to $1.59: (1) positive 6-month topline data from the Allocetra Phase IIa trial demonstrating durable pain reduction, and (2) a $212M PIPE financing at $1.00/share closing November 25. The clinical data supports Phase IIb progression, but the financing creates massive shareholder dilution (~99%) and introduces governance/crypto risks requiring careful assessment. - [MDGL Madrigal Pharmaceuticals Inc](https://www.merlintrader.com/mdgl/): Madrigal (MDGL) is a commercial-stage biopharma focused on metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Its lead product, Rezdiffra (resmetirom), received FDA accelerated approval on March 14, 2024 as the first treatment for adults with noncirrhotic MASH with moderate to advanced fibrosis (F2–F3), to be used with diet and exercise. - [CRMD Cormedix Inc jan 12 Legislative update (KCAPA 2026)](https://www.merlintrader.com/crmd-cormedix-inc/): CorMedix Inc. has crossed a line that many small biotechs never reach. It is no longer a binary, pre-revenue story waiting for a single FDA decision. With DefenCath approved, the Melinta acquisition closed and several hundred million dollars of revenue on the board, CRMD now behaves like a small-cap specialty pharma focused on preventing and treating serious infections linked to vascular access. - [SMMT Summit Therapeutics Inc](https://www.merlintrader.com/smmt-summit-therapeutics-inc-2/): Summit Therapeutics Inc. (NASDAQ: SMMT) has effectively transformed itself into a single-asset, late-stage oncology company centered on ivonescimab (SMT112), a PD-1 × VEGF bispecific antibody licensed from Akeso in January 2023 (FY2024 PR). Ivonescimab is already approved in China (Akeso) and is now in a broad, global Phase III program led by Summit in NSCLC and colorectal cancer. - [RVMD Revolution Medicines](https://www.merlintrader.com/rvmd-revolution-medicines/): Revolution Medicines, Inc. (Nasdaq: RVMD) enters the 44th Annual J.P. Morgan Healthcare Conference as a late-stage, pre-commercial oncology company focused on RAS(ON) inhibitors. The company’s FY24 results release (link) positions RVMD as “a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers,” with a deep pipeline led by daraxonrasib, elironrasib and zoldonrasib. - [OCGN Ocugen Inc](https://www.merlintrader.com/ocgn-ocugen-inc-2b/): Ocugen, Inc. (Nasdaq: OCGN) is a clinical-stage biotechnology company focused on gene therapies for blindness diseases and related ophthalmic biologics. Its core asset base is a “modifier gene therapy” platform built around nuclear hormone receptors (NHRs) designed to reset dysfunctional retinal gene networks rather than replace single mutated genes. The three flagship programs are OCU400 for retinitis pigmentosa (RP), OCU410 for geographic atrophy (GA, late-stage dry age-related macular degeneration) and OCU410ST for Stargardt disease, each targeting sizeable unmet-need populations in inherited and multifactorial retinal disease. - [CLRB Cellectar Biosciences Inc](https://www.merlintrader.com/clrb-cellectar-biosciences-inc/): Cellectar Biosciences (Nasdaq: CLRB) is a late-stage clinical radiopharmaceutical company built around a proprietary phospholipid drug conjugate (PDC) platform. Its lead asset, iopofosine I 131, delivers radioactive iodine-131 directly to tumor cell membranes; the most advanced program is in relapsed/refractory Waldenström macroglobulinemia (WM) after BTK inhibitor therapy, supported by the pivotal CLOVER-WaM Phase 2 data described in the company’s Form 10-K 2024 (Business section). - [DVLT Datavault AI Inc](https://www.merlintrader.com/dvlt-datavault-ai-inc/): Datavault AI Inc. (Nasdaq: DVLT) is a small/micro-cap technology company that wants to sit at the intersection of AI, Web3 and data monetization. It licenses a portfolio of patents and software platforms to tokenize and value “real-world assets” (RWA) – from genomic data and prescription flows to commodities and luxury goods – and still carries the legacy wireless-audio business acquired from WiSA. - [AQST Aquestive Therapeutics](https://www.merlintrader.com/aqst-aquestive-therapeutics/): On 9 January 2026, Aquestive Therapeutics announced that the US FDA had identified “deficiencies” in the NDA for Anaphylm (dibutepinephrine sublingual film). These deficiencies currently preclude discussions of labeling and post-marketing commitments. - [SAVA Cassava Sciences Inc](https://www.merlintrader.com/sava-cassava-sciences-inc-2/): A factual deep dive on where SAVA really stands after shutting down Alzheimer’s, pivoting to TSC-related epilepsy, facing a full FDA clinical hold, settling a $31.25M class action and attracting heavy call-option interest and insider buying. - [KRYS Krystal Biotech Inc](https://www.merlintrader.com/krys-krystal-biotech/): HSV-1 gene therapy platform moves from skin to lung: robust CFTR expression in CF lungs, repeat dosing on deck, and JPM 2026 as the launchpad for a mutation-agnostic CF strategy. - [SPACE & DEFENCE 2026](https://www.merlintrader.com/space-defence/): SIDU, ASTS, LUNR, ONDS and PL are not just “hot tickers”. Their satellites, landers, drones and imaging constellations are becoming building blocks of a Western answer to China’s dual-use space programs, Russia’s drone war and a world where infrastructure and data are contested every single day. - [ONDS Ondas Holdings Inc jan 8](https://www.merlintrader.com/onds-ondas-holdings-inc-jan-8/): This is not a buy/sell note, but a way to show readers how Ondas (ONDS) has been covered on Merlintrader over the last months, how the stock moved from November into early January, and what the upcoming Needham Growth Conference presentation actually adds (or doesn’t add) to the picture. Educational only, not investment advice. - [OMER The Plan](https://www.merlintrader.com/omer-the-plan/): DA approval is in the bag, pricing is out in the open, and the call with transplant KOLs was basically a long “here’s how we want to own TA-TMA”. Let’s unpack what Omeros is really trying to do with YARTEMLEA, beyond the usual headline noise. - [RNXT RenovoRx Inc UPDATED jan 9](https://www.merlintrader.com/rnxt-renovorx-inc/): Micro-cap (~37M $) clinical/commercial biotech developing a targeted drug-device platform (TAMP + RenovoCath) for solid tumors, with a pivotal Phase 3 trial in locally advanced pancreatic cancer (TIGeR-PaC) and a near-term catalyst at ASCO GI 2026 - [KODK Eastman Kodak Co](https://www.merlintrader.com/kodk-eastman-kodak-co/): KODK – Turnaround / Advanced Materials Deep Dive | Merlintrader trading Blog KODK (KODK) – TURNAROUND / ADVANCED MATERIALS & CHEMICALS Mid-cap industrial (≈$800M) in full transition: from legacy photography to commercial print, advanced materials & chemicals, EV battery electrodes and pharmaceutical manufacturing. $1B+ pension reversion completed, term debt cut to $200M, going-concern risk removed. […] - [KOD Kodiak Sciences Inc](https://www.merlintrader.com/kod-kodiak-sciences-inc/): After a brutal Phase 3 failure in diabetic macular edema (DME) and years of being treated as a write-off, Kodiak is back on catalyst watch thanks to strong GLOW1 data in diabetic retinopathy (DR), a fully enrolled confirmatory Phase 3 GLOW2 study and the ongoing DAYBREAK trial in wet AMD. All patients in GLOW2 are expected to complete their primary endpoint visit by the end of January 2026, with topline data guided for the first quarter of 2026. For a name that has historically moved violently on news, this is a critical “reboot or bust” window. - [Encyclopedia of Social Trader Myths – Vol. 2](https://www.merlintrader.com/encyclopedia-of-social-trader-myths-vol-2b/): The slightly less polite, more cynical and more honest companion to the original Encyclopedia of Social Trader Myths. Same dark humour, more uncomfortable truths about how traders really behave on Stocktwits, Reddit, X and Discord. - [SIDU Sidus Space Inc](https://www.merlintrader.com/sidu-sidus-space-inc/): Space and Data-as-a-Service micro-cap building a LizzieSat® small-sat constellation with on-orbit AI processing and a long-term partnership with NASA Stennis’ ASTRA programme. After three LizzieSats launched in 12 months and a fresh equity raise, SIDU has become one of the most watched small-sat names of early 2026. - [DRUG Bright Minds Biosciences](https://www.merlintrader.com/drug-bright-minds-biosciences/): On January 6, 2026, Bright Minds reported positive topline results from its open-label Phase 2 BREAKTHROUGH study of BMB-101 in adults with drug-resistant absence seizures and developmental and encephalopathic epilepsies (DEE) - [ACRV Acrivon Therapeutics Inc](https://www.merlintrader.com/acrv-acrivon-therapeutics-inc/): Clinical-stage precision oncology small cap (~170–190M $) built around the AP3 predictive phosphoproteomics platform, advancing ACR-368 in registrational-intent Phase 2b (with planned confirmatory Phase 3) and ACR-2316, a dual WEE1/PKMYT1 inhibitor, with fresh data coming at the January 8, 2026 webcast - [OMER Omeros Corp 2026](https://www.merlintrader.com/omer-omeros-corp-2026/): After years of being treated as a “show-me story”, Omeros enters 2026 with two key green lights: FDA approval of Yartemlea (narsoplimab-wuug) and a large strategic deal with Novo Nordisk on OMS906. This report walks through the approval process, current US/EU regulatory status, the financial impact of the Novo deal, and a catalyst map for 2026. - [NRXP and the Phantom PDUFA 2](https://www.merlintrader.com/nrxp-phantom-pdufa-2/): Over the last 18–24 months, NRx Pharmaceuticals (NRXP) has built a storyline around NRX-100 (preservative-free IV ketamine) that many retail traders translated into a simple, crisp line: “PDUFA by year-end 2025.” - [ONDS Ondas Holdings Inc jan 06 update](https://www.merlintrader.com/onds-ondas-holdings-inc-jan-06-update/): Ondas Holdings (ONDS) has extended its powerful run into early 2026, hitting new four-year highs and moving decisively into mid-cap territory. The next major test for the story is the OAS Investor Day 2026, where management will present the updated 2026 business plan and financial outlook. This update is a companion to the full deep dive available here: ONDS – Ondas Holdings Inc. (full report) . - [IBIO iBio Inc](https://www.merlintrader.com/ibio-ibio-inc/): iBio (IBIO) has turned into a small but noisy name in the obesity-drug corner of biotech. It’s a micro-cap (~42–45M $) that has radically repositioned itself as an AI-driven antibody company for obesity and cardiometabolic disease, with a clear—if high-risk—angle: “post-GLP-1” biology focused on Activin E, myostatin/Activin A and the amylin receptor. - [NBIX Neurocrine Biosciences, Inc](https://www.merlintrader.com/nbix-neurocine-biosciences-inv/): Companion EN/IT deep dive on Neurocrine Biosciences: INGREZZA as the main cash engine in movement disorders, CRENESSITY as the first new therapy for classic CAH in 70 years, and an expanding psychiatry pipeline (NBI-1117568 and related muscarinic programmes). Focus on 2025–2026 catalysts, risk map and how NBIX fits in a catalyst-driven biotech watchlist. - [INCY Incyte Corp](https://www.merlintrader.com/incy-incyte-corp/): Incyte is a classic mid-cap biotech with a single dominant product (Jakafi) and a long history of oncology R&D. After several high-profile pipeline disappointments, the company has shifted from aggressive expansion to a more selective, risk-controlled development strategy. - [VRTX Vertex Pharmaceuticals- CRISPR-Therapeutics](https://www.merlintrader.com/vrtx-vertex-pharmaceuticals-crispr-therapeutics/): ASGEVY hits primary endpoints in children 5–11 with SCD and TDT – global paediatric filings planned for 1H 2026 Context: ASH 2025 & pre-JPM 2026 – CLIMB-151 (SCD) and CLIMB-141 (TDT) paediatric cohorts (5–11 years). Vertex has presented the first pivotal data for CASGEVY in children aged 5–11 with sickle cell disease and transfusion-dependent beta-thalassemia. In both Phase 3 trials, all evaluable patients with sufficient follow-up achieved the primary endpoints (absence of vaso-occlusive crises for SCD; sustained transfusion independence for TDT) with VOC-free and transfusion-free periods approaching two years in some cases. Safety so far remains consistent with the adult programme. - [JPM Healthcare Conference 2026](https://www.merlintrader.com/jpm-healthcare-conference-2026/): The 44th Annual J.P. Morgan Healthcare Conference is widely considered the most influential healthcare investment meeting in the world. Often described as the “Super Bowl of Healthcare”, it brings together more than 8,000 participants, including C-suite executives, institutional investors, policymakers, analysts and media. - [KALA Kala Bio Inc](https://www.merlintrader.com/kala-bio-inc-2/): Deep dive on KALA BIO after the CHASE Phase 2b collapse, the Oxford Finance default, David Lazar’s $6M rescue, and the December 26, 2025 completion of the $2M debt settlement that wipes out ~$10.6M in obligations. - [HOVR New Horizon Aircraft Ltd](https://www.merlintrader.com/hovr-new-horizon-aircraft-ltd/): Government money and Formula 1 DNA behind the Cavorite X7 In October 2025 Horizon announced an INSAT (Initiative for Sustainable Aviation Technology) grant to fund “Project CRYSTAL”, a 10.5 M CAD all-weather eVTOL programme focused on icing detection and protection. Horizon will receive about 2.0 M CAD in non-dilutive proceeds, working with the Flight Test Centre of Excellence (3C) and the University of Toronto on a propulsion system that can operate in conditions where most helicopters are grounded. - [AUPH Aurinia Pharmaceuticals Inc](https://www.merlintrader.com/auph-aurinia-pharmaceuticals/): AUPH has been on every biotech retail watchlist since the January 22, 2021 FDA approval of LUPKYNIS (voclosporin) for lupus nephritis. The buyout never came, but the company did the one thing that really matters: it built a profitable, growing LN franchise. - [ASTS AST SpaceMobile Inc](https://www.merlintrader.com/asts-ast-spacemobile-inc/): Complete overview of the most talked-about direct-to-cell stock: technology, last 12 months, financials, ownership, analyst views, sentiment and key catalysts into 2026. - [TARA Protara Therapeutics Inc](https://www.merlintrader.com/tara-protara-therapeutics-inc/): Key message: the FDA has granted Breakthrough Therapy and Fast Track designations to TARA-002 for the treatment of pediatric macrocystic and mixed cystic lymphatic malformations (LMs), on top of the existing Rare Pediatric Disease designation and inclusion in the FDA’s CMC Development and Readiness Pilot program. This turns TARA-002 into a rare triple-designation asset in a high-need pediatric space, and gives Protara a clearly accelerated regulatory lane while the stock is still trading in single digits. - [ALT Altimmune](https://www.merlintrader.com/alt-altimmune-3/): Key message: the FDA has granted Breakthrough Therapy Designation (BTD) to pemvidutide for the treatment of MASH, based on 24-week data from the Phase 2b IMPACT trial (company press release, Jan 5 2026 and IMPACT publication). The stock immediately reacts with an intraday move around +15–20% (as reported by outlets like Seeking Alpha and Investing.com). This is not a random bounce, it is a repricing of regulatory risk. - [PDYN Palladyne AI Corp](https://www.merlintrader.com/pdyn-palladyne-ai-corp/): Deep dive on Palladyne AI’s pivot into Palladyne Defense: SwarmOS, GuideTech, Crucis, BRAIN avionics, Banshee and SwarmStrike, with an ambitious target to more than triple 2024 revenue by 2026. - [Weekly Recap and next week outlook dec 29-jan 02 jan 05-jan 09](https://www.merlintrader.com/weekly-recap-and-outlook-jan05-jan09/): From PDUFA shocks to early 2026 catalysts: what just happened and what traders should watch next week. - [PL Planet Labs PBC](https://www.merlintrader.com/pl-planet-labs-pbc-2/): Planet is not “just Earth pictures”. The platform revolves around three layers: High-frequency global monitoring – PlanetScope / SuperDove for broad coverage and fast revisit. High-resolution tasking – SkySat + Pelican for “tell me where and when to look”, with priority and higher detail. Productised analytics / AI – events, alerts, indicators and workflows for defence, intelligence, maritime, disasters, insurance and supply chains, rather than raw pixels. - [APLD Applied Digital Corporation](https://www.merlintrader.com/apld-applied-digital-corporation/): Applied Digital is heavily traded and highly volatile: average daily volume in the tens of millions of shares, beta comfortably above 2, double-digit intraday swings on apparently minor news when shorts and options flows interact. - [LUNR Intuitive Machines Inc](https://www.merlintrader.com/lunr-intuitive-machines-inc/): Moon lander headline magnet – LUNR is the equity proxy for Intuitive Machines’ IM-1 “Odysseus” and IM-2 “Athena” missions: the first U.S. soft landings on the Moon since Apollo 17 and the first commercial landers ever, even if both ended up tilted on their side. Huge 2025/26 story arc – from tiny SPAC to front-page space company with NASA contracts, multiple CLPS missions and now a planned acquisition of Lanteris (Maxar Space Systems) that would take combined revenue to >850M USD with positive adjusted EBITDA and ~920M USD backlog. Short-interest powder keg – short interest sits around 22–23% of the free float, with more than 25M shares sold short and days-to-cover in the 3–4 range: structurally squeezed stock by design. - [PL Planet Labs PBC](https://www.merlintrader.com/pl-planet-labs-pbc/): Massive 2025 rerating – Planet’s stock is up almost 4x in 2025, with several single-day jumps of 30–50% after earnings and news. It went from being treated as a broken SPAC to a “space + AI + defence” favourite. Backlog and cash have exploded – record backlog well above 700M USD, remaining performance obligations multiples of current annual revenue, and end-of-quarter cash and equivalents close to 700M USD. Adjusted EBITDA finally positive – the latest quarters show positive adjusted EBITDA, with management promising a path toward sustainable profitability, even if GAAP net income is still deeply negative. - [OPEN Opendoor Technologies Inc](https://www.merlintrader.com/open-opendoor-technologies-inc/): Huge 2025 comeback – after trading below 1 USD, OPEN staged a massive rebound, with the share price up roughly 400–450% in 2025 on the back of retail enthusiasm, leadership changes and a “short squeeze” narrative. Real business, real losses – this is not a pre-revenue story. Opendoor generated 3.635B USD of revenue in the first nine months of 2025, but still reported a net loss of 204M USD over the same period. Heavy balance sheet usage – the company ended Q3 2025 with 962M USD of cash and 1.79B USD of debt, for a net cash position of about −830M USD. This is not an asset-light software-only model. - [TMC TMC the metals company Inc](https://www.merlintrader.com/tmc-the-metals-company-inc/): TMC is not a traditional small biotech or junior miner. It is a high-beta small/mid cap trying to open an entirely new segment: harvesting polymetallic nodules on the ocean floor in the Clarion-Clipperton Zone, with the idea of feeding the electric-vehicle and strategic metals supply chain. In 2025 the stock moved from just above 1 USD to a peak above 11 USD, closing the year still several hundred percent above the starting point. That kind of move puts TMC firmly on any “small caps of the moment” radar: strong narrative, strong retail interest, highly directional. - [POET Technologies Inc](https://www.merlintrader.com/poet-technologies-inc/): Market cap around 900–950M USD with a one-year increase above 200 percent. Positioned at the intersection of AI, photonics and data centers, with optical engines and interposer technology at the core. Recent production orders for POET Infinity optical engines, with shipments scheduled from the second half of 2026. Extra attention after Marvell’s acquisition of Celestial AI, which uses POET’s technology. - [ONDS Ondas Holdings Inc](https://www.merlintrader.com/onds-ondas-holdings-inc/): 2025 performance in the ballpark of +250–270 percent, among the top performers in the defense group. Growth story tied to autonomous drones and counter-UAS systems in a context of rising defense and security spending. Very ambitious guidance: management is targeting revenues of at least 36M USD in 2025 and 110M USD in 2026. Large free float, growing institutional ownership and high volatility: a classic high-beta small cap where newsflow drives big moves. - [BNGO Bionano Genomics Inc](https://www.merlintrader.com/bngo-bionano-genomics-inc/): Bionano Genomics is one of those names where the technology and the share price seem to live in different universes. On the lab side, optical genome mapping (OGM) keeps racking up publications, clinical use-cases and even a Category I CPT code with a 47% reimbursement boost for blood cancers. - [AXSM Axsome Therapeutics Inc](https://www.merlintrader.com/axsm-axsome-therapeutics-inc/): Axsome Therapeutics is no longer just “the Auvelity company”. In 2025 it quietly turned into a multi-product CNS platform with three marketed drugs, a late-stage pipeline and, now, a Priority Review from the FDA for AXS-05 in agitation associated with Alzheimer’s disease – with a PDUFA action date set for April 30, 2026. - [NVAX Novavax, Inc](https://www.merlintrader.com/nvax-novavax-inc/): From going concern to platform story with a cult retail base For a long stretch of 2023, Novavax was treated as a failed Covid trade. A late vaccine, production issues, a balance sheet that flirted with collapse and a market that moved on to other themes. On paper, the story should have ended there. - [CORT Corcept Therapeutics Inc](https://www.merlintrader.com/cort-corcept-therapeutics-inc/): CRL in one paragraph: The FDA acknowledged that one of Corcept’s Phase 3 trials in Cushing was successful, but another failed its primary endpoint. Given this mixed picture, the agency said it could not reach a favorable benefit-risk assessment without additional evidence of effectiveness and therefore rejected the NDA via CRL. No insurmountable safety issues were cited; the focus is efficacy and consistency. - [SLS http://www.sellaslifesciences.com/](https://www.merlintrader.com/sls-sellas-2/): News of the day (REGAL): On 29 December 2025, SELLAS reported that the contract research organization running the Phase 3 REGAL trial notified the company that 72 of the 80 required events (deaths) had occurred as of 26 December 2025. REGAL is an overall survival study; the final analysis will be triggered once 80 events are reached. SELLAS remains fully blinded, and this one-time update does not change the statistical plan. Source: SELLAS REGAL update PR (Dec 29, 2025) . - [IRWD Ironwood Pharmaceuticals Inc](https://www.merlintrader.com/irwd-ironwood-pharmaceuticals-inc/): News of the day: Ironwood maintained FY2025 guidance and issued FY2026 guidance projecting LINZESS U.S. net sales of $1.125–$1.175B, total revenue $450–$475M, and adjusted EBITDA >$300M, citing improved net pricing driven by a January 1, 2026 Linzess list-price reduction. It also reaffirmed that a confirmatory Phase 3 trial for apraglutide is expected to begin in H1 2026, and that the strategic alternatives review is progressing. Source: BusinessWire (Jan 2, 2026). - [ONCY Oncolytics Biotech, Inc](https://www.merlintrader.com/oncy-oncolytics-biotech-inc/): Oncolytics Biotech (ONCY) — Pelareorep, GI focus, catalysts into Q1–H1 2026 | Oncolytics Biotech (ONCY) — Pelareorep, focus GI, catalyst Q1–H1 2026 EN IT Oncolytics Biotech (ONCY) Panel-style report (EN/IT): news-first, catalyst timelines, fundamentals/cash runway, pipeline, management/ownership, retail sentiment, risk map, and sources. Latest key update Read first FDA alignment on pivotal Phase 3 design […] - [VNDA Vanda Pharmaceuticals Inc](https://www.merlintrader.com/vnda-pharmaceuticals-inc/): The FDA approved NEREUS (tradipitant) for the prevention of vomiting induced by motion in adults — described as the first new FDA-approved pharmacologic treatment in this area in over 40 years. The company expects a commercial launch “in the coming months.” - [DRTS Alpha Tau Medical Ltd Updated jan 8](https://www.merlintrader.com/drts-alpha-tau-medical-ltd/): eep dive on Alpha Tau Medical (DRTS) from a bullish angle: differentiated alpha-radiation platform, multiple late and early-stage trials, solid cash runway and heavy insider ownership. Educational only, not investment advice. - [EKSO Ekso Bionics Holdings Inc](https://www.merlintrader.com/ekso-bionics-holdings/): On December 29, 2025, Applied Digital (APLD) and Ekso Bionics (EKSO) announced a non-binding term sheet for a proposed business combination between Applied Digital’s cloud computing arm, Applied Digital Cloud, and EKSO. - [PALI Palisade Bio Inc](https://www.merlintrader.com/pali-palisade-bio-inc/): The Japan Patent Office has granted a patent titled “Gut Microbiota-Activated PDE4 Inhibitor Prodrug” covering the composition of matter for PALI-2108, Palisade Bio’s lead gut-restricted PDE4 B/D inhibitor for moderate-to-severe ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD). The base patent term runs into 2041 and is eligible for extension based on regulatory review timelines. - [ARDX Ardelyx Inc Updated Jan 8](https://www.merlintrader.com/ardx-ardelyx-inc/): Q3 2025: revenue beat, IBSRELA guidance raised, Street now models ARDX turning profitable in 2026 October–December 2025 – Q3 revenue beat, IBSRELA guidance increased to $270–275M for 2025, XPHOZAH absorbs Medicare shock, analysts talk about 2026 breakeven. - [GLSI Greenwich LifeSciences Inc](https://www.merlintrader.com/glsi-greenwich-lifesciences-inc/): FLAMINGO-01 open-label arm shows ~80% reduction in breast cancer recurrences; Fast Track in place and lock-up extended to 2026 December 2025 – GLSI reports preliminary ~80% recurrence rate reduction in the 250-patient open-label arm of FLAMINGO-01, completes enrollment, and extends insider/pre-IPO lock-up to September 30, 2026, while the stock breaks to new 52-week highs. - [CORT Corcept Therapeutics Inc DEC 31 UPDATE CRL](https://www.merlintrader.com/cort-corcept/): n March 3, 2025, the FDA filed Corcept’s NDA for relacorilant as a treatment for adult patients with endogenous hypercortisolism (Cushing’s syndrome), assigning a PDUFA target action date of December 30, 2025. The NDA is based on the pivotal Phase 3 GRACE study, confirmatory evidence from Phase 3 GRADIENT, long-term extension data and a Phase 2 study in hypercortisolism. - [INO Inovio Pharmaceuticals Inc](https://www.merlintrader.com/ino-inovio/): FDA accepts INO-3107 BLA, Standard Review, PDUFA October 30, 2026 On December 29, 2025 the FDA accepted Inovio’s Biologics License Application for INO-3107 as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The review classification is Standard and the agency set a PDUFA target action date of October 30, 2026. The FDA also indicated that it is currently not planning to hold an Advisory Committee for this dossier. - [BTAI BioXcel Therapeutics Inc](https://www.merlintrader.com/btai-bioxcel-therapeutics-inc/): On 12 December 2025 BioXcel held its virtual Annual Meeting. Shareholders approved all proposals, including a flexible reverse stock split authorization (from 1-for-5 up to 1-for-30) that the Board may implement within 12 months if needed to keep Nasdaq listing compliance. The company is currently compliant, but this vote gives management an emergency tool in case of further price pressure - [MREO Mereo Biopharma Group](https://www.merlintrader.com/mreo-mereo-biopharma-3/): On 29 December 2025, Mereo BioPharma announced Phase 3 ORBIT and COSMIC results for setrusumab (UX143) in osteogenesis imperfecta. Neither trial met its primary endpoint of reduced annualised clinical fracture rate versus placebo (ORBIT) or bisphosphonates (COSMIC), - [RARE Ultragenyx Pharmaceutical Inc](https://www.merlintrader.com/rare-ultragenyx-pharmaceutical-inc/): On 29 December 2025 Ultragenyx announced that the Phase 3 ORBIT and COSMIC studies of setrusumab (UX143) in osteogenesis imperfecta did not meet their primary endpoints of reducing annualized clinical fracture rate versus placebo (ORBIT) or bisphosphonates (COSMIC). - [LPCN Lipocine Inc](https://www.merlintrader.com/lpcn-lipocine-inc/): 16 December 2025: Lipocine reports that its Phase 3 trial of LPCN 1154 (oral brexanolone) in postpartum depression has reached 80% enrollment (66 of 80 planned participants). The second independent Data Safety Monitoring Board (DSMB) review is scheduled for mid-January 2026 and topline results are still guided for the second quarter of 2026. The study is intended to support a 505(b)(2) NDA submission referencing IV brexanolone. - [TDOC Teladoc Health Inc](https://www.merlintrader.com/tdoc-teladoc-health-inc/): Teladoc Health – From pandemic superstar to underpriced cash-flow machine? Virtual care incumbent trading at about 0.6× revenue and mid-teens implied FCF yield, with a new CEO, a shrinking BetterHelp segment and a slow but steady reset toward profitable integrated care - [Big Pharma Goes Shopping – Q4 2025 Biotech M&A Wave and When Retail Fantasy Came True](https://www.merlintrader.com/big-pharma-goes-shopping/): 4 2025 turned into a real M&A season for Big Pharma: multi-billion deals in diagnostics, cardio-metabolic and rare diseases, plus a few cases where retail dreams of a buyout actually became reality. Below you find a structured overview of the main transactions, the strategic themes behind them and the “fantasy came true” section based on frequently mentioned retail ideas on social platforms. - [TNGX Tango Therapeutics Inc](https://www.merlintrader.com/tngx-tango-therapeutics-inc/): Tango Therapeutics (TNGX) – PRMT5, CoREST and a crowded short base into 2026 | Tango Therapeutics (TNGX) – PRMT5, CoREST e una base short affollata verso il 2026 English Italiano Ticker: TNGX (NASDAQ) Tango Therapeutics (TNGX) – PRMT5, CoREST and a crowded short base into 2026 Synthetic lethality biotech with a PRMT5/CoREST pipeline, a sharp […] - [IBRX ImmunityBio Inc](https://www.merlintrader.com/ibrx-immunitybio-inc/): On December 12, 2025, the European Medicines Agency recommended granting a conditional marketing authorization for ANKTIVA (nogapendekin alfa inbakicept) in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with CIS, with or without papillary tumors – effectively mirroring the U.S. label in the EU and leveraging the pivotal QUILT-3.032 data set. - [OCGN Ocugen Inc](https://www.merlintrader.com/ocgn-ocugen-inc/): November 2025 – In its Q3 2025 update, Ocugen reports 1.75 million USD in revenue and a net loss of about 20 million USD, with operating expenses of 19.4 million USD driven mainly by gene therapy R&D. Cash and equivalents stand around 33 million USD after a 20 million USD financing, which management believes funds operations into 2026. - [GERN Geron Corp](https://www.merlintrader.com/gern-geron-corp/): After decades of telomerase debates and more than one boom-and-bust cycle, Geron finally has an FDA-approved product on the market. Rytelo is generating real revenue, IMpactMF is fully enrolled, and a very loyal retail base is watching every quarterly print and every slide deck, trying to understand whether this is the beginning of a long compounding story or just the payoff of a very long wait. - [VKTX Viking Therapeutics Inc](https://www.merlintrader.com/vktx-viking-therapeutics-inc-2/): Viking is trying to crash a party dominated by Eli Lilly and Novo Nordisk with a dual GLP-1/GIP agonist, VK2735, in both weekly injectable and daily oral forms. Phase 2 data are eye-catching, Phase 3 VANQUISH trials are fully underway, and the balance sheet is still heavy with cash – but there is real execution, timing and dilution risk. - [IOVA Iovance Biotherapeutics Inc](https://www.merlintrader.com/iova-iovance-biotherapeutics-inc/): 6 November 2025 – Iovance reports Q3 2025 revenue of about $68 million, up 13% sequentially, with Amtagvi driving the growth. Gross margin improves to 43%, but the company still posts a net loss of over $90 million and burns cash. - [DCTH Delcath Systems Inc](https://www.merlintrader.com/dcth-buyback-story/): 20 November 2025 – Delcath’s board authorizes a $25 million share repurchase program, at a time when the stock has dropped more than 50% in six months and trades close to its 52-week low around $8 per share. The program can be executed via open-market and privately negotiated transactions, with no fixed end-date, funded from cash and operating cash flow. - [BHVN Biohaven Ltd](https://www.merlintrader.com/bhvn-biohaven-ltd/): 24 December 2025 – Biohaven reports that BHV-7000 did not meet the primary endpoint in a six-week Phase 2 MDD study (MADRS change vs placebo). Shares fall about 16–17% after hours. Management says it will stop psychiatric trials with BHV-7000 and focus 2026 resources on immunology, obesity and epilepsy. - [RZLT Rezolute Inc](https://www.merlintrader.com/rzlt-rezolute-inc/): Rezolute (RZLT) Crash Story – sunRIZE Phase 3 Failure in Congenital Hyperinsulinism | EN/IT Crash Story · Biotech RZLT · Rezolute, Inc. Educational only – not investment advice EN IT Rezolute (RZLT) – When a Breakthrough Story Breaks Down From FDA Breakthrough Therapy Designation and glowing Phase 2 data to an 80–90% one-day crash after […] - [SMMT Summit Therapeutics Inc](https://www.merlintrader.com/smmt-summit-therapeutics-inc/): Summit Therapeutics has transformed itself into a single-asset late-stage oncology story around ivonescimab, a PD-1 x VEGF bispecific licensed from Akeso and already approved in China. - [Weekly Recap & Next Week Prep dec 29- Jan 2](https://www.merlintrader.com/weekly-recap-next-week-prep-dec-29/): Reality check: end-of-year sessions are thin and noisy. Spikes and air-pockets are common. Treat this week as “information rich” but structurally fragile in terms of liquidity. - [TRAW, ACRV, GUTS – Three speculative near term names to keep on watchlist](https://www.merlintrader.com/traw-acrv-guts-on-watchlist/): Not a buy list, but three stocks where the next 1–3 months could change the narrative: one antivirale COVID ritonavir-free, una storia di oncology DDR quasi-registrativa e un dispositivo endoscopico per mantenere il peso dopo GLP-1. - [Nasdaq Delisting & Compliance 101](https://www.merlintrader.com/nasdaq-delisting-compliance-101/): A practical guide for small traders: how the Nasdaq $1 rule really works, what “extensions” mean, and what the historic market reactions look like. This article is informational and educational only. It is not legal advice, not investment advice and not a recommendation to buy, sell or hold any security. - [CUE Cue Biopharma](https://www.merlintrader.com/cue-cue-biopharma/): This report focuses on three highly sensitive aspects of Cue Biopharma’s situation: Equity structure and dilution history (last ~24 months) – public offerings, at-the-market (ATM) sales, pre-funded warrants and long-dated warrants. Nasdaq minimum bid price rule (“$1.00 rule”) – including the deficiency letter sent on 12 May 2025, the initial 180-day window ending 10 November 2025, and Cue’s own statement in its Form 10-Q for the quarter ended March 31, 2025 that it may cure the deficiency via a reverse stock split if necessary. Forward-looking pressure – what the next months look like, how much time the company realistically has, and in which window a reverse split becomes a likely tool if the share price does not recover. - [IMRX Immuneering Corp](https://www.merlintrader.com/imrx-immuneering-corp/): On January 7, 2026 Immuneering will host a conference call and webcast to present 12-month overall survival (OS) from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) + modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer. This is the logical follow-up to the 6- and 9-month data that have already attracted significant attention. - [VTGN Vistagen Therapeutics Inc](https://www.merlintrader.com/vtgn-vistagen-therapeutics-inc/): VTGN – From Euphoria to PALISADE-3 Pain and the Road to the Next Readout | VTGN – Dall’euforia al crollo di PALISADE-3 e la prossima speranza Biotech | VTGN VistaGen Therapeutics – Social Anxiety & Pherine Story VTGN – From PALISADE-2 Euphoria to PALISADE-3 Pain, and the Narrow Road to the Next Readout Editorial for […] - [AMRX Amneal Pharmaceuticals Inc](https://www.merlintrader.com/amrx-amneal/): On December 22, 2025 the FDA approved Amneal and mAbxience’s BLAs for Boncresa (denosumab-mobz), a biosimilar referencing Prolia, and Oziltus (denosumab-mobz), a biosimilar referencing XGEVA. The two brands target a combined U.S. market of roughly 5.3 billion dollars over the last 12 months, but join a denosumab biosimilar segment that has been filling up rapidly throughout 2024–2025. - [TVTX Travere Therapeutics Inc UPDATE JAN 2](https://www.merlintrader.com/tvtx-travere-therapeutics-2/): Travere Therapeutics has transitioned in 2025 from a “promising rare-disease biotech” into a genuine kidney franchise story. Filspari is fully approved in IgAN and ramping quickly, while the January 13, 2026 PDUFA on FSGS could make it the first FDA-approved therapy in that indication. - [NRXP and the Phantom PDUFA: When ‘By Year-End’ Isn’t a Date](https://www.merlintrader.com/nrxp-and-the-phantom-pdufa/): NRX-100 was supposed to be one of those year-end catalysts that keep biotech traders awake at night: fast-track status, fee waivers, a new FDA voucher program, and a decision “by year-end 2025”. Yet, as the calendar runs out, the line between guidance and reality still looks blurry. - [Santas Biotech Watchlist: CORT, OTLK, VNDA](https://www.merlintrader.com/santas-biotech-watchlist/): Instead of a sterile list of dates, this piece focuses on context: how Corcept Therapeutics (CORT), Vanda Pharmaceuticals (VNDA) and Outlook Therapeutics (OTLK) are approaching their regulatory events, what their cash situation looks like, what the retail chatter is, and what kind of narrative one can realistically expect in a positive or negative outcome. - [OTLK Outlook Therapeutics DEC 31 Update CRL](https://www.merlintrader.com/otlk-outlook-therapeutics/): The FDA has accepted a new BLA resubmission for ONS-5010 and set a Class 1 PDUFA goal date on 31 December 2025, after a second CRL in August that focused on lack of substantial evidence of efficacy. - [KALA Kala Bio Inc](https://www.merlintrader.com/kala-bio-inc/): KALA BIO has gone from Phase 2b hope story to distressed nano-cap in a few months: KPI-012 failed, the lender swept cash after a default, and the company survived via a rescue deal with David Lazar plus a $10M registered direct offering priced at-the-market. Here’s what that actually means for the equity. - [OMER Omeros Corp](https://www.merlintrader.com/omer-omeros-corp/): News of the day – FDA approval The FDA has approved YARTEMLEA (narsoplimab-wuug) for treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children 2 years and older. YARTEMLEA is the first and only approved inhibitor of the lectin complement pathway and the only FDA-approved therapy for TA-TMA. - [DVAX Dynavax Technologies Corp](https://www.merlintrader.com/dvax-sanofi/): Sanofi has announced a definitive agreement to acquire Dynavax Technologies Corporation for 15.50 dollars per share in cash, representing a total equity value of approximately 2.2 billion dollars. The offer implies a 39 percent premium to Dynavax’s closing price on December 23, 2025, and the transaction is expected to close in the first quarter of 2026, subject to customary conditions - [DRMA Dermata Therapeutics Inc](https://www.merlintrader.com/drma-dermata-therapeutics-inc/): Dermata Therapeutics (DRMA) – 58% Rally, Low Float and OTC Pivot Deep Dive 2025 | Merlintrader trading Blog Dermata Therapeutics (DRMA) – 58% Rally, Low Float and OTC Pivot Deep Dive 2025 Independent research note on Dermata’s +58% move: financing news, ultra-low float dynamics, OTC acne pivot, clinical data, catalysts, technical picture, retail sentiment and […] - [Market backdrop – Christmas Eve mood](https://www.merlintrader.com/market-backdrop/): Wall Street comes into Christmas Eve with the S&P 500 at fresh record highs after several strong sessions driven mainly by mega-cap tech. Today’s session is shortened, volumes are thin and the mood is a mix of “Santa Claus rally” and “better not break anything before the holidays”. - [AGIO Agios Pharmaceuticals](https://www.merlintrader.com/agio-pharmaceuticals/): From FDA approval of AQVESME in alpha/beta-thalassemia to the next catalysts in sickle cell and MDS: a filings-based look at where Agios really stands now. - [RVPH Reviva Pharmaceuticals Update dec 23](https://www.merlintrader.com/rvph-reviva-pharma-dec23/): On 23 December 2025, reviva confirmed in an 8-K and a press release that the FDA, after the pre-NDA meeting, is strongly encouraging a second Phase 3 trial (RECOVER-2) before any NDA submission for brilaroxazine in schizophrenia. - [SAVA Cassava Sciences Inc](https://www.merlintrader.com/sava-cassava-sciences-inc/): As of late 2025, Cassava is a small-cap CNS company trading in the low-single-digit USD range after its lead Alzheimer’s drug, simufilam, failed in Phase 3 and the program was discontinued. - [TBPH Theravance Biopharma Inc](https://www.merlintrader.com/tbph-theravance-biopharma/): Over the last weeks of 2025, several themes have dominated coverage on TBPH: a clearly positive Q3 2025 earnings print (revenue up high-teens percent year-on-year, earnings swinging to a small profit), a sizeable analyst re-rating with average price targets in the mid-to-high twenties per share, and a steady drumbeat of commentary framing Theravance as a “growth” or “momentum” stock again rather than a restructuring situation. - [VRDN Viridian Therapeutics Inc](https://www.merlintrader.com/vrdn-viridian-therapeutics-inc/): Viridian Therapeutics is trying to become the second major commercial player in thyroid eye disease after Amgen’s Tepezza, with a TED franchise built around veligrotug (IV) and VRDN-003 (subcutaneous), plus an FcRn platform (VRDN-006/008) that targets broader autoimmune indications. - [PROK ProKidney Corp](https://www.merlintrader.com/prok-prokidney/): ProKidney is a late clinical-stage cellular therapeutics company focused on a single lead product: rilparencel, also known as REACT (Renal Autologous Cell Therapy). - [MBRX Moleculin Biotech ](https://www.merlintrader.com/mbrx-mileculin-biotech/): Deep dive on Moleculin Biotech, Inc. (NASDAQ: MBRX), a Phase 3 oncology company built around Annamycin (AnnAraC) in relapsed/refractory AML, with additional programs in STS lung metastases, brain tumors and viral indications. We walk through MIRACLE’s design and timelines, Phase 1b/2 AML data, the latest December 2025 updates, the balance sheet and why the stock still trades like a distressed nano-cap. - [ADGM Adagio Medical Holdings](https://www.merlintrader.com/adgm-medical-holdings/): Adagio Medical is not a biotech but a medical device company developing catheter-based ultra-low temperature cryoablation (ULTC) systems for cardiac arrhythmias: atrial fibrillation (AF), atrial flutter and ventricular tachycardia (VT). Its technology uses near-critical nitrogen to reach temperatures as low as −196°C in a linear catheter system, aiming to create rapid, continuous, transmural lesions. - [PCSA Processa Pharmaceuticals Inc](https://www.merlintrader.com/pcsa-processa/): Processa Pharmaceuticals is a clinical-stage company built around a simple idea: instead of discovering entirely new oncology molecules, it re-engineers existing, FDA-approved chemotherapies to improve their therapeutic index. The Next Generation Cancer (NGC) platform aims to keep the same cancer-killing mechanism, while changing metabolism and distribution to reduce toxicity and potentially increase efficacy. - [ICU SeaStar Medical Holding Corp](https://www.merlintrader.com/icu-seastar-medical-holding-inc/): SeaStar Medical is not a typical “pre-clinical biotech on a slide deck”. The company has already crossed the line into real-world use: QUELIMMUNE (the pediatric implementation of the SCD) is approved by the US Food and Drug Administration via HDE and has been adopted by a growing group of leading US children’s hospitals. Early registry data suggest improved survival and kidney recovery in some of the sickest patients in the ICU, with no device-related safety signals reported so far - [DRTS Alpha Tau Medical Ltd Jan Update](https://www.merlintrader.com/drts-apha-tau-medical-ltd-jan-update/): We wrote our original bullish editorial at the very end of December 2025, when the stock was still trading around five dollars and largely under the radar. January brought ASCO GI pancreatic data, a first PMA module to the FDA, a shareholder letter and a sharp re-rating. Here we revisit the thesis, check the fundamentals and map the next catalysts. Educational only, not investment advice. - [CTM Castellum Inc](https://www.merlintrader.com/ctm-castellum-inc/): Castellum starts 2026 with exactly what you want to see in a micro-cap defense name: more work, bigger visibility inside the U.S. missile-defense and Navy ecosystem, and a tape that already gave traders a clean spike-and-fade on the first new contract of the year. - [POET Technologies Inc Jan Recap](https://www.merlintrader.com/poet-technologies-inc-3/): January 2026 has been anything but quiet for POET Technologies. The stock first extended the late-2025 rerating on the “AI optics” narrative and then got hit hard by a US$150 million registered direct offering that erased most of the month’s gains. The industrial thesis around the Optical Interposer has not changed, but the share count has – and the market is repricing that. - [ALLO Allogene Therapeutics Inc](https://www.merlintrader.com/allo-allogene-therapeutics-inc/): Allogene Therapeutics is not the 2+ billion dollar hype story it was a few years ago. After the initial enthusiasm around off-the-shelf CAR T, the stock has been crushed by a sequence of events: an FDA clinical hold in 2021, years of execution risk, pipeline reshuffling and workforce reductions. - [BNAI Brand Engagement Network Inc](https://www.merlintrader.com/bnai-brand-engagement-network-inc-2/): In mid-January we covered BNAI as a tiny, risky AI play with a handful of real enterprise projects and a fragile balance sheet. Two weeks later the stock has printed a 52-week range from $1.18 to an intraday high above $80, short interest has exploded, and the company rushed out multiple press releases on licensing, warrant exercises, debt conversion and a premium private placement. This note is meant to put everything back into one framework: what BEN actually does, what changed in January, how stretched the valuation looks, and which hard catalysts matter once the trading dust settles. - [PLTR Palantir Technologies Inc Updated Feb 3](https://www.merlintrader.com/pltr-palantir-technologies-inc/): Deep dive on Palantir’s dual engine (government + commercial AI), the new U.S. Army Enterprise Agreement and the Innodata partnership for multimodal data in “rodeo analytics” – with an eye on 2026 catalysts. - [AMRN Amarin Corp ADR Update Jan 31](https://www.merlintrader.com/amrn-amarin-corp-adr/): A few years ago, the Amarin story was dominated by a single word: generics. After losing key patent battles on Vascepa, the U.S. business was hit by an aggressive wave of skinny-label competitors, PBM exclusions and net price pressure, to the point where many investors simply filed AMRN under “broken story”. At the start of 2026, the picture is no longer that binary. The company is still far from the glory days, but the trajectory is clearly different: less bleeding, more structure, and a gradual shift from survival mode to controlled recovery. - [SLS SELLAS Life Sciences Group Inc Update Jan 31](https://www.merlintrader.com/sls-sellas-life-sciences-update-jan31/): REGAL Survival Clock, SLS009 Momentum and the Waiting Game Monthly recap on SELLAS Life Sciences: what changed since the December update, how the 72/80 events in the REGAL Phase 3 trial reshaped the narrative, and which catalysts traders are watching next. - [ALT Altimmune Inc](https://www.merlintrader.com/alt-altimmune-inc-2/): From 48-week IMPACT data and a CEO switch to FDA Breakthrough status, a 75M$ raise and a +50% month: how the Altimmune story and the tape have changed in a few weeks - [IBRX ImmunityBio Inc Update Jan 31](https://www.merlintrader.com/ibrx-immunitybio-inc-update-jan31/): Since the last Merlintrader pieces on ImmunityBio, the story has accelerated on several fronts. Anktiva net product revenue exploded to a preliminary 113 million dollars for 2025, a roughly 700 percent year-over-year jump with 38.3 million in the fourth quarter alone, backed by strong unit growth and broader coverage in the United States and abroad, as detailed in the company’s mid-January 2026 update and echoed across financial coverage. - [Week ahead and recap jan 31 2026](https://www.merlintrader.com/week-ahead-and-recap-jan-31-2026/): Week Ahead and Recap – January 31, 2026 Gold near record highs, AI shockwaves in gaming, and a cluster of high-grade biotech catalysts from DF-003 in ROSAH syndrome to camizestrant in ESR1-mutant breast cancer. This is your condensed map for the week. - [SKYX Platforms Corp](https://www.merlintrader.com/skyx-platforms-corp/): SKYX wants to turn the ceiling into the “brain” of the home: a plug & play outlet that makes lights, fans and smart devices safer and easier to install, plus an AI-native platform built on NVIDIA’s cloud ecosystem. Revenues have climbed to record levels through Q3 2025 and the company has just secured new strategic and institutional funding ahead of big launches at Lowe’s and early smart city deployments. - [PLX Protalix BioTherapeutics Inc](https://www.merlintrader.com/plx-protalix-biotherapeutics-inc/): The core of the Protalix model today is Elfabrio (pegunigalsidase alfa) for Fabry disease, commercialized globally by Chiesi under the two Chiesi agreements described in the FY 2024 release and 10-K. :contentReference[oaicite:2]{index=2} Protalix manufactures the drug substance in Carmiel and sells finished product to Chiesi, receiving tiered payments in the 15–35% ex-US and 15–40% US range on average selling price, linked to purchased volumes, as outlined in the “Chiesi Agreements” and “Revenues from selling goods” sections. - [VIVS VivoSim Labs Inc](https://www.merlintrader.com/vivs-vivosim-labs-inc/): Real-time news feeds (RTTNews, MarketScreener, StockTitan, QuiverQuant) and broker dashboards show VIVS up roughly +70–100% in pre-market trading on 30 January 2026, with pre-market prices around 3.0 USD and, in some snapshots, higher peaks depending on the exact timestamp. Versus a previous close of 1.70 USD, this is a classic microcap “gap & squeeze” setting, driven by a mix of genuine news and positioning on a very small float. - [KYTX Kyverna Therapeutics Inc](https://www.merlintrader.com/kytx-kyverna-therapeutics-inc/): Deep dive (as of January 30, 2026) on Kyverna Therapeutics (KYTX): autologous CD19 CAR-T mivocabtagene (miv-cel, KYV-101) in autoimmune diseases, positive registrational KYSA-8 data in stiff person syndrome (SPS), RMAT/Fast Track designations, 2026 BLA ambitions and cash runway into 2027. Educational only, not investment advice - [TLSA Tiziana Life Sciences Ltd](https://www.merlintrader.com/tlsa-tiziana-life-sciences-ltd/): Tiziana Life Sciences is building an entire company around one idea: that intranasal delivery of a fully human anti-CD3 antibody, foralumab, can re-educate the immune system and cool down chronic neuroinflammation without broad systemic immunosuppression. - [QNCX Quince Therapeutics Inc](https://www.merlintrader.com/qncx-quince-therapeutics-inc-2/): Quince Therapeutics (QNCX) released topline results from its pivotal Phase 3 NEAT clinical trial of eDSP (EryDex) in Ataxia-Telangiectasia, a rare pediatric neurodegenerative and immunodeficiency disorder. The press release confirms that the study did not meet its primary endpoint on the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS), with insufficient separation versus placebo despite prior Phase 2 and ATTeST signals - [LUNR Intuitive Machines Inc](https://www.merlintrader.com/lunr-intuitive-machines-inc-jan/): Intuitive Machines is a Houston-based space infrastructure company working on lunar landers, cislunar communications and defense-focused satellite platforms. The stock is one of the purest public plays on the Artemis + Golden Dome “space infrastructure” theme. - [APLD Applied Digital](https://www.merlintrader.com/apld-applied-digital/): Applied Digital Corporation (Nasdaq: APLD) has emerged as one of the most talked-about names in the AI infrastructure space in 2026. Following a decisive pivot from Bitcoin mining and blockchain services (2021–2023) to purpose-built data centers for high-performance computing (HPC) and artificial intelligence workloads, the company has delivered explosive revenue growth - [AARD Aardvark Therapeutics Inc](https://www.merlintrader.com/aard-aardvark-therapeutics-inc/): Aardvark Therapeutics (AARD) is one of the more interesting new names in the rare-disease/obesity intersection: a clinical-stage biotech built around a gut-restricted small-molecule (ARD-101) targeting bitter taste receptors (TAS2Rs) to modulate hunger signaling. The core story is very focused: Prader–Willi syndrome (PWS), an ultra-rare genetic disease dominated by uncontrolled hyperphagia and weight gain, with ARD-101 in a pivotal Phase 3 trial (HERO) that has aligned with the FDA and is intended to support an NDA filing if successful. - [GUTS Fractyl Health Inc](https://www.merlintrader.com/guts-fractyl-health-inc-2/): “Good headline, bad read” session Fractyl reported 6-month randomized midpoint data from a blinded, sham-controlled cohort in REMAIN-1. The release highlights less weight regain vs sham, better cardiometabolic profile, and a De Novo pathway discussion. The stock is getting hit because traders are discounting the quality of the signal and the timeline. - [KALV KalVista Pharmaceuticals Inc](https://www.merlintrader.com/kalv-kalvista-pharmaceuticals-inc/): From “great science” to “great delivery”: Ekterly’s launch is now the purest real-world test of whether KalVista can turn first-in-class oral HAE convenience into durable cash flow before competition closes the gap. - [MBRX Moleculin Biotech](https://www.merlintrader.com/mbrx-moleculin-biotech/): Moleculin Biotech, Inc. (NASDAQ: MBRX) is a Phase 3 clinical-stage pharmaceutical company dedicated to developing innovative therapies for hard-to-treat tumors and viruses. The company's lead candidate, Annamycin, is advancing in the pivotal Phase 3 MIRACLE trial for relapsed/refractory acute myeloid leukemia (AML), with the first unblinding of data anticipated in Q1 2026. - [SER Serina Therapeutics Inc.](https://www.merlintrader.com/ser-serina-therapeutics-inc/): Serina Therapeutics is a clinical-stage biotechnology company based in Huntsville, Alabama, built around its proprietary POZ Platform, a drug optimization technology based on a controlled, water-soluble poly(2-oxazoline) polymer. The platform is designed to tune half-life, exposure and tissue distribution of small molecules, peptides and biologics, with the ambition of generating “best-in-class” dosing profiles versus conventional formulations. - [TVTX Travere Therapeutics Inc](https://www.merlintrader.com/tvtx-travere-therpeutics/): The FSGS decision remains a high-impact regulatory binary. The piece focuses on the run-up logic but does not remove the fundamental FDA risk from the picture. - [CAPR Capricor Therapeutics Update feb08](https://www.merlintrader.com/capr-capricor-therapeutics-update-jan28/): FDA asks for the full HOPE-3 clinical study report but does not require new trials, while Capricor prepares a February BLA update. The stock hovers around 23–24 $, with a market cap near 1.16 B$, after a 2025 rally fuelled by Duchenne data and aggressive retail positioning. - [RGNX Regenxbio Inc Update Jan28](https://www.merlintrader.com/rgnx-regenxbio-in-update-jan28/): FDA places a clinical hold on RGX-111 (MPS I) and RGX-121 (MPS II) programs after a single intraventricular CNS tumor in an RGX-111 patient. Preliminary analysis shows an AAV vector integration event near proto-oncogene PLAG1; causality is still under investigation. NAVSUNLI (RGX-121) BLA for MPS II remains under priority review with a PDUFA date of February 8, 2026; no public change to that date has been announced as of this report. - [Ondas (ONDS) Inc](https://www.merlintrader.com/ondas-optimus-drone/): Ondas Inc. (NASDAQ: ONDS) announced that the Optimus drone from its American Robotics unit has been added to the DCMA “Blue List” of approved unmanned aircraft systems. This confirms compliance with Department of War cybersecurity, supply chain and operational standards and opens a faster lane for U.S. government and defense procurement of Optimus. At Merlintrader we’ve been following Ondas for a while through this steep progression, and today’s move is another step in the transition from a niche wireless/IoT story towards a more clearly defined dual-use autonomous infrastructure profile. - [PDYN Palladyne AI Corp Update Jan 28](https://www.merlintrader.com/pdyn-palladyne-ai-corp-updatejan28/): Today’s move is all about a fresh U.S. Air Force Research Laboratory contract: the headline is “swarming,” but the real keyword is integration—getting drones, ships, ground systems, and now satellites to share ISR and coordinate as one network. Below: what happened, what it could mean, what can still go wrong, and the key numbers double-checked from SEC filings and official releases. - [ROCKET LAB (RKLB)](https://www.merlintrader.com/rocket-lab/): Rocket Lab is one of the few listed names sitting at the intersection of launch services, space infrastructure and US national security. In the last weeks, three threads have converged: a record defence contract for missile-tracking satellites, a visible test failure on the new Neutron rocket, and a high-visibility hardware milestone with the arrival of the “Hungry Hippo” fairing at the Virginia launch complex. - [CRDF Cardiff Oncology Inc](https://www.merlintrader.com/crdf-cardiff-oncology-inc/): As of January 27, 2026, Cardiff Oncology (NASDAQ: CRDF) is trading around 2 dollars per share after a single-session loss of roughly thirty-two percent. The trigger was a GlobeNewswire press release announcing that long-time Chief Executive Officer Mark Erlander and Chief Financial Officer James Levine are both stepping down, with board member Mani Mohindru becoming interim CEO and Senior Vice President of Finance Brigitte Lindsay moving up as interim CFO. - [NTLA Intellia Therapeutics Inc](https://www.merlintrader.com/ntla-intellia-therapeutics-inc/): As of January 27, 2026, Intellia Therapeutics (NASDAQ: NTLA) is back in the spotlight. The FDA has lifted the clinical hold on MAGNITUDE-2, the Phase 3 study of its in vivo CRISPR therapy nexiguran ziclumeran (“nex-z”, formerly NTLA-2001) in hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), while a separate large cardiomyopathy trial (MAGNITUDE, ATTR-CM) remains on hold after a Grade 4 liver event and a subsequent patient death triggered intense scrutiny. - [COYA Therapeutics Holdings Inc](https://www.merlintrader.com/coya-therapeutics-holdings-i/): COYA Therapeutics Holdings represents a high-risk opportunity in the biotech sector, focused on developing innovative therapies for neurodegenerative and autoimmune diseases through regulatory T-cell (Treg) modulation. With a pipeline including candidates for ALS, Alzheimer's, and other complex pathologies, the company positions itself in a therapeutic area with significant unmet medical needs but also with high clinical failure rates. - [KURA Kura Oncology Inc](https://www.merlintrader.com/kura-oncology-inc/): Kura Oncology is a precision oncology company built around one central thesis: targeting oncogenic signalling nodes such as menin and farnesyl transferase can reset the biology of hard-to-treat cancers, especially acute myeloid leukemia (AML). - [RDW Redwire Corporation](https://www.merlintrader.com/rdw-redwire-corporation/): Redwire is moving from niche space supplier to integrated space-and-defense player just as the Golden Dome and SHIELD architectures turn from political slogan into multi-decade procurement programs. The stock has already rerated on expectations; the question now is whether cash flow, backlog and contract wins will catch up with the narrative. - [ATYR Atyr Pharma Inc](https://www.merlintrader.com/atyr-pharma-inc/): aTyr Pharma ($ATYR) is a clinical-stage biotech developing first-in-class therapies from its tRNA synthetase platform, targeting fibrotic and inflammatory lung diseases. The company's lead asset, efzofitimod (a selective NRP2 modulator), suffered a major setback with the Phase 3 EFZO-FIT trial miss in pulmonary sarcoidosis (announced Sept 15, 2025), causing an ~80% stock drop from ~$4-5 to sub-$1 levels. - [VNDA Vanda Pharmaceuticals Inc](https://www.merlintrader.com/vnda-vanda-pharmaceuticals-inc-2/): Vanda is not a pre-revenue biotech: it is a commercial-stage CNS company with three marketed products (Fanapt, Hetlioz, Ponvory) and two late stage assets that matter for the next 12–24 months: Nereus (tradipitant) for motion sickness, now approved, and Bysanti (milsaperidone) with a PDUFA target action date on 21 February 2026 for schizophrenia and bipolar I disorder. - [VRDN Viridian Therapeutics Inc](https://www.merlintrader.com/vrdn-viridian-therapeutics-inc-2/): Viridian Therapeutics (VRDN) has started 2026 by reaffirming its "transformational" year narrative in the January 6 PR, which serves as a comprehensive roadmap update without any timeline shifts or negative surprises. This builds directly on the December 22, 2025 BLA acceptance for veligrotug (VRDN-001) in TED with Priority Review and PDUFA target of June 30, 2026 (as detailed in the previous report). - [Celcuity (Nasdaq: $CELC) Stock Hub: FDA-Approved REVTORPYK, Launch Outlook, VIKTORIA-1 and Next Catalysts](https://www.merlintrader.com/celc-celcuity-inc/): Latest verified update · July 22, 2026 Celcuity is now a commercial-stage oncology launch story after REVTORPYK approval Celcuity crossed a major threshold on July 14, 2026 with FDA approval of REVTORPYK™ / gedatolisib for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer after progression on or after endocrine therapy. The next debate is not whether […] - [RGNX Regenxbio](https://www.merlintrader.com/rgnx-regenxbio/): RGX-121 puts Regenxbio at the threshold of its first potential standalone approval, while the retina (AbbVie) and Duchenne programs build a second and third pillar for 2026–2027. The equity story is a classic “platform + royalty + binary PDUFA” mix, with a balance sheet extended into early 2027 via upfronts and royalty monetization. - [CVKD Cadrenal Therapeutics Inc](https://www.merlintrader.com/cvkd-cadrenal-therapeutics-inc/): Cadrenal Therapeutics (NASDAQ: CVKD) is a clinical-stage biopharma headquartered in Ponte Vedra, Florida, focused on anticoagulation solutions for high-risk patients who are poorly served by current therapies. The company was formed in 2022 around tecarfarin and, through two 2025 acquisitions, has expanded into a broader platform combining VKA, Factor XIa and 12-LOX mechanisms. - [Weekly Briefing – Fed, Geopolitics, GLP-1 Obesity & Small Caps](https://www.merlintrader.com/weekly-briefing-jan-26/): Going into the 27–28 January FOMC, the message is basically “don’t expect fireworks”: after the 2025 cuts, the Fed keeps describing policy as “well positioned”, with inflation gliding down towards (but not yet at) target and real growth still positive. Futures now see a very high probability of a clean hold next week and push the bulk of any extra easing into late 2026. - [Biotech Catalyst Calendar February 2026: PDUFA, BLA & Clinical Results](https://www.merlintrader.com/biotech-catalyst-calendar-february-2026/): Biotech Catalyst Calendar February 2026: PDUFA, BLA & Clinical Results One-page view of the key February 2026 biotech catalysts: only one line per ticker, grouped by date. Fixed PDUFA and BLA events are listed first; the others are February-window guidance from company and Street sources. - [NMRA Neumora Therapeutics](https://www.merlintrader.com/nmra-neumora-therapeutics/): Deep dive on Neumora Therapeutics (NMRA): navacaprant reset, NMRA-511 Alzheimer’s agitation data, M4 franchise and a 2026–2027 catalyst map for biotech run-up traders. Educational only, not investment advice. - [IOVA Iovance Biotherapeutics Inc](https://www.merlintrader.com/iova/): Iovance Biotherapeutics (IOVA) – From first TIL approval to industrial stress-test in solid tumors (Playbook 2026–2027) | Merlintrader trading Blog Merlintrader trading Blog – RunUP Biotech EN IT IOVA – Iovance Biotherapeutics (NASDAQ) Static daily chart from Finviz – click to open full view Chart courtesy of Finviz.com. Educational use only, not investment advice. Ticker: […] - [ETON  Pharmaceuticals Inc](https://www.merlintrader.com/eton-pharmaceuticals-inc/): After years of being “just a pipeline story”, Eton has transitioned into a small but diversified rare-disease platform with multiple approved assets and a focused late-stage pipeline anchored by ET-400 and ET-600. - [AQST & PHAR -Countdown Jan 31 PDUFA](https://www.merlintrader.com/aqst-phar-pdufa-jan31/): We are on Friday, January 23, 2026 (Italy time). For January, in your catalyst tracker there are essentially two PDUFAs still “missing” that matter for this piece: Aquestive (AQST) with Anaphylm and Pharming (PHAR) with the pediatric Joenja sNDA (4–11 years, APDS). Both currently carry a PDUFA target action date of January 31, 2026. - [Space Defence & AI](https://www.merlintrader.com/space-defence-ai/): When you line up the numbers on artificial intelligence in space operations, autonomous systems and new-generation missile defence, it becomes very clear we are not looking at a “nice theme” to trade for a few quarters. We are watching the birth of a structural, AI-native arms race that stretches easily over the next 20–30 years. - [KPTI Karyopharm Therapeutics](https://www.merlintrader.com/kpti-karyopharm-therapeutics/): At the dawn of 2026, Karyopharm Therapeutics stands at a critical inflection point that will determine not only near-term share performance, but in many respects the long-term viability of the company. After spending the last five years building a commercial foothold in late-line relapsed/refractory multiple myeloma, Karyopharm has repositioned the selinexor franchise toward two potentially transformative Phase 3 readouts: the SENTRY trial in myelofibrosis and the XPORT-EC-042 trial in endometrial cancer maintenance. - [IONS Ionis Pharmaceuticals](https://www.merlintrader.com/ions-ionis-pharmaceuticals/): Ionis is one of the long-standing pioneers of antisense oligonucleotide (ASO) therapeutics. Founded in 1989, the company has taken antisense from a controversial idea to an approved therapeutic class with multiple marketed products and a deep late-stage pipeline. - [HELP Helus Pharma Inc](https://www.merlintrader.com/help-helus-pharma-inc/): Helus Pharma is the new brand for Cybin, now trading under the ticker HELP on the Nasdaq Global Market and on Cboe Canada. The company is trying to position itself as a “psychedelic 2.0” / mental-health pure play, built around proprietary novel serotonergic agonists (NSAs) rather than classic psychedelic molecules - [BMEA Biomea Fusion Inc](https://www.merlintrader.com/bmea-biomea-fusion-inc/): Biomea Fusion has quietly morphed from an oncology story into a pure diabetes and obesity medicines company, with a potentially first-in-class oral menin inhibitor (icovamenib) for insulin-deficient type 2 diabetes and an oral GLP-1 receptor agonist (BMF-650) aimed at obesity. 2026 is all about execution: Phase II programs in T2D, first human weight-loss data for BMF-650 and a cash runway that, after the 2025 down-rounds and cost cuts, now stretches into 2027. - [FULC Fulcrum Therapeutics Inc](https://www.merlintrader.com/fulc-fulcrum-therapeutics-2/): This note is a follow-up to the previous Merlintrader deep dive on Fulcrum Therapeutics (link to the earlier report). Since then, Fulcrum has reshaped its story around pociredir, an oral HbF inducer for sickle cell disease (SCD), delivered a series of positive PIONEER data updates and, crucially, raised fresh capital to extend runway well beyond the next set of readouts. - [ALT Altimmune Inc](https://www.merlintrader.com/alt-altimmune-inc-jan21/): As of the afternoon session on 21 January 2026, Altimmune is trading around 4.5–4.6 USD, up roughly 9% versus the prior close. Volumes are clearly above a quiet day but not at “capitulation” or “meme-stock” levels. There is no new 8-K or press release dated today, and the official IR feed has not dropped fresh clinical or corporate news. - [LXRX Lexicon Pharmaceuticals Inc](https://www.merlintrader.com/lxrx-lexicon-pharmaceuticals-inc-2b/): From INPEFA reset to pilavapadin, SONATA-HCM, Zynquista and LX9851: a compact roadmap for the next 18–24 months. - [ONDS Ondas Inc](https://www.merlintrader.com/onds-ondas-inc/): Five Wall Street firms push targets to the 16–25 USD band on the back of Ondas’ 2026 ramp story – while the stock trades around the low teens after a 500%+ 12-month run. - [BNAI Brand Engagement Network update jan 21](https://www.merlintrader.com/bnai-brand-engagement-network-update-jan-21/): Brand Engagement Network (BNAI) – Africa AI Licensing Daily Hit | Merlintrader trading Blog Daily Hit – quick EN / IT snapshot on BNAI’s Africa AI licensing deal. Daily Hit – panoramica rapida EN / IT sull’accordo di licensing AI in Africa di BNAI. EN IT BNAI · Brand Engagement Network Africa AI Licensing Daily […] - [NVAX Novavax and Pfizer](https://www.merlintrader.com/nvax-novavax-and-pfizer/): The short version: Novavax is no longer just fighting for survival as a COVID single-product story. With Sanofi first and Pfizer now, Matrix-M is slowly turning into a royalty platform. The balance sheet is still tight and the story remains binary, but the “all-or-nothing” risk has shifted a bit more towards “long-duration option on partner execution”. - [GUTS Fractyl Health Inc Update jan 20](https://www.merlintrader.com/guts-fractyl-health-in-updatejan20/): Fractyl Health is a small-cap metabolic therapeutics company listed on Nasdaq under the ticker GUTS. The company’s core bet is that a one-time endoscopic procedure on the duodenum, combined eventually with gene therapy, can offer a durable “off-ramp” for patients who need or want to come off GLP-1 drugs but would otherwise regain weight quickly. - [US Airline Sector 2026](https://www.merlintrader.com/us-airline-sector-2026/): The U.S. airline sector in early 2026 is the product of two overlapping cycles. The first is the post-COVID recovery wave: a violent rebound in demand, especially leisure and international, that allowed the big carriers to refill their cash tanks, repair balance sheets and renegotiate labor. The second is the return of classic airline constraints: high capital intensity, structurally volatile fuel costs, periodic labor shocks and the need to keep debt under control without sacrificing network relevance. - [SHPH Shuttle Pharmaceuticals Holdings Inc](https://www.merlintrader.com/shph-shuttle-pharmaceuticals-holdings-inc/): The 2026 biotech landscape is increasingly bifurcated between traditional development stories and “tech-bio” platforms that use AI to de-risk and compress timelines. Shuttle Pharmaceuticals positions itself at this intersection: a small oncology company built around radiosensitizers and a newly acquired AI platform, Molecule.ai, targeting the problem of radio-resistant tumors and inefficient drug development. - [CRVS Corvus Pharmaceuticals Inc](https://www.merlintrader.com/crvs-corvus-pharmaceuticals-inc/): Corvus Pharmaceuticals is a clinical-stage biotech now almost entirely defined by soquelitinib, an oral, highly selective ITK inhibitor designed to “rebalance” T-cell responses. The drug sits at the intersection of two very different but complementary franchises: inflammatory skin disease (atopic dermatitis) and T-cell lymphomas (PTCL and related entities). - [GERN Geron Corp](https://www.merlintrader.com/gern-geron-corp-2026/): Geron enters 2026 as a newly minted commercial hematology company with one marketed product, RYTELO (imetelstat), and a late-stage program that could pivot the story from niche LR-MDS anemia to broader myelofibrosis survival if the Phase 3 IMpactMF study delivers. - [IBRX ImmunityBio](https://www.merlintrader.com/ibrx-immunitybio/): Over the last few weeks ImmunityBio has done pretty much everything a biotech can do to light up screens: big revenue jump, new regulatory approvals and sexy cell-therapy data. The stock has reacted exactly the way you would expect in a heavily shorted name – vertical move, news sites still talking about it days later, social media on fire. In this piece we are going to do something boring but necessary: stack all the verifiable positives (with links), then put them next to the very real risks. Only at the end we’ll talk about the “everybody is still pushing this story” part and why that’s exactly the moment when you want to cool your head. - [BNAI Brand Engagement Network DeepDive](https://www.merlintrader.com/bnai-brand-engagement-network-deepdiv/): AI platform targeting highly regulated clients. Q4 2025 marked a “turning point”: a top-10 pharma engagement project, the Skye Salud sovereign healthcare JV in Mexico, and a first step in cleaning up a heavily diluted balance sheet. - [Novocure’s TRIDENT Miss: Why the Glioblastoma Setback Matters for the $NVCR Pipeline](https://www.merlintrader.com/nvcr-novocure-ltd/): Novocure’s Phase 3 TRIDENT study did not show a statistically significant overall-survival advantage for starting Tumor Treating Fields earlier during chemoradiation in newly diagnosed glioblastoma. The result is not a collapse of the TTFields platform, but it is a serious reset for the near-term narrative: the company must now prove that its growth story can be carried by commercial execution, pancreatic cancer, brain metastases from NSCLC, and the next wave of combination trials. - [ATOS Atossa Therapeutics Inc](https://www.merlintrader.com/atos-atossa-therapeutics-inc/): Atossa Therapeutics is a small-cap, clinical-stage biotech built around a single platform asset, the oral selective estrogen receptor modulator (SERM) (Z)-endoxifen. Until 2025 the investment story was mostly about breast cancer treatment and risk reduction, but in the last few months the company has opened a new front in Duchenne muscular dystrophy (DMD). - [OGN Organon & Co](https://www.merlintrader.com/ogn-organon-co/): The FDA has approved an extension of the indicated duration of Nexplanon (etonogestrel implant) up to 5 years for the prevention of pregnancy, versus the previous 3-year label. Nexplanon is the flagship long-acting reversible contraception (LARC) product of Organon and one of the core pillars of its Women’s Health division. - [Weekly Recap and Briefing Jan 12-17](https://www.merlintrader.com/weekly-recap-and-briefing-jan-12-17/): eek of 12–17 January 2026 – a structured overview of what is really moving markets, geopolitical risk and the most talked-about tickers. - [NVAX Novavax Inc at JPM CC](https://www.merlintrader.com/nvax-novavax-inc-jpm26/): Why this NVAX update after JPM 2026 Novavax is a rare case where the narrative matters almost as much as the numbers. The company went from “late Covid vaccine laggard” to “maybe dead”, then back to life thanks to a sequence of deals and restructurings. The 44th J.P. Morgan Healthcare Conference was the moment where CEO John Jacobs tried to lock in a new story: Novavax as a lean, partner-driven, Matrix-M platform company with a visible (not guaranteed) path to sustainability. - [ONDS Ondas Holdings Inc update jan 17](https://www.merlintrader.com/onds-ondas-holdings-inc-update-jan17/): Why it is a “stock of the moment” ONDS is one of the most closely watched names in the community: explosive rally, very strong narrative around Israel/defense, and now an Investor Day that pushes the bar even higher with 2026 guidance and very aggressive 5-year targets. It is a classic case where enthusiasm and risk coexist: great to follow, dangerous to underestimate. - [RZLV Rezolve AI Limited](https://www.merlintrader.com/rzlv-rezolve-ai-limited/): Rezolve AI (RZLV) – Agentic commerce hype vs. fragile fundamentals Generative-AI retail platform guiding to explosive revenue growth, but starting from tiny 2024 sales, heavy losses and limited cash. - [POET Technologies Inc](https://www.merlintrader.com/poet-technologies-inc-2/): This article is the natural continuation of the analysis published on January 3, 2026 on Merlintrader. Since then, POET has gone through a very busy few weeks: a strong share price move, intense options activity, fresh buzz around AI photonics, the long shadow of Marvell’s acquisition of Celestial AI, and a stream of unconfirmed rumours in retail communities. - [IBRX - CGON - ENGN - NMIBC bladder-sparing race](https://www.merlintrader.com/ibrx-cgon-engn/): igh-risk non-muscle-invasive bladder cancer after failure of BCG has become one of the hottest oncology niches of 2025–2026. ImmunityBio with ANKTIVA is already on the market, while CG Oncology and enGene are coming fast with late-stage programs. This report compares mechanisms, clinical data, timelines and sentiment, so traders can look beyond the single name that is dominating the headlines in these weeks. - [ASND Ascendis Pharma](https://www.merlintrader.com/asnd-ascendis-pharma/): Achondroplasia already has one FDA-approved therapy on the market (BioMarin’s Voxzogo), so TransCon CNP is a “second entrant” story. That means the regulatory decision matters, but so will positioning, differentiation, and adoption post-approval. - [JFBR Jeffs Brands Ltd](https://www.merlintrader.com/jfbr-jeffs-brands-ltd/): Jeffs’ Brands Ltd is a tiny Israeli micro-cap originally built around a data-driven Amazon FBA portfolio. That legacy business is still there: roughly $13.7M revenue in FY2024 against a net loss of about $7.8M, with a very small equity value and high operating leverage. The last twelve months have been brutal for long-term holders, with a price trajectory closer to a ski slope than a growth story. - [OCUL Ocular Therapeutix Inc](https://www.merlintrader.com/ocul-ocular-therapeutix-ic/): Daily Hit on Ocular Therapeutix after the latest spike on renewed takeover chatter and ahead of the 52-week phase 3 SOL-1 readout for AXPAXLI (suprachoroidal axitinib). Cash-heavy balance sheet, a single pivotal asset at the centre of the story, and a market now trying to price both M&A optionality and binary clinical risk. - [PDYN Palladyne AI Corp update jan 15](https://www.merlintrader.com/pdyn-palladyne-ai-corp-update-jan-15/): Defense & Industrial AI – 2026 Inflection Plan Embedded AI autonomy for defense and industrial operators (IQ 2.0, UAV swarms, advanced avionics, precision manufacturing). Analysis updated after Needham 2026 & new revenue guidance. - [IBRX ImmunityBio Inc Update jan 14](https://www.merlintrader.com/ibrx-immunitybio-inc-update-jan14/): Deep-dive update on ImmunityBio after the Saudi Food and Drug Authority granted approval to ANKTIVA + BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, on top of existing approvals in the U.S., U.K. and conditional approval in the EU. Focus on the non-muscle invasive bladder cancer franchise, commercial trajectory, balance sheet and the next catalysts around QUILT-3.032 and QUILT-2.005. - [OMER - Omeros – YARTEMLEA TA-TMA launch](https://www.merlintrader.com/omer-omeros/): Short update on Omeros after the FDA approval of YARTEMLEA (narsoplimab-wuug) for TA-TMA, the start of the U.S. launch and the analyst upgrades published in early January 2026. For the full story, background and detailed scenarios, see the main OMER reports on Merlintrader. - [VKTX Viking Therapeutics Inc](https://www.merlintrader.com/vktx-viking-therapeutics-inc-3/): Short update on VK2735 after the Phase 2 VENTURE data were published in the journal Obesity and after CEO Brian Lian’s comments at the J.P. Morgan Healthcare Conference 2026. For the full story, fundamentals and detailed scenarios, see the main VKTX report on Merlintrader. - [BCTX BriaCell Therapeutics](https://www.merlintrader.com/bctx-briacell-therapeutics/): BriaCell Therapeutics (BCTX) is the definition of a high-beta biotech: a tiny, heavily dilutive, clinical-stage immuno-oncology company with a real science story, now colliding head-on with a brutal funding reality. On January 13, 2026, the company reported an 11-month sustained complete resolution of a lung metastasis in a 78-year-old metastatic breast cancer patient treated with Bria-OTS in Phase 1/2a – no dose-limiting toxicities, stable disease at other sites, Phase 1 completed and Phase 2a combo underway. That headline sent the stock vertical. Within hours, BriaCell followed up with a $30M best-efforts public unit offering at $5.59 per unit, each unit including one common share (or pre-funded) + one listed warrant at $6.93 (BCTXL) with five-year maturity. The market’s response: a pre-market gap down to ~$5.0, more than -50% vs the prior close at $10.92, and a reset of the whole technical picture. - [BNAI Brand Engagement Network Inc](https://www.merlintrader.com/bnai-brand-engagement-network-inc/): AI platform for regulated clients. Q4 2025 pivot built on a top-10 pharma engagement project, the Skye Salud sovereign healthcare JV in Mexico and a first step of balance-sheet clean-up with Nasdaq compliance restored. - [NRXP NRX Pharmaceuticals Inc](https://www.merlintrader.com/nrxp-nrxx-pharmaceuticals/): NRx has licensed a nationwide Real-World Evidence dataset from Osmind covering more than 70,000 patients treated with IV ketamine or intranasal esketamine for major depression with suicidal ideation. The full analysis will be submitted to the FDA in support of an Accelerated Approval application for NRX-100, the preservative-free ketamine IV formulation already under Fast Track Designation for suicidal ideation in depression and bipolar depression. - [Briefing Space-AI-Defence stocks jan 14](https://www.merlintrader.com/briefing-space-ai-defence-stocks-jan-14/): Briefing Space-AI-Defence stocks Jan 14 Daily overview on defence, space and AI-linked military names: Grok enters Pentagon networks, MBDA strengthens its position in Brazil and space small caps swing between rational euphoria and technical risk. - [TVTX Travere Therapeutics Inc UPDATE jan 13 PDUFA Extension to april 13 2026](https://www.merlintrader.com/tvtx-travere-therapheutics-inc/): Travere confirmed that the PDUFA date for the FILSPARI sNDA in FSGS is January 13, 2026. In the latest corporate update (press release) and at the JPM conference, management explained that the FDA recently sent a series of additional information requests “to further characterize the clinical benefit of FILSPARI” and that Travere has now submitted complete responses, which are under review. - [XAIR Beyond Air Inc](https://www.merlintrader.com/xair-beyond-air-inc/): Beyond Air (XAIR) – Nitric Oxide Platform, NeuroNOS Deal and LungFit PH Expansion | Merlintrader trading Blog IT EN Beyond Air (XAIR) – Nitric oxide platform, NeuroNOS deal and a 170% day Beyond Air (XAIR) is a commercial-stage medtech/biopharma company built around the LungFit® nitric oxide platform and a set of spinoff programs (oncology and […] - [OCGN Ocugen Inc](https://www.merlintrader.com/ocgn-ocugen-inc-3/): Ocugen has been rallying on rising price and volume, trading close to its 52-week high. The key trigger is the official announcement of a January 15, 2026 webcast to discuss 12-month data from the Phase 2 ArMaDa trial of OCU410 in GA, as outlined in the company’s press release - [BCTX BriaCell Therapeutics Corp](https://www.merlintrader.com/bctx-briacell-therapeutics-corp/): In its January 13, 2026 press release, BriaCell announced the durable and sustained complete resolution of a lung metastasis in a patient treated with Bria-OTS™ (off-the-shelf personalized immunotherapy). The release describes a 78-year-old woman with metastatic breast cancer who achieved complete resolution after four doses of Bria-OTS monotherapy, with confirmation out to 11 months. - [QNCX Quince Therapeutics Inc](https://www.merlintrader.com/qncx-quince-therapeutics-inc/): NEAT is clearly positive, Quince can be re-rated as a near-launch rare-disease company with credible billion-dollar potential and strategic appeal. If NEAT fails or is weak, equity value could be severely impaired given the single-asset focus, limited cash and EIB debt. - [FBIO Fortress Biotech Inc](https://www.merlintrader.com/fbio-fortress-biotech-inc/): Focus: FDA approval of Zycubo (copper histidinate, ex CUTX-101) as first treatment for Menkes disease in children – monetisation of milestones, royalties and potential PRV for Fortress/Cyprium. - [TVTX Travere Therapeutics Inc](https://www.merlintrader.com/tvtx-travere-therapeutics-inc/): Today is about one thing: uncertainty around the FDA decision timing/outcome for the FILSPARI FSGS sNDA. The company explicitly highlighted FDA information requests right before the target date. - [PL Planet Labs PBC](https://www.merlintrader.com/pl-planet-labs-pbc-3/): Focus: multi-year low 9-figure Satellite Services contract with the Swedish Armed Forces – third sovereign-space deal in 12 months, >$500M combined. - [TENX Tenax Therapeutics Inc](https://www.merlintrader.com/tenx-tenax-therapeutics-inc/): Tenax Therapeutics (TENX) – Deep Dive / Analisi Approfondita (Jan 2023 – Oggi) Tenax Therapeutics (TENX) – Deep Dive / Analisi Approfondita (Jan 2023 – Oggi) Full deep dive on TENX: financials, pipeline, catalysts, shareholder structure, insider activity, dilution, analyst views, retail sentiment and CEO profile. Deep dive completo su TENX: dati finanziari, pipeline, catalyst, […] - [IDYA Ideaya Biosciences Inc](https://www.merlintrader.com/idya-ideaya-biosciences-inc/): Precision oncology company built around synthetic lethality, with darovasertib in uveal melanoma and a broad pipeline (MAT2A, PRMT5, PARG, ADCs) backed by more than 1.1 billion dollars in cash and a guided runway into 2030. - [RCKT Rocket Pharmaceuticals ](https://www.merlintrader.com/rckt-rocket-pharmaceuticals/): Focus: FDA PDUFA for KRESLADI™ (LAD-I) on March 28, 2026 – gene therapy, rare pediatric disease. - [ATRA Atara Biotherapeutics Inc Jan 12 Update](https://www.merlintrader.com/atra-atara-biotherapeutics-inc-jan-11-update/): Yesterday’s report framed ATRA around a PDUFA-window setup, with the assumption that the 2025 CRL was primarily a CMC/GMP story and that the ALLELE trial remained acceptable as the pivotal efficacy dataset. Today that premise is broken: the FDA has issued a second Complete Response Letter (CRL) for tabelecleucel/tab-cel in EBV+ PTLD. - [Market Review | Preview for the Week of Jan 12](https://www.merlintrader.com/market-review-preview-for-the-week-of-jan-12/): Biotech catalysts, small-cap rotation, space & defence names already on the Merlintrader radar, Trump factor, geopolitics (Ukraine, Red Sea, Venezuela, Greenland) and J.P. Morgan Healthcare Conference 2026. - [SANA Biotechnology](https://www.merlintrader.com/sana-biotechnology/): As of January 10, 2026, Sana Biotechnology (NASDAQ: SANA) stands as a clinical-stage pioneer focused on the development of engineered cells as a new modality of medicine. Founded on the belief that cell therapy will follow small molecules and biologics as the "third pillar" of therapeutics, Sana has built a platform to address the two primary bottlenecks of the industry: Immune Evasion and Scalable Manufacturing. - [Ocular Therapeutix Inc ( $OCUL) Feb25 Update : superiority achieved, durability confirmed, what comes next](https://www.merlintrader.com/ocular-therapeutics-inc-feb25-update/): Phase 3 SOL-1 delivered the first statistically significant superiority versus an approved anti-VEGF in wet AMD, with year-long durability from a single injection and a clean safety profile. The market reaction has been volatile; the strategic picture for the next 24–36 months is clearer than the tape suggests. - [Geron Corp ( $GERN ) Good Year, Tough Quarter Feb 2026](https://www.merlintrader.com/geron-corp-gern-good-year-tough-quarter-feb-2026/): The first full commercial year of RYTELO brought ~$184M in revenue and a growing base of prescribing centers, but a softer Q4 versus expectations and unchanged 2026 guidance triggered a sharp pullback in the stock. Here is what actually happened, why the market reacted this way, and how it fits into the long-term thesis we’ve been following on Merlintrader. - [Rocket Lab and DART AE($RKLB) The night Australia aims for its first hydrogen scramjet flight (Updated feb26)](https://www.merlintrader.com/rocket-lab-australian-night/): On many launch days at Wallops, you could drive past Launch Complex 2 and, at a glance, not realise that a rocket is waiting. The Atlantic haze flattens the horizon, the gantry is half-hidden in mist and sodium lights, and only the traffic at the gate and the rhythm of the countdown clocks betray that something is about to happen. Today, that something is a little different from the usual satellite run. - [SoundHound AI Inc ($SOUN)](https://www.merlintrader.com/soundhound-ai-inc-feb2026/): SoundHound AI started as a voice and music-recognition company and gradually evolved into a broader conversational-AI provider. It now positions itself as a global platform for voice and agentic AI, powering restaurant phone ordering and drive-thrus, in-car voice assistants, smart devices and enterprise customer-service agents across financial services, healthcare, retail and more. - [Alpha Tau Medical Ltd ($DRTS)](https://www.merlintrader.com/alpha-tau-medical-japan-approval-feb2026/): Alpha Tau Medical is trying to build an entire platform around one idea: using very short-range, high-energy alpha particles to burn tumors from inside the lesion, instead of bathing a large region of the body in external radiation. With the Japanese Ministry of Health, Labour and Welfare (MHLW) now granting full Shonin marketing approval for Alpha DaRT in unresectable, locally advanced or locally recurrent head and neck cancer, the company has just obtained its first real proof that regulators outside Israel are willing to treat this as a commercial therapy, not only an experimental one. - [Edesa Biotech ($EDSA)](https://www.merlintrader.com/edesa-biotech/): Edesa Biotech (NASDAQ: EDSA) is a clinical-stage biopharmaceutical company developing host-directed therapeutics (HDTs) – drugs that modulate the body's own immune response rather than targeting a specific pathogen. The company's lead asset, paridiprubart (EB05), is a first-in-class anti-TLR4 monoclonal antibody being evaluated as a treatment for Acute Respiratory Distress Syndrome (ARDS). - [Iovance Biotherapeutics Inc ($IOVA)](https://www.merlintrader.com/iovance-biotherapeutics-fen24/): As of February 24, 2026, Iovance Biotherapeutics is a small-cap oncology company (~$1.5B market cap) focused on TIL cell therapies for solid tumors, with AMTAGVI (lifileucel) already approved in the U.S. for advanced melanoma and a growing pipeline exploring TIL in other indications, including soft-tissue sarcomas. The stock trades around $3.80 with roughly 364M shares outstanding, after a volatile path that has seen heavy dilution in past years but now combines commercial revenues (~$264M FY25) with a cash runway into Q3 2027 thanks to cost controls and better gross margins on AMTAGVI. The new 50% objective response rate (ORR) in the very difficult setting of advanced UPS/DDLPS sarcomas is what the market is reacting to right now. - [AST SpaceMobile ($ASTS) — HALO Europa: $30M SDA prototype award](https://www.merlintrader.com/ast-spacemobile-asts-halo-europa-30m-sda-prototype-award/): ASTS AST SpaceMobile Open chart SEC filings Chart: static image. Click opens Finviz (affiliate link applied only on click). AST SpaceMobile (ASTS) — HALO Europa: $30M SDA prototype award, what it signals, what to watch Deep Dive “ALDX-signed”, mobile-first, light theme. Focus: the official SDA award + the company’s current funding posture and near-term catalysts. […] - [Fortress Biotech Inc ($FBIO)](https://www.merlintrader.com/fortress-biotech-inc-prv200m/): Fortress Biotech (NASDAQ: FBIO) is a diversified biopharmaceutical company with a unique portfolio acquisition and value-creation model. Rather than pursuing a single blockbuster drug, Fortress systematically acquires, advances and partners assets across oncology, dermatology and rare diseases, generating returns through product revenue, equity holdings, royalties and strategic asset sales. - [SELLAS Life Sciences Group Inc ($SLS) Updated feb 23](https://www.merlintrader.com/sellas-life-sciences-group-feb23/): SELLAS Life Sciences Group (NASDAQ: SLS) is a clinical‑stage biotechnology company focused on cancer immunotherapies and targeted therapies. The current story is driven by the cancer vaccine galinpepimut‑S (GPS), a Wilms Tumor 1 (WT1)–targeting immunotherapy, and by a CDK9 inhibitor program for hematologic and solid tumors. - [ImmunityBio Inc Logbook Feb 23 / It Could Not Be Missing](https://www.merlintrader.com/immunitybio-inc-feb23/): The latest BusinessWire release finally puts hard numbers and structure around what we had already been tracking on IBRX: ~113 million USD of ANKTIVA net product revenue in 2025 (~700% year-over-year), ~750% unit growth, a regulatory footprint in 33 countries across four major jurisdictions, the first lung cancer approval in Saudi Arabia in combination with checkpoint inhibitors, and explicit patent protection for ANKTIVA combinations beyond 2035. On top of that, management now frames a clear three-year strategy with ANKTIVA as a “backbone” immunotherapy across multiple tumor types. - [Rackspace Technology (RXT) – AI Turnaround Story After the Palantir Partnership](https://www.merlintrader.com/rackspace-technology/): Rackspace Technology (NASDAQ: RXT) is a heavily leveraged hybrid multicloud and managed services provider that is trying to reposition itself as an “AI-first” infrastructure and operations partner. After years of revenue decline, recurring losses and a difficult competitive landscape, the February 18, 2026 strategic partnership with Palantir has triggered a violent rerating of the stock and reopened the turnaround debate. - [ADMA Biologics ($ADMA) meeting or exceeding guidance Feb25?](https://www.merlintrader.com/adma-biologics-feb23/): ADMA Biologics (NASDAQ: ADMA) is a commercial-stage biopharmaceutical company specializing in plasma-derived immunoglobulins for the treatment of patients with primary humoral immunodeficiency (PI) and others at risk of certain infections. The company operates a fully integrated business model encompassing plasma collection, fractionation, manufacturing and commercialization. - [Ardelyx Inc (ARDX) Growth is real, panic is optional: what Q4 2025 earnings really say](https://www.merlintrader.com/ardelyx-inc-feb22/): The market reaction to Ardelyx’s Q4 2025 earnings was simple and brutal: the stock lost roughly fifteen percent in the days after the print, sending a message that “something is wrong”. If you stop at the chart, it looks like a broken story. If you read the filings, the picture is very different: this is a company that is clearly growing, but still paying a high price in operating expenses to sustain that growth. - [AI retail and Merlintrader](https://www.merlintrader.com/ai-retail-merlintrader/): When people talk about artificial intelligence in trading and investing, I almost always see two opposite – and both wrong – reactions. On one side you have those who demonise it by default: “it’s dangerous”, “it fills your head with nonsense”, “it’s useless, markets are moved by others anyway”. On the other side you have those who treat it like a modern oracle: “tell me what to buy”, “give me the next 10-baggers”, “build me the perfect watchlist”. I work with AI every single day to build Merlintrader’s content, and I can tell you something very simple: the truth is neither here nor there. AI is not an enemy to fight, and it’s not a guru to worship. It is a tool. Extremely powerful if you use it well. Dangerous if you use it badly. Useless if you ignore it. - [Weekly Recap & Briefing – Biotech, Space, Defense & AI Feb 21 2026](https://www.merlintrader.com/weekly-recap-feb21-2026/): This week’s recap walks through a classic “binary” market: indices inch higher while gold hits new records and oil creeps up on tariff and Iran risk. In biotech we see clean wins (VNDA, Telix) versus brutal setbacks (GRAIL, RGNX), while defense and space keep riding record military spending and drone/missile contracts. The briefing for February 23–28 closes with what really matters next: Nvidia’s earnings, the U.S. PPI print, and the first concrete signs from the Pentagon’s USD 1.1bn drone program. - [Vanda Pharmaceuticals Inc ($VNDA)](https://www.merlintrader.com/vanda-pharmaceuticals-inc-bysanti-approval/): The FDA has approved BYSANTI™ (milsaperidone) tablets as a first-line atypical antipsychotic for the acute treatment of manic or mixed episodes in bipolar I disorder and for the treatment of schizophrenia in adults. This is Vanda’s second FDA approval in under two months, following NEREUS™ for motion-induced vomiting prevention. - [LightPath Technologies (LPTH) – Q2 FY2026 Surge and Strategic Catalysts](https://www.merlintrader.com/lightpath-technologies/): ?? English ?? Italiano NASDAQ: LPTH · Optics & Photonics · Defense & Commercial LightPath Technologies (LPTH) – Q2 FY2026 Surge and Strategic Catalysts Comprehensive report on LightPath Technologies: Q2 FY2026 results, financial position, strategic backlog and growth scenarios for 2026-2027. ? Report Date: February 21, 2026 ? Financial Data Updated to Q2 FY2026 (December […] - [Oscar Health Inc ($OSCR) Update 20 Feb](https://www.merlintrader.com/oscar-health-2025-reset/): Tech-enabled health insurer focused on Affordable Care Act individual and small-group markets, trying to recover from a difficult 2025 with a 2026 guidance that points back toward operating profitability, under the shadow of U.S. healthcare policy and subsidy decisions. - [ImmunityBio Inc ($IBRX) Update Feb 20](https://www.merlintrader.com/immunitybio-inc-saudi-arabia/): ImmunityBio announced a commercial partnership with Biopharma and Cigalah Healthcare to launch ANKTIVA in Saudi Arabia and, over time, across the wider Middle East and North Africa, backed by an SFDA registration certificate with pricing. It’s not a new label approval, but it is a concrete step in the global monetization of the ANKTIVA franchise. - [Satellogic Inc ($SATL) Update Feb 19](https://www.merlintrader.com/satellogic-space-imaging/): Pure-play Earth observation and satellite delivery name listed on Nasdaq, riding a wave of new government contracts and capital raises. This report looks at the real size of the backlog, the evolving mix between satellite sales and data-as-a-service, the cash runway after multiple offerings, and where the risk/reward sits for event-driven traders. - [Tandem Diabetes Care Inc ($TNDM)](https://www.merlintrader.com/tandem-diabetes-care/): After crossing 1 billion dollars in annual revenue and reporting record gross margins, Tandem enters 2026 in a delicate transition phase: rolling out a pay-as-you-go pharmacy model, expanding direct international operations and pushing its Control-IQ+ automation to more patients, while still carrying net losses and a sizeable convertible note stack. - [Solid Biosciences ($SLDB)](https://www.merlintrader.com/solid-biosciences-sldb/): Solid Biosciences Inc. (NASDAQ: SLDB) is a precision genetic medicines company developing AAV‑based gene therapies for rare neuromuscular and cardiac diseases, with a lead focus on Duchenne muscular dystrophy (DMD), Friedreich’s ataxia (FA), and catecholaminergic polymorphic ventricular tachycardia (CPVT) - [Starfighters Space ($FJET)](https://www.merlintrader.com/starfighters-space/): Supersonic test platform based at NASA Kennedy Space Center, no meaningful revenue yet, big ambitions on STARLAUNCH and a valuation already pricing in a lot of execution. - [Planet Labs ($PL) Space, AI and sovereign satellites after the 600% rerating](https://www.merlintrader.com/planet-labs-space-ai-satellites/): From “space small cap in free fall” to one of the most aggressive re-ratings in the space-tech universe, powered by defense demand, sovereign satellite deals and the shift from imagery to full-stack AI analytics. - [Corcept Therapeutics Inc ($CORT) Feb 19 Update](https://www.merlintrader.com/corcept-therapeutics-inc/): Quick EN/IT follow-up after the U.S. Court of Appeals for the Federal Circuit upheld the New Jersey decision that Teva’s proposed generic Korlym does not infringe two Corcept patents, clearing a key legal hurdle for generic competition. We look at what this means for Korlym cash flows, how it interacts with the recent relacorilant CRL and why the ovarian cancer PDUFA remains the central medium-term catalyst. - [Hims & Hers Health Inc ($HIMS)](https://www.merlintrader.com/hims-hers-health-inc-hims/): A deep dive into Hims & Hers after the GLP-1 “pill gambit”, the Novo Nordisk lawsuit, and the transformative acquisition of Eucalyptus: business model, financials, balance sheet, insiders, retail crowd and key catalysts for 2026–2027 - [Red Cat Holdings, Inc.($RCAT)](https://www.merlintrader.com/red-cat-holdings-inc/): RCAT has a small analyst following relative to larger defense primes, but those who do cover the name generally frame it as a high-risk, high-reward play on secure U.S. and allied drone demand. Consensus ratings tilt toward “buy” or “speculative buy” in many summaries, with target prices that imply substantial upside from depressed levels – but also embed assumptions about revenue ramp and contract wins that are far from guaranteed. - [Ondas ($ONDS) eyes Aeronautics](https://www.merlintrader.com/ondas-eyes-aeronautics/): Israeli business media report that Ondas has submitted an offer to buy Aeronautics, the unmanned systems subsidiary of Rafael. It is a proposal under review, not a completed acquisition. Below: what is confirmed, the political and regulatory risk, and how retail traders are reacting. - [Grace Therapeutics (GRCE) April 23 Fda Decision](https://www.merlintrader.com/grace-therapeutics-aprl23-decision/): NASDAQ: GRCE · Biotech · aSAH / nimodipine IV Grace Therapeutics (GRCE) – GTx-104 and the 2026 FDA Decision Deep dive on Grace Therapeutics ahead of the April 23, 2026 PDUFA date for GTx-104, the company’s IV nimodipine for aneurysmal subarachnoid hemorrhage (aSAH). Focus on data, cash runway, binary scenarios and retail/institutional positioning. Report date: […] - [ParaZero ($PRZO) DefendAir intercepts a hostile drone at ~70 mph ](https://www.merlintrader.com/parazero-przo-feb18/): The company says this is its first successful net-based interception at that speed, positioning DefendAir for “on-the-move” protection against fast FPV-style threats and other tactical drones. - [Geron Corp ($GERN) Feb 18 Update](https://www.merlintrader.com/geron-corp-feb18/): Almost one month after our long-form report at around $1.30, Geron is trading near $1.80. A slow but steady grind higher, driven more by positioning and expectations than by new hard data – with the first catalyst window now approaching: Q4 earnings and the first full-year RYTELO outlook under the new CEO. - [NRX Pharmaceuticals Inc ($NRXP)](https://www.merlintrader.com/nrx-pharmaceuticals-inc-feb18/): NRx Pharmaceuticals is a micro-cap biotech focused on severe psychiatric conditions: suicidal depression, bipolar depression with suicidality, PTSD and related disorders. The core of the story is NRX-100, a preservative-free intravenous ketamine program supported by a large Real-World Evidence dataset, and NRX-101, an oral D-cycloserine + lurasidone combination with Breakthrough designation. Around those assets, the company is building HOPE Therapeutics, a network of interventional psychiatry clinics that should both validate the care model and generate revenue. - [T1 Energy Inc. ($TE) ](https://www.merlintrader.com/t1-energy-inc/): Next business catalyst Late February 2026 – expected Q4 2025 earnings and business update, with more detail on 45X tax credit monetization, Giga America ramp and FEOC-compliant sourcing. - [War Ai and the X Ecosystem](https://www.merlintrader.com/war-ai-x-ecosystem/): SpaceX launches satellites, Starlink keeps front lines online, X shapes the information space, and xAI’s Grok is being wired into military networks. A new Pentagon contest for voice-controlled autonomous drones shows how these pieces are starting to lock together into a single, highly political war-tech stack. - [Ocular Therapeutix Inc ($OCUL)](https://www.merlintrader.com/ocular-therapeutix-axpaxli3/): Positive 52-week SOL-1 data position AXPAXLI as a potential long-acting option versus aflibercept, yet the stock sells off as investors question trial design, real-world relevance and the regulatory path. - [Castellum Inc ($CTM) Now Debt Free](https://www.merlintrader.com/castellum-in-debt-free/): From heavily leveraged roll-up to cash-rich, debt-free federal contractor: what changes after the last note payoff, how the Navy “Big 3” contracts reshape visibility, and what still can go wrong for shareholders. - [ImmunityBio Inc ($IBRX) ANKTIVA in EU Ok!](https://www.merlintrader.com/immunitybio-anktiva-euok/): European Commission Grants Final Conditional Marketing Authorization for ANKTIVA® in EU Decision C(2026)1197: Final, binding authorization allowing commercial launch across 27 EU member states + Iceland, Norway, Liechtenstein for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). - [ImmunityBio (IBRX) — Saudi SFDA engagement](https://www.merlintrader.com/immunitybio-saudi-sfda-engagement/): Two items in one tape-read: (1) a fresh BusinessWire update on Saudi regulatory engagement (rBCG dossier + ANKTIVA/CPI expansion discussions), and (2) a sell-side note in circulation reiterating a $24 price target from D. Boral Capital (note dated Jan 13, 2026 in the sources below). - [Compass Pathways Plc ADR ($CMPS) Updated post CC](https://www.merlintrader.com/compass-pathways-plc-adr-cmps/): Release of new clinical data from two Phase 3 trials (COMP005 and COMP006) on COMP360 in TRD + management webcast Tradable short-term event: additional clinical data (specific portions of studies) and official management narrative. This is the type of event that changes the perception of probability/quality of clinical evidence, and thus volatility too. - [AI in Biotech 2026 $RXRX $TEM $EXAI](https://www.merlintrader.com/ai-in-biotech/): Recursion, Tempus AI and Exscientia are three “pure-play” examples of what it really means to put artificial intelligence at the centre of a biotech business model. Used properly, AI can compress timelines, surface non-obvious biology and make better use of messy data. Used badly, it can amplify errors, burn cash faster and create stories the clinic will never confirm. - [Precision Biosciences Inc ($DTIL)](https://www.merlintrader.com/precision-biosciences-inc-dtil/): Next catalyst H1 2026 – Updated ELIMINATE-B Phase 1/2 data in chronic hepatitis B (PBGENE-HBV), including higher-dose biopsy readouts. Secondary 2026 catalyst: first sites activated and initial multi-patient data from the FUNCTION-DMD Phase 1/2 trial of PBGENE-DMD after FDA IND clearance (Study May Proceed) in February 2026. - [Aldeyra Therapeutics (ALDX) PDUFA March 2026](https://www.merlintrader.com/aldeyra-therapeutics-pdufa-march2026/): Aldeyra Therapeutics (NASDAQ: ALDX) is a clinical-stage biotechnology company developing modulators of reactive aldehyde species (RASP) for immune-mediated and metabolic diseases. The key late-stage asset is reproxalap, an ophthalmic RASP modulator for dry eye disease (DED) and allergic conjunctiviti - [2026 Decisive year for three cult biotech stocks $IOVA $IBRX $ALT](https://www.merlintrader.com/2026-decisive-year-iova-ibrx-alt/): A parallel “year of truth” roadmap for Iovance Biotherapeutics (IOVA), ImmunityBio (IBRX) and Altimmune (ALT), three names with huge retail followings, real science on the table and very little room for execution mistakes. - [Weekly Market Briefing (February 16–20, 2026)](https://www.merlintrader.com/weekly-market-briefing-feb-16-20-2026/): Wall Street just closed a choppy week where enthusiasm about AI and data-center spend ran into valuation nerves, while inflation data kept the “soft landing” narrative alive. The coming days will be dominated by U.S. GDP, the Fed’s preferred inflation gauge (core PCE), fresh PMIs and a cluster of sector-specific catalysts across biotech, space, defense and AI small/mid caps. - [Top 10 AI Mid & Small Cap Stocks for 2026](https://www.merlintrader.com/top-10-ai-stocks-small-medium-cap/): The logic of this basket is to follow the AI value chain from data to models to deployment, without touching the mega-cap hyperscalers. Each ticker is plugged into a different piece of that chain: some provide platforms, some sell services, some sell hardware that enables AI workloads. - [Top 10 Space Mid & Small Caps 2026](https://www.merlintrader.com/top-10-space/): A simple way to think about this basket is to imagine the space stack as layers: access to orbit, sensing, communications, infrastructure and exploration. Each of the ten names here owns a useful slice of that stack, often in niches that the mega-caps either do not want or cannot address efficiently. - [Top 10 Us Defense Stocks With Real Growth Optionality](https://www.merlintrader.com/top10-us-defense-stocks/): The big defense primes will always dominate the headlines, but the real optionality for capital gains usually sits one step below, in the names that own a niche. In this basket the niches are clear: tactical drones and loitering munitions (KTOS, AVAV), hypersonic testing and missile-defense space constellations (KTOS, RKLB), naval power and combat systems (DRS), training and simulation (CAE), advanced composites (HXL), electronic-warfare computers (MRCY), spectrum and cyber for national security (CACI, SAIC) and high-margin aerospace components (HEI). - [Outlook Therapeutics Inc ($OTLK)](https://www.merlintrader.com/outlook-therapeutics-inc/): A post-CRL, post-Type A meeting request deep dive on ONS-5010/LYTENAVA, EU/UK launch reality, funding pressure and how much option value is left in a sub-$35M market cap. - [Top 10 Biotech Stocks to Watch in H2 2026 — PDUFA Dates & Catalysts](https://www.merlintrader.com/top10-us-biotech-stocks-now/): Ten US-listed small- and mid-cap biotech stocks with key H2 2026 catalysts, including PDUFA dates, FDA advisory committees and pivotal Phase 3 readouts. Exact dates are separated from company-guided windows; the original H1 2026 analysis remains available as a historical archive. - [Space Stocks in Free Fall](https://www.merlintrader.com/space-stocks-free-fall/): In the last 30 days the “space trade” has flipped from poster child of risk-on to textbook case of brutal risk-off. Launch, satcom and geospatial names are bleeding double-digit days, while some defense-linked players hold up. Under the surface, it is a story of funding, dilution anxiety, macro rates and a sector where AI and defense still pull in structural demand. - [Neumora Therapeutics Inc ($NMRA) Feb 12 2026](https://www.merlintrader.com/neumora-therapeutics-in/): Key idea. In January we framed Neumora as a post-crash special situation: a neuroscience platform that had just blown up its lead asset navacaprant in Phase 3 MDD, wiping out about 80% of the market cap in one session, but still sitting on a sizeable cash pile and a broad pipeline. The weeks since then have added three crucial pieces: (1) full Phase 1b signal-seeking data for NMRA-511 in Alzheimer’s agitation, (2) a more detailed 2026 pipeline strategy, and (3) better visibility on ownership, institutional support and analyst appetite post-crash. This second deep dive doesn’t repeat the full story — it extends it and tries to answer a simple question: is NMRA slowly rebuilding a credible equity story, or just trading on residual hope and short-term speculation? - [Jiade Ltd ($JDZG)](https://www.merlintrader.com/jiade-ltd-jdzg/): Jiade is a micro-cap education-support company listed on Nasdaq, best known for providing tutoring and training services for adult and vocational education in China. A strategic cooperation with a South Korea–based AI education brand adds an international angle, but the story still sits at the intersection of cross-border ambitions, regulatory risk and the harsh math of small-cap liquidity. - [Viking Therapeutics Inc (VKTX)](https://www.merlintrader.com/viking-therapeutics-inc-vktx/): Viking has just reported fourth-quarter and full-year 2025 numbers and given a dense update on its obesity and metabolic pipeline. The picture is clear: spending is ramping, the cash pile is still very strong, and the company is steering both injectable and oral VK2735 toward the next wave of pivotal trials while preparing a new amylin program and keeping VK2809/VK0214 alive in the background. - [AI disruption 2026 – winners, losers and what it really means for people](https://www.merlintrader.com/ai-disruption/): The core idea is blunt but useful: markets are paying up for the “picks and shovels” of AI – chips, foundry, high-bandwidth memory, data centres, cybersecurity, observability – and they are putting a heavy discount on businesses whose main value proposition can be replicated by AI agents, plug-ins and low-cost automation. It is not just about which tickers are in fashion; it is about which roles and workflows are becoming cheaper to automate. - [Moderna Inc ($MRNA) Flu Shot? No Shot](https://www.merlintrader.com/moderna-mrna/): Why this Daily Hit, if Moderna is not a small biotech? Moderna is obviously not a small-cap biotech living hand-to-mouth. Yet the refusal-to-file (RTF) letter that the U.S. Food and Drug Administration (FDA) just sent for its seasonal flu vaccine mRNA-1010 is such an outlier in terms of process and signalling that it deserves a dedicated “hit” article. - [Denali Therapeutics Inc ($DNLI)](https://www.merlintrader.com/denali-therapeutics/): Denali Therapeutics is moving into the most delicate phase of its evolution: from a blood–brain-barrier platform story to a commercial-stage rare-disease company. The centre of gravity is tividenofusp alfa (DNL310), a TransportVehicle-enabled enzyme replacement therapy for Hunter syndrome (MPS II) designed to address both systemic and central nervous system manifestations, something that current standard ERTs cannot do. - [TuHURA Biosciences ($HURA)](https://www.merlintrader.com/tuhura-biosciences/): TuHURA announces that Kintara’s REM-001 trial in metastatic cutaneous breast cancer has met its primary safety endpoint in ten patients with early signs of clinical efficacy. This triggers the contractual milestone under the Kintara CVR Agreement and unlocks the distribution of 1,539,958 HURA shares to legacy Kintara shareholders holding CVRs. - [uniQure N.V ($QURE)](https://www.merlintrader.com/uniqure-n-v-qure/): Updated preliminary Phase I/IIa data in Fabry disease show sustained, dose-dependent α-Gal A activity far above normal and allow enzyme-replacement withdrawal in more than half of treated patients, while safety findings trigger a pause in higher-dose cohorts. At the same time, AMT-130 for Huntington’s disease faces a tougher regulatory path after FDA feedback that current Phase I/II data are unlikely to support a BLA as primary evidence. This report connects Fabry, Huntington and the broader AAV5 platform story under the lens of balance sheet, catalyst map, key risks and retail sentiment. - [Maze Therapeutics Inc ($MAZE)](https://www.merlintrader.com/maze-therapeutics-inc/): Maze trades as a high-expectations play on APOL1-mediated kidney disease: the stock has rerated into a roughly mid-cap valuation on the back of a very strong balance sheet and the upcoming proof-of-concept data from the HORIZON Phase 2 trial in a broad AMKD population. The key tension now is simple: can the first substantive MZE829 dataset justify how far the share price has already come. - [AST SpaceMobile Inc ($ASTS)](https://www.merlintrader.com/ast-spacemobile/): In January you saw the “National Defense Strategy / Deep Tech” macro piece: defense budgets, uranium enrichment, electronic warfare and reusable launch infrastructure all moving at once. In that map, AST SpaceMobile sits on the space-based connectivity layer: a company trying to build cell towers in orbit that can serve both civilian and military customers, at a time when governments explicitly talk about resilient communications, contested environments and independent infrastructure. This note takes that macro lens and zooms back into ASTS. - [REGENXBIO (RGNX)](https://www.merlintrader.com/regenxbio-rgnx/): The FDA has sent a Complete Response Letter (CRL) for RGX-121 (clemidsogene lanparvovec) in MPS II, rejecting the BLA under the accelerated approval pathway and questioning the external control, the neuronopathic eligibility criteria and the CSF HS D2S6 biomarker. Management plans a Type A meeting and aims to resubmit, but the ultra-rare MPS II path is now longer and more complex, against a backdrop of recent clinical holds on the company’s ultra-rare MPS programs. - [Quince Therapeutics Inc ($QNCX)](https://www.merlintrader.com/quince-therapeutics/): Quince Therapeutics has announced that it has engaged LifeSci Capital as its exclusive financial advisor to assist with a restructuring process and a formal review of “strategic alternatives” with the stated goal of maximizing shareholder value. The menu of options explicitly listed by the company includes partnerships, joint ventures, mergers, acquisitions, licensing deals or other strategic transactions, and LifeSci will also support any restructuring of the company’s liabilities. - [Ensysce Biosciences Inc ($ENSC)](https://www.merlintrader.com/ensysce-biosciences-inc/): Ensysce Biosciences has provided a new operational update on its pivotal Phase 3 trial PF614-301, which evaluates PF614, a next-generation oxycodone prodrug, in patients with moderate to severe acute pain following abdominoplasty surgery. The company reports that the study has now enrolled 50% of the subjects targeted for the planned interim review, a meaningful operational milestone for a small clinical-stage pain company trying to move an abuse- and overdose-resistant opioid toward the market. - [Humacyte $HUMA](https://www.merlintrader.com/humacyte-huma/): From FDA approval of Symvess for vascular trauma to Ukrainian war-zone data and fresh U.S. support for biologic vascular repair, Humacyte is trying to turn a once “sci-fi” idea – off-the-shelf human vessels grown in a factory – into something routine in emergency rooms and military hospitals. - [ImmunityBio Inc $IBRX](https://www.merlintrader.com/immunitybio-inc-feb09/): Potential resubmission of the supplemental BLA for BCG-unresponsive papillary NMIBC following the January 20 FDA meeting. The company committed to deliver additional analyses within 30 days, without new clinical trials. If the resubmission is accepted, the review clock could define the next major run-up window. - [Biofrontera Inc $BFRI](https://www.merlintrader.com/biofrontera-inc/): Biofrontera (BFRI) – Positive Phase 3 trunk/extremities data for Ameluz PDT, sharp micro-cap sell-off Biofrontera reports that its Phase 3 study of Ameluz® PDT for actinic keratoses on the extremities, neck and trunk met the primary endpoint, strengthening the case for a 2026 sNDA – but the stock trades lower intraday, reminding investors how noisy tiny-cap price action can be. - [Protara Therapeutics  $TARA](https://www.merlintrader.com/protara-therapeutics/): Protara Therapeutics (TARA) — TARA-002 Phase 2 NMIBC catalyst at the end of February 2026 Protara Therapeutics is a small-cap biotech that has quietly moved from “option on survival” to a fully funded late-stage story built around a single, high-leverage asset: TARA-002. The drug is a TLR2/NOD2 agonist derived from the same cell bank as the long-used immunotherapy OK-432 (Picibanil) and is being developed both for non-muscle invasive bladder cancer (NMIBC) and for pediatric lymphatic malformations. The near-term catalyst now staring at the tape is an updated Phase 2 read-out in BCG-unresponsive NMIBC that will be presented on 27 February 2026 and that the company itself frames as aligned with the registrational pathway for this setting. - [AI, drones and US defense after the Singapore Airshow 2026](https://www.merlintrader.com/ai-drones-defense-after-singapore-airshow-2006/): The Singapore Airshow 2026 is not just a nice backdrop for air displays and static jets. It is a live x-ray of how fast the Indo-Pacific balance of power is shifting, and how quickly drones and AI-enabled systems have moved from the fringe to the centre of the defence conversation. While China shows off fighters and commercial jets to signal that it wants a bigger slice of the regional market, US and allied firms are quietly doing something just as important: locking in long-term positions across drones, autonomy and “AI-ready” hardware. - [Golden Dome $PL $BKSY $SATL](https://www.merlintrader.com/golden-dome/): For years, “space” was mostly a story about launch costs and broadband dreams. In 2026 the narrative is shifting: satellites are becoming the nervous system of a new defence architecture built around missile warning, tracking and resilient communications - [Cognition Therapeutics $CGTX](https://www.merlintrader.com/cognition-therapeutics-cgtx/): Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative, small-molecule oligomer antagonists for age-related degenerative disorders of the central nervous system, primarily Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB). - [Compass Therapeutics (CMPX)](https://www.merlintrader.com/compass-therapeutics/): Clinical-stage oncology company focused on bispecific antibodies that couple angiogenesis and immune modulation. - [KOD Kodiak Sciences Feb 08 2026](https://www.merlintrader.com/kod-kodiak-sciences-feb08/): KOD Kodiak Sciences Inc. Late-stage retina biotech riding a multi-hundred-percent run-up into a dense 2026–2027 catalyst cluster (tarcocimab, KSI-501 and KSI-101). Chart from Finviz, always double-check the latest quote and news. - [OCUL Ocular Therapeutix run-up Updated Feb 16 2026](https://www.merlintrader.com/ocul-ocular-therapeutix/): Deep dive on Ocular Therapeutix: from DEXTENZA to the late-stage AXPAXLI retina franchise, with SOL-1 topline data in wet AMD coming in late February 2026 and a balance sheet funded into 2028. - [Weekly Briefing Feb 9 2026](https://www.merlintrader.com/weekly-briefing-feb9-2026/): Week of 9–15 February 2026 – the setup is unusual: the U.S. government shutdown pushed key releases into the same week, so the market gets a jobs + CPI combo while earnings keep dictating leadership. - [AGIO Agios Pharmaceuticals Inc](https://www.merlintrader.com/agio-agios-pharmaceuticals-inc/): A year ago, Agios was still mostly a “promise stock”: one approved niche drug for pyruvate kinase deficiency and a lot of hope around sickle cell disease. Today the picture is more complex but also more concrete: mitapivat now has two U.S. approvals, a full rare-disease haematology franchise is forming, and 2026 has a surprisingly busy catalyst map. - [PLSE Pulse Biosciences Inc](https://www.merlintrader.com/plse-pulse-biosciences-inc/): First-in-human data for the nPulse™ Cardiac Catheter Ablation System show high pulmonary vein isolation durability and low SAE rate in atrial fibrillation – but this is still a pre-commercial, single-platform story. - [RCKT Rocket Pharmaceuticals ](https://www.merlintrader.com/rckt-rocket-pharmaceuticals-2/): Gene therapy for ultra-rare immunodeficiency (LAD-I), a hard reset after last year’s CRL and the Danon shock, and a March 28, 2026 PDUFA that could flip sentiment in a name now trading near multi-year lows. This is a classic “platform vs. execution” test in gene therapy – with an additional potential upside lever in the form of a Rare Pediatric Disease Priority Review Voucher (PRV) if approval comes through. - [RGTI Rigetti Computing Inc](https://www.merlintrader.com/rgti-rigetti-computing-inc/): Rigetti is one of the few pure-play public quantum computing hardware names. It designs and manufactures superconducting quantum processors, integrates the control stack and cryogenics around them, and exposes these systems through a cloud platform so that enterprises, governments and researchers can experiment with quantum algorithms and hybrid quantum-classical workflows. - [ALVO Alvotech Feb 2026](https://www.merlintrader.com/alvo-alvotech/): Alvotech is not a typical development-stage biotech: it is a vertically integrated biosimilar platform that already generates hundreds of millions of dollars in revenue from launched products like AVT02 (adalimumab) and AVT04 (ustekinumab), while also running a crowded late-stage pipeline. The stock sits in that awkward middle ground between “early growth” and “heavy balance sheet”, with over 1B$ of debt but also positive adjusted EBITDA and operating profit in the latest 9-month period. - [CRMD Thinking After Hours](https://www.merlintrader.com/crmd-thinking-after-hours/): This after-hours note starts from a simple, honest message in the comments. A reader who first bought CRMD around 11 USD, then averaged down at 9 USD and again at 6.5 USD, with one clear idea: one day, selling “north of 15” if the CorMedix story plays out. - [RNXT RenovoRx Inc](https://www.merlintrader.com/rnxt-renovo-rx/): Quick take: RenovoRx brings fresh clinical data on its TAMP™ therapy platform to SIO 2026 (February 6). The event is not a registrational readout, but it is a real-world test of how much the market still cares about this targeted intra-arterial delivery story as the company starts to generate device revenues. - [DFTX Definium Therapeutics Inc.](https://www.merlintrader.com/dftx-definium-therapeutics-inc/): Definium Therapeutics (DFTX) is not a mature commercial pharma story; it is a clinical‑stage CNS and mental health company whose equity behaves like a classic high‑beta biotech: the tape is dominated by expectations around clinical data, regulatory interactions, and the company’s ability to fund its programs through to value‑defining milestones. - [ONCY Oncolytics Biotech, Inc](https://www.merlintrader.com/oncy-oncolytics-biotech-inc-2/): On February 4, 2026, Oncolytics announced that the FDA granted Fast Track designation to pelareorep combined with bevacizumab and FOLFIRI for adults with KRAS-mutant, microsatellite-stable metastatic colorectal cancer (MSS mCRC) in the second-line setting, after progression on a first-line oxaliplatin-based regimen. The designation is based on clinical signals from the REO 022 study and prior pelareorep experience across GI tumors and breast cance - [BKSY BlackSky Technology](https://www.merlintrader.com/bksy-blacksky-technology/): Small-cap geospatial intelligence pure play with a fast-growing Gen-3 satellite constellation, recurring U.S. and international defense contracts and strong leverage to the new U.S. space and missile-defense cycle. - [VSTM Verastem Inc](https://www.merlintrader.com/vstm-verastem-inc-2/): Verastem Oncology enters 2026 as a very different story compared with two years ago. The company now has a commercial product, Avmapki Fakzynja (avutometinib + defactinib), approved under the FDA’s accelerated approval pathway for adult patients with KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC) after at least one prior systemic therapy. - [ADMA Adma Biologics Inc](https://www.merlintrader.com/adma-biologics-inc/): Commercial IG platform with three FDA-approved products, a yield-enhanced manufacturing process, and a revenue ramp from $500M in a handful of years. Not a binary biotech story, but an execution and capacity game that the market is finally treating like a growth compounder. - [CCL Carnival Corporation February 2026](https://www.merlintrader.com/ccl-carnival-corporation-feb-2026/): A comprehensive February 2026 strategic analysis of Carnival Corporation after the Q4 2025 earnings, the Excellence-class LNG fleet expansion, and the accelerated rollout of Carnival AI Operations Platform. Updated with latest SEC filings, January 2026 bookings data, and 2026-2027 sustainability targets. Educational only. - [ONDS Ondas Inc](https://www.merlintrader.com/onds-ondas-inc-jan-recap/): In early January we started to follow Ondas Inc. (ONDS) more closely on Merlintrader, first with a long-form deep-dive on the transformation of the group into an autonomous defense “system-of-systems” platform, and then with a sequence of updates as new contracts and Investor Day details emerged. Those articles focused on the structural story, the DCMA “Blue UAS” listing for Optimus and the growing defense pipeline. - [OMER Omeros Corporation](https://www.merlintrader.com/omer-omeros-corporation-2/): What happened in January: Omeros successfully transitioned from pre-commercial biotech to commercial-stage rare disease company with the FDA approval of YARTEMLEA on December 23, 2025 and first commercial sales announced January 27, 2026. - [PDYN Palladyne AI Updated feb 08](https://www.merlintrader.com/pdyn-palladyne-ai/): Palladyne AI announced a new contract with a major U.S. defense prime to deliver a mission-critical propulsion subsystem for an existing U.S. missile system. Management expects the award to generate nearly $1M in revenue, all booked in 2026, with hardware deliveries completed by the end of Q3 2026 according to the BusinessWire press release. - [CYN Cyngn Inc](https://www.merlintrader.com/cyn-cyngn-inc/): Cyngn (ticker CYN) sits in a corner of the market that many traders only notice when the tape goes vertical: micro-cap industrial autonomy. This is not a classical biotech binary, not a cash-generating SaaS giant, and definitely not a clean “AI story” with nine-figure revenues. It is a company trying to turn a fairly sophisticated autonomy stack into a repeatable, contract-driven business in forklifts, tuggers and other industrial vehicles – while burning real money and living under the constant threat of dilution. - [BBAI BigBear.ai Holdings Inc](https://www.merlintrader.com/bbai-bigbear-ai-holdings-inc/): BigBear.ai started as a data-fusion and analytics contractor, grew via acquisitions and went public through the GigCapital4 SPAC at the end of 2021. The company’s value proposition is to make sense of messy data streams and provide actionable recommendations for operators in defense, intelligence, border security, logistics and other complex environments. To do that, it combines traditional analytics, AI/ML models, simulation, and mission-planning tools into a single decision-intelligence laye - [2026 The New Era - Watchlist Space-AI-Defense](https://www.merlintrader.com/2026-the-new-era/): 2026 opens in a geopolitical environment that looks like a “Cold War 2.0” – but running at a much higher speed and across more domains than anything we have seen before. Classic threat pillars – nuclear deterrence, air and sea control, conventional superiority – are still there, but they have been reshaped by disruptive technologies that make them far more lethal and unpredictable. - [BFRI Biofrontera Inc](https://www.merlintrader.com/bfri-biofrontera-inc/): Photodynamic-therapy specialist with a single commercial franchise (Ameluz + RhodoLED) in U.S. dermatology, entering a dense 2026 data and regulatory window while revenues scale from the low–mid $40M range and the balance sheet remains tight. - [PHAR Pharming Group Adr-CRL](https://www.merlintrader.com/phar-pharming-group-adr-crl/): On February 1, 2026, Pharming announced that the U.S. FDA issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja (leniolisib) in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). The letter does not question the fundamental clinical benefit of leniolisib in APDS but raises two specific technical concerns - [AQST Aquestive Therapeutics Inc](https://www.merlintrader.com/aqst-aquestive-therapeutics-inc/): From the January “deficiencies” shock to a Complete Response Letter focused on packaging and administration, why the market is suddenly relieved and why the story is still a multi-quarter grind. - [CRMD CorMedix Inc](https://www.merlintrader.com/crmd-cormedix-inc-2/): CorMedix is no longer the pre-revenue story that dialysis investors watched from a distance. After the U.S. launch of DefenCath in 2024, the company has delivered its first profitable quarter, acquired the Melinta anti-infective portfolio, built a meaningful cash position and, as of February 2026, added a $75 million share repurchase program on top. - [ARTV Artiva Biotherapeutics Inc](https://www.merlintrader.com/artv-artiva-biotherapeutics-inc/): Artiva Biotherapeutics is a clinical-stage biotech company focused on off-the-shelf allogeneic NK cell therapies built on a standardized, donor-derived, manufacturing platform. The lead asset, AlloNK (AB-101), is being developed in combination with anti-CD20 therapy both in B-cell non-Hodgkin lymphoma (NHL) and in autoimmune d - [SIDU Sidus Space Inc](https://www.merlintrader.com/sidu-sidus-space-inc-2/): From “space-as-a-service” niche player to SHIELD radar contributor: what changed for Sidus Space after our first deep dive, how the December 2025 capital raise reshaped the runway, and why LizzieSat-4 plus AI/ML payloads make 2026 a crucial execution year. - [ImmunityBio Inc ( $IBRX ) today’s NK-cell manufacturing milestone is real](https://www.merlintrader.com/immunitybio-nk-cell-manufacturing/): Today’s official release from ImmunityBio was about cell-manufacturing execution, not about ANKTIVA sales, not about a fresh FDA approval, and not about a pivotal top-line readout. The company said it has completed manufacturing engineering programs that established a reproducible leukapheresis-to-manufacturing pathway for its autologous M-ceNK platform. In simple English, ImmunityBio is telling the market that it has moved another step from “interesting immunology concept” toward “repeatable cell-therapy process that can be run at scale.” - [5 energy stocks under $2 billion to watch in march ( $PUMP $EGY $RNGR $GEOS $KLXE )](https://www.merlintrader.com/5-energy-stockes-under-2bn/): This article compares five U.S.-listed energy names below $2 billion in market value that could benefit, directly or indirectly, from a stronger oil tape, firmer field activity, or renewed investor appetite for smaller-cap energy exposure: ProPetro (PUMP), VAALCO Energy (EGY), Ranger Energy Services (RNGR), Geospace Technologies (GEOS) and KLX Energy Services (KLXE). - [Immutep Limited ( Nasdaq $IMMP ) after TACTI-004 futility](https://www.merlintrader.com/immutep-limited-tacti-futility/): Core fact On March 13, 2026 Immutep said the Independent Data Monitoring Committee recommended discontinuing the registrational Phase III TACTI-004 study following the planned futility analysis. - [US Airlines in the Energy Storm ( $AAL ) ( $DAL ) ( $UAL )](https://www.merlintrader.com/us-airlines-energy-storm/): The current energy crisis is not hitting every U.S. airline the same way. Higher oil matters, but higher jet fuel matters more, and the market is now separating airlines by pricing power, customer mix, balance-sheet flexibility and margin resilience rather than by simple traffic growth. - [XTI Aerospace ( $XTIA ): Defense Drones and Urban Air Mobility at an Inflection Point](https://www.merlintrader.com/xti-aerospace-defense-drones-2026/): XTI Aerospace, Inc. (NASDAQ: XTIA) is an aerospace and technology platform combining vertical flight aircraft development, unmanned aircraft systems, and enterprise drone distribution. As of March 2026, the company is in the early scaling phase following its transformational November 2025 acquisition of Drone Nerds. - [Firefly Aerospace Inc ( $FLY ) March 12 2026](https://www.merlintrader.com/firefly-aerospace-inc-march26/): Thursday’s move in Firefly Aerospace was not just a momentum spike on a cool rocket headline. The market reacted because Alpha Flight 7 checked several boxes at once. Firefly did not merely launch. It reached orbit, delivered a Lockheed Martin technology demonstrator, completed a stage-two engine relight, and used the mission to validate meaningful pieces of its next hardware iteration, Alpha Block II. In the space business, especially for a newer public company still earning its institutional reputation, those are not cosmetic details. - [BlackSky (NYSE: $BKSY) — why the story looks stronger in March 2026](https://www.merlintrader.com/blacksky-march-2026-stronger/): BlackSky has turned a familiar speculative space name into something the market is finally trying to reprice as real defense-tech infrastructure. Fourth-quarter numbers were solid, backlog expanded, a new seven-figure NGA Luno delivery order added another official validation point, and then management followed with two operational milestones that matter more than the typical space-company headline: Gen-3 first light arrived within hours, and the fourth Gen-3 satellite was commissioned in less than a week, opening general availability of the company’s best-in-class 35-centimeter imagery and AI-enabled analytics to global customers. The bullish case is no longer based only on a distant dream of “space growth.” It is increasingly built on the idea that BlackSky is becoming a usable, taskable, software-connected intelligence layer for governments that need decisions faster, not just prettier satellite pictures. - [Ondas and Palantir ( $ONDS ) ( $PLTR ) a real defense-tech stack? (Part 2)](https://www.merlintrader.com/ondas-and-palantir-part2/): The first article explained the announcement. This second one tackles the harder question: whether the Ondas–Palantir–World View structure can evolve into something commercially meaningful, or whether the market is still looking at a strategically attractive partnership that remains too early to change fundamentals. - [Palantir Ondas and World View just sketched a much bigger story than a normal partnership headline (Part 1)](https://www.merlintrader.com/palantir-ondas-partnership-part1/): Palantir, Ondas and World View announced a partnership to develop a next-generation multi-domain intelligence platform, using Palantir AIP across production, mission planning and edge operations. - [Artiva Biotherapeutics Inc ( $ARTV ) March 11th](https://www.merlintrader.com/artiva-biotherapeutics-inc-earniongs-catalyst-path/): Artiva Biotherapeutics rallied sharply after its full-year 2025 results and business update put the spotlight back where biotech traders care most: near-term clinical readouts, FDA path visibility, analyst support, and whether the balance sheet is strong enough to carry the story into the next real value-inflection point. - [Hims & Hers ( $HIMS ) from GLP-1 backlash to a big strategic reset](https://www.merlintrader.com/hims-hers-hims-from-glp-1-backlash-to-a-big-strategic-reset/): A few weeks ago the core question was whether Hims had pushed the GLP-1 trade too far and invited a regulatory and legal backlash that could damage one of the market’s favorite growth stories. That question has not disappeared. But the story has changed meaningfully. The company now has a formal strategic shift in U.S. weight loss, a public collaboration with Novo Nordisk, access to branded Wegovy and Ozempic on the platform, a dropped lawsuit, and still the pending Eucalyptus acquisition that could reshape the company from a fast U.S. telehealth operator into a broader global consumer-health platform. - [Ocugen Inc ( $OCGN ) why the stock exploded, what the dual analyst boost really means](https://www.merlintrader.com/ocugen-inc-ocgn-dual-analyst-upgrade/): Ocugen came back to life on a violent session after a stacked sell-side day: one firm initiated with an Outperform and a $10 target, while another raised its target to $22 from $15 and kept a Buy rating. But the move does not sit on analyst language alone. It lands on top of a Phase 3 enrollment-complete lead program, a visible BLA path, multiple ocular follow-on catalysts, a high-beta retail base, meaningful short interest, and a balance sheet that is improved from panic but still nowhere near bulletproof. - [Planet Labs ( $PL )moving toward strategic infrastructure](https://www.merlintrader.com/planet-labs-strategic-infrastructure/): The new delay on Middle East imagery is not enough, by itself, to make a full article. But as an editorial trigger, it is strong. It forces a bigger question: is Planet still mainly a commercial satellite-imagery company, or is it becoming a strategic information utility that increasingly operates inside the security architecture of the United States and its allies? - [Rocket Pharmaceuticals Inc ( $RCKT ) refreshes its ATM 17 days before the March 28 PDUFA](https://www.merlintrader.com/rocket-pharmaceuticals-refreshes-atm/): This was not a classic overnight equity raise. Rocket filed a new ATM framework with Cantor Fitzgerald, terminated the prior TD/Cowen agreement, and did so with the March 28, 2026 PDUFA for KRESLADI now close enough to matter in every financing read-through. - [X and the Nasdaq question](https://www.merlintrader.com/x-and-the-nasdaq-2026/): A careful bilingual deep dive on whether X could realistically find a route to Nasdaq exposure after today’s Reuters reports, why the answer is more indirect than many headlines suggest, and how payments, regulation, competition and corporate structure change the picture. - [Capricor Therapeutics Inc ( $CAPR ) FDA PDUFA Approval Target (August 22, 2026)](https://www.merlintrader.com/capricor-therapeutics-inc-pdufa-aug22/): On March 10, 2026, Capricor Therapeutics announced that the FDA has lifted its Complete Response Letter (CRL) and resumed review of the Biologics License Application (BLA) for Deramiocel. The agency assigned a new PDUFA target action date of August 22, 2026—a pivotal moment after months of regulatory uncertainty. - [Castellum ($CTM) — 2025 repaired the story](https://www.merlintrader.com/castellum-2025-cleanup-year/): Castellum came out of 2025 looking cleaner, less leveraged and more credible than it did a year earlier. Revenue grew, operating losses narrowed sharply, cash improved, debt was almost fully gone by year-end and then fully eliminated shortly after. The central question now is no longer whether CTM can tell a better story, but whether it can turn backlog, contract wins and pipeline into durable margins and more repeatable cash generation in 2026. - [ImmunityBio (NASDAQ: IBRX) — FDA resubmission](https://www.merlintrader.com/immunitybio-bla-resubmitted/): What happened today Today’s real headline is straightforward: ImmunityBio announced that it has resubmitted the supplemental biologics license application to the FDA for ANKTIVA plus BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary disease. According to the company, it had already submitted information requested by the FDA in February 2026, but in March the agency then requested updated efficacy information based on longer follow-up, which ImmunityBio says has now been included in the resubmitted package. - [Ondas (NASDAQ: $ONDS) — preliminary 2025 earnings beat and Mistral merger agreement Updated mach 10](https://www.merlintrader.com/ondas-preliminary-2025-earnings-beat/): A long-form bilingual deep dive on what changed in Ondas’ preliminary fourth-quarter and full-year 2025 update, why the revenue beat matters more than the raw numbers alone, how the Mistral agreement changes the strategic map, and what investors should watch next as ONDS tries to move from fast-growing defense-tech vendor to a broader autonomous systems platform with prime-contractor access. - [IMMP under halt: what may really be behind it ( $IMMP )](https://www.merlintrader.com/immp-under-halt/): Immutep’s Nasdaq-listed ADRs were halted on Friday, March 6, 2026 under code T1 / News Pending. On the Australian side, the public halt notice points to an announcement regarding the outcome of the pre-specified interim futility analysis for the Phase III TACTI-004 trial. That single detail matters a lot: it shifts the center of gravity from wild speculation to a very specific clinical event. What follows is a structured look at the facts, the company, the pipeline, and the full range of plausible scenarios. - [Weekly Recap & Briefing – Oil Shock, Weak Jobs, Iran War and a More Selective Tape (Mar 2–6, 2026)](https://www.merlintrader.com/weekly-recap-briefing-oil-war-mar-2-6-2026/): The week that closed on Friday 6 March was the first full trading week in which markets had to process the new Middle East war regime rather than just react to a weekend headline. The U.S.–Israeli campaign against Iran and the retaliation that followed kept energy, shipping and inflation risk at the centre of the tape, while the S&P 500 ended the week lower, the VIX climbed to its highest level since April 2025 and Brent crude pushed above 90 dollars a barrel. On top of that, Friday’s U.S. jobs report added a second layer of stress: payrolls unexpectedly fell and the unemployment rate moved up, pushing investors into an awkward mix of growth fear and inflation fear at the same time. - [PMV Pharmaceuticals Inc ( $PMVP )](https://www.merlintrader.com/pmv-pharmaceuticals-inc-pmvp/): PMV Pharmaceuticals is a precision oncology company built around rezatapopt (PC14586), an oral small-molecule reactivator of p53 designed for tumors harboring the TP53 Y220C mutation. The story matters because TP53 is one of the most important tumor suppressor genes in cancer biology, and because PMV has now moved from mechanism-only interest into clinically visible efficacy data. The company’s registrational PYNNACLE study has produced an overall 34% ORR across evaluable Phase 2 patients and a 46% ORR in the ovarian cohort at the September 4, 2025 cutoff, with the company later reporting a 50% ORR in the same ovarian cohort after that cutoff. FDA Orphan Drug Designation granted on March 2, 2026 adds meaningful regulatory support. PMV says it plans to submit an NDA in Q1 2027 for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation. - [Obesity Medicines 2026 — Part 1: sector map for investors](https://www.merlintrader.com/obesity-medicines-2026-part1/): A stock-market overview built around the names that matter most in the public conversation today: Novo Nordisk (NVO), Eli Lilly (LLY), Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), Altimmune (ALT), Fractyl Health (GUTS) and Zealand Pharma (ZEAL). This first part is not a medical explainer. It is a market map: who already has real commercial power, who is still trying to earn strategic relevance, and which catalysts actually matter for the shares. - [Obesity Medicines 2026 Part 2](https://www.merlintrader.com/obesity-medicines-2026-part-2a/): Part 2 moves from the sector to the stocks themselves. Each company is examined through the same lens: ticker, core asset, stage, regulatory standing, commercial position, why the market cares, bull case, bear case and the next likely stock-moving issues. The goal is not to crown a winner but to show what each public name really is today. - [ONDS vs DRSHF (ASX:DRO) — two ways to play the drone / counter-drone boom](https://www.merlintrader.com/onds-vs-drshf-counter-drone-boom/): ONDS vs DRSHF (ASX:DRO) — Counter-Drone Deep Dive Comparison | Merlintrader EN IT Comparative Deep Dive ONDS vs DRSHF (ASX:DRO) — two ways to play the drone / counter-drone boom This report compares Ondas and DroneShield from every angle that matters to a serious reader: business model, product portfolio, commercial traction, customers, end markets, audited […] - [ZenaTech Inc ( $ZENA ) deep dive on the story filings ownership governance](https://www.merlintrader.com/zenatech-inc-zena-deep-dive-on-the-story/): A structured review built around the most relevant SEC filings from the last year, with special attention to what is real already, what is still mostly forward story, how the acquisition machine is being used to create revenue, and where the governance and financing risks are concentrated. - [Drone stocks explained: the listed names that matter $AVA $ONDS $RCAT $DPRO $KTOS $UMAC](https://www.merlintrader.com/drone-stocks-explained/): A comparative, long-form guide to the main quoted drone and counter-drone names retail investors keep putting in the same basket — from AeroVironment and Kratos to Ondas, Red Cat, Draganfly and Unusual Machines — with a focus on what each company really does, where the real business sits, and where the story is still more narrative than scale. - [Rumble Inc ( $RUM )](https://www.merlintrader.com/rumble-inc-q42025-update/): Executive summary Rumble is no longer just a politically differentiated video platform. After FY 2025 results, the company is trying to present itself as a three-layer story: a creator and media platform, an advertising and subscription monetization engine, and a cloud / GPU infrastructure business that could become much more material if the Northern Data transaction closes. - [The War Economy](https://www.merlintrader.com/the-war-economy/): The market is no longer treating Middle East escalation as a passing geopolitical shock. It is increasingly pricing it as a broader economic regime: one that reprices oil and LNG, lifts defense and dual-use space names, pressures airlines and small caps, and forces investors to rethink the physical vulnerability of cloud infrastructure - [Three March PDUFAs retail biotech traders are watching most closely](https://www.merlintrader.com/three-march-pdufas-26/): March is packed with biotech catalysts, but for many retail traders the shortlist comes down to three names: Lantheus, Aldeyra and Rocket Pharmaceuticals. They are very different stories — one radiopharma platform name, one dry-eye binary, one rare-disease gene-therapy approval setup — but all three have the ability to move fast around FDA timing, market expectations and headline interpretation. - [Horizon Aircraft Ltd ( $Hovr ) lower-cost VTOL pitch gets sharper](https://www.merlintrader.com/new-horizon-aircrafts-vtol/): Horizon Aircraft’s latest update was not about a signed order or a certification milestone. It was a commercial positioning update: management is now leaning harder on the argument that the Cavorite X7 could operate at materially lower cost than helicopters, while continuing a visible March–April industry-events circuit to keep the platform in front of operators, investors and policy stakeholders. - [Planet Labs ( $PL ) Europe, defence and sovereign satellite demand](https://www.merlintrader.com/planet-labs-europe-expansion/): Planet is no longer a simple “satellite imagery story” to be judged on a vague promise of future demand. The company now sits at the intersection of recurring Earth-data subscriptions, defence and intelligence workflows, sovereign demand for dedicated capability, and a broader European push toward strategic autonomy in space and geospatial data. The stock has already been re-rated hard, so the real question is no longer whether Planet has become more relevant. It clearly has. The real question is whether this growing strategic relevance can convert into cleaner revenue quality, stronger margins, and a more durable case into the next earnings event. - [Zeta Global Holdings Corp ( $ZETA )](https://www.merlintrader.com/zeta-global-holdings-corp/): Zeta Global ended 2025 with roughly $1.3 billion in revenue, high-20s growth, expanding margins and a still-modest GAAP net loss, while launching a strategic collaboration with OpenAI to power Athena, its enterprise AI marketing agent. The investment case now revolves less around “can they grow” and more around “can they sustain growth, expand margins and prove that their data and AI stack is truly differentiated. - [SeaStar Medical Holding Corp ( $ICU )](https://www.merlintrader.com/seastar-medical-holding-update-march/): SeaStar Medical announced completion of the FDA-mandated enrollment requirement (50 patients) for the SAVE Surveillance Registry evaluating QUELIMMUNE safety in pediatric AKI with sepsis requiring continuous kidney replacement therapy (CKRT). - [Atara Biotherapeutics (ATRA): after the new tabelecleucel update, a second attempt at an FDA path ](https://www.merlintrader.com/atara-biotherapeutics-march-update/): Two months after the FDA’s complete response letter on tabelecleucel for EBV+ PTLD, Atara and partner Pierre Fabre are back in Washington with a Type A meeting request and a thick briefing book. The goal is simple but ambitious: convince the agency that the data set behind EBVALLO, already approved in Europe, can still support a viable U.S. path despite the sudden change of tone on the ALLELE trial. - [Altimmune Inc ( $ALT ) Q4 2025 results and plans 2026 global Phase 3 MASH](https://www.merlintrader.com/altimmune-inc-q4-20025-results/): Altimmune closes 2025 with $274 million in cash and short-term investments and roughly $340 million pro forma after a January 2026 direct offering, while its lead asset pemvidutide moves toward a global Phase 3 trial in MASH and a key Phase 2 readout in alcohol use disorder (RECLAIM) expected in Q3 2026. - [CorMedix (CRMD) – From single-asset grind to commercial anti-infective platform ](https://www.merlintrader.com/cormedix-crmd-platform/): A narrative and technical deep dive on CorMedix after full-year 2025 and Q4 numbers: what DefenCath plus Melinta really changed, how the new P&L looks, and where the risk-reward sits going into 2026–2027. - [Castellum Inc ($CTM) – FY 2025 Results & 2026 Execution](https://www.merlintrader.com/castellum-inc-fy2025-results/): On March 4, 2026, Castellum Inc. announced its unaudited FY 2025 financial results, and the numbers reveal a company that has fundamentally shifted trajectory. After years of acquisition-driven roll-up activity, balance sheet stress, and constant capital raises, CTM is now reporting organic revenue growth, positive adjusted EBITDA, and—perhaps most significantly—has completely eliminated all outstanding debt. This is not a dramatic overnight turnaround; rather, it is the culmination of methodical execution: progressive debt paydown, operational efficiency improvements, successful Navy contract wins, and a disciplined capital allocation strategy that prioritizes sustainability over growth-at-any-cost. - [BioXcel Therapeutics Inc ( $BTAI ) BXCL501 in opioid withdrawal](https://www.merlintrader.com/bioxcel-therapeutics-inc-btai-bxcl501-in-opioid-withdrawal/): Positive topline Phase 2 results from a Columbia University-led study suggest that BXCL501 may match or outperform lofexidine in opioid withdrawal, with a cleaner tolerability profile. But BioXcel is still a small-cap with a fragile balance sheet: can this new data point reshape the long-term story for IGALMI/BXCL501 and the broader pipeline? - [Palladyne AI Corp ( $PDYN ) Deep Dive after Q4 & 2025 Full year Results](https://www.merlintrader.com/palladyne-ai-2025-results/): A detailed look at Palladyne AI’s fiscal 2025 numbers, backlog and capital structure after the latest annual report and guidance update. - [Verastem Oncology ( $VSTM )](https://www.merlintrader.com/verastem-oncology-vstm/): First commercial year for AVMAPKI FAKZYNJA CO-PACK in KRAS-mutant LGSOC delivered $30.9M in net product revenue, Japan’s RAMP 201J bridged exposure and responses in both KRAS-mutant and wild-type disease, and management now promises a self-sustaining LGSOC franchise by 2H 2026 — with RAMP 301 confirmatory data only in mid-2027. - [Aquestive Therapeutics ( $AQST ): Anaphylm after the CRL](https://www.merlintrader.com/aquestive-therapeutics-mar04-update/): Aquestive remains pre-commercial on Anaphylm, with a manufacturing-driven revenue base, a sizeable cash cushion and a clearly negative EBITDA profile in 2026 as it funds the resubmission and maintains a pre-launch infrastructure. - [BriaCell Therapeutics Corp ( $BCTX ) Phase 3 BRIA-ABC](https://www.merlintrader.com/briacell-therapeutics-corp-phase3/): BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company developing cell-based therapies for advanced breast cancer and other solid tumors. The core asset, Bria-IMT™ plus a checkpoint inhibitor, is in a pivotal Phase 3 study (BRIA-ABC) in heavily pre-treated metastatic breast cancer (MBC) under FDA Fast Track designation. - [SNDL Inc. ( $SNDL ) from meme cannabis trade to cash-rich retail platform](https://www.merlintrader.com/sndl-inc-meme-cannabis/): SNDL today is a hybrid animal: one of Canada’s largest private liquor and cannabis retailers, a vertically integrated cannabis operator and an investment platform deploying capital into the North American industry. The numbers are getting cleaner, the balance sheet is strong, but the equity story is still controversial. - [Aurora Cannabis Inc ( $ACB ) Medical Cannabis Leader + Strategic Pivot to Global Markets](https://www.merlintrader.com/aurora-cannabis-inc/): Aurora Cannabis is a Canadian medical cannabis company undergoing a strategic transformation. In Q3 FY2026 (ended December 31, 2025), Aurora reported estimated $94.2M CAD in net revenue (+7% YoY), with record medical cannabis revenue of $76.2M CAD (+12% YoY). The company is pivoting aggressively toward high-margin global medical markets (especially Germany, Poland, Australia, UK), exiting lower-margin consumer segments in Canada, and divesting its plant propagation business. - [Ocugen Inc ( $OCGN ) MAR 04 Bussines Update](https://www.merlintrader.com/ocugen-inc-mar04-bussines-update/): Q4 2025 business update in focus: where Ocugen stands after another loss-making year, how the OCU400/410 platform is evolving, and what really matters for the next 18–24 months in gene therapy and anti-aging. - [Klotho Neurosciences Inc. ( $KLTO )](https://www.merlintrader.com/klotho-neurosciences-inc/): EN IT NASDAQ: KLTO Klotho Neurosciences Inc. Gene Therapy for Neurodegeneration + Strategic Minerals Division Market Cap: ~$39.6M | Price: $0.54 | YTD: -86.2% Chart: 1-year daily bars | Current Price: $0.54 | 52-week range: $0.11–$3.91 Data as of March 4, 2026 NEXT MAJOR CATALYST Greenland Mines Integration & KLTO-202 Progress Completed March 4, 2026: […] - [Ondas – $20M initial border-defense order ( $ONDS )](https://www.merlintrader.com/ondas-20m-border-defense/): Ondas’ Airobotics subsidiary has received a $20 million initial purchase order as prime contractor under a strategic national Autonomous Border Protection Program – the formal launch of a multi-year, multi-phase architecture built around thousands of AI-driven drones. - [Can-Fite Biopharma Ltd ADR ( $CANF )](https://www.merlintrader.com/can-fite-biopharma/): Deep dive after the March 4, 2026 Phase IIa update of Namodenoson in advanced pancreatic ductal adenocarcinoma (PDAC), with a full look at pipeline, balance sheet, governance, bull & bear case, and retail sentiment. - [Actelis Networks ( $ASNS ) – Cyber-Hardened Networking For Critical Infrastructure In 2026](https://www.merlintrader.com/actelis-networks-2026/): Ultra-microcap deep dive on Actelis Networks after a series of transportation, utility and carrier orders, reverse split and financing moves. Focus on the core technology, recent contracts, balance sheet stress and the asymmetry between operational progress and capital structure risk. - [Asana Inc ( $ASAN ) Scaling SaaS & 2026 Growth Trajectory](https://www.merlintrader.com/asana-inc-2026-growth/): Asana Inc. (ASAN) – Work Management Platform & 2026 Growth Trajectory NYSE: ASAN · SaaS · Work Management Platform Asana Inc. (ASAN) – Scaling SaaS and 2026 Growth Trajectory SaaS deep-dive report – focus on product platform, financial performance, customer metrics and growth scenarios around FY2026 results and the FY2027 outlook. Report date: 4 March […] - [Ocugen Inc ( $OCGN )](https://www.merlintrader.com/ocugen-mar04-2026/): Headline today: Ocugen will host its Q4 and full-year 2025 conference call and live webcast today at 8:30 a.m. ET (14:30 CET), giving investors a first chance to hear management on cash, strategy and the OCU400 program, just days after the company announced completion of enrollment in the Phase 3 liMeliGhT trial for retinitis pigmentosa. - [Mobix Labs Inc ( $MOBX )](https://www.merlintrader.com/mobix-labs-inc-tomahawk-demand/): Mobix Labs, a tiny defense and connectivity component supplier, just caught a massive bid after announcing a new production order for its high-reliability filtering component inside the U.S. Navy Tomahawk cruise missile program. Behind the headline, the story is a mix of real programs (Tomahawk, M-1 Abrams, drone platform), aggressive M&A, heavy dilution and a very tight liquidity position. - [Tilray Brands Inc ( $TLRY ) From cannabis hype to beer-and-cannabis conglomerate](https://www.merlintrader.com/tilray-brands-inc/): From cannabis hype to beer-and-cannabis conglomerate: how Tilray is trying to turn a decade of dilution and volatility into a diversified, cash-generating platform built on craft beverages, medical distribution and North American optionality. - [Canopy Growth Corporation ( $CGC )](https://www.merlintrader.com/canopy-growth-corporation/): Canada-based cannabis company with operations spanning adult-use and medical cannabis in Canada and international markets, medical brands (including expanding insured-patient channels) and inhalation hardware via premium vaporizer brand Storz & Bickel. - [Another war in the "Gulf"](https://www.merlintrader.com/another-war-in-the-gulf/): A few days after the first wave of attacks, the war is no longer just a story of missiles over Tehran. It now stretches from southern Lebanon to the Strait of Hormuz, from Syrian and Iraqi corridors to the LNG hubs of Qatar and Saudi Arabia, with oil and gas prices repricing risk in real time. - [Intuitive Machines Inc ( $LUNR )](https://www.merlintrader.com/intuitive-machines-tracking-layer/): L3Harris selects Intuitive Machines to provide satellite platforms for the Tracking Layer of the Space Development Agency’s Proliferated Warfighter Space Architecture (PWSA): a key step in LUNR’s transition from “lunar lander pure play” to integrated space-infrastructure and defense supplier, with rapidly changing fundamentals and a capital-intensive profile. - [Red Cat Holdings Inc ( $RCAT )](https://www.merlintrader.com/red-cat-holdings-allen-control/): Red Cat has announced that Allen Control Systems (ACS), a specialist in autonomous precision weapon systems, is joining the Red Cat Futures Initiative – the company’s consortium aimed at accelerating advanced robotics and autonomy for modern warfare. The core of the deal is the integration of ACS’s Bullfrog system, an AI-driven robotic weapon station designed for counter-drone and precision engagement roles. - [AST SpaceMobile Inc ( $ASTS )](https://www.merlintrader.com/ast-spacemobile-q425-earnings/): Revenue $54.3M in Q4 · $70.9M in FY 2025 First year as a revenue-generating company: gateway deliveries and initial U.S. government contracts pushed 2025 sales to $70.9M, with Q4 alone at $54.3M. The model is still loss-making: FY 2025 net loss attributable to common stockholders was about $342M, with Q4 loss around $74M and EPS of –$0.26 per share. - [Strata Critical Medical Inc ( $SRTA ) Q4 2025 results and 2026 guidance](https://www.merlintrader.com/strata-critical-medical-q4results/): Time-critical logistics and clinical services for organ transplantation, now operating as a pure-play medical services platform after exiting passenger air mobility. Q4 2025 marks the first full quarter including Keystone’s perfusion business and a substantial reset of the 2026 growth trajectory. - [Tonix Pharmaceuticals ( $TNXP ) uplisted to Nasdaq Global Select Market](https://www.merlintrader.com/tonix-pharmaceuticals-uplisted/): Tonix Pharmaceuticals (TNXP) moves from Nasdaq Capital Market to the higher-tier Nasdaq Global Select Market and confirms a visible presence at TD Cowen and Barclays healthcare conferences in early March 2026. - [Plug Power Inc ( $PLUG ) Hydrogen Turnaround or Capital-Intensive Value Trap?](https://www.merlintrader.com/plug-power-inc-plug/): Plug Power wants to be more than a meme hydrogen stock. In its filings and official presentations, the company describes itself as a provider of comprehensive hydrogen solutions that cover: – Electrolyzers for green-hydrogen production, – Production plants and liquefaction/purification infrastructure, – Distribution and logistics (trailers, storage, on-site equipment), and – End-use systems for material handling, stationary power and mobility. - [BigBear.ai Holdings Inc ( $BBAI ) Q4 2025 reset, cash arsenal & 2026 AI-defense roadmap](https://www.merlintrader.com/bigbear-ai-holdings-inc-q4202/): The company prints a sharp revenue decline but a much narrower net loss, closes Ask Sage and CargoSeer, and walks into 2026 with over $460 million in cash and investments — at the price of massive dilution and a complex capital structure. Retail is back in the name, but the story is anything but low-risk. - [uniQure N.V ( $QURE ) FDA says AMT-130 data not enough yet, shares collapse](https://www.merlintrader.com/uniqure-amt130-data-not-enough/): uniQure’s stock is getting crushed after the company disclosed that the U.S. Food and Drug Administration does not consider current Phase I/II data for AMT-130 in Huntington’s disease sufficient to support a marketing application, and is instead recommending a fresh prospective, randomized, double-blind, sham surgery-controlled Phase III trial. - [Red Cat Holdings Inc ( $RCAT ) From niche drone supplier to all-domain autonomy play](https://www.merlintrader.com/red-cat-holdings-inc-drone-supplier/): Red Cat is positioning itself as a U.S.-based provider of all-domain unmanned and autonomous systems rather than as a simple “drone stock”. The company aggregates several assets under one umbrella: - [Outlook Therapeutics Inc ( $OTLK ) Updated march 6 post type A meeting with FDA](https://www.merlintrader.com/outlook-therapeutics-inc-comeback-story/): Outlook Therapeutics has become a fault line: some investors see a possible turnaround built on LYTENAVA’s European rollout and an FDA dialogue still technically open, others see only years of CRLs, value destruction and structural dilution risk. To really understand the stock you have to hold both sides of the story at the same time. - [Ondas Inc ( $ONDS ) $10M stratospheric ISR bet with World View](https://www.merlintrader.com/ondas-stratospheric-isr/): $10M strategic equity investment in World View and a partnership to integrate persistent stratospheric platforms (Stratollite®) with Ondas’ autonomous UAS and counter-drone capabilities for multi-layer ISR and airspace defense. - [Intellia Therapeutics Inc ( $NTLA )](https://www.merlintrader.com/intellia-therapeutics-march26/): The FDA has lifted the clinical hold on MAGNITUDE, the Phase 3 trial of nexiguran ziclumeran (nex-z, ex NTLA-2001) in transthyretin cardiomyopathy. After months of uncertainty following a severe liver event and a patient death, Intellia and Regeneron can enrol again. This update revisits the thesis we outlined in the previous Merlintrader deep dive and asks what this decision really changes for the risk/reward profile of Intellia's in vivo CRISPR platform. - [US Energy Corp ( $USEG )](https://www.merlintrader.com/us-energy-corp/): With oil back in focus after U.S.–Israeli strikes on Iran and renewed risk around the Strait of Hormuz, U.S. Energy Corp. (USEG) offers a very different angle from the majors: a small, vertically integrated platform trying to combine legacy oil and gas production with a large industrial gas and carbon management project at Kevin Dome in Montana. This is a deep dive into what USEG really is, how Kevin Dome fits into the 2026 energy landscape, and which catalysts matter from here. - [Lantheus ( $LNTH ) 2026: radiopharma at a crossroads with two March FDA decisions](https://www.merlintrader.com/lantheus-2026-crossroads/): March 6, 2026 – FDA PDUFA for new PSMA PET formulation (prostate cancer imaging) and March 29, 2026 – FDA PDUFA for OCTEVY, a new radiodiagnostic asset. These two decisions define the short-term binary risk / reward for LNTH after the Q4 2025 reset, while a third PDUFA for the tau tracer MK-6240 is scheduled for mid-August. - [Taxing unrealised gains: why the Dutch “experiment](https://www.merlintrader.com/taxing-unrealized-gains-nl/): Taxing unrealised gains: why the Dutch “experiment” is a red line for investors A closer look at the Actual Return Box 3 proposal in the Netherlands, why a 36% tax on unrealised portfolio gains is structurally toxic, and what this could mean for retail investors in the rest of Europe. Capital taxation · Netherlands · […] - [WAR US–Israel vs Iran, 2026 Small & mid-cap potential “winners & losers”](https://www.merlintrader.com/war-us-israel-iran-2026/): Focus on factual developments of the last few days (Strait of Hormuz, tankers at anchor, oil spike) and on a sector-based watchlist – not on trying to predict the endgame of the conf - [Karyopharm Therapeutics ( $KPTI ) ENTRY phase 3 readout approaching](https://www.merlintrader.com/karyopharm-therapeutics-inc-phase3-entry/): After a challenging 2025 but with a stable revenue base from XPOVIO, Karyopharm enters 2026 with three critical late-stage selinexor shots on goal: the Phase 3 SENTRY readout in myelofibrosis around March, the Phase 3 XPORT-EC-042 trial in endometrial cancer around mid-year, and the Phase 3 XPORT-MM-031 study in multiple myeloma in the second half of the year. This Daily Hit summarizes the latest management commentary and how the near-term risk/catalyst profile is set up. - [Aardvark Therapeutics Inc ( $AARD )pause of Phase 3 HERO trial in Prader](https://www.merlintrader.com/aardvark-therapeutics-pause-trial/): A closer look at the decision to voluntarily pause the Phase 3 HERO trial of ARD-101 in Prader–Willi syndrome, the emerging safety signal, the new competitive landscape in hyperphagia and the key milestones that will shape the path forward into and beyond the Q2 2026 update. EN IT - [BioNTech SE ADR ( $BNTX )From Covid Breakout to Oncology Powerhouse in the Making](https://www.merlintrader.com/biontech-se-adr/): How a Mainz-based research project turned into a global vaccine champion, and how the company is now trying to convert an unprecedented Covid cash pile into a multi-product oncology franchise built on mRNA, individualized vaccines and next-generation immunotherapies. - [Arcturus Therapeutics Holdings Inc ( $ARCT ) March 3 earnings test](https://www.merlintrader.com/arcturus-therapeutics-holdings/): With Q4 2025 results and a strategic update due on March 3, 2026, Arcturus enters a high-stakes phase: the inhaled mRNA program in cystic fibrosis (ARCT-032) must justify its continuation after mixed Phase 2 data, while vaccine royalties, cost controls and a long cash runway are asked to support a pipeline increasingly focused on rare diseases. - [War in Iran 2026 – Geopolitics, Oil Shock Risk and Market Winners & Losers](https://www.merlintrader.com/war-in-iran-feb2026/): An editorial look at what the new Iran–Israel–US conflict could mean for global power balances, for oil and shipping routes, and for the sectors and individual stocks that tend to benefit or suffer when the Middle East becomes the epicentre of risk. EN IT - [Weekly Recap & Briefing –  Iran War Risk, Energy Shocks and Catalyst Trading (Feb 23–27, 2026)](https://www.merlintrader.com/weekly-recap-briefing-iran-war/): The new week opens with markets forced to reprice global risk after coordinated US–Israel strikes on Iran and retaliatory missile attacks on US bases across the Gulf and on Israel itself. Oil and shipping risk premia jump, while gold and defense stocks rediscover their role as hedges. At the same time, AI and chips are coming off a volatile stretch after Nvidia’s “beat and fade” reaction, Rocket Lab posts record revenue and backlog, and small-cap biotech continues to trade on single-name catalysts rather than broad factor flows. This recap looks at where we are, how the Iran conflict feeds into energy and risk assets, and which names go on the watchlist for the coming days across defense, energy, space, biotech and AI. - [Uranium Energy Corp ( $UEC ) From explorer to integrated U.S. uranium supplier?](https://www.merlintrader.com/uranium-energy-corp/): UEC is positioning itself as one of the key U.S. uranium names for the new nuclear cycle: in-situ recovery hubs in Texas and Wyoming, a large resource and project base in the United States and Canada, and the launch of a dedicated refining and conversion vehicle designed to move the company beyond the role of “pure miner” into the broader fuel value chain. - [IREN Ltd ( $IREN )](https://www.merlintrader.com/iren-ltd-iren/): IREN Limited, formerly Iris Energy, is rapidly transforming itself from a cyclical Bitcoin miner into a vertically integrated AI infrastructure provider, combining long-duration power contracts, hyperscale data centres and multi-year GPU cloud deals with blue-chip counterparties. The next phase of the story is all about execution: how fast the company can switch its asset base to AI, how stable those cloud revenues become and how it balances growth ambitions with leverage and dilution. - [AtaiBeckley Inc. ( $ATAI ) Building a late-stage psychedelics platform Updated March & 2025](https://www.merlintrader.com/ataibeckley-inc-atai/): AtaiBeckley is no longer just “another psychedelics stock”: after the combination between atai Life Sciences and Beckley Psytech, the company now controls one of the most advanced late-stage pipelines focused on interventional psychiatry for treatment-resistant depression (TRD) and social anxiety disorder (SAD). The three flagship assets — BPL-003, VLS-01 and EMP-01 — are all in Phase 2 or entering Phase 3 planning, which puts AtaiBeckley structurally ahead of most early-stage psychedelics peers still working through small, single-site trials. - [i-80 Gold Corp ( $IAUX ) Nevada hub-and-spoke gold growth story under construction](https://www.merlintrader.com/i-80-gold-corp-iaux/): i-80 Gold Corp (IAUX) – Nevada hub-and-spoke gold growth story 2026 Gold & Precious Metals – Deep Dive 2026 i-80 Gold Corp (IAUX) – Nevada hub-and-spoke gold growth story under construction A Nevada-focused gold developer trying to turn a cluster of underground and open-pit deposits plus the Lone Tree processing hub into a scalable production […] - [BigBear.ai Holdings Inc ( $BBAI )](https://www.merlintrader.com/bigbear-ai-holdings-inc/): BigBear.ai is trying to turn years of work in defense intelligence, mission planning and logistics optimization into a scalable AI platform story, boosted by large capital raises and the acquisition of generative-AI partner Ask Sage. Revenues are meaningful and the cash cushion is large, but the path from contract wins to durable, profitable growth remains complex and execution-dependent. - [SKYX Platforms Corp ( $SKYX ) Smart Ceiling Plugs](https://www.merlintrader.com/skyx-platforms-corp-skyx-smart-ceiling-plugs/): SKYX Platforms is trying to turn a seemingly boring standard – the ceiling light socket – into a plug-and-play infrastructure layer for lighting and smart-home devices, backed by dozens of patents, distribution partnerships and collaborations with larger technology players. Revenue growth is strong and the product vision is ambitious, but the business is still loss-making and depends on external capital, disciplined execution and a long time horizon. - [Rocket Pharmaceuticals ( $RCKT ) — Q4/FY 2025 results Road to March28-Pdufa](https://www.merlintrader.com/rocket-pharmaceuticals-march28-pdufa/): This update is anchored to the company’s latest filing that laid out (1) the reiterated March 28, 2026 FDA action date for KRESLADI, (2) the resumption plan for Danon dosing in 1H 2026, and (3) the year-end 2025 cash position and runway guidance. The goal is to keep it neutral: what was said, what it implies, and where the remaining uncertainty still lives. - [New Found Gold Corp ( $NFGC )](https://www.merlintrader.com/new-found-gold-corp-nfgc/): From pure exploration play to potential emerging producer: where New Found Gold stands after years of drilling at Queensway and the fresh Hammerdown PEA, and what really matters for risk/reward over the next cycle. - [Americas Gold and Silver Corp ( $USAS ) Record production and the 2026 Inflection](https://www.merlintrader.com/americas-gold-and-silver-corp-usas/): Americas Gold and Silver Corporation (NYSE American: USAS / TSX: USA) is a Toronto-based junior silver producer with three active mining assets in the United States and Mexico. After years of restructuring, the company has entered a genuine inflection phase: FY2025 silver production reached a record 2.65 million ounces (+52% YoY), the Q3 FY2025 adjusted EBITDA turned positive for the first time, and analyst consensus revenue forecasts for FY2026 have been revised up by +265% to $383 million. - [United States Antimony ( $UAMY ) – domestic critical minerals with a multi-year Pentagon angle](https://www.merlintrader.com/united-states-antimony/): UAMY operates the only antimony smelters in North America and is trying to evolve from a small specialty-metals producer into a strategic supplier to the U.S. defense stockpile, underpinned by record revenue growth, a five-year Defense Logistics Agency contract and fresh capital to expand mining and processing capacity. - [Kopin Corp ( $KOPN ) Defense-grade optical systems and NeuralDisplay pivot](https://www.merlintrader.com/kopin-corp-optical-systems/): Two-year timeline, current pipeline and ownership structure for a small-cap U.S. microdisplay specialist transitioning from R&D-heavy contracts to higher-margin defense and industrial production. - [Mannkind Corp ( $MNKD ) after the Tresmi shock](https://www.merlintrader.com/mannkind-corp-mnkd/): A first full-scope look at MannKind after Q4 2025 results and United Therapeutics’ new soft-mist treprostinil product (“Tresmi”), with focus on revenue mix, 2026 catalysts, balance sheet, insider and institutional positioning, analyst expectations and retail sentiment around the latest 35–40% drawdown. - [Intuitive Machines ( $LUNR ) 175M Equity Raise Lanteris Integration and the Road to a Space Prime](https://www.merlintrader.com/intuitive-machines-feb26-update/): Update as of late February 2026: how the new 175M strategic equity investment, the Lanteris and KinetX acquisitions and NASA’s Near Space Network roadmap reshape the Intuitive Machines story – and when dilution turns into real infrastructure. - [Ondas Holdings ( $ONDS ) Asia-Pacific defence contract Feb 2026](https://www.merlintrader.com/ondas-holdings-asi-pacific-contract/): A new multi-phase contract with an Asia-Pacific government for autonomous unmanned aerial systems adds another piece to the Ondas puzzle – and fits into a broader defence-spending upswing that is favouring drone, counter-drone and autonomous surveillance platforms. - [BlackSky Technology Inc ( $BKSY )](https://www.merlintrader.com/blacksky-technology-inc-bksy/): Q4 2025 delivered record quarterly revenue and a sharply narrower net loss, while management doubled down on Gen-3 very-high-resolution satellites and real-time AI analytics. At the same time, the new $100 million at-the-market equity program changed the risk-reward for equity holders. This report puts the latest numbers, the 2026 guidance and the capital structure into context, with a focus on how BKSY fits into the broader “Golden Dome” and space-defence narrative we follow at Merlintrader. - [Novavax ( $NVAX ) Q4 2025 and the Matrix-M platform](https://www.merlintrader.com/novavax-q42025-matrix/): Q4 2025 finally shows what the long Novavax story on Merlintrader was pointing to: revenue above 1.1 billion dollars for the year, a clean return to GAAP profitability in the quarter, and a 2026–2028 roadmap where Sanofi, Pfizer and other partners, not Novavax alone, carry most of the execution risk around Matrix-M. - [Biocryst Pharmaceuticals Inc ( $BCRX )Feb26 2026](https://www.merlintrader.com/biocryst-pharmaceuticals-inc-feb2026/): FY 2025 marks an inflection point for BioCryst. After years of heavy investment to launch ORLADEYO, the company has finally delivered a clearly profitable year: total revenue reached roughly 875M USD in 2025, versus ~451M USD in 2024, and the P&L flipped from a small operating loss to more than 340M USD of operating profit. The key driver was ORLADEYO net revenue of about 602M USD, up nearly 40% year on year, supported by strong new-patient growth in the U.S. and a better-than-guided performance overall. - [Teva- Pharmaceutical Industries ( $TEVA ) Feb26 2026](https://www.merlintrader.com/teva-pharmaceutical-industries-teva-feb26-2026/): As of late February 2026, Teva combines a still-massive generics footprint with a focused innovative portfolio in CNS and immunology. After a lost decade of litigation, write-downs and restructuring, the company is now delivering mid-single-digit top-line growth, expanding non-GAAP margins and generating roughly $2.4B of free cash flow per year while steadily reducing debt. - [Protalix BioTherapeutics Inc ( $PLX ) March 2026 catalyst window](https://www.merlintrader.com/protalix-biotherapeutics-inc-march-2026/): Follow-up to our previous PLX work: from CHMP’s positive view on the every-four-week Elfabrio regimen to a binary European decision, a new earnings call in mid-March and the next steps for the uncontrolled-gout program PRX-115 – with PLX now trading back into a resistance area close to last year’s highs. - [Cardiff Oncology Inc ( $CRDF ) 2025 results CRDF-004 data](https://www.merlintrader.com/cardiff-oncology-inc-2025results/): 2025 results, CRDF-004 data - [Eton Pharmaceuticals Inc ( $ETON) Feb25 FDA OK](https://www.merlintrader.com/eton-pharmaceuticals-inc-2/): The U.S. Food and Drug Administration has approved DESMODA (desmopressin acetate) oral solution for the treatment of central diabetes insipidus, also known as arginine vasopressin deficiency (AVP-D), in adults and pediatric patients. This is the first and only FDA-approved ready-to-use oral solution of desmopressin, a meaningful upgrade in day-to-day management of this rare water-balance disorder. - [POET Technologies Inc ( $POET ) 2025–2026 Capital Ramp](https://www.merlintrader.com/poet-technologies-inc-poet/): Updated overview of POET Technologies after the 2025 production orders, equity financings and the 2026 Lightwave award: technology, product line, financial profile, partnerships, retail sentiment and key risk factors. - [Redwire QKDSat – European Quantum Security and the Broader 2026 Narrative](https://www.merlintrader.com/redwire-qkdsat-european-quantum-security-2026/): Redwire’s 2 April 2026 QKDSat announcement matters less for immediate revenue math and more for what it says about the company’s position inside the next layer of European sovereign space infrastructure. According to publicly reported company news on 2 April 2026, Redwire was awarded a contract connected to the European Space Agency’s Quantum Key Distribution Satellite (QKDSat) program. The mission is framed around a quantum-secure spacecraft and sits within the broader ESA ARTES ecosystem, which is designed to support advanced telecommunications and secure connectivity programs. - [Foundayo gets there first, and it is a pill: why this approval really changes the competitive setup for Altimmune and Viking](https://www.merlintrader.com/altimmune-vinking-foundayo-apr2026/): The FDA approval of Foundayo, Eli Lilly’s oral small-molecule GLP-1, does not automatically destroy the cases for Altimmune or Viking Therapeutics. But it does make the field more selective and far less forgiving. Lilly is not just early. Lilly is early with an approved product, near-term availability, an already powerful weight-management brand, a pill format that lowers the psychological barrier to starting therapy, and a commercial message built around access and simplicity. From this point forward, it is no longer enough to say that an obesity candidate has promising data. The real question is why the market should wait for it when the category leader has already put a real pill, ready for launch and ready for normalization inside the treatment pathway, on the table. - [Eli Lilly ( $LLY ) — Foundayo’s FDA approval may be more than a product launch](https://www.merlintrader.com/eli-lilly-foundayo-approval-apr2-2026/): The FDA approval of Foundayo, the brand name for oral small-molecule GLP-1 orforglipron, matters well beyond the usual “new drug approved” headline. Lilly already had one of the most powerful obesity franchises in the world through Zepbound. What it lacked was a simpler oral front door into the same therapeutic universe. Foundayo changes that. It adds a once-daily pill, no food restrictions, no water restrictions and an immediate commercial launch path. More importantly, it gives Lilly a second format that could widen the patient funnel, reduce psychological barriers to treatment initiation and deepen control over the obesity journey from entry-level adoption to higher-intensity therapy. - [Artemis II — A Tribute to the Brave Who Walk Toward the Future](https://www.merlintrader.com/artemis-tribute-to-the-brave/): Apollo was one of the defining achievements of the twentieth century, but it also left behind a strange inheritance. It proved that human beings could leave Earth, navigate across cislunar space, land on another world, and come home. Then, after proving it, the United States stopped going. The Moon remained in the cultural imagination, in schoolbooks, documentaries, museum halls, and old family conversations, but not in the rhythm of ordinary current events. - [Firefly Aerospace ( $FLY ) Alpha Flight 7 worked](https://www.merlintrader.com/firefly-aerospace-alpha-flight/): Firefly is easier to understand after March 2026 than it was a few months ago. Alpha Flight 7 reached orbit, delivered a Lockheed Martin payload, performed a stage-two relight, and validated key Block II upgrades ahead of Flight 8. That matters because the company badly needed a clean operational proof point after prior launch and test setbacks. The core story today is no longer “can Firefly do anything?” but “can Firefly string multiple wins together without burning too much cash along the way?” - [Tilray Brands ( $TLRY ): Q3 FY2026 says the story is still alive](https://www.merlintrader.com/tilray-brands-q3fy2026/): In early March, the core question around Tilray was not whether the company could tell a big story. It was whether that story was finally becoming tangible. Q3 FY2026 does not solve every doubt, but it does move the debate forward: cannabis improved, distribution stayed strong, margins held up better than feared, adjusted EBITDA grew, and the balance sheet still looks workable. The weak point remains the same one the market keeps circling around: beverage execution and the long shadow of dilution. - [Sidus Space ( $SIDU )after Q4 2025: our thesis, what is being confirmed, and what still needs to be proven](https://www.merlintrader.com/sidus-space-sidu-after-q4-2025/): Sidus Space has become one of those names that attract attention for a reason. It sits at the intersection of several powerful themes — small satellites, on-orbit processing, dual-use space and defense technology, edge AI, and the broader U.S. national-security buildout. But attractive themes alone are not enough. The real question for investors has always been simpler and harder at the same time: is Sidus merely assembling a compelling narrative, or is it actually building a business that can one day justify the story? - [Omeros ( $OMER ): the post-approval story is finally turning, early commercial momentum is here, and the next upside chapter may be starting](https://www.merlintrader.com/omeros-post-approval-march31-2026/): The new March 31, 2026 press release did not simply deliver an earnings update. It effectively marked the first real post-approval checkpoint for Omeros. The company is no longer only a regulatory event story. After the December 23, 2025 FDA approval of YARTEMLEA for TA-TMA and the January 2026 U.S. launch, the central question has changed. The market is now asking whether the company can convert medical need, regulatory exclusivity and first-mover status into a durable commercial franchise. - [Aquestive Therapeutics After the CRL ( $AQST ): what changed, what still matters, and how much balance-sheet room is left](https://www.merlintrader.com/aquestive-therapeutics-after-crl-march2026/): Where the story stands today is more nuanced than the tape action around the January disappointment made it look. The FDA did not throw out the Anaphylm package because the drug failed on efficacy, because the core clinical bridge broke, or because major chemistry, manufacturing, and controls issues surfaced. The company’s February disclosure said the Complete Response Letter was focused on administration, labeling guidance, human factors deficiencies, and one supportive pharmacokinetic study tied to the packaging and labeling changes. In plain English, this was bad news, but it was not the same thing as a fundamental collapse of the program. The market then needed a second question answered: would management actually get the FDA onto a defined remediation path, or would this turn into a vague, open-ended delay? The March 30 Type A meeting update is important because it is the first sign that the post-CRL process is becoming more concrete. AQST said the FDA gave clarifying feedback on both the PK and human factors study designs, acknowledged the changes to the pouch opening mechanism, and aligned on the concept of using labeling language to manage potential chewing of the film rather than demanding additional clinical data. That does not mean approval is in the bag. It does mean the company has moved from uncertainty to a more actionable playbook. - [Axsome Therapeutics ( $AXSM ) — April 24 update, 2026 deep dive: setup to the April 30 PDUFA](https://www.merlintrader.com/axsome-therapeutics-march31-2026-dd/): A full follow-up report built from the January 2, 2026 setup and updated through March 31, 2026, focused on the Alzheimer’s disease agitation PDUFA, commercial momentum, management depth, cash and dilution risk, ownership, sell-side posture, retail sentiment, forward catalysts, scenarios, red flags and bottom line. - [Polar Power Inc ( $POLA )](https://www.merlintrader.com/polar-power-inc-dd31mar-2026/): Polar Power, Inc. (NASDAQ: POLA) is a Gardena, California-based designer and manufacturer of direct current (DC) power generation systems serving telecommunications, military, commercial, and industrial markets globally. As of the quarter ended September 30, 2025 and filed on November 19, 2025, POLA was in severe financial distress. Primary-source review confirms $4K cash, sharp year-over-year sales deterioration in Q3 2025, and material pressure on liquidity and financing. The original draft referenced a going concern warning from auditors, an eviction summons on the headquarters facility, lender covenant breach, and a $5.3M backlog. Of these, the cash position and broader distress are confirmed directly by the 10-Q; some of the more specific legal and audit formulations require direct supporting passages beyond what was fully retrieved in this review. This remains a binary turnaround speculation, not an investment-grade opportunity. Execution on backlog, continued lender tolerance, and facility continuity could support survival. Failure on one or more of those fronts would materially increase restructuring or bankruptcy risk. - [Agios Pharmaceuticals ( $AGIO ): the story did not end with the sickle-cell disappointment](https://www.merlintrader.com/agios-pharmaceuticals-march31-2026/): Agios is not the same story it was one year ago, and it is not even the same story it was right after the market reacted badly to the November 2025 RISE UP data. The cleanest way to frame the company today is not as a single-product binary biotech and not as a fully de-risked rare-disease compounder either. It sits somewhere in the middle. There is now a real commercial base, a very strong balance sheet by biotech standards, a broader geographic footprint for mitapivat in thalassemia, and a reopened regulatory path in sickle cell disease that most investors had at least partially discounted after the mixed Phase 3 readout. - [Sangamo Therapeutics ( $SGMO ) — Q4 2025 earnings, rolling BLA progress, cash pressure and dilution risk](https://www.merlintrader.com/sangamo-therapeutics-q4-2025/): Sangamo’s March 30, 2026 earnings release did not break the SGMO story. It clarified it. The company still has one asset that can genuinely change perception — ST-920 in Fabry disease — and one problem that can still overwhelm everything else — money. The clinical and regulatory side remains credible enough to keep the name alive. The balance sheet remains weak enough to keep common shareholders on a short leash. - [Virgin Galactic (SPCE): why the stock jumped after earnings, what the March 30 update really changed, and what the market will watch next](https://www.merlintrader.com/virgin-galactic-march30-update/): Virgin Galactic’s after-hours rebound was not about a sudden return to revenue. It was about a cleaner execution story: ticket sales reopened at $750,000 per seat, the first of the new SpaceShips is moving into ground testing in April, flight testing is still targeted for Q3 2026, commercial operations remain on track for Q4 2026, and the second ship is now framed for service between late Q4 2026 and early Q1 2027. In a stock as depressed and timeline-sensitive as SPCE, that combination was enough to trigger a sharp relief move. - [Encyclopedia of Social Trader Myths – Vol. 3The Self-Inflicted Edition](https://www.merlintrader.com/encyclopedia-social-trader-vol3/): The first myths of social trading usually come from outside: the trending ticker, the guru thread, the magical catalyst calendar, the cult of “smart money,” the promise that one more breakout will fix your year. But the deeper myths are the private ones. They appear after the chart turns ugly, after the timing fails, after the confidence starts cracking. That is when the internal narrator goes to work. This third volume is about those myths. Not the noisy lies from the feed, but the polished lies traders tell themselves when they need to protect pride, postpone discomfort, and keep a bad trade emotionally alive for just a little longer. These myths sound reasonable in real time. That is exactly why they are dangerous. - [Summit Therapeutics (SMMT): ELCC 2026 posters, stronger cash, and why retail is trying to rebuild the ivonescimab story](https://www.merlintrader.com/summit-therapeutics-elcc-2026-posters/): The latest Summit update does not magically erase the old debate around overall survival, but it does add new material that retail traders and long-form biotech readers can use to reframe the case: deeper intracranial data, quality-of-life support, a visible FDA date, and a balance sheet that gives the company room to keep pushing an unusually broad ivonescimab program. - [Golden Dome is no longer just a slogan: where the first real money may go](https://www.merlintrader.com/golden-dome-march-2026/): Golden Dome now looks less like a pure political slogan and more like the early framework of a real spending cycle. The most important development is not that the U.S. wants a giant missile shield in the abstract. It is that the discussion has become more operational: estimated cost has moved higher, specific capability layers have been identified for acceleration, and Reuters reported that Anduril and Palantir are working on the software layer while traditional primes such as Lockheed Martin, RTX and Northrop Grumman are involved on the industrial side. - [Viridian Therapeutics ( $VRDN ): why the stock crashed on “positive” REVEAL-1 data](https://www.merlintrader.com/viridian-therapeutics-crashed-on-positive/): Viridian’s REVEAL-1 press release was positive in the narrow, technical sense that matters most for binary biotech trading: the phase 3 trial hit its primary endpoint. Elegrobart, the company’s subcutaneous IGF-1R antibody for active thyroid eye disease, delivered a 54% proptosis responder rate in the every-four-week arm and 63% in the every-eight-week arm, versus 18% on placebo. The Q4W arm also showed strong diplopia data, including 51% complete resolution versus 16% on placebo. That is not failure language. That is a live asset with real activity. And yet the stock was hit as if something had gone badly wrong. - [Lithium Americas ( $LAC ) DD march 30 2026](https://www.merlintrader.com/lithium-americas-dd-march2026/): Lithium Americas is no longer a story that should be read like a generic lithium exploration name. At this stage, it is much closer to a highly leveraged construction-and-financing story centered on one asset, one timetable, and one capital structure: Thacker Pass in Nevada. The company has already crossed the part of the curve where the market mainly debates whether the resource is real. That is not the core issue anymore. The resource and reserve base is already large enough to make the project strategically important, and the company now frames Thacker Pass as the largest known measured-and-indicated lithium resource and proven-and-probable reserve in the world. The market’s real question is simpler and more brutal: can management convert that geological scale into an operating business without losing control of timing, cost, or shareholder dilution? - [Replimune ( $REPL) • Biotech • Oncolytic Immunotherapy](https://www.merlintrader.com/replimune-repl-biotech-oncolytic-immunotherapy/): Replimune is not a “nice little pipeline story” going into spring 2026. It is a high-beta, high-volatility, very real binary event name whose valuation, narrative, financing flexibility, and strategic credibility are all tied in a major way to one date: April 10, 2026. That is the FDA target action date for the resubmitted BLA for RP1 plus nivolumab in advanced melanoma after anti-PD-1 failure. The market already treated the October 2025 acceptance of the resubmission as a major event, and for good reason. This was not a routine update. It was the market’s signal that the story had gone from post-CRL damage control back to live regulatory possibility. - [Altimmune ( $ALT ) May Be One of the Last Shots on Goal in the Obesity-MASH Convergence 2026](https://www.merlintrader.com/altimmune-last-clean-shot-obesity-2026/): After Breakthrough Therapy Designation, 48-week IMPACT data, a financing reset and a clearer 2026 roadmap, the real question is no longer whether Altimmune can generate attention. The real question is whether pemvidutide still deserves to be viewed as one of the last relatively clean independent shots on goal at the intersection of obesity, MASH and broader metabolic-liver disease. - [Perfectly Timed Trades Before Trump’s Moves . Coincidences or an Information Leak in the Market?](https://www.merlintrader.com/perfectly-timed-trades-march-2026/): In recent days, Reuters pulled together a series of episodes that, taken one by one, could look like simple strokes of luck. Seen together, however, they tell a more troubling story: extremely well-timed financial trades placed shortly before political decisions or geopolitical developments tied to the White House and capable of generating very large profits in futures, options and prediction markets. Reuters says it has not proved a direct link between those traders and the Trump administration, but it also says the pattern is serious enough to raise hard questions and to warrant regulatory attention. That distinction matters. The story is not that wrongdoing has been proved. The story is that the timing has become too precise, too repeated and too profitable to be brushed away casually. - [Nektar Therapeutics ( $NKTR ): a full deep dive March 29 2026](https://www.merlintrader.com/nektar-therapeutics-march29/): Nektar has gone from being, for years, a biotech many investors considered tired and heavily scarred to one of the most discussed U.S. biotech stories of 2025–2026. The reason is not empty narrative. It is the combination of the clinical relaunch of rezpegaldesleukin, two dermatology indications that reignited attention, a balance sheet materially strengthened after the large February 2026 financing, and a pipeline that, while still far from commercial stage, now looks much more readable than it did just twelve months ago. - [Astrotech ($ASTC ) Deep Dive — a tiny public shell wrapped around real detection technology](https://www.merlintrader.com/astrotech-deep-dive-march28-2026/): Astrotech is one of those names that can fool almost everyone at first glance. The company name still carries a legacy aerospace flavor, the ticker is tiny, the market capitalization is microscopic, and the chart can make it look like a forgotten penny stock with occasional bursts of life. But once you actually go through the filings, the press releases, the management changes, and the product portfolio, a more nuanced picture appears. Astrotech today is not really a “space” business in the way casual traders might assume. It is a commercialization vehicle built around proprietary mass spectrometry and gas chromatography platforms, with the strongest current business relevance in security screening and detection through 1st Detect, and a secondary emerging angle in field environmental testing through EN-SCAN. - [SpaceX IPO Mania: Why the Internet Is Acting Like the Stock Is Already Public](https://www.merlintrader.com/spacex-ipo-mania/): The quick angle Some companies prepare for a stock-market debut quietly. They hire banks, polish presentations, file paperwork, and wait for the financial press to notice. SpaceX is clearly not doing that. Long before a confirmed public debut, it has already turned into a giant conversation online. That alone makes the story interesting. But what makes it irresistible is the mix: rockets, Elon Musk, the promise of huge demand, and the feeling that this could become one of those rare public moments when finance starts to look like pop culture. - [Wall Street weekly recap ($SPY) and next-week setup - March 30–April 3](https://www.merlintrader.com/wall-street-weekly-recap-spy-and-next-week-setup-march-30-april-3/): The week that just ended was not simply another ugly week for equities. It was a deeper tightening of market tolerance. By Friday, March 27, the S&P 500 had closed at 6,368.85, the Dow at 45,166.64, the Nasdaq at 20,948.36 and the Russell 2000 at 2,449.70. The S&P 500, Dow and Nasdaq all recorded a fifth straight weekly loss, while the Dow confirmed correction territory from its February high and the Nasdaq and Russell were already there. The message was blunt: this is no longer a market that shrugs off macro stress and instantly rotates back into the same crowded stories. - [Top 10 Defense-Tech Stocks to Watch – April 2026](https://www.merlintrader.com/top-10defense-stocks-to-watch-april2026/): Ten defense-tech names worth monitoring as drones, tactical systems, battlefield software, military electronics, training platforms and strategic infrastructure continue to reshape the market’s view of modern defense. This watchlist focuses on names with stronger retail attention, thematic clarity and visible speculative or strategic relevance. - [Top 5 Space Stocks to Watch – April 2026](https://www.merlintrader.com/top-5-space-stocks-to-watch-april2026/): Why space matters again The listed space sector has matured just enough to become interesting again, but not enough to become comfortable. That tension is exactly what makes it useful. Investors are no longer looking only at “space” as a futuristic headline. They are increasingly focusing on what part of the stack a company really owns: imagery, analytics, launch, orbital infrastructure, communications, mission execution or defense-adjacent data services. In practice, this means the better stories are no longer the ones with the biggest cosmic vocabulary. They are the ones that can plausibly tie their business to recurring demand, sovereign capability, geospatial intelligence, communications resilience or long-duration technology relevance. - [Top 10 Energy Stocks Watchlist – April 2026](https://www.merlintrader.com/top-10energy-stocks-watchlist-april2026/): Why this group matters now Energy is strategic again. Oil remains essential, uranium has returned to the spotlight through energy-security and baseload-power debates, and electricity demand from industrial reshoring, AI infrastructure and grid pressure has made the sector more relevant than many investors expected. Small-cap energy stocks are especially interesting because they can move with much more torque than large integrated names. But they also carry more fragility. The market is no longer rewarding vague resource stories as easily as before. It is rewarding names with understandable business models, workable balance sheets, visible macro exposure and a believable path to re-rating. - [IOVANCE BIOTHERAPEUTICS (NASDAQ: $IOVA) March 27 2026 DD](https://www.merlintrader.com/iovance-biotherapeutics-march27-dd/): Iovance enters the next stretch in a very different place than where the bull case used to live. The stock still has a powerful story behind it: AMTAGVI is already commercial, the TIL platform is no longer theoretical, and the company is trying to push that proof into larger and commercially more meaningful opportunities such as NSCLC. But this is also a company that the market punished hard when execution, European regulatory ambition and financing optics stopped matching the earlier narrative. That history matters because it explains why each new positive data point now has to pass a tougher test with investors. - [Rocket Pharmaceuticals ( $RCKT ) — KRESLADI approved, PRV granted, and what this changes now](https://www.merlintrader.com/rocket-pharmaceuticals-kreladi-approved/): Rocket Pharmaceuticals (RCKT) — KRESLADI approved, PRV granted, and what this changes now | Merlintrader Static Finviz chart loads without affiliate parameters. Referral is applied only if the reader clicks through to the interactive page. RCKT deep dive · approval day retrospective Rocket Pharmaceuticals (RCKT) — KRESLADI approved, PRV granted, and what this changes now […] - [Top 5 Cruise Lines Watchlist April 2026: Pricing Power, Geopolitics and the Outlook for the Year](https://www.merlintrader.com/top-5cruise-lines-watchlist-apreil2026/): The global cruise industry enters the year with resilient leisure demand, continued focus on onboard spending, and growing investor attention on balance sheet quality, deployment flexibility and pricing discipline. Five listed names stand out for scale, brand relevance and strategic positioning: Carnival, Royal Caribbean, Norwegian, Viking and Lindblad. - [Iran, US and Israel war: the world (G20) is not lining up behind the Gulf conflict ( $SPY )](https://www.merlintrader.com/iran-us-israel-war-march27-20026/): The most important change in the last few days is not only inside the Gulf itself. It is outside it. Europe is trying to separate maritime security from direct war participation, Asian importers are already in emergency-management mode, Brazil and South Africa are dealing with the inflation damage at home, Spain is using the conflict to draw a sharper anti-war line, Italy is trying to stay aligned with the West without getting pulled into a frontline mission, Russia is using the crisis to weaken Western cohesion, China is pushing for talks, India is focused on energy and macro stability, and Pakistan has emerged as one of the clearest mediation channels. This is no longer just a Middle East story. It is already a global positioning story. - [Top 5 U.S. Airlines Watchlist April 2026](https://www.merlintrader.com/top-5airlines-watchlist-april26/): The U.S. airline industry remains one of the most closely watched corners of the transportation market because it compresses several themes into a single sector: consumer resilience, premium spending, corporate travel, fuel sensitivity, labor discipline, network strategy, loyalty economics, and capital market sentiment. Airlines are never just airlines. They are moving indicators of confidence, pricing power, operational quality, and macro fragility all at once. This watchlist focuses on five listed carriers that matter most from a market and competitive perspective: Delta Air Lines, United Airlines, American Airlines, Southwest Airlines, and Alaska Air Group. The aim is not to assign explicit recommendations, but to map the current landscape in a way that helps readers immediately grasp which names stand out for quality, which rely more heavily on cyclical momentum, which are in operational or financial transition, and which deserve extra attention because the narrative surrounding them may not yet be fully settled. - [Cannabis Stocks Watchlist April 2026](https://www.merlintrader.com/cannabis-stocks-watchlist-april26/): ACB, TLRY, SNDL, CGC, CRON: an expanded editorial read on the best-known cannabis names, where fragile balance sheets, regulatory optionality, restructuring efforts and international medical exposure now matter more than old legalization slogans. - [Battalion Oil Corporation ( $BATL ) — Full Deep Dive on a Highly Levered Permian E&P](https://www.merlintrader.com/battalion-oil-corporation-dd/): Battalion Oil is one of those names that can look much simpler from a distance than it really is. The surface narrative is easy enough to sell: a small-cap Delaware Basin operator with torque to oil prices, a stressed balance sheet, and enough volatility to attract both turnaround bulls and opportunistic traders. But that framing is only the starting point. The real BATL story is not just about crude prices or acreage quality. It is about whether a leveraged upstream operator can convert real asset value into durable value for common shareholders while simultaneously managing debt, liquidity, equity optionality and strategic transactions. - [BlackSky (NYSE: $BKSY) deep dive March 2026 (Updated apr 1 ADDENDUM)](https://www.merlintrader.com/blacksky-deep-dive-march2026/): BlackSky is one of those names that forces investors to do more work than usual. On the surface, it offers almost everything that can ignite both enthusiasm and skepticism at the same time: space, defense, AI-enabled analytics, government demand, sovereign customers, a proprietary constellation, backlog growth and next-generation satellites. On the other side sit the issues that always make this type of story fragile: GAAP losses, capital intensity, dilution risk, execution risk, uneven revenue conversion and a stock that can move faster than the underlying business. - [Genmab A/S ( $GMAB ) — Large-Cap Biotech Growth and Pipeline Expansion](https://www.merlintrader.com/genmab-growth-pipeline-expansion/): Genmab occupies an unusual position in biotechnology. It is neither a pure commercial pharmaceutical company with fully mature revenue streams nor a fragile development-stage biotech whose future depends on one clinical event and the next financing window. That in-between status is precisely what makes the company interesting. It already has a meaningful economic engine through Darzalex-related royalties, yet it still offers real upside if management can broaden the company’s commercial base and sustain the productivity of its antibody platform. - [SeaStar Medical ( $ICU )the clinical case is stronger, but the balance sheet still has not caught up . Updated mach 30 with Addendum](https://www.merlintrader.com/seastar-medical-clinical-case/): SeaStar Medical has spent the last month moving out of the zone where it could be dismissed as a tiny, story-heavy healthcare name with a nice scientific pitch and not much underneath it. The pediatric commercial story is now more tangible, the post-approval burden around SAVE has eased, and the adult pivotal trial has crossed the halfway mark. But that progress has not erased the core financial problem. This is a company with a more credible operating narrative than it had a few months ago, yet still one that openly says it does not have enough capital to fund the next twelve months of planned operations. That tension is the whole ICU story right now. - [Kodiak Sciences ( $KOD ): GLOW2 hits cleanly, Zenkuda clears the second major diabetic retinopathy hurdle](https://www.merlintrader.com/https-www-merlintrader-com-kodiak-sciences-positive-topline-results/): Positive GLOW2 topline data do more than add one more green headline to the tape. They materially strengthen the diabetic retinopathy package around Zenkuda, reduce the “one-study wonder” risk left after GLOW1, and push the KOD debate toward the next question that really matters: how much value the market should assign to a program that now looks BLA-ready across multiple retinal settings, while still carrying the memory of earlier setbacks and the need to deliver again in DAYBREAK. - [Artelo Biosciences ( $ARTL ) — Final March 2026 Update: hard Nasdaq deadline, fragile balance sheet, and a real separation between pipeline promise and financing reality](https://www.merlintrader.com/https-www-merlintrader-com-artelo-biosciences-artl-final-march-2026-update/): Next Catalyst / Prossimo catalyst: March 30, 2026 Nasdaq compliance deadline on the stockholders’ equity rule, based on the company’s disclosed panel extension. EN / IT toggle inside the content area, with mirrored sections. EN IT Artelo Biosciences (ARTL) — Final March 2026 Update: hard Nasdaq deadline, fragile balance sheet, and a real separation between […] - [Corcept Therapeutics ( $CORT ): FDA Approval of Lifyorli and the Path from CRL Devastation to Oncology Redemption](https://www.merlintrader.com/corcept-therapeutics-approval/): In one of the most striking turnarounds in biotech over the past three months, Corcept Therapeutics has moved from potential extinction to validation of a core thesis. On March 25, 2026, the U.S. FDA approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic regimens. This is Corcept's second commercially approved product and, more importantly, the first FDA-approved selective glucocorticoid receptor antagonist (SGRA) in oncology. This approval comes exactly 12 weeks after the December 31, 2025 Complete Response Letter (CRL) that sent CORT plummeting 50% in a single day and raised serious questions about whether Corcept's relacorilant program was a scientific and commercial mirage. It also arrives 5 weeks after the Federal Circuit affirmed that Corcept's key Korlym patents do not prevent Teva's generic, further pressuring the company's legacy cash engine. The stock opened up +40% on the approval news, erasing much of the CRL damage. But the narrative is now far more complex: Cushing's syndrome access to relacorilant has been effectively closed off until Corcept runs a new trial (likely 3-5 years away), while ovarian cancer and emerging programs in MASH, ALS, and other indications are now in focus. The balance sheet remains strong (>$500M cash, profitable), but investor sentiment has fractured into those betting on Lifyorli's oncology success and those worried about execution, dilution, and the class action lawsuits now pending against management. - [NRx Pharmaceuticals ( $NRXP ) After FY2025: A Multi-Asset Story with Regulatory, Commercial, and Strategic Upside](https://www.merlintrader.com/nrx-pharmaceuticals-fy2025/): EN IT Merlintrader Deep Dive | NRXP NRx Pharmaceuticals After FY2025: A Multi-Asset Story with Regulatory, Commercial, and Strategic Upside NRx is no longer just a one-line speculative ketamine story. After the March 2026 annual report and earnings call, the investment case is broader, messier, and more ambitious: KETAFREE as the nearest hard regulatory shot, […] - [Intuitive Machines ( $LUNR ) Aggressive 2026 Guidance, and the $180.4M NASA CLPS Award](https://www.merlintrader.com/intuitive-machines-nasa-award/): Intuitive Machines is now asking the market to believe two things at the same time. First, that FY2025 weakness was transitional rather than structural. Second, that the combined company after the Lanteris acquisition can grow into a much larger, more diversified space and defense platform without losing control of margins, working capital, or mission execution. The tension is obvious. On one side, the March 19, 2026 results were underwhelming: full-year revenue of $210.1 million, fourth-quarter revenue of $44.8 million, negative free cash flow of $56.0 million, and a business still relying heavily on external capital to support growth. On the other side, management is now pointing to a very different 2026 picture: full-year revenue guidance of $900 million to $1.0 billion, positive adjusted EBITDA, roughly $943 million of combined backlog as of late February, and then a fresh $180.4 million NASA CLPS award announced on March 24 that pushes the contract narrative forward again. The problem is that backlog and awards are not the same thing as clean execution. A company can win contracts, accumulate backlog, and still disappoint shareholders if the gross margin profile stays weak, if receivables do not convert into cash in a timely way, if integration creates friction, or if high-visibility missions keep generating mixed operational outcomes. That is why this story now has to be judged on business quality, not just on headline wins. - [Rezolute ( $RZLT ) after the FDA meeting: the congenital HI story is not dead, but the bar is still high](https://www.merlintrader.com/rezolute-fda-meeting/): Rezolute remains a classic high-volatility rare-disease biotech story, but the shape of the binary has changed. After sunRIZE missed its primary endpoint in December 2025, many traders effectively treated congenital hyperinsulinism as broken. The March 2026 FDA update forces a more careful read. The agency did not endorse management’s interpretation, yet it also did not dismiss the program outright. Instead, FDA encouraged the submission of comprehensive reports from sunRIZE and the ongoing open-label extension, together with the relevant analysis datasets, for independent evaluation. - [Sidus Space Inc ( $SIDU ) Space Infrastructure, Commercial Payloads, Capital Pressure and the March 31 Earnings Test](https://www.merlintrader.com/sidus-space-march31-earning/): Sidus Space heads into its March 31 earnings event with a familiar mix of promise and pressure. On one side, the company continues to build the narrative it wants the market to believe: a nimble space infrastructure player with satellite heritage, hosted payload capability, and a path toward recurring higher-value data services. On the other side, the financial picture remains fragile, commercial scale is still limited, and capital structure risk has become impossible to ignore. The stock therefore sits in a classic micro-cap tension zone. Technical milestones and partnerships are real, but the real question is whether they are beginning to translate into more stable revenue visibility. That is why the upcoming earnings call matters so much. It is less about one quarter in isolation and more about whether management can narrow the gap between operational progress and financial credibility. - [ADMA Biologics, Culper Research, and the revenue quality debate ( $ADMA ) (UPDATED march 27 2026 ADMA Fires Back at Culper)](https://www.merlintrader.com/adma-biologics-culper-research-and-the-revenue-quality-debate-adma/): On March 24, 2026, Culper Research disclosed a short position in ADMA Biologics and published a report arguing that the company’s growth story would be overstated by what it described as a channel stuffing scheme involving rebates, extended payment terms, inventory loading, and an undisclosed related-party distributor. Public summaries of the report say Culper’s central claim is stark: absent the alleged sell-in distortion, ADMA’s 2025 revenue would have declined rather than grown. That was enough to break the prior narrative around ADMA as a premium commercial plasma story with unusually strong operating leverage. - [Planet Labs ( $PL ): Berlin expansion adds industrial depth to a stock already repriced by earnings](https://www.merlintrader.com/planet-labs-berlin-expansion/): Today’s Berlin manufacturing update is not a “headline contract” event, but it matters because it fits the exact story the market has been rewarding in recent weeks: Planet is being re-rated less as a pure imagery vendor and more as a strategic geospatial infrastructure platform with sovereign, defense and AI-linked relevance. - [Sangamo Therapeutics ( $SGMO ) – Fabry BLA, delivery platform and dilution risk](https://www.merlintrader.com/sangamo-therapeutics-march2026/): NASDAQ: SGMO · Biotech · Genomic Medicine · Fabry / CNS Delivery Sangamo Therapeutics (SGMO) – Fabry BLA, delivery platform and dilution risk Biotech report – focus on ST-920 in Fabry disease, Lilly partnership, capital structure and 2026 scenarios. Report date: 24 March 2026 Updated sources: SEC filings and company press releases, 2025–2026 Educational only […] - [ImmunityBio’s FDA warning letter is serious — but the market now has to separate management risk from the medicine itself. ( $IBRX )](https://www.merlintrader.com/immunitybio-fda-warning/): EN IT Chart source: Finviz. Referral applies only on click. IBRX • Warning Letter • Regulatory Credibility ImmunityBio’s FDA warning letter is serious — but the market now has to separate management risk from the medicine itself ImmunityBio’s sharp March 24 selloff was not a random collapse and it was not an empty sell-the-news reaction. […] - [Spire Global ( SPIR ): Satellite Data Monetization Re-Rated by Execution, Not Hype](https://www.merlintrader.com/spire-global-data-monetization/): Spire Global is no longer an early-stage “space story” being valued on imagination alone. The company has already built and deployed one of the largest listening constellations in low Earth orbit, it has exited a major strategic restructuring, and it now trades on a far more concrete question: can the business convert its satellite infrastructure and government relevance into durable profitability? That question became more important after the company’s fourth-quarter and full-year 2025 results on March 18, 2026. Reported fourth-quarter revenue was $15.8 million. Because the maritime business was sold in April 2025, the year-over-year comparison needs context: management highlighted that fourth-quarter revenue was up 44% versus the comparable ex-maritime base, while the company also improved non-GAAP gross margin to 43%, reduced operating cash outflow to -$4.3 million, and closed the year with $81.8 million in cash and no debt. - [Satellogic ( $SATL )Slingshot expansion, Merlin roadmap and the next defense-style de-risking cycle](https://www.merlintrader.com/satellogic-slinghot-expansion/): The March 24 update matters because it pushes Satellogic further away from the old “small-cap imagery vendor” label and deeper into a more valuable identity: a company trying to build low-latency, defense-relevant, AI-enabled orbital infrastructure. Slingshot II and III expand the ONR-linked roadmap to eight dedicated ISL-ready assets, while Merlin remains the bigger medium-term prize: a daily global one-meter monitoring architecture meant to scale persistent awareness, not just occasional imaging. For Merlintrader readers, the setup is familiar. The story you already outlined in earlier SATL pieces still holds: this is a volatile, execution-sensitive space small-cap, but the quality of the narrative has improved. Revenue accelerated sharply in Q4 2025, full-year revenue rose to $17.7 million, the balance sheet is much stronger than a year ago, and remaining performance obligations of $65.1 million give the company more visibility than it used to have. At the same time, the stock is still a classic “prove it” story: the market wants delivery, not just roadmap slides. - [Ocugen Inc ( $OCGN ) after the OCU410 12-month readout: alive, arguable, and still risky](https://www.merlintrader.com/ocugen-ocu410-readout/): There is a lazy way to write this story and a careful way to write it. The lazy way is to say OCU410 either crushed expectations or disappointed the market. The careful way is to admit that the March 24 readout leaves enough evidence for both sides to keep arguing. Ocugen reported that the medium dose chosen for Phase 3 showed a 31% reduction in geographic atrophy lesion growth versus control at 12 months with statistical significance, a 27% slower decline in ellipsoid zone integrity, and no OCU410-related serious adverse events or adverse events of special interest reported to date. That is enough to keep the program alive, credible, and worthy of ongoing attention. It is not enough to eliminate all doubt. - [AeroVironment ( $AVAV ): Defense Tech Giant in Integration Mode](https://www.merlintrader.com/aerovironment-defense-tech-giant/): In March 2026, AVAV reported Q3 results that exposed cracks in the integration story: revenue of $408M and record backlog of $1.1B masked a $151.3M goodwill impairment (BlueHalo), net loss of $156.6M, and revised guidance now expecting a loss of $218–201M despite $1.85–1.95B revenue. The market repriced sharply downward, then stabilized. The bull case: validated DoD procurement relationships, $2.1B quarterly bookings, massive secular tailwinds in drone warfare and counter-UAS demand, and optionality from space/directed energy segments. The bear case: BlueHalo integration is tougher than expected, margins are under pressure, negative free cash flow is burning through runway, and competition from nimble startups (Anduril, Shield AI) and larger primes is intensifying. - [Ondas ( $ONDS ): the final 2025 earnings release turns a drone story into a much bigger test of execution](https://www.merlintrader.com/ondas-execution-2026/): Defense / Autonomy / Earnings Deep Dive Ondas (ONDS): from drone story to autonomous defense platform? Why the final 2025 earnings release may be the most important ONDS document yet The March 23, 2026 release did more than confirm a strong quarter. It raised the stakes around what Ondas is trying to become: not merely […] - [IDEAYA Biosciences ($IDYA): darovasertib timing shift, OptimUM-02 setup, and a full pre-readout deep dive](https://www.merlintrader.com/ideaya-biosciences/): IDEAYA is one of the more interesting oncology small/mid-cap stories going into spring 2026 because the company sits at the intersection of three things the market tends to pay up for: a registrational catalyst, a platform narrative that is broader than a single-asset biotech, and a balance sheet that is unusually strong for a company still in the clinical stage. The key near-term question is not whether IDEAYA has science or ambition. It does. The real question is narrower and more practical: can darovasertib plus crizotinib in first-line HLA-A2-negative metastatic uveal melanoma deliver a result in OptimUM-02 that is clean enough, strong enough, and regulatorily usable enough to support a credible accelerated-approval path in the United States? - [Palantir ( $PLTR ) and the Pentagon raise the stakes: Maven becomes core military infrastructure, not just another AI tool](https://www.merlintrader.com/palantir-and-the-pentagon/): The Pentagon’s move to formalize Maven as a “program of record” matters far beyond one headline. It strengthens Palantir’s strategic position, deepens its lock-in inside U.S. defense workflows and forces the market to ask a bigger question: is PLTR still just an AI trade, or is it becoming a permanent layer of military decision infrastructure? - [The Vortex of War: between the Iranian threat, energy chaos, and political incoherence](https://www.merlintrader.com/the-vortex-of-war/): This article starts from a position many investors and Western policymakers share, but often fail to articulate carefully enough. Iran’s nuclear ambitions are not a theoretical concern. A state that has openly threatened another state’s existence cannot be treated as if its strategic intentions are morally or geopolitically neutral. There is a coherent argument that Tehran had to be stopped, contained, or at least denied a plausible path to a nuclear endgame. - [The Ten Commandments of the Trader](https://www.merlintrader.com/the-ten-commandments-of-the-trader/): Why these commandments matter Many people think trading is mainly about finding the right stock, the right indicator, or the right catalyst. In reality, the hardest part is not the entry itself. The hardest part is making repeated decisions under uncertainty without letting emotion, urgency, ego, or frustration take control. That is why these commandments matter. They are not magic rules and they do not guarantee profits. What they do is far more useful: they help traders avoid some of the most common and expensive mistakes, especially in volatile environments where speed and pressure can easily lead to poor judgment. This page is designed as educational content for readers who want a stronger foundation. Before strategy comes discipline. Before conviction comes risk management. Before confidence comes process. - [Omeros Corporation ( $OMER ) YARTEMLEA launch, balance-sheet reset, and the real execution test ](https://www.merlintrader.com/omeros-corporation/): Omeros is no longer primarily a regulatory story. That phase changed materially on December 23, 2025, when the FDA approved YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and pediatric patients aged two and older. From that point forward, the central question stopped being “can they get this approved?” and became “can they turn a highly specialized approval into durable commercial traction inside a very concentrated transplant market?” - [Weekly recap and next-week setup March 23–27](https://www.merlintrader.com/weekly-recap-march23-2026/): The week that just ended was not simply another down week for U.S. equities. It was a week in which the market became more severe, more selective and much less willing to pay for fragile narratives. The S&P 500 closed Friday at 6,506.48, the Dow at 45,577.47, the Nasdaq at 21,647.61 and the Russell 2000 at 2,438.45, extending the losing streak for the major U.S. indexes to a fourth consecutive week. The Russell 2000 is now in correction territory from its January high, which matters because it says the weakness is not just about a few mega-cap wobbles. The market is repricing risk appetite more broadly, especially for smaller and more rate-sensitive equities - [Travere Therapeutics ( $TVTX ) pre-catalyst deep dive PDUFA APR 13 2026](https://www.merlintrader.com/travere-therapeutics-pre-catalyst-dd/): TVTX is not the typical pre-PDUFA biotech where everything depends on one unproven idea and the balance sheet is already screaming for a financing. Travere enters the April 13, 2026 decision with a drug already commercial in the United States, a meaningful revenue base, a still-usable cash position, and a management team that has already taken FILSPARI from accelerated approval to full approval in IgA nephropathy. That matters. It changes the quality of the setup. It means the market is not being asked to price pure hope. It is being asked to decide how much additional franchise value belongs to FILSPARI if the FDA agrees that the FSGS package is strong enough for approval. - [Milestone Pharmaceuticals ( $MIST ) after CARDAMYST approval: from binary FDA story to commercial execution test](https://www.merlintrader.com/milestone-pharmaceuticals-2026-commercial/): Milestone Pharmaceuticals is no longer the same equity story it was in the second half of 2025. For months, the stock traded primarily as a regulatory event setup tied to the resubmitted U.S. application for etripamil in paroxysmal supraventricular tachycardia, or PSVT. That phase ended on December 12, 2025, when the FDA approved CARDAMYST, the company’s first commercial product, as a self-administered nasal spray for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults. Since that moment, the question has changed completely. The market is no longer asking whether Milestone can get approved. It is asking whether Milestone can launch, obtain access, build prescription momentum, sustain funding discipline, and then extend the same franchise into atrial fibrillation with rapid ventricular rate, or AFib-RVR. - [BioCryst after the transition ( $BCRX ) DD march 20 2026](https://www.merlintrader.com/biocryst-after-transition/): English Italiano RARE DISEASES · HAE · EARNINGS · FRANCHISE EXPANSION BioCryst after the transition: why BCRX is no longer just an ORLADEYO story, and why the next leg depends on execution BioCryst is not the same company the market was looking at one or two years ago. ORLADEYO is no longer a launch-phase promise […] - [SELLAS ( $SLS ): March 19 2026 . No longer just a one-shot REGAL trade, but still a high-risk biotech story that has to earn its rerating](https://www.merlintrader.com/sellas-march19-2026/): SELLAS enters 2026 in a stronger position than it did only a few months ago. The company now has a better-funded balance sheet, a pivotal Phase 3 program that remains the center of gravity for the story, and a second clinical asset that is beginning to matter in a more serious way. That does not make the risk disappear. It simply means the equity story is richer, more credible and more demanding than before. - [Planet Labs after the jump: why these results change the story, and why the hard part starts now](https://www.merlintrader.com/planet-labs-after-the-jump/): Planet Labs did not rally simply because it posted a good quarter. The market reacted because the company finally delivered a set of numbers strong enough to support a much larger narrative: Planet is no longer being framed only as a satellite-imagery vendor, but as a possible strategic geospatial infrastructure platform sitting at the intersection of sovereign data, defense demand, satellite services and AI-enabled analytics. - [Intuitive Machines ( $LUNR ): weak quarter, huge 2026 guide](https://www.merlintrader.com/intuitive-machines-weak-quarter/): Intuitive Machines did not just report a mixed quarter. It effectively asked the market to stop thinking of LUNR as a single-mission lunar name and start treating it as a much larger, post-acquisition space infrastructure company built around manufacturing scale, defense programs, GEO communications, civil-space work, and eventually higher-margin network services. That is why these earnings matter. They were less about the quarter just reported and much more about whether investors are willing to believe the company can support a near-billion-dollar 2026 revenue target only a few weeks after absorbing Lanteris. - [Satellogic ( $SATL ): Merlin, FY2025 earnings, and the strategic reset behind the stock](https://www.merlintrader.com/satellogic-merlin-fy2025/): This is the continuation of the March SATL work, updated after the March 18 Merlin announcement and the March 19 fourth-quarter and full-year 2025 results. The key point is that these were not just ordinary earnings. Taken together, the two releases tried to reposition Satellogic from a small Earth observation operator into a daily global monitoring platform with sovereign, defense and persistent intelligence relevance. - [Fulcrum Therapeutics Inc ( $FULC ) DD March 19 2026](https://www.merlintrader.com/fulcrum-therapeutics-inc-dd-march19/): FULC trades on NASDAQ. The stock has benefited from positive Phase 1b PIONEER data announced in late February 2026, which showed robust HbF induction at the 20 mg dose. Current valuation reflects pre-commercialization risk and the clinical timeline for the registration-enabling trial expected in H2 2026. - [Cardiff Oncology ( $CRDF ) new AACR breast-cancer angle](https://www.merlintrader.com/cardiff-oncology-dd-march19-2026/): Cardiff Oncology has a fresh scientific talking point after announcing preclinical AACR 2026 data around onvansertib in therapy-resistant HER2-low breast cancer models. That headline matters because it expands the mechanistic narrative around the asset. But it does not change the center of gravity of the story. The main valuation engine is still onvansertib in first-line RAS-mutated metastatic colorectal cancer, the company’s cash runway into 2027, and management’s ability to rebuild credibility after the January leadership shock. - [Spectral AI ( $MDAI ): DeepView, BARDA backing, FDA De Novo path,](https://www.merlintrader.com/spectral-ai-dd-march19/): Spectral AI is one of those very small companies where the story looks simple on the surface and much more complicated once you open the hood. The company is trying to bring its DeepView burn-imaging platform through the FDA while using non-dilutive government support to fund part of the journey. The setup is interesting because it combines a real clinical problem, a potentially differentiated imaging workflow, and a government countermeasure angle. The catch is that this is still a micro-cap name with execution risk, regulatory risk, and financing risk that cannot be ignored. - [ProKidney (PROK) after FY 2025 earnings](https://www.merlintrader.com/prokidney-fy2025-earnings/): ProKidney’s FY 2025 release did not deliver a dramatic twist, and that is exactly why it matters. Investors were not looking for revenue, because there is none. They were not looking for normal operating leverage, because this is still a pre-commercial biotech. What they needed to see was whether the company could still credibly defend the bridge from today’s balance sheet to the one milestone that truly matters, the Q2 2027 Phase 3 eGFR-slope readout in PROACT 1. For now, the answer remains yes. - [SeaStar Medical ( $ICU ) before FY2025 earnings](https://www.merlintrader.com/seastar-medical-before-earnings/): SeaStar Medical goes into its March 25, 2026 earnings date with a story that is more credible medically than it was a few months ago, but not yet more comfortable financially. That distinction matters. In ultra-small medtech and biotech names, better clinical framing can improve perception, but it does not automatically repair a pressured capital structure. SeaStar’s recent updates created a more solid pediatric narrative around QUELIMMUNE, yet the company still faces the far more difficult question of whether that narrative can become durable adoption, durable funding and a less fragile 2026 outlook. - [Geron ( $GERN ) after FY2025 earnings: RYTELO growth is real, but 2026 now becomes an execution year](https://www.merlintrader.com/geron-fy2025-earnings-growth/): Geron’s latest earnings did not kill the bullish case and did not fully validate it either. What they did was more useful: they forced the story into a more serious phase, where commercial consistency, spending discipline and the coming IMpactMF readout matter more than launch excitement. - [Protalix BioTherapeutics (PLX) reported fiscal 2025 results on March 18 2026](https://www.merlintrader.com/protalix-biotherapeutics-reported-fiscal-2025/): Protalix BioTherapeutics (PLX) reported fiscal 2025 results on March 18, 2026, with $51.8 million in revenues from selling goods, $52.7 million in total revenues, and a net loss of $6.6 million. The most important near-term development was not just the annual print itself, but the combination of that print with the European Commission approval of the every-four-weeks dosing regimen for Elfabrio, which triggered a $25 million milestone payment from Chiesi. - [Aldeyra ( $ALDX ) : 3 attempts were not enough](https://www.merlintrader.com/aldeyra-3aatempts-were-not-enough/): I deliberately waited at least one full day before writing this piece. Not to stall, but to look at the March 17, 2026 Complete Response Letter with a colder head, outside the immediate chaos of the tape. What follows is not a quick reaction article. It is a long-form reconstruction of how Aldeyra reached a third rejection in dry eye disease, why that matters far beyond one bad headline, where management deserves a tougher standard, and whether any credible path still exists for reproxalap in DED. - [Kosmos Energy Ltd ( $KOS ) Deep Dive Update](https://www.merlintrader.com/kosmos-energy-ltd-dd-march18/): Kosmos Energy is one of those companies that can look dramatically different depending on the lens used. If the lens is geology and resource base, there is real substance here: Ghana remains a meaningful production engine, GTA has moved from long-promised concept into actual LNG production, and the company still retains additional development and exploration optionality. If the lens is capital structure, however, the picture is much less forgiving. High debt, prior operational disappointments, start-up cost inflation, and the need to actively manage maturities have made KOS a much harder story for equity investors than a simple “oil up, stock up” thesis. - [Ovid Therapeutics Inc ( $OVID ) expanded deep dive on OV329, the KCC2 platform, capital structure, dilution risk, and the 2026 catalyst path](https://www.merlintrader.com/ovid-therapeutics-dd-march2026/): Ovid Therapeutics is a New York-based biopharmaceutical company focused on small-molecule medicines for brain disorders driven by impaired inhibitory signaling and neuronal hyperexcitability. The current story is built around two mechanistic pillars: OV329, a next-generation GABA-AT inhibitor for refractory epilepsies, and OV4071, a first-in-class oral KCC2 direct activator for psychosis-related and broader neuropsychiatric indications. What makes Ovid more interesting now than a few quarters ago is not just pipeline breadth, but the combination of fresh clinical support, a much stronger balance sheet, and a clearer 18–24 month cadence of milestones. On March 18, 2026, the company reported new 7 mg OV329 safety and PK data, expanded OV329 into tuberous sclerosis complex seizures and infantile spasms, confirmed Australian clearance for OV4071 Phase 1 work, and paired those updates with a new $60.0 million private placement. That package materially changed the near-term risk profile versus the leaner cash position seen in 2025. - [Artelo Biosciences ( $ARTL ) — Full Deep Dive March 2026](https://www.merlintrader.com/artelo-biosciences-full-dd-2026/): Artelo is one of those names where two truths live side by side and both matter. The first truth is that this is not an empty shell. The pipeline is real, there are multiple shots on goal, and at least two of the programs have enough substance to justify serious attention from specialist biotech traders. ART27.13 has generated actual human data in cancer-related anorexia and now has a new ophthalmology expansion angle in glaucoma or ocular hypertension. ART26.12 has crossed the line into human testing with a completed single-ascending-dose study. ART12.11, while earlier, has regulatory progress and intellectual-property support that make it more than just a speculative line item. - [Palladyne AI  ( $PDYN ) Defense stack now forming](https://www.merlintrader.com/palladyne-ai-defense-stack/): Executive view. Today’s Navy ALRRM award matters, but not because the dollar amount alone changes the company overnight. What matters is that the award fits into a sequence that has become hard to ignore: first the AFRL HANGTIME work, then the missile propulsion subsystem contract, then the post-acquisition repositioning around GuideTech and defense manufacturing, and now a Navy near-hypersonic missile development award. Put differently, PDYN is no longer just trying to sell an autonomy story. It is trying to become a more complete defense-and-industrial platform where software, avionics, manufacturing, propulsion and program access all reinforce each other. - [ZenaTech ( $ ZENA) adds a new low-cost interceptor drone to the counter-UAS story](https://www.merlintrader.com/zenatech-new-interceptor-drone-march17/): Quick take. This is a meaningful story update, not a fundamental de-risking event. ZenaTech says it is developing a low-cost, single-use autonomous interceptor drone called Interceptor P-1 for the broader ZenaDrone counter-UAS platform. The logic is clear: defeat cheap hostile drones with cheaper, faster, more scalable interceptors instead of relying only on high-cost conventional air-defense responses. That makes conceptual sense. What still matters more, however, is the gap between concept and proof: this remains a development-stage defense product announcement, not a disclosed contract, not a production milestone, and not a booked revenue line. - [Ondas Inc Evolution 2026( $ONDS )](https://www.merlintrader.com/ondas-inc-evolution-2026/): EN IT Ondas, Evolution How ONDS is trying to become a multi-domain defense platform in 2026 — and why the story now looks both more coherent and more demanding than it did just a few months ago. Ticker: ONDS Focus: Defense-tech transformation Period: Jan–Mar 2026, with pre-2026 context Angle: Platform build vs execution risk Next […] - [Greenwich LifeSciences ( $GLSI ): FLAMINGO-01 Reorders the Story, but the Trial Is Still Binary](https://www.merlintrader.com/greenwich-lifesciences-reorders-story/): GLSI is exactly the kind of name that can look much cleaner in a press release than it does in real portfolio construction. The company has one lead asset, one pivotal clinical thesis, limited cash, ongoing need for financing, and a story that can produce violent stock reactions because the float is relatively small and the clinical promise is easy to narrate. That is why the most useful way to rebuild the article in the new format is to put the scientific signal and the financing reality in the same frame from the first page. - [Planet Labs PBC ( $PL )](https://www.merlintrader.com/planet-labs-strategic-infrastructure-nvidia/): Planet Labs—not NVIDIA—officially announced on March 16, 2026 that it is building a GPU-native AI engine for planetary intelligence with NVIDIA. The news matters not because it creates a completely new Planet story, but because it reinforces a strategic transition Merlintrader had already identified: Planet is moving beyond raw imagery delivery toward a faster, higher-value geospatial intelligence layer built on AI processing, semantic search and real-time operational utility. By Merlintrader | Updated March 17, 2026 - [Olema Pharmaceuticals Inc ( $OLMA )  deep dive march 17 2026](https://www.merlintrader.com/olema-pharmaceuticals-inc-march17-dd/): Olema sits in one of the most interesting transition zones in clinical-stage biotech. It is no longer a company that can be dismissed as little more than a speculative preclinical story, because it now has a late-stage development strategy centered on palazestrant, a second clinical engine in OP-3136, and a balance sheet that looks strong enough to bridge the company through several major milestones. At the same time, Olema is not yet a diversified oncology company with multiple independent late-stage assets that can absorb a major failure without a violent valuation reset. That is why the stock remains so fascinating. It offers a genuine setup for a re-rating if execution continues, but it also remains highly exposed to a narrow band of high-information events. - [Momentus Inc ( $MNTS )– complete deep dive on the recent timeline, government milestones, customer contracts, backlog signals, cash stress and execution risk](https://www.merlintrader.com/momentus-inc-deep-dive-march26/): Momentus is one of those small-cap space names that keeps surviving by refusing to stay simple. If you look only at the financial statements, MNTS still looks fragile: revenue is very small, cash remains thin, net losses are large relative to the company’s size, and the latest quarterly filing still explicitly raised substantial doubt about the company’s ability to continue as a going concern. But if you look only at the press releases, you get a different picture: government-linked milestones, NASA work, DARPA-related progress, U.S. Space Force vehicle eligibility, commercial payload partnerships, and a near-term mission that could function as an operational showcase. - [Structure Therapeutics Inc ADR ( $GPCR ) DD march 16 2026](https://www.merlintrader.com/structure-therapeutics-inc-march16-2026/): Structure Therapeutics was founded with a singular mission: to build a structure-based GPCR (G-protein-coupled receptor) drug discovery platform. The company's name literally reflects its core intellectual property—the belief that understanding the three-dimensional structure of GPCR proteins could enable design of highly selective, potent small molecule drugs that traditional high-throughput screening couldn't easily find. - [Annovis Bio ( $ANVS ) – Deep Dive on Buntanetap 2026](https://www.merlintrader.com/annovis-bio-deep-dive-march-2026/): Annovis is one of those biotech names that looks tiny on the screen but can become very large in narrative terms whenever the market wants a fresh Alzheimer’s angle. The company’s March 16, 2026 fiscal-year update did not announce an approval, an acquisition or a phase-changing headline readout. What it did provide was something more practical: a clean status check on the one thing that matters most for Annovis today, namely whether its pivotal Alzheimer’s program is moving forward fast enough to keep the investment story alive before the cash window narrows too much. - [United States Antimony ( $UAMY ) – Pentagon Demand, Commercial Scale and the 2026 Execution Test](https://www.merlintrader.com/united-states-antimony-2026-test/): United States Antimony Corporation (NYSE American: UAMY) has positioned itself as a critical-minerals player through two landmark contracts announced in late 2025: a five-year, sole-source IDIQ agreement with the U.S. Defense Logistics Agency worth up to $245 million, and a new five-year commercial supply deal with a major U.S. industrial fabric manufacturer valued at approximately $107 million. Together, these contracts—announced over a 60-day period in September–October 2025—represent combined long-term visibility of up to $352 million. - [NRx Pharmaceuticals ( $NRXP ) – FDA Minutes Lock In the NRX-100 NDA Path](https://www.merlintrader.com/nrx-pharmaceuticals-nda-path/): NRx Pharmaceuticals finally got the kind of news biotech traders usually wait for: not just another optimistic corporate interpretation, but formal written FDA minutes that document the regulatory path. In today’s release, the company said it received the confirmatory written minutes from its February 17, 2026 in-person Type C meeting with the FDA. According to NRx, those minutes support a path to file an NDA for NRX-100 by June 2026 using existing adequate and well-controlled clinical trial data together with confirmatory Real World Evidence. The company also said the FDA confirmed that no additional clinical trials and no bridging studies are required for the preservative-free formulation - [Redwire Corporation ( $RDW )Space infrastructure, defense tech, and execution risk all colliding in 2026](https://www.merlintrader.com/redwire-corporation-defense-execution-2026/): Redwire enters 2026 with a much stronger strategic narrative than it had a year ago. The company is no longer just a small-cap space infrastructure name trying to prove relevance. It now has a larger defense-tech footprint after the Edge Autonomy deal, a more visible sovereign-Europe angle after the Belgian MATTEO award, and a record year-end backlog that gives management a real basis for projecting a major step-up in 2026 revenue. That is the good side of the story. The harder side is that Redwire still has not earned the right to be treated as a clean execution story. FY2025 showed real top-line progress, but it also exposed how fragile the model remains when development programs run into estimate-at-completion adjustments, integration costs, and heavy cash burn. Revenue grew. Backlog improved. Book-to-bill improved. Yet the company still posted a much larger net loss and very weak free cash flow. The core question for RDW in 2026 is therefore simple: can Redwire convert strategic relevance into operational credibility? If the answer becomes yes, the stock can look too cheap versus its backlog, government exposure, and 2026 guide. If the answer stays uncertain, the name can remain trapped as an interesting story with inconsistent economics. - [POET Technologies Inc ( $POET ) after the LITEON partnership](https://www.merlintrader.com/poet-technologies-liteon-partnership/): POET arrived at the industry’s key optical-communications event with fresh news in hand: the new co-development announcement with LITEON, plus demonstrations of Blazar and Starlight products aimed at AI-related optical connectivity. In practical terms, this is the first immediate stage where the market can gauge whether the latest headline gets traction beyond the press release itself. - [ROCKET LAB ( $RKLB ) COMPLETE DEEP DIVE march 15 2026](https://www.merlintrader.com/rocket-lab-complete-deep-dive/): Rocket Lab is no longer just a “small rocket” story. That framing is outdated. The business that reported 2025 results is a broader space infrastructure company with three engines under the hood: Electron launch services, a much larger and increasingly important Space Systems segment, and Neutron, the still-unproven but strategically vital medium-lift program. - [Vertex Pharmaceuticals ( $VRTX ) no longer just a cystic fibrosis machine](https://www.merlintrader.com/vertex-pharmaceuticals-march15-update/): Vertex Pharmaceuticals remains one of the highest-quality large-cap biotech stories in the market, but the real reason the name deserves a first full Merlintrader deep dive now is not simply scale, profitability or balance-sheet strength. The more important point is that the company has reached a stage where investors can begin to judge whether the long-promised diversification beyond cystic fibrosis is becoming economically meaningful rather than merely aspirational. - [Weekly Market Recap & Next Week Prep — March 15, 2026](https://www.merlintrader.com/weekly-market-recap-march15/): The week that ended on Friday, March 13, did not deliver a clean “risk-on” or “risk-off” message. It delivered something more difficult and, for active traders, more important: a selective tape in which macro stress was real, energy shock risk was impossible to ignore, but not every pocket of the market reacted in the same way. That distinction matters. A market that falls together can often bounce together. A market that starts separating winners from losers under pressure is usually telling you that stock-picking, catalyst timing and sector choice are starting to matter more than headline beta. - [Sidus Space Inc ( $SIDU ) March 14 2026 Deep Dive](https://www.merlintrader.com/sidus-space-inc-march14-dd/): Sidus Space Inc (NASDAQ: SIDU) is an innovative space mission enabler operating at the intersection of commercial satellite manufacturing, artificial intelligence-enabled space-based data solutions, and defense technology integration. Founded in 2012 and based on Florida's Space Coast in Merritt Island, the company operates a 35,000-square-foot integrated manufacturing, assembly, and testing facility with direct access to launch infrastructure. - [AeroVironment Inc ( $AVAV ) Defense Technology | Uncrewed Systems & Tactical Missiles](https://www.merlintrader.com/aerovironment-inc-defense-technology/): AeroVironment (AVAV) operates at the intersection of two powerful secular trends: the electrification and autonomy of military platforms, and the rising geopolitical demand for precision defense systems. As a leader in uncrewed aircraft systems (UAS), loitering munitions (Switchblade series), counter-unmanned aerial systems, and space-based directed energy platforms, the company is uniquely positioned to benefit from a multi-decade modernization cycle driven by conflicts in Ukraine, the Middle East escalation, and NATO expansion. - [Satellogic Inc ( $SATL ) Vertically Integrated Earth Observation & Persistent Monitoring March14 DD](https://www.merlintrader.com/satellogic-vertically-integrated-observation/): Satellogic is one of those names that can look much bigger, much smaller, much safer or much more dangerous depending on the exact week in which an investor or trader meets the story. In a hot tape, the company can be pitched as a pure-play Earth observation platform exposed to sovereign demand, AI-driven geospatial workflows and a possible shift toward more recurring monitoring contracts. In a colder tape, exactly the same company can be described as a low-margin, cash-consuming, serially dilutive small cap whose commercial wins still need to prove that they can scale into a durable business rather than a string of eye-catching press releases. Both sides are seeing a piece of the truth. That is why a SATL report is only useful if it keeps those two realities on the page at the same time. - [Intuitive Machines Inc ( $LUNR ) Deep Dive March 14/2026](https://www.merlintrader.com/intuitive-machines-inc-march14-2026/): Intuitive Machines Inc (LUNR) is a diversified space infrastructure company with four core business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products & Infrastructure. Founded in 2013, IM has emerged as a prime contractor for NASA lunar missions, U.S. Department of Defense space architecture programs, and emerging commercial lunar economy players. The company's 2024 milestone—landing the Nova-C lunar lander on the Moon's South Pole region—marked the first crewed-space-capable U.S. lunar return since Apollo 17, positioning IM as the dominant platform for American lunar access for the foreseeable future. - [Aldeyra Therapeutics ( $ALDX ): past, present and future around reproxalap and the March 2026 FDA decision](https://www.merlintrader.com/aldeyra-therapeutics-final-dd-mar16/): A long-form bilingual deep dive built around the full regulatory arc of Aldeyra, from the first dry-eye filing to the 2025 collapse and the current March 2026 binary setup. The focus here is not only on what happened, but on why the market still cares, what could realistically change if reproxalap is approved, what the damage would look like if it is rejected again, and how retail traders are framing the setup in the final stretch before the decision. - [Intellia Therapeutics (Nasdaq: $NTLA): HAELO Turns Lonvo-z Into the Next Major In Vivo CRISPR Test](https://www.merlintrader.com/intellia-therapeutics-april2026-precatalyst-update/): Intellia Therapeutics is entering one of the most important moments in its public-company history. On April 24, 2026, the company announced that it will report topline clinical data from the global Phase 3 HAELO trial of lonvoguran ziclumeran, also known as lonvo-z, in hereditary angioedema on Monday, April 27, 2026, with a webcast scheduled for 8:00 a.m. ET. Intellia describes this as the world’s first Phase 3 readout for an in vivo CRISPR gene-editing candidate. That phrase matters because NTLA is not simply reporting another late-stage biotech trial. The company is attempting to prove that a one-time in vivo CRISPR therapy can move from elegant science and early clinical promise into a pivotal dataset capable of supporting a regulatory filing. - [Wall Street weekly recap and next-week setup april27-2026 ( $SPY )](https://www.merlintrader.com/wall-street-weekly-recap-and-next-week-setup/): What defined last week The S&P 500 and Nasdaq closed at record highs, powered by a powerful semiconductor rally and renewed confidence that AI infrastructure spending is still translating into real earnings momentum. - [AEye Inc. (Nasdaq: $LIDR): Retail Momentum Meets the LiDAR Turnaround Story Ahead of Q1 Earnings](https://www.merlintrader.com/aeye-inc-april2026-deep-dive/): Why LIDR is suddenly interesting again AEye Inc. has re-entered the trader conversation because three ingredients arrived at the same time: fresh analyst attention, a clean technology narrative and unusually strong retail interest around a small-cap ticker. Craig-Hallum initiated coverage with a Buy rating and a $3.50 price target on April 24, 2026, giving the market a simple headline to trade. AEye also has a near-term event on the calendar, with first-quarter 2026 results scheduled for May 13, 2026 after the close, followed by a conference call and webcast. - [OneMedNet Corporation (Nasdaq: $ONMD): Palantir, iRWD and the Micro-Cap Real-World Data Pivot](https://www.merlintrader.com/onemednet-corporation-april2026-dd/): OneMedNet Corporation is a micro-cap healthcare data company focused on regulatory decision-grade Real-World Data, with a particular specialization in imaging-heavy, multimodal clinical datasets. The story changed materially on April 22, 2026, when the company announced that its iRWD™ platform, built on Palantir Foundry, was live and fully operational. The announcement stated that customers can now search across billions of records, 80 million patient journeys and 251 million studies in seconds, with approximately 47 million tokenized patients available through Datavant linkage and two new customers already contracted for the platform. - [Oklo Inc. (NYSE: $OKLO): Nvidia Partnership, AI Power Demand and Nuclear Deployment Outlook](https://www.merlintrader.com/oklo-nvidia-partnership-ai-power/): Oklo is becoming one of the market’s most visible nuclear-for-AI infrastructure stories after the NVIDIA and Los Alamos collaboration, but the investment case still depends on licensing, fuel, customer conversion and first deployment. - [SES AI Corporation (NYSE: $SES): Earnings Beat, Revenue Growth and 2026 Outlook](https://www.merlintrader.com/ses-ai-corporation-earnings-beat/): SES AI’s April 2026 earnings update changes the tone of the story. For most of its public-market life, SES has been discussed primarily as a lithium-metal battery technology platform with large automotive ambitions, long timelines and heavy cash consumption. The Q1 2026 report does not remove those risks, but it adds a more tangible commercial layer: revenue came in at $6.7 million, up 47% sequentially and well above published consensus estimates, while the company reaffirmed full-year 2026 revenue guidance of $30 million to $35 million. - [Starfighters Space Deep Dive ( $FJET): FJET’s Space-Test Platform, C-STARS Catalyst, Blackstar Optionality, Insider Picture and Funding Risk](https://www.merlintrader.com/13055-2/): Starfighters Space is one of the more unusual public-market stories in the listed space and aerospace universe. The company is not a conventional orbital launch provider, it is not a pure satellite manufacturer, and it is not merely an aviation services company with a space label attached. Its core asset is a scarce commercial fleet of modified F-104 aircraft positioned around sustained Mach 2+ flight, high-altitude testing, launch-support profiles, training, payload development, microgravity-adjacent research and future air-launch optionality. That makes the company difficult to value through a normal revenue-multiple framework, because the investment case is still being built around platform scarcity, mission optionality and the possibility that customers need faster and more flexible access to real flight-test environments. - [Grace Therapeutics ( $GRCE): the clinical thesis is still alive, but the FDA CRL resets the clock](https://www.merlintrader.com/grace-therapeutics-crl-april23/): After the April 23, 2026 CRL, the next real catalyst is not a vague hope trade. It is a sequence: Grace needs clarity from the FDA through a Type A meeting request, then it needs to show investors that the cited CMC, packaging/leachables, toxicology-risk, and contract manufacturing issues are finite, fixable, and not the start of a much larger manufacturing breakdown. - [BigBear.ai Holdings Inc. ( $BBAI ) April 2026 DD](https://www.merlintrader.com/bigbear-ai-holdings-inc-bbai-april-2026-dd/): 2026 guidance remains the main numerical anchor: management guided to revenue of $135 million to $165 million for full-year 2026. That is the range the market will use to judge whether Ask Sage, CargoSeer, and the broader reset story are actually translating into growth or merely postponing another disappointment. The most important change is simple: BBAI is not trading like a near-term balance-sheet emergency anymore. The solvency panic that haunted the stock for much of 2024 and 2025 has eased materially. The debate has shifted from “Can they survive?” to “Can they execute well enough to justify the capital they raised and the acquisitions they made?” - [Kyverna Therapeutics ( $KYTX ) April 2026 Deep Dive](https://www.merlintrader.com/kyverna-therapeutics-aprill2026-dd/): Kyverna Therapeutics entered AAN 2026 with one of the more closely watched neuroimmunology data packages in small-cap biotech, and the company delivered a data set that materially strengthens the case for miv-cel as a potential first approved autoimmune CAR-T therapy. Across stiff person syndrome and generalized myasthenia gravis, management is trying to prove something much bigger than symptom management: a durable immune reset after a single treatment. - [Rigel Pharmaceuticals ( $RIGL ) – Deep Dive After Eli Lilly ( $LLY ) Walks Away from the RIPK1 Partnership](https://www.merlintrader.com/rigel-pharmaceuticals-rigl-end-partnership/): Rigel Pharmaceuticals is not the same company it was a few years ago. What used to look like a small hematology biotech tied closely to a limited number of assets has evolved into something much more substantial: a small-cap commercial hematology-oncology platform with three marketed products, real revenue, and a pipeline that still matters. That distinction is crucial when analyzing the recent news that Eli Lilly has chosen to terminate the remaining RIPK1 collaboration with Rigel. - [Tonix Pharmaceuticals ( $TNXP ): FDA approval is now real, but the real fight is commercialization versus dilution](https://www.merlintrader.com/tonix-pharmaceuticals-tnxp-april2026/): Tonix is finally no longer the same story it was for years. That matters. For a long time TNXP was treated by the market as a classic small biotech loop: broad pipeline, recurring scientific updates, periodic optimism, repeated financing pressure, and little proof that any of the development effort would ever mature into an actual commercial franchise. That status changed in August 2025 when the FDA approved TONMYA for fibromyalgia, and it changed again in November 2025 when the company actually launched the product. That is the real break in the old narrative. Tonix now has a marketed flagship medicine, two legacy acute migraine products, a real commercial field effort, and enough liquidity to keep the whole machine running for a while. But it is equally true that none of this eliminates the capital structure problem. Tonix still sits in that awkward zone where it is meaningfully more credible than the average microcap biotech, yet still vulnerable to the same shareholder pain that has defined much of its history. - [The Insurance Wall: Why $LLY, $NVO, $HIMS, $UNH, $CVS, $CI, and $WW Are at the Center of Weight Loss Drug Adoption](https://www.merlintrader.com/the-insurance-wall-april2026/): The central issue is no longer demand. It is reimbursement. In 2026, oral GLP-1 drugs pushed down the US cash entry price aggressively. Foundayo starts at 149 dollars per month, and oral Wegovy also starts at 149 dollars for entry doses. But official list prices remain far higher: Foundayo launched with list prices ranging from 499 to 799 dollars depending on dose, while Wegovy remains around 1,349 dollars, and comparable injectables still orbit roughly between 1,086 and 1,349 dollars per month. - [Outlook Therapeutics ( $OTLK ) — FDR Meeting Done, Formal FDA Answer Now Becomes the Real Binary](https://www.merlintrader.com/outlook-therapeutics-april21-202/): Outlook Therapeutics remains one of the market’s purest high-risk ophthalmology regulatory stories. The company has a real product with European and UK authorization, but in the U.S. it is still stuck in a brutal loop: one 2023 CRL tied to manufacturing deficiencies, then two more CRLs in 2025 focused on insufficient evidence of effectiveness for wet AMD. That is the core problem the equity has been trading around for months. - [POET Technologies ( $POET ) — PFIC Clarification, U.S. Redomicile Plan and the Real Execution Test Ahead](https://www.merlintrader.com/poet-technologies-april2026/): Market chatter Sivers-NVIDIA read-across, AI photonics enthusiasm and unusual call activity are influencing short-term POET sentiment - [Red Cat Holdings — All-Domain Autonomy & Execution in 2026](https://www.merlintrader.com/red-cat-holding-april2026/): From the NATO Black Widow order and the Apium acquisition to HADDY-enabled manufacturing scale, Ukraine collaboration, Arastelle tethered ISR and Bullfrog integration, Red Cat has built one of the market’s most aggressive multi-domain defense narratives. The real question now is no longer whether the story sounds strategic. It is whether execution can keep pace with ambition. - [NRx Pharmaceuticals ( $NRXP ) — From FDA Alignment to Presidential Backing](https://www.merlintrader.com/nrx-pharmaceuticals/): NRx Pharmaceuticals has become a far more layered story than the version many traders were following a few months ago. It is no longer just an abstract ketamine thesis or a speculative real-world-evidence talking point. As of April 20, 2026, the company has three separate but connected tracks worth watching: a near-term generic-drug approval set-up through KETAFREE™, a potentially more valuable but still higher-risk NDA strategy for NRX-100, and an expanding clinic / neurotechnology ecosystem designed to create commercial infrastructure around both drug assets. - [X4 Pharmaceuticals (XFOR): post-approval reset, new management, and a binary-but-cleaner road toward the 4WARD readout](https://www.merlintrader.com/x4-pharmaceuticals-april2026-deepdive/): Nearest real company-level catalyst: a possible European Commission decision on mavorixafor in WHIM syndrome in Q2 2026, following the positive EMA CHMP opinion announced by X4. After that, the bigger valuation driver remains the 4WARD Phase 3 chronic neutropenia program, with full enrollment expected in Q3 2026, top-line data targeted for 2H 2027, and a potential U.S. approval path in 2028. No exact EC decision date has been publicly provided by the company as of April 19, 2026. - [Esperion Therapeutics ( $ESPR ): Guidelines, Global Expansion And A Higher-Stakes 2026 Setup](https://www.merlintrader.com/esperion-therapeutics-april2026-deepdive/): Over the last twelve months, ESPR has moved from being a story driven almost exclusively by a single bempedoic acid franchise to a more articulated commercial-stage biotech case with three concurrent drivers: commercial growth in the United States, monetization of its international partner network, and portfolio expansion through the acquisition of Corstasis Therapeutics and the product Enbumyst. On the fundamentals side, 2025 closed with total revenue of $403.1 million, up 21% year over year, with U.S. net product revenue at $159.6 million, up 38%, while the fourth quarter showed a very strong acceleration in revenue to $168.4 million, helped in part by Japanese milestones. - [Candel Therapeutics ( $CADL ) – Deep Dive On CAN-2409, CAN-3110, Capital, Catalysts And The 2026 Setup](https://www.merlintrader.com/candel-therapeutics-april2026-deepdive/): Candel Therapeutics is one of the more interesting small-cap oncology stories because it is trying to bridge a classic biotech gap: moving from a platform narrative to a late-stage, filing-oriented commercial narrative without yet being a fully de-risked company. The core of the story isaglatimagene besadenovec (CAN-2409), an adenovirus-based multimodal immunotherapy candidate. The company already has apositive phase 3 study in localized intermediate- to high-risk prostate cancer, conducted under a Special Protocol Assessment, and now plans aBLA submission - [Alpha Tau Medical ( $DRTS ) : Japan Approval, Pancreatic DDW 2026, GBM Optionality and a Technical Setup That Finally Looks Awake](https://www.merlintrader.com/alpha-tau-medical-april2026-deepdive/): Alpha Tau Medical is no longer just a quirky radiotherapy story that biotech tourists glance at and move on from. It now has a first non-Israeli approval in Japan, five U.S. trials running in parallel, a live pancreatic catalyst at DDW 2026, a GBM program that can materially alter the narrative, a modular PMA path in recurrent cSCC, insider-heavy ownership, and a chart that appears to be compressing directly beneath a multi-year decision zone. - [Two parallel biotech catalysts for next week , $IDYA and $SABS](https://www.merlintrader.com/two-parallel-biotech-catalysts-april2026/): The coming week offers a compact but unusually clean biotech catalyst sequence. IDEAYA Biosciences heads into AACR 2026 with three named poster presentations tied to IDE034, IDE574 and IDE892, including two key April 21 morning posters in the same epigenetic modulators session. SAB Biotherapeutics arrives at the 21st Immunology of Diabetes Society Congress in Brisbane with two April 21 posters and an April 22 oral presentation built around SAB-142 in type 1 diabetes. These are not vague attendance headlines. They are scheduled scientific disclosures with official timing, identified programs, and company-stated plans to post presentation materials on their websites. - [Definium Therapeutics ($DFTX) Deep Dive: From MindMed Rebrand to a Three-Readout 2026 Setup](https://www.merlintrader.com/definium-therapeutics-deepdive-april2026/): Definium Therapeutics is no longer just a “psychedelics headline stock.” Over the last year the company has rebranded from MindMed, expanded and financed a late-stage psychiatry platform, completed enrollment in one Phase 3 study, moved multiple pivotal trials toward 2026 readouts, and started to look much more like a serious event-driven biotech name than a concept trade. The key question now is simple: can management turn a stronger balance sheet and a cleaner story into top-line data that the market will actually trust? - [Psyence Biomedical ($PBM) – Speculative Spike or Emerging Clinical Setup? UPDATED Apr 18](https://www.merlintrader.com/psyence-biomedical-speculative-april2026/): Psyence Biomedical Ltd. (NASDAQ: PBM) is a tiny clinical-stage biotech focused on natural psilocybin-based therapies for mental health conditions in palliative care settings. After the April 16, 2026 trading explosion, the stock suddenly moved from an obscure micro-cap name into the type of chart that attracts momentum traders, skeptical short-term observers, and readers looking for the real story beneath the tape. - [Quantum Leap: The Sector Calculates the Future — and the Profits $IONQ $QBTS $RGTI](https://www.merlintrader.com/quantum-leap-calculates-future-april2026/): Quantum computing is no longer a theoretical exercise. In the span of a few weeks in April 2026, three publicly traded quantum companies — IonQ (IONQ), D-Wave Quantum (QBTS), and Rigetti Computing (RGTI) — produced a synchronised breakout that caught the attention of investors well beyond the specialized tech community. IONQ surged more than 20% in a single session, dragging QBTS and RGTI higher with it, in a coordinated move driven by genuine fundamental catalysts rather than sector hype alone. - [$HUT Deep Dive April 2026: Hut 8 from Bitcoin Miner to Power-First AI Infrastructure Platform](https://www.merlintrader.com/deep-dive-apri2026-hut8/): Hut 8 is no longer an easy one-line story. The old label of “bitcoin miner” is now too narrow, but the new label of “AI infrastructure platform” is still only partially earned. That gap between narrative and proof is exactly why the stock matters right now. Readers are not just looking at another crypto proxy. They are looking at a company trying to turn power access, digital infrastructure, and capital markets agility into a premium multiple. - [ADMA Biologics: How Margin Expansion, FDA-Approved Yield Technology, and a Crisis Response After Culper Reframed the Story](https://www.merlintrader.com/adma-biologics-april2026-dd/): ADMA is no longer just a “biotech that is growing.” It is increasingly being priced like a plasma platform with real operating leverage. The key question now is whether the company’s stronger production economics and rising margins are powerful enough to outlast the lingering revenue-quality debate triggered by Culper Research. The balanced but moderately bullish view is that the business has become stronger than the controversy, even if the controversy has not disappeared. - [New FDA Genome Editing Rules .](https://www.merlintrader.com/new-fda-editing-rules-april2026/): FDA Genome Editing Draft Guidance • April 2026 English Italiano New FDA Standards for Genome Editing What They Mean for $VRTX $CRSP $NTLA $EDIT $BEAM $PRME $DTIL $CRBU $CLLS $ALLO $SGMO $MGX $SANA $IPSC Nuovi standard FDA per il genome editing Impatto su $VRTX $CRSP $NTLA $EDIT $BEAM $PRME $DTIL $CRBU $CLLS $ALLO $SGMO $MGX […] - [$BIRD / NewBird AI: the pivot that turned a broken footwear story into the market’s most attention-grabbing AI trade](https://www.merlintrader.com/newbird-pivot-story-april2026/): Allbirds did not just announce a strategic update. It detonated one of the strangest speculative episodes of the year: a company that sold its footwear brand and had been moving toward dissolution suddenly reappeared as “NewBird AI,” backed by a $50 million convertible facility meant to fund a GPU infrastructure strategy. The result was a volume shock, a retail frenzy, and a debate over whether the market is pricing execution or simply pricing narrative. - [Space Wars](https://www.merlintrader.com/space-wars-april2026/): The question is no longer whether the Space Force truly exists as an autonomous armed service. After the April 15 release and B. Chance Saltzman’s remarks at the 41st Space Symposium, the point is that U.S. leadership is asking markets, industry and Congress to treat it as a fully operational, combat-credible force: a force no longer living on doctrine alone, but one that has already produced real effects in recent operations and now wants to translate that legitimacy into architectures, personnel, industrial production and multiyear contracts - [Hims & Hers Health ($HIMS): April 2026 deep dive after the GLP-1 reset, the Novo pivot, and the new peptide optionality](https://www.merlintrader.com/hims-hers-health-april2026-deepdive/): A full April 2026 Merlintrader-style update built on our prior HIMS work and focused on what changed since the last report: the Q4 and full-year 2025 numbers, the strategic reset in U.S. weight loss, the agreement with Novo Nordisk, the still-pending Eucalyptus acquisition, the slowing but still meaningful 2026 growth outlook, and the fresh peptide angle that has suddenly reopened part of the long-term story. - [Elon Musk, Tesla, SpaceX, xAI and Grok: Building an Ecosystem for Humanity’s Future](https://www.merlintrader.com/elon-musk-hunanity-future-april2026/): Elon Reeve Musk, born on June 28, 1971, in Pretoria, South Africa, has become one of the most influential and polarizing entrepreneurs of the modern era. Over the past three decades, he has played a central role in reshaping digital payments, electric vehicles, reusable rockets, satellite connectivity, artificial intelligence, neural interfaces and social platforms. More than a businessman in the traditional sense, Musk positions himself as an engineer-entrepreneur obsessed with long-term civilizational questions. - [$IMMP After TACTI-004: What Broke, What Survived, and Why Immutep Still Has a Real Recovery Debate](https://www.merlintrader.com/immutep-after-tacti-dd-april2026/): Immutep is no longer a simple high-upside oncology story. It is now a damaged but still very much alive recovery case. The flagship Phase III dream in first-line NSCLC broke hard, the stock’s credibility took a real hit, and the market had to reprice the company in a hurry. But the company did not come out of that blow as an empty shell. It still has cash, still has surviving clinical branches, still has outside validation, and now has a fresh FDA orphan drug designation in soft tissue sarcoma that puts a real regulatory spotlight back on eftilagimod alfa. - [Can Cannabis Regulation in Maryland, Massachusetts, and California Become a Sector Catalyst for $ACB, $CGC, $TLRY, $CRON, and $SNDL?](https://www.merlintrader.com/cannabis-regulation-2026-catalyst/): Three separate state-level moves — Maryland’s public-health labeling discussion, Massachusetts’ near-term governance and licensing overhaul, and California’s pesticide testing rulemaking — may not look like classic headline catalysts at first glance. But for cannabis operators, labs, manufacturers, packaging vendors, distributors, and investors watching margin pressure, market access, and compliance risk, these are exactly the types of regulatory shifts that can quietly reshape the sector. - [Robinhood Markets ($HOOD): why the new intraday-margin era matters, and why the story is bigger than the old PDT rule](https://www.merlintrader.com/robinhood-markets-april2026/): Robinhood Markets, Inc. (NASDAQ: HOOD) is a commission-free, SEC-registered brokerage that has fundamentally disrupted retail investing access in the U.S. Since its 2013 founding and 2021 IPO, Robinhood has amassed ~24 million funded accounts managing $1.5+ trillion in assets. The platform generates revenue through payment for order flow (PFOF), margin lending, and cryptocurrency services—not traditional commissions. - [Interactive Brokers (IBKR) – Complete Report on Business Quality, Earnings Drivers and Risk Framework](https://www.merlintrader.com/interactive-brokers-april2026-deepdive/): Interactive Brokers is one of the more interesting names in listed financials because it combines brokerage, technology, market infrastructure and scale economics in a way that is not easy to replicate. The stock is often discussed as if it were just another read-through on retail trading activity or interest rates. That framing is too narrow. - [Webull ($BULL) Deep Dive: Why the End of the Legacy Pattern Day Trader Rule Could Matter More Here Than Almost Anywhere Else](https://www.merlintrader.com/webull-deep-dive-april2016/): Webull is one of the most direct public-market expressions of a very specific regulatory story: the SEC has approved FINRA’s proposal to remove the old pattern day trader regime, including the long-standing $25,000 minimum equity requirement and the three-day-trade limit that restricted smaller margin accounts. That does not mean the new system is live everywhere today. It means the direction of travel is now official, the market can underwrite the path, and brokers most exposed to active retail behavior suddenly have a new narrative runway. - [Safe Pro Group ( $SPAI ) Deep Dive: Why Today’s U.S. Army Exercise Matters](https://www.merlintrader.com/safe-pro-goup-deepdive-april2026/): Today’s update did not change the fact that Safe Pro is still a very early, very promotional, very high-risk small cap. What it did change is the quality of the operating narrative. Safe Pro is no longer talking only about future opportunity in defense AI. It is now stacking a visible sequence of milestones: a government subcontract, rapid delivery, Army exercises, commercial rollout of NODE-X, and another field validation event announced today. - [Aurora Cannabis ( $ACB ) Is Building a Medical Export Engine, Not Waiting for U.S. Legalization](https://www.merlintrader.com/aurora-cannabis-april2026/): The real Aurora story in 2026 is not a vague bet on American reform. It is a much more specific and, arguably, much more investable thesis: a disciplined medical cannabis platform using Germany, Australia, EU-GMP infrastructure, and capacity expansion to build a higher-margin international business while many peers remain trapped in weaker market structures. - [Amazon ($AMZN), Globalstar ($GSAT), and AST SpaceMobile ($ASTS): why Amazon’s Globalstar deal matters far beyond one takeover](https://www.merlintrader.com/amazon-globalstar-ast-spacemobile-april2026/): Amazon’s move on Globalstar is not just another satellite headline. It is a deeper attempt to own spectrum, device-level connectivity, Apple continuity, and a bigger slice of the space economy at the same time. That has immediate implications for Globalstar, material strategic implications for Amazon, and a more complicated read-through for AST SpaceMobile. - [Sidus Space ( $SIDU ): Lonestar StarVault Expansion, FY2025 Deep Dive & the LS-4 Test](https://www.merlintrader.com/sidus-space-lonestar-starvault-april2026/): Lonestar just expanded its StarVault relationship with Sidus, but the real question is not whether the story sounds exciting. The real question is whether Sidus can convert contracts, hosted payload wins and defense positioning into revenue before burn and dilution overwhelm the setup. - [What Axsome ($AXSM), Rhythm ($RYTM), Crinetics ($CRNX), and Veracyte ($VCYT) Have in Common](https://www.merlintrader.com/axsome-rhythm-crinetics-veracyte-common2026/): Plenty of companies announce an earnings date. Very few deserve a dedicated article just because of that. What makes this group worth watching is that each company is walking into its next business update with a specific pressure point that matters more than the quarter itself. - [Fastly (FSLY): verified April 2026 deep dive on the edge-security rerating thesis](https://www.merlintrader.com/fastly-april2026-deepdive/): Fastly is no longer the same simple “broken CDN turnaround” story it looked like a couple of years ago. The April 2026 setup is more nuanced. The business is showing real improvement in mix and operating profile, 2025 revenue accelerated to 15% growth, free cash flow turned positive, non-GAAP operating income turned positive for the full year, and management guided to another year of revenue growth plus positive non-GAAP operating income in 2026. That is the hard foundation the market was missing for a long time. - [Draganfly ( $DPRO ) Deep Dive: balance sheet first, defense optionality second, execution proof still required](https://www.merlintrader.com/draganfly-deep-dive-april2026/): A full bilingual EN/IT report for WordPress Custom HTML on Draganfly’s current setup, product stack, defense traction, financial reality, dilution profile, scenario map, and the catalysts that matter after the company’s early-2026 funding reset. - [Teva Pharmaceuticals: Pivot to Growth, Now Under Real Market Scrutiny](https://www.merlintrader.com/teva-pharmaceuticals-april14-deep-dive/): Teva entered 2026 with a more credible transformation story than it had just a few years ago. The company reported 2025 revenue of $17.3 billion, up 4% year over year, marking its third consecutive year of growth. That matters because Teva is still carrying the legacy of a global generics business, but the mix is gradually shifting toward innovative medicines, biosimilars, and pipeline assets that management believes can support more durable long-term growth. - [Travere Therapeutics ( $TVTX ) after FILSPARI’s FDA approval in FSGS](https://www.merlintrader.com/travere-therapeutics-fda-approval-april14/): Travere Therapeutics did not just clear another FDA box on April 13, 2026. It materially changed the shape of its equity story. FILSPARI, already commercial in IgA nephropathy, now has a second FDA-approved kidney disease indication: reduction of proteinuria in adults and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis, or FSGS, without nephrotic syndrome. That is a narrower label than the most aggressive bulls had once hoped for, but it is still a real commercial approval, not a consolation prize, and it makes FILSPARI the first and only FDA-approved medicine for FSGS. - [HOTH Therapeutics (NASDAQ: $HOTH): today’s HT-VA GDNF update matters, but the balance sheet still controls the story](https://www.merlintrader.com/hoth-therapeutics-april2026-dd/): Hoth added another mechanistic layer to its HT-VA obesity / fatty-liver narrative today, with gene-level data showing reduced Srebf1 and increased Pparα in a VA / Emory CRADA model. That strengthens the scientific story, but it does not remove the core market question: can HOTH turn early preclinical promise and encouraging HT-001 oncology-supportive data into a financed, executable development path without crushing dilution? - [One Stop Systems ( $OSS ) Deep Dive April 2026 UPDATED May 06](https://www.merlintrader.com/one-stop-systems-deep-dive-april2026/): From edge-AI pitch to real program conversion: what today’s autonomous-energy-node order says about OSS, how the business changed after the Bressner divestiture, and what still has to go right before this can be treated as a durable public-market winner. - [Momentus ( $MNTS ) Deep Dive 2026 UPDATED APRIL15](https://www.merlintrader.com/momentus-deep-dive-april2026/): Momentus is still one of the most binary small-cap space stories on the board, but after the last two weeks it is harder to dismiss the company as a pure concept trade. The central reason is not a promotional headline. It is sequence. For a company like MNTS, sequence is everything. - [Ondas ( $ONDS) Deep Dive 2026 UPDATED APRIL 15](https://www.merlintrader.com/ondas-deep-dive-april2026/): Static Finviz chart at the top. Referral applies only if a reader clicks through. NASDAQ: ONDS Defense · Counter-UAS · ISR · Robotics Updated April 13, 2026 Ondas (ONDS) Deep Dive April 2026 From a narrow drone narrative to a layered defense-systems platform: what April actually changed, what still needs to be proven, and why […] - [Allogene Therapeutics (ALLO) Deep Dive April 2026](https://www.merlintrader.com/allogene-therapeutics-deepdive-april2026/): Allogene Therapeutics has spent years trying to prove that allogeneic, off-the-shelf CAR-T can become something more than a clever scientific pitch. Today’s ALPHA3 interim futility analysis does not finish that argument, but it materially changes the tone of it. - [Revolution Medicines ( $RVMD ) Deep Dive April 2026](https://www.merlintrader.com/revolution-medicines-deepdive-april2026/): Daraxonrasib just turned a long-building RAS story into a frontline market conversation. The key question is no longer whether Revolution Medicines has a serious pancreatic program. The question now is how large the platform can become, how quickly the company can convert today’s Phase 3 win into approvals, and how much upside still remains after a violent breakout. - [Biotech Catalyst Day: IDEAYA ( $IDYA) and Spyre ( $SYRE) head into a parallel clinical readout window](https://www.merlintrader.com/biotech-catalyst-day-ideaya-idya-and-spyre-syre-head-into-a-parallel-clinical-readout-window/): Two biotech names, two very different clinical stories, one synchronized release window. IDEAYA and Spyre are both scheduled to report clinically meaningful updates on Monday, April 13, 2026 at 8:00 a.m. ET, creating an unusually clean side-by-side setup for traders watching biotech volatility, narrative rotation, and cross-flow behavior before the actual readouts hit. - [AMC Entertainment ( $AMC) Deep Dive – April 2026](https://www.merlintrader.com/amc-entertainment-deepdive-april2026/): AMC is showing genuine operating improvement, but the common stock is still a highly leveraged instrument sitting underneath a very heavy capital structure. - [Plug Power ( $PLUG) Deep Dive — April 2026](https://www.merlintrader.com/plug-power-deepdive-april2026/): The tone around PLUG has improved because the company finally delivered concrete signs of stabilization: positive Q4 gross profit, lower cash burn, a clearer execution roadmap, a new CEO, a signed strategic asset sale, and a fresh commercial win in electrolyzers. The key question now is no longer just survival. It is whether improving liquidity can translate into sustainable industrial execution. - [USA Rare Earth ( $USAR ): a strategic mine-to-magnet buildout, not a simple rare-earth headline trade](https://www.merlintrader.com/usa-rare-earth-april2026-deepdive/): A long-form look at how USA Rare Earth is trying to build an integrated non-China rare earth chain across Texas, Oklahoma, the U.K. and France, why the story now matters far beyond mining, and where the real upside and real execution risk sit today. - [Ocean Power Technologies ( $OPTT): Full Deep Dive on the Transition Story, the Capital Risk, and What Has to Happen Next](https://www.merlintrader.com/ocean-power-april-deepdive/): OPTT is no longer just the old “wave energy” micro-cap many traders remember. The company is trying to reposition itself as a maritime domain awareness and autonomous ocean systems story, with PowerBuoys, WAM-V platforms, Merrows software, defense-adjacent deployments, and a growing pipeline. The opportunity is obvious. The problem is obvious too: the revenue line is still tiny, the cash burn remains heavy, and the balance sheet still leans on dilution and convertible financing. - [Telix Pharmaceuticals ADR (TLX) PDUFA goal date set for September 11, 2026](https://www.merlintrader.com/telix-pharmaceutocals/): TLX101-Px accepted by FDA; PDUFA goal date set for September 11, 2026 The clearest near-term regulatory focal point is now TLX101-Px, Telix’s brain cancer imaging candidate for recurrent or progressive glioma. Management has also kept a H1 2026 target for the TLX250-Px / Zircaix BLA resubmission after working through the post-CRL comparability package. - [Cingulate (NASDAQ: $CING): first full deep dive into the May 31, 2026 FDA binary](https://www.merlintrader.com/cingulate-april2026-dd-pdufamay31/): Cingulate is one of those micro-cap biotech stories where the entire equity case has compressed into a narrow window: one lead ADHD asset, one PDUFA date, a visible commercialization build-out, and a very real dilution overhang. - [The Trend Is Your Friend](https://www.merlintrader.com/the-trend-is-your-friend-april2026/): There are trading phrases that survive because they are useful, and there are trading phrases that survive because they are easy to repeat. “The trend is your friend” belongs to both categories. It is useful, but only when treated as a probabilistic framework rather than a religious commandment. Used well, it keeps a trader aligned with momentum, liquidity, and market psychology. Used badly, it turns into a license to chase, overstay, and confuse a mature move with a fresh opportunity. - [A World on Edge](https://www.merlintrader.com/a-world-on-edge-april2026/): There are days when the future feels distant, theoretical, something that belongs to policy papers and conference panels. Then there are days when the future stops waiting politely and arrives all at once. April 11, 2026 feels like one of those days. The geopolitical map is unstable, supply chains are once again hostage to geography, financial markets are discovering that volatility is not a passing phase, and the labor market is beginning to absorb the first serious psychological shock from artificial intelligence. - [Wall Street weekly recap and next-week setup: why April 6–10 became the market’s strongest week since November](https://www.merlintrader.com/wall-street-weekly-recap-april11-2026/): A broad and detailed market recap of the week just ended, plus a forward-looking framework for the next one, with focus on inflation spillover, oil structure, U.S.-Iran diplomacy, bank earnings, producer prices and the increasingly important gap between a stabilizing tape and a still-strained real economy. - [Voyager Technologies (NYSE: VOYG) — April 2026 deep dive](https://www.merlintrader.com/voyager-technologies-april2026-deepdive/): Voyager Technologies is one of the more interesting space-defense names because it is not a clean, single-theme stock. It is not just a commercial space dream. It is not just a defense contractor. It is not just a speculative “future station” vehicle either. It is a hybrid company where a real operating business in defense and mission services sits next to a very large long-duration bet on the future commercial low-Earth-orbit economy. That mix is what makes VOYG potentially powerful, but it is also exactly what makes it difficult to value. - [Celldex Therapeutics (CLDX): the full April 2026 deep dive on barzolvolimab, pipeline breadth, financing, competition and what still has to go right](https://www.merlintrader.com/celldex-therapeutics-april2026-deepdive/): This is our first full Merlintrader deep dive on CLDX. The core of the story is simple: Celldex is being valued primarily as a barzolvolimab company, but the real debate is whether barzolvolimab can move from an unusually strong phase 2 setup into a durable commercial immunology franchise across CSU, inducible urticarias and potentially additional inflammatory skin diseases. - [POET Technologies ( $POET ) — April 2026 deep dive](https://www.merlintrader.com/poet-technologies-april2026-deepdive/): From narrative-rich AI photonics story to execution test: POET now has a far bigger balance sheet, a broader partnership map and a clearer 2026–2027 roadmap — but the market still wants the same proof as always: real shipments, repeat revenue and evidence that the Optical Interposer can scale outside press releases. - [Replimune after the second CRL: why RP1 was stopped again, what still stands, and where the IOVA comparison truly fits](https://www.merlintrader.com/replimune-after-the-second-crl/): The FDA’s second no on RP1 plus nivolumab in advanced melanoma does not look like a simple administrative delay. It is a rejection that hits the core regulatory thesis, reopens the debate around the program’s near-term value and forces a broader reassessment of the Replimune story as a strategic reset rather than a delayed approval thesis. - [Vera Therapeutics (VERA): April 2026 Deep Dive](https://www.merlintrader.com/vera-therapeutics-april2026-dd/): Vera has moved from a pure data story into a real pre-commercial FDA story. The old thesis was about whether atacicept could produce strong enough renal data to justify a major rerating. The April 2026 thesis is narrower and more demanding: can Vera convert strong upstream biology, a clean Phase 3 interim package and a differentiated at-home profile into approval, a credible first launch, and a durable place in an IgAN market that is no longer empty? - [SoFi after the hype reset: profitable scale, a bigger platform ambition, and the real debate on valuation](https://www.merlintrader.com/sofi-hype-reset-april2026-aupdate/): This April update revisits SoFi with fresh context after the Q4 2025 numbers, the March short-seller clash, the expansion of the Loan Platform Business, and the launch of Big Business Banking. The core question is no longer whether SoFi can grow; it is whether the market is looking at a durable multi-engine financial platform or still at a premium-priced lender with more execution risk than bulls admit. - [United States Antimony ( $UAMY ): April 2026 update on earnings, Gary Evans, new projects, and the real execution test ahead](https://www.merlintrader.com/united-states-antimony-april2026-update/): UAMY is no longer just a tiny legacy smelter story. After a violent 2025 growth year, the company now sits at the intersection of domestic critical-minerals policy, military antimony demand, vertical integration ambitions, and an increasingly complex balance sheet. The market narrative has become much bigger, but the same question now matters even more: can management turn a promotional national-security story into durable, cash-generating industrial execution? - [Verrica Pharmaceuticals (VRCA): deep dive 2026 after the balance-sheet reset, the YCANTH ramp and the renewed VP-315 scientific story](https://www.merlintrader.com/verrica-pharmaceuticals-deepdive-april2026/): VRCA is no longer a simple one-product dermatology story. The company now combines a real commercial base in YCANTH, a large common-warts expansion opportunity with unusually helpful cost-sharing economics, and a basal cell carcinoma asset in VP-315 that continues to add regulatory and scientific credibility. The stock still carries the usual small-cap biotech risks, but the narrative is broader and more interesting than the older “just molluscum and financing stress” version. - [Oscar Health and Clover Health: two very different ways to play the health-insurance trade](https://www.merlintrader.com/oscar-health-clover-health-april2026/): The market often throws Oscar Health and Clover Health into the same retail bucket because both names sit at the intersection of healthcare, software, insurance and volatility. That shortcut is convenient, but it misses the real story. - [Achieve Life Sciences (Nasdaq: $ACHV): Cytisinicline Faces a Probable FDA CRL, but the Story Shifts to Adare, Cash Runway and a Q4 2026 Resubmission](https://www.merlintrader.com/achieve-life-sciences-april2026-dd/): ACHV is no longer just a development-stage nicotine-dependence story. It is now a very specific FDA review, launch-prep, manufacturing-readiness and balance-sheet story centered on cytisinicline, with a June 20, 2026 PDUFA date and a second optionality leg in vaping cessation. - [Milestone Pharmaceuticals ( $MIST ) — from approval to execution](https://www.merlintrader.com/milestone-pharmaceuticals-approval-execution-2026/): The key change since the December 2025 approval is simple: the stock is no longer being judged mainly on whether CARDAMYST can reach the market, but on whether Milestone can actually turn that approval into real access, real prescriptions, real repeat physician behavior, and eventually a broader etripamil franchise beyond PSVT. That sounds less dramatic than a PDUFA setup, but it is usually the more important phase. Approval can rerate a story for a week. Commercial traction is what can rerate it for much longer. - [ImmunityBio (IBRX): from the FDA advertising warning to the company’s fix plan, lawsuit noise, and stronger early Q1 revenue](https://www.merlintrader.com/immunitybio-april9-2026-update/): This update picks up the story where the earlier Merlintrader pieces left it: global expansion, label-expansion ambition and clinical momentum were still moving forward, but the market narrative suddenly shifted when the FDA’s Office of Prescription Drug Promotion publicly challenged how ANKTIVA had been promoted. The key question now is not whether the issue existed — it did — but whether the company’s remediation plan is enough to contain the damage while the underlying commercial story keeps improving. - [Trump Media & Technology Group ( $DJT ) April 2026](https://www.merlintrader.com/trump-media-technology-group-djt-april-2026/): From SPAC story to narrative-driven ticker: what is left of Truth Social, what changed with the pivot toward crypto, financial services and the TAE merger, and why DJT now trades more like a speculative vehicle than a classic media company. - [Ocular Therapeutix (OCUL) in April 2026 (Updated april 14)](https://www.merlintrader.com/ocular-therapeutix-april2026/): This April update picks up the OCUL story where our earlier Merlintrader pieces left it: from the pre-readout run-up and takeover chatter, through the February SOL-1 topline and the violent sell-the-news reaction, to the next regulatory, scientific and commercial steps that now matter most. - [UiPath ( $PATH ): from classic RPA leader to agentic automation platform](https://www.merlintrader.com/uipath-leader-agentic-automation/): This deep dive looks at where UiPath stands now after fiscal 2026 results, the strategic shift toward agentic automation, the current balance between improving profitability and still-moderate growth, the state of the balance sheet and buyback, the role of Daniel Dines and governance, what institutions and analysts are likely watching, how retail sentiment is split, and what a realistic bull and bear framework looks like from here. - [PMGC Holdings (NASDAQ: $ELAB) — update deep dive April 2026](https://www.merlintrader.com/pmgc-holdings-elab-dd-april2026/): ELAB is no longer just a tiny “obesity + AI + low float” story. Since the prior Merlintrader article, the company has added another manufacturing asset, widened the NorthStrive pipeline, opened a new defense-tech lane, and fully tapped a $20 million Streeterville facility. That gives it more operational breadth, but it also hardens the core problem: cash is less immediate, dilution is more real, and execution now has to work across biotech, industrial integration and defense optionality at the same time. - [Applied Digital (APLD) — Deep Dive April 2026](https://www.merlintrader.com/applied-digital-deep-dive-april2026/): Applied Digital is one of the more interesting infrastructure stories in the market because it sits at the intersection of three forces that investors have spent the last year chasing aggressively: hyperscaler demand, power scarcity, and the belief that the economic winners of the AI cycle will not only be the model builders but also the owners of the physical capacity that makes those workloads possible. That is the seductive version of the story, and it is easy to understand why it caught such a bid. - [Cue Biopharma ( $CUE ) — updated deep dive after the CUE-401 push, CEO transition, and fresh Boehringer milestone](https://www.merlintrader.com/cue-biopharma-updated-deep-dive-april2026/): Cue Biopharma is trying to turn a once messy, multi-angle small-cap biotech story into a more focused autoimmune thesis. The company now has a clearer lead asset in CUE-401, a meaningful external validation point through CUE-501 and Boehringer Ingelheim, a recent CEO transition, and a balance sheet that is improved versus the most stressed phase of 2025 but still fragile enough that financing risk cannot be pushed into the background. - [Lexicon Pharmaceuticals ( $LXRX ): can Zynquista come back?](https://www.merlintrader.com/lexicon-pharmaceuticals-zynquista-return-2026/): A full bilingual deep dive built around the real moving parts of the Lexicon story in April 2026: the Zynquista resubmission path after the 2024 complete response letter, the mid-2026 enrollment target for SONATA-HCM, the cash and dilution picture after the January-February 2026 financing, the economics of the Novo Nordisk LX9851 deal, and the structural risks that still make this name a high-volatility small-cap biotech setup. - [Adagio Medical Holdings( $ADGM ) Deep Dive April 2026](https://www.merlintrader.com/adagio-medical-holding-ddapril-2026/): Adagio Medical is a very small-cap, pre-commercial medtech name trying to carve out a meaningful niche in ventricular tachycardia ablation with its proprietary ultra-low temperature cryoablation platform. What makes the story relevant now is not revenue momentum, because there really is not much of that yet, but the combination of a pivotal study that has already completed enrollment, encouraging acute data, and a fresh FDA IDE expansion that lets the company clinically evaluate its next-generation ventricular catheter while the broader regulatory path remains open. - [Aehr Test Systems ( $AEHR ): deep dive on AI burn-in momentum, silicon photonics growth, and the hard execution test still ahead](https://www.merlintrader.com/aehr-test-systems-deep-dive-april-2026/): Revenue fell 44% year over year to $10.3M, while non-GAAP EPS came in at a loss of $0.05. At the same time, quarterly bookings surged to $37.2M and effective backlog reached a record $50.9M. Management also said full-year FY26 revenue should land on the high side of the previously guided $45M-$50M range, while second-half bookings should come in at the high end of the prior $60M-$80M range. - [Kratos Defense ( $KTOS) april 2026: not just a drone stock anymore](https://www.merlintrader.com/kratos-defense-april-2026/): A long-form look at how Kratos is positioning across space-based missile tracking, hypersonics, propulsion, autonomous systems and defense infrastructure, and why the stock now deserves to be analyzed as a broader strategic architecture story rather than a simple drone momentum name. - [The war’s real bill: how Washington and Tel Aviv ignited a global economic shock and fractured the Atlantic alliance](https://www.merlintrader.com/the-wars-real-bill/): Iran remains a dangerous regime. That does not erase a basic political fact: the present war phase was opened by U.S.-Israeli strikes, and the bill was then exported to the world through oil, inflation, shipping disruption and a deeply irresponsible attempt to treat NATO as if it were an offensive instrument. - [Outlook Therapeutics ( $OTLK ) after the new FDA dispute-resolution meeting. What this April review is.](https://www.merlintrader.com/outlook-therapeutics-april2026-fdrr/): After three Complete Response Letters and a long fight over what counts as sufficient evidence for ONS-5010 / LYTENAVA in wet AMD, Outlook Therapeutics has now moved into a formal FDA dispute-resolution process. This article walks through the CRL history, the new April 2026 meeting, and the real powers of the FDA deciding official — without hype, but also without pretending the door is already shut. - [From Artemis to the Battlefield: why $LUNR, $FLY, $SIDU, $PDYN and $BKSY no longer belong to separate stories](https://www.merlintrader.com/from-artemis-to-the-battlefield/): For years, the market framed companies like Intuitive Machines, Firefly, BlackSky, Palladyne AI or Sidus Space as disconnected speculative names orbiting around rockets, satellites or futuristic concepts. That framing is becoming outdated. In 2026, the more useful lens is strategic infrastructure. What matters now is who can move payloads, who can see first, who can process data faster, who can coordinate autonomous systems, and who can fit into the increasingly blurred boundary between civil space, defense tech, sovereign priorities and lunar logistics. - [When Good News Is No Longer Enough](https://www.merlintrader.com/when-good-news-is-no-longer-enough/): There are moments when a positive headline no longer lights a fire under a stock. It opens green, holds for a moment, then fades. That is not always an anomaly. Quite often, it is the market quietly telling you that the story alone is no longer enough. - [CorMedix ($CRMD): the real second chapter after commercialization](https://www.merlintrader.com/cormedix-second-chapter-2026/): DefenCath is no longer just a launch story, and CorMedix is no longer easy to reduce to a one-drug binary. The company now has real revenue, positive adjusted EBITDA, a broader anti-infective platform after the Melinta transaction, and an approaching Phase 3 readout for REZZAYO. But it also has one very specific pressure point that still dominates the equity story: the July 1, 2026 reimbursement transition for DefenCath. This report is built to cover every major angle ahead of the ReSPECT topline update and to explain, from first principles, why the reimbursement framework matters so much. - [REPL, TVTX, GRCE: three April 2026 PDUFA decisions that matter](https://www.merlintrader.com/repl-tvtx-grce-april2026-pdufa/): A full editorial deep dive on the three most interesting April biotech FDA setups still ahead: Replimune, Travere Therapeutics and Grace Therapeutics. Each story carries a different kind of risk. Replimune is the credibility test after a prior CRL. Travere is the commercial expansion test for a product that already sells. Grace is the classic small-cap binary setup where one approval could change the company’s profile very quickly. - [Atea Pharmaceuticals ( $AVIR ) Deep Dive](https://www.merlintrader.com/atea-pharmaceuticals-avir-deep-dive/): Atea Pharmaceuticals is now best understood as a concentrated, late-stage antiviral bet built around a single core opportunity: the fixed-dose combination of bemnifosbuvir and ruzasvir for chronic hepatitis C. The company is not being valued today for a sprawling platform with multiple near-term revenue paths. It is being judged mainly on whether its HCV regimen can validate in Phase 3, differentiate clinically and commercially, and then support a credible regulatory path into 2027. - [KULR Technology Group (NYSE American: $KULR)](https://www.merlintrader.com/kulr-technology-group-apr2026/): A hybrid and high-volatility story: a real industrial platform tied to batteries, drones, telecom backup, defense and AI infrastructure, but also a stock whose identity has been materially reshaped by its Bitcoin treasury strategy, prior dilution and retail-driven narrative. - [Red Cat Holdings ($RCAT) — a full 2026 deep dive after earnings, Apium, Ukraine and the new NATO order](https://www.merlintrader.com/red-cat-holdings-apr2026/): Red Cat is trying to move from being treated like a single-product drone story into a broader autonomy and defense platform. The company has given the market a dense sequence of catalysts in less than three weeks. The real question now is not whether the story sounds better. It clearly does. The real question is whether that upgraded story can hold up once investors start demanding harder commercial evidence. - [Viridian Therapeutics (VRDN): after the crash, what still matters now?](https://www.merlintrader.com/viridian-therapeutics-after-crash-apr2026/): Why this follow-up exists REVEAL-1 did not kill the TED thesis, but it changed the bar. The debate has moved from “does the drug work?” to “can Viridian still build a differentiated TED franchise that deserves premium valuation?” - [Wall Street weekly recap and next-week setup: why March 30–April 3 became a relief week](https://www.merlintrader.com/wall-street-weekly-reca-papr4/): Executive summary The week that ended on Friday, April 3, was not a clean return to bullish calm. It was a relief week inside an unresolved macro problem. U.S. markets were closed on Good Friday, so the real trading week ended on Thursday, April 2. By then, the S&P 500 had posted a weekly gain and broken its five-week losing streak, while Wall Street had spent the entire week bouncing between fear of an extended energy shock and hope that the war-driven disruption around Iran and the Strait of Hormuz might not become a permanent economic wound. - [Cannabis policy 2026: what Schedule III could really change](https://www.merlintrader.com/cannabis-policy-2026/): The most interesting part of the current cannabis setup is not a headline or a price spike. It is the possibility that the United States is slowly moving from a regime of blanket federal hostility to one of selective federal accommodation. That would be a major change. It would not, however, be the same thing as a clean legalization story. - [Soligenix ( $SNGX ): HyBryte vs. Valchlor, the full story from the first comparison to today](https://www.merlintrader.com/soligenix/): Soligenix is a micro-cap biotech whose current equity story lives or dies largely on the fate of HyBryte in early-stage cutaneous T-cell lymphoma. The April 2, 2026 press release is real and meaningful, but not because it introduces the HyBryte-versus-Valchlor numbers for the first time. Those numbers were already disclosed in 2024. What is genuinely new is that the dataset has now been republished and reframed in a scientific setting, giving more external legitimacy to the claim that HyBryte may be clinically differentiated. - [Lipocine ($LPCN) — after the 78% collapse: what is left, what broke, and what management can realistically do now](https://www.merlintrader.com/lipocine-collapse-april2/): Lipocine entered April 2 as a micro-cap biotech still largely defined by one late-stage binary event. It exits the day as a radically repriced company. The reason is simple: LPCN 1154 failed its Phase 3 primary endpoint in postpartum depression. In the full study population of 90 patients, the company said the drug did not show a statistically significant reduction versus placebo in HAM-D17 at hour 60. That single fact destroyed the old near-term bull case and triggered a collapse of roughly 78% in the stock. What the market is doing is not subtle. It is saying that the company’s main value-driving asset just lost most of its immediate strategic and regulatory premium. - [Ballard Power Systems: from hydrogen hype to operational turnaround – execution matters now](https://www.merlintrader.com/ballard-power-systems/): Ballard Power Systems entered 2026 after one of the clearest operational resets seen across listed hydrogen names. After a painful 2024, when revenue fell 45% and the company announced a major restructuring, FY 2025 brought a real reversal in the numbers: revenue of $99.4 million, up 43% year over year, nearly 800 fuel cell engines delivered and more than 75 megawatts shipped, and gross margin of 5% for the full year, compared with deeply negative levels in 2024. Most importantly, Q4 2025 generated $11.4 million of cash flow from operating activities, while full-year cash usage fell by 50% versus 2024. - [AbCellera Biologics ( $ABCL ) — deep dive on platform, pipeline, cash, insiders, institutions, and the road ahead](https://www.merlintrader.com/abcellera-biologics-april2026/): There is an old way to describe AbCellera and a newer, more accurate way. The old way is to call it a technology platform for antibody discovery that collaborates with larger pharmaceutical companies and occasionally captures royalties or milestone economics downstream. That is still partly true, but it no longer captures the real center of gravity. The company says explicitly that it has evolved from using the platform primarily for partner programs toward building its own internal pipeline of AbCellera-owned assets, and by 2025 that strategic transition had effectively reached the clinic. - [EagleNXT / AgEagle Aerial Systems (NYSE American: $UAVS): U.S.-Made eBee VISION, Army Awards and the Counter-Drone Pivot](https://www.merlintrader.com/counter-drone-pivot-may2026-deepdive-uavs/): A full Merlintrader deep dive on UAVS: the company’s transition from an agricultural and mapping-drone vendor into a defense, public-safety, sensor and counter-drone platform; the recent U.S. Army orders; the Allen, Texas manufacturing shift; the ThirdEye USA counter-UAS venture; the Aerodrome loitering-munition option; the financial reality behind the headlines; and the catalysts that can decide whether this remains a speculative micro-cap story or becomes a more credible U.S.-made unmanned-systems supplier. - [Silexion Therapeutics Corp. (Nasdaq: $SLXN): KRAS-Driven Pancreatic Cancer, SIL204, and the Very Thin Balance-Sheet](https://www.merlintrader.com/silexion-therapeutics-may2026-deepdive/): Silexion is trying to move a second-generation siRNA therapy into a Phase 2/3 program for locally advanced pancreatic cancer. The scientific story is focused and potentially interesting; the trading story is extremely high-risk because cash, Nasdaq compliance, dilution and execution now matter almost as much as the biology. - [MetaVia Inc. (Nasdaq: $MTVA): ADA Late-Breaking Posters, DA-1726 Obesity Signal, and the Financing Wall Behind the Run](https://www.merlintrader.com/metavia-inc-may2026-deepdive/): MetaVia is trying to place itself inside one of the hottest areas in biotech: obesity, MASH and next-generation cardiometabolic drugs. The story is interesting because DA-1726 has early human weight-loss data and fresh ADA visibility. The story is dangerous because the company is tiny, cash is limited, dilution risk is real, and the next major value test is still clinical execution, not social-media excitement. - [Regeneron Pharmaceuticals (Nasdaq: $REGN): Melanoma Setback Reopens the 2026 Growth Debate](https://www.merlintrader.com/regeneron-pharmaceuticals-melanoma-setback/): Regeneron Pharmaceuticals is not a fragile biotech story. It is one of the most successful U.S. biotechnology companies of the last two decades, with a deep research culture, internally built technology platforms, a historic ophthalmology franchise around Eylea, a massive immunology engine through Dupixent with Sanofi, and a growing ambition in oncology. That is exactly why the latest melanoma setback matters. The issue is not whether Regeneron can survive one failed study. The real question is - [The 3 Biggest Insider Buys of May 2026:$KLRA, $ODTX and $ARTV](https://www.merlintrader.com/insider-buys-may2026/): MerlinTrader — Insider Flow Analysis · May 2026 The 3 Biggest Insider Buys of May 2026:$KLRA, $ODTX and $ARTV OpenInsider SEC Form 4 data for April–May 2026 shows three small- and mid-cap biotechs — $KLRA, $ODTX, $ARTV — where insiders deployed a combined $317+ million in purchases. Not grants. Not option exercises. Actual open-market and […] - [The Smart Money Is Buying These 3 Small Caps Before Anyone Notices: $IMSR, $BHVN, $AVLN](https://www.merlintrader.com/smart-money-buying-small-caps/): Institutional Money Is Loading 3 Small Caps — $IMSR, $BHVN, $AVLN | Merlintrader Merlintrader — Institutional Flows Q1 2026 The Smart Money Is Buying These 3 Small Caps Before Anyone Notices: $IMSR, $BHVN, $AVLN Finviz Elite screener data and recent public-market activity highlight three tickers — $IMSR, $BHVN, $AVLN — where institutional ownership, 13F filings, […] - [BriaCell Therapeutics Corp. (Nasdaq: $BCTX): Phase 3 Breast Cancer, ASCO 2026 And A Rapid Pipeline Expansion](https://www.merlintrader.com/briacell-therapeutics-corp-may2026-deepdive/): Merlintrader Deep Dive Updated May 18, 2026 Biotech / Immuno-Oncology BriaCell Therapeutics Corp. (Nasdaq: $BCTX): Phase 3 Breast Cancer, ASCO 2026 And A Rapid Pipeline Expansion BriaCell is no longer only a tiny Phase 3 metastatic breast cancer binary. Since the last Merlintrader deep dive, the company has added new clinical sites, reported a larger […] - [Fortress Biotech (Nasdaq: $FBIO): Q1 2026 Turns the Story Into a Portfolio-Model Test](https://www.merlintrader.com/fortress-biotech-q12026-update/): Fortress Biotech is one of the more unusual stories in the U.S. small-cap biotech universe because it should not be analyzed like a normal single-drug development company. FBIO is a biopharma platform that creates, finances, controls or participates in multiple companies and programs, trying to monetize value through product revenue, royalties, milestones, asset sales, equity stakes and strategic transactions. That structure makes the stock more complicated than a classic biotech catalyst trade. - [SolarEdge Technologies (Nasdaq: $SEDG): Turnaround, Nexis, Storage and the Profitability Test](https://www.merlintrader.com/solaredge-technologies-may2026-deepdive/): SolarEdge is no longer just a classic residential solar inverter story. The current investment debate is about whether the company can convert its 2025 restructuring, inventory normalization and product refresh into a durable return to profitable growth. Q1 2026 gave bulls enough material to argue that the worst of the cycle may be behind the company: revenue grew 46% year over year, gross margin held above 20%, free cash flow remained positive, and Q2 guidance pointed to another sequential improvement. But the bear case has not disappeared - [Golden Dome, Current Situation: $RKLB, $RTX and $VOYG in the New U.S. Space-Based Missile Defense Race](https://www.merlintrader.com/golden-dome-may2026-situation/): Golden Dome, Current Situation: $RKLB, $RTX and $VOYG in the New U.S. Space-Based Missile Defense Rac - [Defense Stocks Weekly Recap: Ondas, Karman and Red Cat Show Why the Drone-Defense Trade Is No Longer Just a Theme ($ONDS, $KRMN, $RCAT)](https://www.merlintrader.com/defense-stocks-weekly-recap-may12/): This week’s defense tape gave traders a useful reminder: the drone-defense and dual-use aerospace trade is alive, but it is no longer a simple “buy the theme” market. The strongest moves are now being separated by revenue quality, backlog visibility, margin path, balance-sheet needs and whether companies can convert battlefield relevance into funded, repeatable commercial execution. - [Syntec Optics (Nasdaq: $OPTX): A Small-Cap Photonics Manufacturer at the Crossroads of Space, Defense and AI Wearables](https://www.merlintrader.com/syntec-optics-may2026-update/): A weak Q1 headline, a guided Q2 revenue reset, fresh space-optics production data, a defense micro-camera order, and a strengthened balance sheet make Syntec Optics a small-cap industrial technology story worth watching carefully — without ignoring dilution, margin volatility and execution risk. - [Microbot Medical (Nasdaq: $MBOT): First LIBERTY Revenue, Real Doctors and the Small-Cap Robotics Test](https://www.merlintrader.com/microbot-medical-may2026-deepdiv/): Microbot Medical is not a clean “robotics stock” headline. It is a much more interesting, messier and more human story: a small public medical device company trying to commercialize a remotely operated, single-use robotic system for endovascular procedures, while the market debates whether the first commercial signs are meaningful enough to justify the risk. The company has now reported first-quarter 2026 revenue tied to the limited market release of LIBERTY, says Q2 revenue had already exceeded Q1 revenue by mid-quarter, and has scheduled a May 18 investor call where real physician users of the system are expected to join management. - [Arrive AI (Nasdaq: $ARAI): The Microcap Building Smart Delivery Points for Drones, Robots and Real People](https://www.merlintrader.com/arrive-ai-may2026-deepdive/): Arrive AI is the kind of small-cap story that can look almost too simple at first glance: a smart mailbox. But the deeper question is more interesting. If drones, ground robots, autonomous vehicles, couriers, hospitals, retailers and consumers are all supposed to participate in a more automated logistics network, where does the physical handoff actually happen? Arrive AI’s answer is the Arrive Point: a secure, climate-assisted, sensor-rich endpoint designed to receive and transfer goods asynchronously. - [AI Infrastructure, Optical Engines and Aviation-Tech Optionality: $DTST, $POET and $JTAI Move Into Focus After May 15 Updates](https://www.merlintrader.com/ai-infrastructure-optical-aviation-tech-may2026-update/): Data Storage Corporation, POET Technologies and Jet.AI each delivered May 15 updates that speak to a broader market theme: artificial intelligence is no longer only a software story. It is becoming an infrastructure story, a photonics story, a power-and-data-center story, and in some cases a corporate-transformation story. These three companies sit in different corners of that map. $DTST is trying to build a regulated-industry AI continuity platform on top of a recurring telecom and connectivity base. $POET is trying to become a core optical-engine and wafer-level photonic-integration supplier for AI networks and hyperscale data centers. $JTAI is the most complex and speculative of the three, combining AI cloud infrastructure, data-center power access, a pending aviation merger with flyExclusive, strategic holdings and a SpaceX-linked economic interest. - [AI Drones, Quantum Defense and the Commercial Space Race: $SPAI, $QUCY and $LUNR Move Into Focus](https://www.merlintrader.com/ai-drones-defense-space-may2026-focus/): Safe Pro Group, Quantum Cyber and Intuitive Machines offer three different ways to read the current convergence of artificial intelligence, drones, defense technology and commercial space. Safe Pro Group is the most numbers-driven update in this group, with record first-quarter revenue, a sharp increase in AI product sales and strong gross margins. Quantum Cyber is the most narrative-driven defense platform story, using the launch of quantum-cyber.ai to frame a broader System-of-Systems strategy across autonomous drones, counter-UAS, EMP-hardened components, autonomous demining and quantum antenna communications. Intuitive Machines is the most mature and institutionally visible company in the group, with record quarterly revenue, positive adjusted EBITDA, a record backlog and full-year guidance that still points to a much larger commercial space business in 2026. - [Viral Threats, Liver Fibrosis and Muscle Regeneration: $TRAW, $GALT and $MSLE Add Another Layer to the May 15 Biotech Tape](https://www.merlintrader.com/viral-threats-may2026-update/): Merlintrader Biotech Update Published / Aggiornato: May 15, 2026 $TRAWDaily chart $GALTDaily chart $MSLEDaily chart $TRAW $GALT $MSLE Biotech May 15 Updates Viral Threats, Liver Fibrosis and Muscle Regeneration: $TRAW, $GALT and $MSLE Add Another Layer to the May 15 Biotech Tape Traws Pharma, Galectin Therapeutics and Satellos Bioscience delivered three May 15 updates with […] - [Regulatory Paths, PDUFA Risk and Pivotal Oncology: $ATYR, $BTAI and $MBRX After the May 15 Updates](https://www.merlintrader.com/regulatory-paths-updates-may2026/): The final May 15 biotech group is not built around early proof-of-concept excitement. It is built around regulatory execution, pivotal-stage risk and the constant question that follows small and mid-sized biotech companies: can the next regulatory or clinical milestone arrive before financing pressure becomes the dominant market narrative? aTyr Pharma, BioXcel Therapeutics and Moleculin Biotech all issued updates on May 15 that give traders and long-form biotech readers a concrete catalyst map, but each company also comes with a very different risk profile. - [Alzheimer’s, RAS Oncology and iNKT Cell Therapy: $ANVS, $IMRX and $INKT Enter the May 15 Biotech Watchlist](https://www.merlintrader.com/alzheimer-oncology-celltherapy-may2026-update/): The May 15 biotech tape delivered another group of earnings and business updates that deserve more than a quick headline scan. Annovis Bio pushed its neurodegenerative disease story forward with a Phase 3 Alzheimer’s update, 85% enrollment in its pivotal Alzheimer’s disease trial, a positive DSMB safety recommendation, a Parkinson’s open-label extension study now 40% enrolled, and an outlined NDA path for buntanetap. Immuneering reported a very different type of update, centered on atebimetinib in pancreatic cancer, an upcoming ASCO oral presentation, a pivotal Phase 3 MAPKeeper 301 trial now recruiting, and a strong cash position of $198.6 million expected to fund operations into 2029. MiNK Therapeutics added a smaller but clinically interesting cell-therapy angle, advancing its off-the-shelf iNKT platform into randomized Phase 2 validation in severe acute lung injury and critical illness, with additional clinical data scheduled for ATS on May 20. - [Clinical Signals, Commercial Execution and Regulatory Paths: $TNYA, $SPRY and $BCDA After the May 15 Updates](https://www.merlintrader.com/clinical-signals-updates-tnya-spry-bcda-may2026/): Clinical Signals, Commercial Execution and Regulatory Paths: $TNYA, $SPRY and $BCDA After the May 15 Updates - [Innate Pharma (Nasdaq: $IPHA): Cancer Immunotherapy, PACIFIC-9, Lacutamab and the 2026 Catalyst Window](https://www.merlintrader.com/innate-pharma-may2026-deepdive/): Innate Pharma static chart — IPHA Static Finviz image. Referral applies only if the chart is clicked. The image is loaded without an affiliate parameter. The affiliate referral is attached only to the outbound chart link. Merlintrader Stock Hub · Deep Dive · Updated May 14, 2026 Innate Pharma (Nasdaq: $IPHA): Cancer Immunotherapy, PACIFIC-9, Lacutamab […] - [Cingulate Inc. (Nasdaq: $CING): Q1 Cash Build, Commercial Readiness and the Final Stretch Toward the May 31 FDA Catalyst](https://www.merlintrader.com/cingulate-inc-may2026-earnings-pre-pdufa/): Static Finviz chart. Affiliate referral is attached only to the outbound chart link, not to the image load. Latest Insight · May 14, 2026 Nasdaq: $CING Q1 2026 · FDA Catalyst Cingulate Inc. (Nasdaq: $CING): Q1 Cash Build, Commercial Readiness and the Final Stretch Toward the May 31 FDA Catalyst Cingulate’s Q1 2026 update strengthens […] - [Three Biotech Earnings Reports, Three Different Catalyst Stories: Gene Therapy, Autoimmune Cell Therapy and Oncology in Focus — $RGNX, $CABA, $KPTI](https://www.merlintrader.com/three-biotech-earnings-rgnx-caba-kpti-may2026/): REGENXBIO, Cabaletta Bio and Karyopharm all reported first-quarter 2026 updates on the same day, but the investment debate is not simply about quarterly EPS. The real story is a cluster of catalyst paths: Duchenne gene therapy and AbbVie-partnered retinal disease at REGENXBIO, rese-cel autoimmune cell therapy at Cabaletta, and a selinexor franchise trying to extend beyond multiple myeloma at Karyopharm. - [Three Biotech Earnings Stories Moving in Different Directions: $PGEN, $AQST and $ALLO](https://www.merlintrader.com/biotech-earnings-may2026-pgen-aqst-allo/): The May 2026 biotech earnings window produced three very different stories in Precigen, Aquestive Therapeutics and Allogene Therapeutics. They belong to the same broad sector, they all sit inside the volatile small-to-mid-cap biotechnology universe, and they all trade with catalyst sensitivity. - [Three Biotech Stocks With Fresh May 13 Updates: $TYRA, $SPRB and $PDSB](https://www.merlintrader.com/biotech-updates-tyra-sprb-pdsb-may2026/): May 13 delivered another packed biotech earnings and business-update session. For traders, the hard part is not simply finding companies that issued a press release. The hard part is separating routine quarterly updates from updates that actually change the near-term story. The three names in this article — Tyra Biosciences, Spruce Biosciences and PDS Biotech — all fit that second category, but for very different reasons. - [$CRON, $OGI, $SNDL: Cannabis Earnings Show a Split Sector Before the June 29 Policy Catalyst](https://www.merlintrader.com/cannabis-earnings-show-may2026/): The cannabis trade is no longer just about reform headlines. Cronos, Organigram and SNDL have now reported fresh numbers, and the message is clear: the sector may have a policy catalyst, but operating quality, balance-sheet strength, international exposure and margin discipline are starting to separate the stronger stories from the more fragile ones. - [Kopin Corporation (Nasdaq: $KOPN): Q1 2026 Results, Fabric.AI Optionality And The Defense Microdisplay Reset](https://www.merlintrader.com/kopin-corporation-may2026-deepdive/): Kopin’s first-quarter update is not a simple revenue story. The headline number was almost flat year over year, but the mix underneath changed sharply, the defense order flow accelerated after quarter end, the company moved deeper into domestic OLED production, and the Fabric.AI collaboration added a speculative but potentially meaningful AI-infrastructure layer to a business still anchored in defense-grade optical systems. - [Plug Power (Nasdaq: $PLUG): Q1 2026 Earnings, Trend Reversal Attempt, and the Long Road from Hydrogen Hype to Execution](https://www.merlintrader.com/plug-power-may2026-deepdive/): Merlintrader Deep Dive Updated May 12, 2026 · Educational analysis · Not financial advice PLUG static chart first — trend context before the article Referral applied only on click, not on image load Static Finviz chart for visual context only. The chart should be read as a trading reference, not as a recommendation. Price action […] - [DroneShield (OTC: $DRSHF): Record Q1, SaaS Ambition and the Governance Test Behind the Counter-Drone Boom](https://www.merlintrader.com/droneshield-ambition-governance-may2026-deepdive/): DroneShield has moved from being an interesting counter-drone hardware story into something more dangerous for lazy valuation work: a fast-growing defense technology company trying to attach software, command-and-control, AI updates, warranty, service, and repeat procurement dynamics to a hardware-heavy installed base. That does not automatically make it a classic SaaS company. It does, however, make the margin and revenue-quality debate much more interesting than a simple “guns, jammers and sensors” narrative. - [IonQ and SkyWater: Why the $IONQ–$SKYT Deal Turns Quantum Into a U.S. Manufacturing Story](https://www.merlintrader.com/ionq-skywater-merger-may2026/): SkyWater stockholders have approved the merger agreement with IonQ. The vote does not close the deal yet, but it moves one of the most unusual quantum transactions of 2026 into its next phase: regulatory review, supply-chain strategy, and the question of whether quantum companies need more than algorithms and cloud access to scale. - [Three Different Ways to Play the AI Photonics Race $POET, $COHR and $AAOI](https://www.merlintrader.com/photonics-race-may2026-deepdive/): The artificial intelligence infrastructure boom is not only a story about GPUs, accelerators, memory, power, cooling and real estate. It is also, increasingly, a story about light. As AI clusters become larger, denser and more power hungry, the bottleneck shifts from raw compute alone to the movement of data between processors, racks, data halls and campuses. Electrical interconnects still matter, but the further the AI buildout moves into high-bandwidth, low-latency and energy-constrained architectures, the more optical networking becomes one of the critical hidden layers of the trade. - [Drone Defense Mid-Caps: Ondas, Red Cat and Kratos Put $ONDS, $RCAT and $KTOS in the Same War-Tech Conversation](https://www.merlintrader.com/drone-defense-may2026-comparison/): Ondas Holdings, Red Cat Holdings and Kratos Defense & Security Solutions represent three very different ways to read the drone-defense trade: an aggressive autonomous-systems platform buildout, a focused tactical-drone procurement ramp, and a scaled defense-technology contractor with real backlog and unmanned-systems revenue. - [Small-Cap Defense Drones: Unusual Machines, Palladyne AI and Draganfly Enter the 2026 Tactical Autonomy Race ($UMAC $PDYN $DPRO)](https://www.merlintrader.com/small-cap-defense-drones-may2026-deepdive/): The defense-drone market is moving through a strange phase. Everyone understands that drones matter. Ukraine made that obvious to the public, but the deeper shift was already underway inside military planning: low-cost autonomy, small-unit reconnaissance, counter-UAS defense, distributed ISR, attritable systems and the need to reduce dependence on vulnerable or adversary-linked supply chains. The harder question is not whether drones matter. It is which companies can actually turn the new procurement mood into production, contracts, margins and revenue quality. - [Three 2026 FDA Decisions Testing Whether New Drugs Can Beat Imperfect Standards: Unicycive, Protagonist and Savara ($UNCY $PTGX $SVRA)](https://www.merlintrader.com/three-2026-fda-decisions/): A PDUFA date is easy to understand. It creates a countdown, gives traders a calendar anchor and makes a biotech story feel tradable. But the FDA date is rarely the whole thesis. In near-approval biotech, the first question is whether the drug can be approved. The second question, often more important for long-term value, is whether the drug can change behavior after approval. That second question is where many apparently clean catalyst stories become complicated. - [Viking Therapeutics $VKTX, Structure Therapeutics $GPCR and Altimmune $ALT: The Next Obesity Drug Race](https://www.merlintrader.com/viking-structure-alt-the-next-race/): The obesity-drug market has moved from discovery excitement into commercial combat. That is the central change investors have to absorb. In 2023 and 2024, it was still possible to build a strong biotech story around the idea that a company had an obesity asset with meaningful weight-loss data. In May 2026 that is no longer enough. The benchmark is no longer theoretical. Patients can already get injectable semaglutide, injectable tirzepatide, oral semaglutide and oral orforglipron in the U.S. market, while older weight-management drugs still occupy price-sensitive, generic or non-incretin niches. Novo Nordisk's Wegovy pill was approved in December 2025 as an oral GLP-1 option for weight management, and Eli Lilly's Foundayo, orforglipron, was approved in April 2026 as a once-daily oral GLP-1 pill that Lilly says can be taken without food or water restrictions. Those approvals make the next phase more difficult, but also more valuable, because they validate patient demand for convenience and scale. 3 1 2 - [3 Biotech Stocks Facing Near-Term FDA Catalysts: MannKind ($MNKD), Viridian Therapeutics ($VRDN) and Vera Therapeutics ($VERA)](https://www.merlintrader.com/biotech-fda-catalysts-near-term/): Biotech does not need to be vague to be speculative. The best watchlist stories usually sit in the middle: visible enough to be researched, near enough to matter, but still uncertain enough to create price discovery. MannKind ($MNKD), Viridian Therapeutics ($VRDN) and Vera Therapeutics ($VERA) fit that profile heading into late May, June and July 2026. - [3 Biotech Stocks to Watch: PTC Therapeutics ($PTCT), Enliven Therapeutics ($ELVN) and Edgewise Therapeutics ($EWTX)](https://www.merlintrader.com/biotech-stocks-to-watch-may09-2026/): Biotech watchlists are most useful when they separate the type of risk behind each ticker. PTC Therapeutics is not the same story as Enliven Therapeutics, and Enliven is not the same story as Edgewise Therapeutics. $PTCT is now a commercial execution and guidance story. $ELVN is a clean oncology catalyst story built around a potential Phase 3 transition in chronic myeloid leukemia. $EWTX is a broader clinical-platform story where investors are watching both cardiac and muscular dystrophy programs for data that could reshape the company’s valuation narrative before the end of 2026. - [Cingulate ( $CING ) vs Aytu BioPharma ( $AYTU ): What a Commercial ADHD Peer Can — and Cannot — Tell Us Before CING’s May 31 PDUFA](https://www.merlintrader.com/cingulate-vs-aytu-biopharma-may2026-comparison/): CING is a pre-commercial FDA catalyst story built around CTx-1301. AYTU is a commercial specialty pharma/CNS story with real ADHD revenue, EXXUA optionality, debt, warrants and execution complexity. The useful comparison is not “which one is better,” but what kind of risk each company represents. - [Pentagon UFO Files, Space Stocks and the Market’s New “Alien Premium” . Related tickers : $LUNR $RKLB $FLY $PL $BKSY $RDW $ASTS $SPIR $SATL](https://www.merlintrader.com/pentagon-ufo-files-may2026/): On May 8, 2026, the U.S. Department of War launched the Presidential Unsealing and Reporting System for UAP Encounters, or PURSUE, and began publishing a first wave of records tied to unidentified anomalous phenomena. That part is not internet folklore. It is an official government release, framed by the administration as a transparency push and explicitly tied to President Donald Trump’s February 19, 2026 directive to identify, review, declassify and release unresolved UAP-related records. - [YPF Sociedad Anónima (NYSE: $YPF): Vaca Muerta, Argentina LNG and the High-Beta Energy Turnaround](https://www.merlintrader.com/ypf-sociedad-anonima-may2026-deepdive/): A complete May 2026 deep dive on Argentina’s national energy champion: Q1 2026 profit recovery, shale oil growth, Vaca Muerta, export optionality, LNG ambitions, downstream exposure, state-control risk, litigation overhang, macro sensitivity and the bull/base/bear framework. - [IREN Ltd (Nasdaq: $IREN): From Bitcoin Miner to AI Cloud Infrastructure Contender](https://www.merlintrader.com/iren-ltd-may2026-deepdive/): A complete May 2026 deep dive on IREN’s transformation, the Microsoft and NVIDIA contracts, the 5GW data-center pipeline, the Mirantis acquisition, financial execution, dilution risk, and the bull/base/bear framework investors should understand before treating the stock as a pure AI infrastructure story. - [SKYX Platforms Corp. (Nasdaq: $SKYX): Smart Ceiling Infrastructure, Retail Expansion, AI Optionality and the Execution Test](https://www.merlintrader.com/skyx-platforms-corp-may2026-deepdive/): SKYX Platforms Corp. is not a simple smart-home gadget story. It is a small-cap infrastructure-adoption story trying to turn the ceiling into a safer, standardized, plug-and-play access point for lighting, fans, heaters, smart devices, builders, hotels, retailers and eventually software-enabled building systems. That ambition is large enough to make the stock interesting, but also large enough to require much more proof than product announcements and channel headlines. - [Traws Pharma (Nasdaq: $TRAW): Hantavirus Urgency, Antiviral Pipeline and the High-Risk Reset Story](https://www.merlintrader.com/traws-pharma-hantavirus-urgency-antiviral-pipeline/): Traws is trying to reposition itself around clinical-stage antiviral assets for respiratory and outbreak-prone viral threats. The new hantavirus initiative adds a timely public-health narrative, but the investment story still depends on execution around tivoxavir marboxil, ratutrelvir, regulatory risk, financing mechanics and the company’s ability to convert scientific optionality into credible clinical progress. - [IonQ (NYSE: $IONQ): From Quantum Hype to Platform Ambition After Q1 2026](https://www.merlintrader.com/ionq-quantum-hyper-may2026-deepdive/): IonQ has moved from being a speculative quantum computing name to becoming the main public-market test case for whether quantum can evolve into a real commercial platform before the decade is over. The company’s Q1 2026 results changed the conversation: $64.7 million of quarterly revenue, 755% year-over-year growth, full-year guidance raised to $260–270 million, and remaining performance obligations rising to $470 million. - [Backlog Quality Matters: Why $RKLB, $BKSY, $RDW and $BBAI Are Now Being Judged on Conversion, Not Just Contracts](https://www.merlintrader.com/backlog-quality-matters-may2026-editorial/): In every strong thematic market, there comes a moment when investors stop rewarding the story and start grading the machinery underneath it. Space, defense technology and AI-enabled government software have all enjoyed powerful narrative support: satellite constellations, national-security budgets, hypersonic testing, geospatial intelligence, autonomous systems, battlefield decision software, and the broader AI infrastructure cycle. But after the latest earnings wave, the central question has become sharper and more practical: how much of the reported backlog can actually convert into durable revenue, margin improvement and cash-flow progress? - [LightPath Technologies (Nasdaq: $LPTH): The Backlog Story Gets Stronger, But the Margin for Error Gets Smaller](https://www.merlintrader.com/lightpath-technologies-may2026-deepdive/): LightPath Technologies has reached the point where the market no longer needs to be convinced that the story is interesting. The story is clearly interesting. The company sits at the intersection of infrared imaging, U.S. and allied defense supply-chain reshoring, germanium substitution, optical assemblies, camera systems, and a broader geopolitical effort to reduce dependence on fragile or adversarial sources of critical materials. That is exactly the kind of small-cap industrial-defense narrative that can attract trader attention quickly. - [Rackspace Technology (Nasdaq: $RXT): May 2026 Deep Dive After Q1 Results and the AMD AI Infrastructure MOU](https://www.merlintrader.com/rackspace-technology-may2026-deepdive/): Merlintrader Deep Dive · May 2026 Educational content only · No buy/sell recommendation NASDAQ: $RXT · Enterprise AI Infrastructure Rackspace Technology (Nasdaq: $RXT): May 2026 Deep Dive After Q1 Results and the AMD AI Infrastructure MOU Rackspace is trying to turn an old managed-cloud story into a governed enterprise AI infrastructure story. The May update […] - [Atara Biotherapeutics (Nasdaq: $ATRA): FDA Type A Meeting Opens a Narrower Resubmission Path for Tabelecleucel](https://www.merlintrader.com/atara-biotherapeutics-resubsmission-path/): Atara Biotherapeutics has received the kind of regulatory update that can revive a micro-cap biotech narrative, but only if investors read it with discipline. The May 7, 2026 announcement is not a new approval, not a BLA acceptance, and not a PDUFA date. It is something more technical and, for this specific story, potentially more important: after a Type A meeting, FDA has agreed that a single-arm study using an appropriate historical control, conducted in a pre-specified manner and applicable to the trial population, could serve as an adequate and well-controlled study to support a future marketing application for tabelecleucel, also known as tab-cel. - [Humacyte Inc. (Nasdaq: $HUMA): Symvess Is Approved, But the Real Test Is Commercial Execution UPDATED May 13](https://www.merlintrader.com/humacyte-may2026-deepdive/): Humacyte is no longer just a speculative pre-approval biotechnology story. The company has an FDA-approved product, a real commercial launch, hospital ordering activity, international regulatory work, military and trauma relevance, and a near-term Phase 3 dialysis catalyst. That alone makes the story more mature than many small-cap biotech names trading purely on hope. - [Ultragenyx Pharmaceutical Inc. (Nasdaq: $RARE): May 2026 Deep Dive](https://www.merlintrader.com/ultragenyx-pharmaceuticals-inc-may2026-deepdive/): Ultragenyx Pharmaceutical enters May 2026 as a rare-disease platform that has already been through the emotional part of a major reset. The December 2025 failure of setrusumab, also known as UX143, in the Phase 3 ORBIT and COSMIC studies for osteogenesis imperfecta changed the equity story. Before that readout, part of the market still treated UX143 as a potential next commercial pillar. After the readout, that assumption had to be removed or heavily discounted. The drug improved bone mineral density, but it did not deliver statistically significant fracture-rate reductions in the pivotal studies. In rare-disease investing, that distinction matters. Biology can look encouraging; regulators, payers and investors still need clinically persuasive outcomes. - [aTyr Pharma Inc. (Nasdaq: $ATYR): The EFZO-FIT Collapse, the Rebuild Trade and the FDA Path That Now Defines the Story](https://www.merlintrader.com/atyr-pharma-may2026-deepdive/): aTyr Pharma is no longer the clean Phase 3 binary story that traders were watching before September 2025. It is now a post-collapse biotech reconstruction trade. The difference matters. Before EFZO-FIT read out, the market could frame ATYR around a simple question: would efzofitimod show a statistically persuasive ability to reduce oral corticosteroid use in pulmonary sarcoidosis? After the readout, the question changed completely. The Phase 3 trial did not meet its primary endpoint. The drug is not de-risked. The company now has to defend the clinical relevance of secondary and supportive signals, persuade regulators that the totality of evidence may still deserve a path forward, protect the balance sheet, and keep investors from reducing the entire story to a failed late-stage asset. - [American Shared Hospital Services (NYSE American: $AMS): Oncology Infrastructure, Direct Patient Care and Balance-Sheet Risk](https://www.merlintrader.com/american-shared-hosplital/): Static Finviz chart. The image loads without referral parameters; the sponsored referral is attached only to the outbound chart link. Merlintrader Deep Dive • Healthcare Infrastructure • Micro-Cap Watch American Shared Hospital Services (NYSE American: $AMS): Oncology Infrastructure, Direct Patient Care and Balance-Sheet Risk A long-form stock hub style analysis of a tiny but real […] - [Small-Cap AI Valuation Reset 2026: BigBear.ai ($BBAI), Innodata ($INOD) and the KPIs That Actually Matter](https://www.merlintrader.com/ai-valuation-reset-2026/): The most important change in small-cap AI is not that the artificial-intelligence theme has disappeared. It has not. The real change is that the market has become far less willing to pay for a story without financial confirmation. In 2023 and 2024, the AI label itself was often enough to pull valuation multiples higher. By 2026, that shortcut is much less reliable. Investors are now differentiating between companies that have a real commercial engine and companies that still depend mainly on presentation-deck language. - [Bio-Digital Defense: FY 2026 NDAA Catalyst for $AVAV, $BBAI and $EBS](https://www.merlintrader.com/bio-digital-defense-fy2026-catalyst/): The real story is not that Washington is simply spending more on biodefense. The real story is that the FY 2026 NDAA turns biotechnology into a national-security infrastructure layer: biological data, AI-ready repositories, synthetic DNA/RNA supply, trusted procurement, biomimetic materials, chemical-biological detection and domestic manufacturing capacity now sit inside the same strategic frame. - [MannKind Corporation (Nasdaq: $MNKD): Ralinepag DPI, Tyvaso/Tresmi, Afrezza and the Next Catalyst-Rich Chapter Updated](https://www.merlintrader.com/mannkind-corporation-may2026-deepdive/): MannKind is not a clean story. That is precisely why it deserves a deep dive. This is a company with one of the most tortured histories in small-cap biotech: years of hope around Afrezza, a painful Sanofi breakup, repeated market skepticism, debt and dilution concerns, and a long struggle to prove that inhaled therapeutics could become more than a scientific idea. Yet MannKind is still here, and the current version of the company is meaningfully different from the old single-product Afrezza story. - [Recursion Pharmaceuticals (Nasdaq: $RXRX): Q1 2026 turns the AI-biotech story into an execution test](https://www.merlintrader.com/recursion-pharmaceuticals-may2026-deepdive/): Recursion Pharmaceuticals did not report a “commercial” quarter in the traditional biotech sense. There is still no approved product, no drug-sales revenue and no recurring product line that can be valued like a de-risked commercial-stage company. But Q1 2026 still matters because it updates the three pillars of the RXRX story: the AI-powered platform is generating real clinical programs, the company is reducing burn versus 2025, and lead asset REC-4881 in familial adenomatous polyposis is moving into the stage where FDA alignment becomes the key inflection point. - [$SUPN, $RLAY and $ADPT: Three Q1 2026 Earnings Reports, Three Different Biotech Risk Profiles](https://www.merlintrader.com/supn-rlay-adpt-three-q12026-earnings/): This report looks at three Q1 2026 biotech earnings releases that are worth grouping together because they show three very different types of healthcare equity risk. Supernus Pharmaceuticals is a commercial CNS company trying to scale growth products while absorbing spending and legacy erosion. Relay Therapeutics is a clinical-stage precision oncology company with a long cash runway, but still heavy operating losses. Adaptive Biotechnologies is a commercial diagnostics company where MRD growth and clonoSEQ volume are the central story. - [Rigel Pharmaceuticals (Nasdaq: $RIGL): Q1 2026 Profitability, the Lilly Reset and the Harder Test for a Commercial Biotech Turnaround](https://www.merlintrader.com/rigel-pharmaceuticals-may2026-deepdive/): Why This Deep Dive Matters Now The timing is what makes Rigel worth a fresh, event-driven deep dive. The company entered 2026 after a much stronger 2025, with record net product sales, full-year profitability and a larger cash position. That already made the stock more relevant for small-cap biotech investors searching for companies with real revenue rather than purely clinical speculation. Then came the Eli Lilly termination. That changed the framing immediately. Before the termination, Rigel could be described as a commercial-stage biotech with three marketed products and a potentially meaningful partnered RIPK1 program backed by one of the most important pharmaceutical companies in the world. After the termination, investors have to remove part of that long-term optionality from the story. - [Verrica Pharmaceuticals: VP-315 Phase 2 Data Put a Fresh Spotlight on Basal Cell Carcinoma](https://www.merlintrader.com/verrica-pharmaceuticals-may2026-update/): Verrica Pharmaceuticals returned to the biotech watchlist on May 5 with a clinically interesting update on VP-315 / ruxotemitide, its investigational oncolytic peptide program in basal cell carcinoma. The headline is not merely that the company will present at the 2026 Society for Investigative Dermatology Annual Meeting in Chicago. The important part is that Verrica is highlighting Phase 2 data showing tumor reductions in lesions that were not directly injected with VP-315. - [Ocugen (Nasdaq: $OCGN): Q1 2026, Convertible Financing, Pipeline Catalysts and the New Risk/Reward Map](https://www.merlintrader.com/ocugen-may2026-update/): Ocugen has just reset the financial framework around its equity story. The company entered 2026 as a high-beta, pre-commercial biotech with a pipeline that had visible clinical and regulatory milestones but a balance sheet that still looked too narrow for the size of the opportunity it was trying to pursue. The May 2026 financing changes that discussion. Ocugen priced $115 million aggregate principal amount of 6.75% convertible senior notes due 2034, with an option for the initial purchaser to acquire up to an additional $15 million. The company expects the transaction to close on May 7, 2026, subject to customary conditions, and expects net proceeds of roughly $99.5 million before the optional additional notes. A portion of the proceeds, approximately $32.7 million, is expected to be used to fully repay the Avenue Capital debt facility, including principal, accrued and unpaid interest, a prepayment fee, and related expenses. - [Oculis Holding AG (Nasdaq: $OCS): the June 2026 DIAMOND readout is the real test](https://www.merlintrader.com/oculis-holdings-may2026-deepdive/): Oculis Holding AG is not a generic small biotech waiting for a vague future update. It is a late-stage ophthalmology and neuro-ophthalmology company approaching a defined Phase 3 readout in diabetic macular edema, one of the most commercially relevant retina indications in eye care. The core of the story is OCS-01, a high-concentration dexamethasone eye drop built on the company’s OPTIREACH® formulation technology. The thesis is easy to understand but difficult to prove: if a topical eye drop can deliver clinically meaningful benefit in a posterior-segment disease such as diabetic macular edema, Oculis could open a new therapeutic category in a market still dominated by intravitreal injections and invasive treatment pathways. - [Ocular Therapeutix (Nasdaq: $OCUL): Sanofi Rumor, AXPAXLI and the Real Takeover Logic Behind the Wet AMD Story](https://www.merlintrader.com/ocular-therapeutics-sanofi-rumor-may2026/): Ocular Therapeutix is back in focus after media reports linked Sanofi to a possible takeover approach. According to reports citing French publication La Lettre, Sanofi previously approached Ocular with an offer around $16 per share, Ocular’s board reportedly rejected that initial proposal, and Sanofi may be considering or preparing a higher bid. Neither Ocular Therapeutix nor Sanofi has confirmed a transaction, and that distinction matters. The confirmed foundation of the story is not the takeover rumor; it is AXPAXLI, Ocular’s investigational axitinib intravitreal hydrogel implant, which recently produced positive Phase 3 SOL-1 data in wet age-related macular degeneration. - [Skycorp Solar Group (Nasdaq: $PN): When a Solar Microcap Becomes a Full-Control Acquisition Story](https://www.merlintrader.com/skycorp-solar-group-may2026-deepdive/): Skycorp Solar Group Limited is a China-based solar photovoltaic product provider listed on Nasdaq under ticker PN. The company is primarily known for solar PV cables and connectors, with additional exposure to high-performance computing products and, after the Nanjing Cesun transaction, a broader renewable-energy footprint that may include server equipment sales, inverter production, photovoltaic power station operation and energy management systems. - [Wall Street weekly recap and next-week setup: $PLTR, $AMD, $RKLB lead a catalyst-heavy watchlist as AI earnings, cannabis policy and space-defense names move back into focus](https://www.merlintrader.com/wall-street-weekly-recap-may4/): The week ended May 1 kept the bullish market structure alive. U.S. equities came out of an earnings-heavy stretch with the S&P 500 and Nasdaq still pressing record levels, helped by strong corporate results, renewed confidence around AI infrastructure spending and a late-week easing in crude oil pressure. The market entered May with momentum, and that matters because the old “sell in May” warning is not enough by itself to override a tape that still has earnings, flows and leadership behind it. - [Rezolute, Inc. (Nasdaq: $RZLT): sunRIZE is not rescued yet — but the PES data make the FDA-package story harder to ignore](https://www.merlintrader.com/rezolute-inc-may2026-update/): Rezolute’s latest update is important because it gives the congenital hyperinsulinism story a second act. It does not erase the first act. The first act remains the December 2025 disclosure that the Phase 3 sunRIZE trial of ersodetug missed its primary endpoint and its key secondary endpoint. That failure damaged the clean registration narrative and forced the company into a more complex argument: the drug may have shown meaningful biological and clinical activity, but the trial’s primary endpoint may have been confounded by behavioral and measurement issues tied to self-monitored blood glucose. - [Fate Therapeutics (Nasdaq: $FATE): iPSC Cell Therapy, FT819 and the High-Stakes Autoimmune CAR-T Reset Updated 04 may 2026](https://www.merlintrader.com/fate-therapeutics-may2026-deepdive/): Fate Therapeutics is one of the more interesting “fallen platform” stories in biotech. The company is not a single-asset microcap built around one binary Phase 2 readout; it is a long-running cell therapy platform company trying to prove that induced pluripotent stem cells, or iPSCs, can support standardized, off-the-shelf cellular medicines across autoimmune disease and oncology. The market, however, is no longer paying a premium for platform ambition alone. After several difficult years for allogeneic and off-the-shelf cell therapy names, investors want evidence: durable clinical activity, manageable safety, realistic manufacturing economics, regulatory clarity and a capital structure that does not punish existing shareholders before the platform has time to mature. - [Reddit, Inc. (NYSE: $RDDT): AI-Powered Ads, Human Conversation and the Profitability Re-Rating](https://www.merlintrader.com/reddit-inc-ai-powered-may2026-deepdive/): Reddit, Inc. is no longer being judged only as a chaotic social platform with a passionate user base and uncertain monetization. After Q1 2026, the market is increasingly treating Reddit as a scaled, high-margin internet asset with three linked growth engines: performance advertising, search-driven discovery, and commercial value from its archive of human conversation. - [Summit Therapeutics ( $SMMT ): the HARMONi-3 selloff does not kill the story, but it changes the burden of proof](https://www.merlintrader.com/summit-therapeutics-may2026-deepdive/): Summit Therapeutics is not a normal quarterly earnings story. The company has no commercial revenue profile to dissect in the usual way, no product-sales margin trend to model, and no near-term EPS narrative that matters more than its clinical and regulatory path. $SMMT is a concentrated bet on ivonescimab, also known as SMT112 in Summit’s licensed territories, a PD-1/VEGF bispecific antibody that has become one of the most closely watched potential challengers to the PD-1 oncology establishment. - [Ardelyx Inc. (Nasdaq: $ARDX): The Growth Story Is No Longer Theoretical](https://www.merlintrader.com/ardelyx-inc-may2026-growth-story/): Ardelyx is now a commercial-stage biotech where the core debate has moved from “can the product sell?” to “can the company turn rapid product growth into durable operating leverage?” That shift matters. It means $ARDX is no longer trading purely as a binary FDA story or early-launch hope. It is trading as a real revenue company with two approved U.S. products, a differentiated NHE3 biology platform, a growth engine in IBSRELA, a more complicated but still relevant kidney franchise in XPHOZAH, and a pipeline extension strategy that could make today’s commercial infrastructure more valuable over time. - [Contineum Therapeutics (Nasdaq: $CTNM): PIPE-791 Puts Chronic Pain Back on the Map](https://www.merlintrader.com/contineum-therapeutics-may2026-deepdive/): Contineum Therapeutics is a clinical-stage biotechnology company focused on oral small molecules for neuroscience, inflammation and immunology, a space the company abbreviates as NI&I. The stock is back in focus because Contineum reported positive topline data from an exploratory Phase 1b trial of PIPE-791 in chronic pain on April 30, 2026. The market setup is simple: a small biotech with a relatively concentrated pipeline just produced fresh human data in a high-interest indication, while already carrying a separate Phase 2 IPF program and a partnered Johnson & Johnson asset in depression. - [Axsome Therapeutics (Nasdaq: $AXSM): AUVELITY Approval Changes the Alzheimer’s Agitation Story](https://www.merlintrader.com/axsome-therapeutics-auvelity-approval-april2026/): Axsome is no longer just a high-growth CNS name with a pending binary catalyst. After the FDA approval of AUVELITY for agitation associated with dementia due to Alzheimer’s disease, the debate shifts to launch execution, payer access, physician adoption, label positioning and whether the market has already priced in a large part of the upside. - [Spyre Therapeutics 2026 (Nasdaq: $SYRE): When Great Clinical Data Matter More Than Promises](https://www.merlintrader.com/spyre-therapeutics-may2026-deepdive/): Spyre Therapeutics is now one of the more important clinical-stage IBD stories on the U.S. biotech radar. The company is not commercial, it has no approved product, and it remains a high-risk development-stage name. But after the April 13, 2026 SPY001 Phase 2 SKYLINE-UC Part A induction data, the market has a real clinical datapoint to underwrite rather than a pure slide-deck narrative. - [Lithium Argentina AG (NYSE/TSX: $LAR): When Resources Matter More Than Spot Prices](https://www.merlintrader.com/lithium-argentina-may2026-deepdive/): Lithium Argentina AG is one of the more interesting lithium brine names in South America because it is no longer in the purely promotional phase common among many explorers. Its main asset, Cauchari-Olaroz, is producing in Jujuy Province, Argentina, with Stage 1 nameplate capacity of 40,000 tonnes per year of lithium carbonate. The company owns 44.8% of the operation, in partnership with Ganfeng Lithium at 46.7% and JEMSE at 8.5%. - [C3.ai, Inc. (NYSE: $AI): Deep Research Report](https://www.merlintrader.com/c3ai-inc-may2026-deepdive/): C3.ai, Inc. is a U.S. enterprise software company focused on artificial intelligence applications for large organizations. The ticker is almost too perfect: AI. The business story, however, is no longer being valued as a clean AI momentum trade. As of April 30, 2026, C3.ai is a genuine turnaround case: real enterprise software, real blue-chip customers, major cloud partnerships, a meaningful federal/defense angle, but also a severe FY2026 revenue reset, heavy operating losses, workforce reductions, leadership transition and a market that wants proof rather than promises. - [Revelation Biosciences, Inc. (Nasdaq: $REVB): Gemini, AKI, CKD and the High-Risk Micro-Cap Repricing Setup](https://www.merlintrader.com/revelation-biosciences-may2026-deepdive/): Revelation Biosciences, Inc. (NASDAQ: REVB) is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing therapies designed to modulate the innate immune system. Its lead product candidate, Gemini, is a proprietary intravenous formulation of PHAD® (phosphorylated hexaacyl disaccharide), a Toll-like receptor 4 agonist intended to rebalance innate immune activity and reduce organ damage associated with acute and chronic inflammatory stress. - [Viking Therapeutics (Nasdaq: $VKTX): the May 2026 Deep Dive](https://www.merlintrader.com/viking-therapeutics-may2026-deepdive/): VK2735 has moved from promise to execution: two subcutaneous Phase 3 VANQUISH trials are fully enrolled, maintenance-dose data are expected in Q3 2026, oral Phase 3 development is now guided for Q4 2026, and the Q1 update confirms both the opportunity and the spending intensity of Viking’s obesity strategy. - [XTL Biopharmaceuticals Ltd. $XTLB: Psyga Bio Deal Turns a Tiny IP Portfolio Story Into a Psychedelic Biotech Catalyst Trade](https://www.merlintrader.com/xtl-biopharmaceuticals-psyga-deal-april2026/): XTL Biopharmaceuticals has signed a definitive agreement to acquire Psyga Bio, an Israeli psychedelic and functional mushroom platform with a licensed GMP-ready manufacturing facility, a proprietary mushroom-strain library and seven approved Phase 2a human clinical trials. The opportunity is obvious. So are the risks: shareholder approval, Nasdaq listing status, interested-party governance, liquidity, dilution and the need to convert an exciting headline into real clinical execution. - [Teva Pharmaceutical Industries (NYSE: $TEVA): Q1 2026 Turns the Pivot to Growth Into a Harder-to-Ignore Story](https://www.merlintrader.com/teva-pharmaceuticals-industries-q1-2026-growth/): Teva’s Q1 2026 report is important because it compresses the entire turnaround debate into one clean question: is this still a heavily indebted generics company trying to defend mature assets, or has it become a hybrid biopharma platform where innovative medicines, biosimilars and late-stage pipeline optionality can finally outweigh the drag from legacy generics? - [Unusual Machines ( $UMAC ): The American Drone Components Re-Rating](https://www.merlintrader.com/unusual-machines-april2026-deepdive/): Unusual Machines, Inc. has become one of the more visible small-cap drone names because it sits directly inside a powerful market narrative: the United States wants more domestic drone manufacturing, defense and public-safety customers increasingly need NDAA-compliant components, Chinese supply-chain exposure is becoming a strategic problem, and FPV-style drone technology has moved from hobby culture into battlefield and counter-drone relevance. - [LightPath Technologies (Nasdaq: $LPTH): Defense Optics, BlackDiamond Glass and the High-Stakes IR Systems Re-Rating](https://www.merlintrader.com/lightpath-technologies-april2026-deepdive/): LightPath Technologies, Inc. is no longer just the quiet precision-optics name that many traders associated with molded glass components and industrial laser applications. The company has spent the last year repositioning itself around infrared imaging, defense demand, domestic optical supply chains and a broader “systems” strategy. The February 2026 Merlintrader report already captured the first major inflection: Q2 FY2026 revenue reached $16.4 million, up 120% year over year, gross margin rose to about 37%, adjusted EBITDA turned positive, and backlog reached roughly $97.8 million. - [Aclaris Therapeutics (Nasdaq: $ACRS): ATI-052 Phase 1a Data, ATI-2138 Lichen Planus Pivot and the 2026 Catalyst Reset](https://www.merlintrader.com/aclaris-therapeutics-april2026-catalyst-reset/): Aclaris Therapeutics is back on the biotech catalyst radar because the April 28, 2026 update gives the market two things it was waiting for: more complete first-in-human data for ATI-052 and a clearer development path for ATI-2138. The new story is not a single-asset binary event. It is a pipeline reset around immuno-inflammatory diseases, where Aclaris is trying to build a differentiated position with one long-acting biologic and one oral T-cell pathway inhibitor - [Fabric.AI / StableX Technologies $SBLX and Kopin Corporation $KOPN: the MicroLED Interconnect Trade](https://www.merlintrader.com/fabric-ai-stablex-kopin-april2026/): This is the kind of story that can light up the small-cap tape quickly because it combines several ingredients that retail traders actively chase: artificial intelligence infrastructure, data-center bottlenecks, optical interconnects, MicroLED, a low-float style microcap setup, a corporate name change, a ticker change, a financing, and a visible connection to a company with real operating history in advanced displays and optical systems. StableX Technologies, trading as $SBLX at the time of the announcement, is now presenting itself as Fabric.AI and intends to trade as $FABC. The new pitch is straightforward: AI factories need more than GPUs; they need faster, lower-power ways to move data between compute nodes. Fabric.AI wants to start with MicroLED-based optical interconnects, and Kopin is the enabling MicroLED partner. - [FLASH2 Futility Changes the Soligenix Story: HyBryte Reset, Cash Pressure and What Can Still Matter Next](https://www.merlintrader.com/soligenix-flash2-futility-april2026/): Soligenix has moved from a late-stage CTCL catalyst story into a post-failure restructuring story. The April 28, 2026 update is not a small delay, not a clean statistical miss that can be quickly reframed, and not merely a volatility event around a binary readout. The company announced that the Data Monitoring Committee completed the interim efficacy analysis of the pivotal Phase 3 FLASH2 trial evaluating HyBryte in cutaneous T-cell lymphoma and recommended that the study halt for futility. For a microcap biotech whose most visible near-term value driver was HyBryte’s path toward potential regulatory approval, this materially resets the risk profile. - [Nauticus Robotics $KITT: Ocean Robotics, Reverse Split Risk and the 2026 Commercialization Test](https://www.merlintrader.com/nauticus-robotics-april2026-deepdive/): MerlinTrader Deep Dive Nauticus Robotics (Nasdaq: $KITT): Ocean Robotics, Reverse Split Risk and the 2026 Commercialization Test A full EN/IT deep dive on Nauticus Robotics, its autonomous subsea robotics platform, SeaTrepid integration, East Coast offshore activity, UAE expansion plan, financial runway, dilution risk and what investors should watch after the latest reverse split. Ticker: KITT […] - [Northern Dynasty Minerals (NYSE American: $NAK): The Pebble Project’s Long War](https://www.merlintrader.com/northern-dinasty-minerals-aprile2026-deepdive/): Northern Dynasty Minerals is not a conventional “mine is coming online next year” story. It is not a producer, it has no operating mining revenue, and the Pebble Project is not currently a permitted development-ready asset. The stock is instead a high-volatility legal and regulatory optionality vehicle tied to one of the largest undeveloped copper-gold systems in North America. Pebble is big enough to keep attracting speculative attention, but controversial enough to have remained trapped for years between environmental opposition, federal permitting decisions, an EPA Clean Water Act veto, and a long chain of litigation. - [CorMedix Therapeutics (Nasdaq: $CRMD): Rezzayo Delivers, the Platform Thesis Gets Stronger](https://www.merlintrader.com/cormedix-therapeutics-rezzayo-delivers-april2026/): Today’s ReSPECT readout removes one major clinical uncertainty from the CorMedix story. The next layer is execution: pre-NDA interaction with FDA, a targeted sNDA in the second half of 2026, DefenCath pricing after July 1, 2026, possible 2027 add-on improvement, and any favorable evolution in the policy/legal framework around TDAPA and dialysis-drug access. - [POET Technologies (Nasdaq: $POET): Marvell cancelled the Celestial AI purchase orders — failure, freeze, or corporate reset?](https://www.merlintrader.com/poet-technologies-cancelled-orders-april2026/): POET Technologies has entered a much more delicate phase of its AI photonics story. The April 27, 2026 purchase-order update is materially negative because the company confirmed that all purchase orders received from Celestial AI have been cancelled after Marvell acquired Celestial. But the headline is also easy to oversimplify. Based on the wording available today, the stated issue is not product failure, failed qualification, or a public technical rejection of POET’s platform. The stated issue is confidentiality and disclosure discipline. - [U.S. Energy Corp (Nasdaq: $USEG): the helium contract that turns Big Sky from story into execution risk](https://www.merlintrader.com/us-energy-corp-heluim-contract-april2026/): Simple contract math: if the full 14.4 MMCF annual Phase 1 volume is delivered at $285/MCF, the gross plant-gate helium revenue implied by the contract is about $4.1 million per year before operating costs, taxes, timing/ramp effects, CPI escalation, any year-three redetermination, and non-helium revenue streams. This is arithmetic from the disclosed price and volume, not formal company guidance. - [Compass Therapeutics (Nasdaq: $CMPX): after COMPANION-002, what is left beyond the OS miss?](https://www.merlintrader.com/compass-therapeutics-trial-results-april2026/): Compass Therapeutics just changed shape. The April 27, 2026 COMPANION-002 update is not a clean failure, but it is not the clean survival win many biotech traders wanted either. Tovecimig plus paclitaxel delivered a highly statistically significant progression-free survival benefit in second-line biliary tract cancer, confirmed the previously announced objective-response-rate win, and created a plausible FDA discussion path. At the same time, the study did not meet the overall survival secondary endpoint in the intent-to-treat analysis. That single sentence is enough to reset the debate around $CMPX. - [Cytokinetics, Incorporated (Nasdaq: $CYTK): MYQORZO Launch, Q1 Earnings Setup and the ACACIA-HCM Moment](https://www.merlintrader.com/cytokinetics-myqorzo-launch-april2026/): Cytokinetics has moved from a long, often frustrating development-stage narrative into one of the cleanest “now prove the launch” stories in cardiovascular biotech. The company’s first approved medicine, MYQORZO (aficamten), is approved in the United States, China and the European Union for adults with symptomatic obstructive hypertrophic cardiomyopathy, and the U.S. launch began in January 2026 with the REMS, specialty pharmacy network and patient-support system active at availability. That changes the way $CYTK should be analyzed. The old question was whether aficamten could reach the market. The new question is whether Cytokinetics can convert a differentiated label into durable prescriptions, reimbursement access, center adoption and eventually a self-sustaining specialty cardiology franchise. - [Intellia Therapeutics $NTLA: Positive HAELO Data Put Lonvo-z on a Rolling BLA Path](https://www.merlintrader.com/intellia-therapeutics-positive-update-april2026/): Intellia Therapeutics has moved from a pre-readout binary setup into a post-data regulatory and commercial execution story. On April 27, 2026, the company reported positive topline results from HAELO, the global Phase 3 trial of lonvoguran ziclumeran, known as lonvo-z, in hereditary angioedema. The trial met its primary endpoint and all key secondary endpoints. The company also reported favorable safety and tolerability data, with no serious adverse events observed in the lonvo-z arm as of the February 10, 2026 data cutoff. - [Onconetix Inc. $ONCO: The Realbotix Pivot and the Risk Behind the Microcap Story](https://www.merlintrader.com/onconetix-inc-realbotix-pivot-april2026/): The cleanest way to read $ONCO today is this: the move is less about a traditional biotech catalyst and more about a microcap market repricing a pending reverse-merger-style pivot into AI-powered humanoid robotics. Onconetix entered into a definitive share exchange agreement to acquire 100% of Realbotix LLC, and company communications point to closing in the second half of 2026, subject to shareholder approval, required regulatory approvals and other closing conditions. - [FDA, Psychedelics and the New Hunt for Sympathy Plays $CMPS, $ATAI, $CYBN, $MNMD, $GHRS](https://www.merlintrader.com/fda-psychedelics-and-the-new-hunt-for-sympathy-plays/): The important news is not simply that the FDA has moved to accelerate selected psychedelic or psychedelic-adjacent programs for serious mental illness. The real stock-market story is that a beaten-down, highly emotional and thinly traded sector has suddenly received something it had been missing for years: a near-term regulatory frame. - [Cannabis Stocks Watch: $MSOS, $TLRY, $CGC, $CRON, $ACB and the June 29 Hearing](https://www.merlintrader.com/cannabis-stocks-watch-april2026/): The cannabis sector is back on trader radar because Washington finally gave the market something concrete to trade around. The Department of Justice placed FDA-approved marijuana products and qualifying state-licensed medical marijuana products into Schedule III, while also pointing to a new administrative hearing beginning June 29, 2026, on the broader marijuana rescheduling process. - [Akanda Corp. (Nasdaq: $AKAN) – Cannabis Rescheduling, Micro-Float Rally and Balance Sheet Risk](https://www.merlintrader.com/akanda-corp-april2926-dd/): Akanda Corp. is one of the clearest examples of how a powerful sector catalyst can ignite an extremely small, structurally fragile, low-float equity without necessarily changing the underlying business. The April 2026 rally was real as a market event, but it should not be misread as fundamental confirmation. The stock moved because federal cannabis reform returned to the front page, because Akanda had just completed a 1-for-4.5 reverse stock split, and because the post-split share structure made the name unusually sensitive to retail momentum, scanner activity and possible short-covering dynamics. - [Intel Corporation (Nasdaq: $INTC): AI CPU Demand, Foundry Turnaround and the Return of a Historic Chip Giant](https://www.merlintrader.com/intel-corporation-april2026-dd/): Intel has spent years as one of the market’s most painful semiconductor turnaround stories. The company lost technological prestige, watched AMD take share in CPUs, watched TSMC become the gold standard in advanced manufacturing, and watched Nvidia capture the center of the artificial intelligence investment cycle. For a long time, Intel was the stock people remembered more than the stock people wanted to own. - [Three Biotech Microcaps Heating Up: $MBRX, $CRBP, and $NTHI — Catalysts Are Approaching](https://www.merlintrader.com/three-biotech-microcaps-heating-up-mbrx-crbp-nthi/): Three biotech microcaps are entering a critical stretch of 2026 with meaningful near-term events that could shift their fundamental narratives. MBRX is the highest-binary nano-cap in the group, with a pivotal AML trial unblinding imminent; CRBP is the best-capitalized of the three, with FDA-aligned randomized registrational trials and an ASCO presentation weeks away; NTHI is the smallest, with two simultaneous CNS catalysts approaching simultaneously in brain cancer. - [Palvella Therapeutics (Nasdaq: $PVLA): Rare Skin Disease Catalyst Ahead of ISSVA 2026](https://www.merlintrader.com/palvella-therapeutics-april2026-deepdive/): Palvella Therapeutics is not the usual early-stage biotech story built around a distant scientific promise and a fragile balance sheet. The company is already past a major clinical readout in its lead indication, has a clearly defined regulatory path it wants to pursue in the second half of 2026, and now has a near-term medical-meeting catalyst that can refresh investor attention within the next thirty days. The key date is May 20, 2026, when Palvella is scheduled to present late-breaking results from the Phase 3 SELVA study in microcystic lymphatic malformations and the Phase 2 TOIVA study in cutaneous venous malformations at the International Society for the Study of Vascular Anomalies World Congress in Philadelphia. - [Compass Pathways ( $CMPS ): FDA Priority Voucher, Rolling NDA Review and the COMP360 Psychedelic Medicine Breakthrough](https://www.merlintrader.com/compass-pathways-april2026-dd/): Nasdaq: $CMPS FDA Priority Voucher Rolling NDA Review COMP360 / TRD Compass Pathways (Nasdaq: $CMPS): FDA Priority Voucher, Rolling NDA Review and the COMP360 Psychedelic Medicine Breakthrough Compass Pathways has moved from a post-Phase 3 psychedelic biotech story into a regulatory test case for the future of controlled psilocybin-based medicine in the United States. The […] - [Vistagen Therapeutics (Nasdaq: $VTGN): Refisolone FDA Green Light, PALISADE-3 Failure and the High-Stakes PALISADE-4 Catalyst](https://www.merlintrader.com/vistagen-therapeutics-april2026-dd/): Executive summary Vistagen Therapeutics is not a clean “good news” story. It is a post-collapse biotech story with one fresh positive regulatory event, one still-important Phase 3 catalyst, one recently failed Phase 3 trial, a compressed valuation, a formal liquidity warning in its SEC filing, a Nasdaq minimum bid issue, and a retail base trying to decide whether the stock is a fallen angel or a value trap. - [$ADXN / $DFTX / $MLTX / $CVM — From the Biotech World Today: Four Smaller Headlines Worth Watching](https://www.merlintrader.com/biotech-world-smaller-headlines-jun22/): Addex Therapeutics, Definium Therapeutics, MoonLake Immunotherapeutics and CEL-SCI do not belong to the same biotech story. But today’s updates show four very different types of biotech catalysts: a financial and pipeline update, a Phase 3 psychiatry readout event, long-term immunology data tied to a future BLA strategy, and an international commercialization pathway for an investigational oncology asset. - [Aurinia Pharmaceuticals (Nasdaq: $AUPH) – Deep Dive: LUPKYNIS, CEO Insider Buy and Autoimmune Pipeline Risks to Reassess](https://www.merlintrader.com/aurinia-pharmaceuticals-jun2026-deepdive/): Educational report – business, clinical, financial and scenario analysis for Aurinia Pharmaceuticals after CEO Kevin Tang's large indirect insider purchase (~$12.46M), the EULAR 2026 LUPKYNIS data, and the reassessment of the former Kezar pipeline. - [Keel Infrastructure Corp. (Nasdaq/TSX: $KEEL): From Bitcoin Miner To AI Power Infrastructure — A High-Beta Data Center Pivot To Watch](https://www.merlintrader.com/keel-infrastructure-corp-jun2026-deepdive/): Keel Infrastructure is trying to transform the former Bitfarms platform into a North American AI/HPC data center and power infrastructure story. The market narrative is powerful, the asset base is strategically relevant, and the balance sheet has been strengthened — but the investment case still depends on execution, customer leases, capital discipline and proof that megawatts can become durable infrastructure cash flow. - [Biotech Catalyst Tape: Approval, Manufacturing Delay and the Next FDA Date — $SPRO / $ACHV / $VRDN](https://www.merlintrader.com/biotech-catalyst-tape/): Three biotech catalyst stories are converging at the end of June: Spero/GSK have moved from binary FDA risk to Utebzi approval follow-through; Achieve Life Sciences has shifted from a clean PDUFA calendar story to a manufacturing-related resubmission path; and Viridian Therapeutics is approaching a June 30 FDA target action date for veligrotug in thyroid eye disease. The common thread is simple: in catalyst biotech, the calendar matters — but the label, manufacturing path, economics, launch readiness and balance sheet matter even more. - [FedEx (NYSE: $FDX) Earnings Preview: The Real-Economy Checkpoint and the FedEx Freight Spin-Off Test — $FDX / $FDXF / $UPS](https://www.merlintrader.com/fedex-earnings-preview-real-economy-checkpoint/): FedEx reports Q4 FY26 on June 23, just weeks after completing the FedEx Freight spin-off and two days before FedEx Freight’s first separate Q4 call. That makes this more than an earnings preview. It is a test of the post-spin FedEx story, the “One FedEx” operating model, freight-cycle normalization, logistics demand, oil exposure, e-commerce activity, cost discipline, and the market’s willingness to reward transportation restructuring after a strong run. - [The AI Infrastructure Rally Faces Its Next Reality Check: Micron Earnings And The Memory Bottleneck Trade — $MU / $NVDA / $AVGO](https://www.merlintrader.com/infrastructure-rally-june2026/): Micron Technology is about to report earnings at a moment when the market is treating artificial intelligence less like a single-stock story and more like a full infrastructure cycle. Nvidia still sits at the center of the trade. Broadcom has become one of the clearest public vehicles for custom AI accelerators and AI networking. But Micron occupies a different and increasingly important layer: the memory and storage layer that determines whether AI systems can feed accelerators, sustain inference workloads, handle longer context windows and scale data-center token output efficiently. - [The OpenAI-Anthropic IPO Wave Could Pull the Entire AI Infrastructure Trade Into Focus — Some Possible Protagonists: $VRT / $ETN / $CEG](https://www.merlintrader.com/openai-anthropic-ipo-wave-into-focus/): Why the expected public-market debuts of OpenAI and Anthropic could shift investor attention toward the listed companies powering data centers, grid expansion, cooling, nuclear energy, gas, networking and the physical backbone of artificial intelligence. - [Rocket Pharmaceuticals & Denali Therapeutics (Nasdaq: $RCKT / $DNLI): Priority Review Vouchers, Non-Dilutive Cash and Runway](https://www.merlintrader.com/rocket-denali-priority-review-voucher-cash/): Two FDA approvals in the same March 2026 window. Two Priority Review Voucher monetizations. One common theme: fresh non-dilutive cash that materially changes the financial runway debate for both companies. - [Accenture: AI Disruption, Bookings Pressure And The IT Services Repricing — $ACN](https://www.merlintrader.com/accenture-ai-disruption/): Accenture's Q3 FY2026 report was not an operational collapse. Revenue grew, EPS improved and free cash flow remained solid. But weaker Managed Services bookings, softer guidance, a sharp analyst repricing and renewed anxiety about agentic AI turned the quarter into a warning shot for the traditional IT services model. - [AI Power Bottleneck Trade: $SEI, $WTS and $BE Beyond the Chip Story](https://www.merlintrader.com/ai-power-bottleneck-trade/): The AI trade has spent most of the last cycle worshipping at the altar of GPUs, networking chips and hyperscale cloud capex. That made sense. Without compute, there is no AI boom. But the market is now being forced to confront a less glamorous and potentially more durable question: what happens when the servers are ready, the capital is available, the customer demand is real, but the power is not? - [Lockheed Martin, Northrop Grumman and RTX ($LMT $NOC $RTX): Why the U.S. Air Force CCA Awards Mark a New Phase in Defense AI](https://www.merlintrader.com/lockheed-northrop-rtx-defense-ai/): The U.S. Air Force has moved Collaborative Combat Aircraft from prototype momentum toward engineering, manufacturing development, production and software competition. General Atomics and Anduril won the airframe contracts, but Lockheed Martin, Northrop Grumman and RTX Collins Aerospace are now inside the mission autonomy software pool — making $LMT, $NOC and $RTX the public-market way to follow a defense-AI shift that could reshape airpower over the next decade. - [AIRO Group (Nasdaq: $AIRO): Why the RQ-70 Drone Story Is Suddenly Back on the Radar](https://www.merlintrader.com/airo-group-june2026-deepdive/): AIRO Group is moving back into focus because its RQ-70 Dainn drone story combines several themes that investors are watching closely: long-range ISR, AI-enabled autonomy, GNSS-denied operations, NATO-aligned demand, European defense capacity and small-cap defense momentum. - [Corvus Pharmaceuticals ($CRVS)The ITK Inhibitor at the Center of Atopic Dermatitis and PTCL](https://www.merlintrader.com/corvus-pharmaceuticals-june2026-deepdive/): Soquelitinib, an oral selective ITK inhibitor, has shown encouraging clinical signals even in patients with prior systemic therapy exposure, including cases non-responsive to dupilumab or JAK inhibitors. With $236.7M in cash as of March 31, 2026, a company-stated runway into Q2 2028 in corporate communications, and an ongoing oncology Phase 3, CRVS remains a catalyst-heavy biotech story. - [Rackspace Technology (Nasdaq: $RXT): AMD’s 30MW AI Compute Deal, Riyadh Expansion and the 2028 Debt Wall](https://www.merlintrader.com/rackspace-technology-riyadh-expansion/): Rackspace has suddenly become one of the market’s most aggressive AI infrastructure turnaround stories: a definitive AMD agreement for 30 MW of AI compute, a regional headquarters in Riyadh, a 15% workforce reduction and a stock price that has moved faster than the balance sheet. The story is real. The execution risk is real too. - [uniQure (Nasdaq: $QURE): FDA Reversal Puts AMT-130 Back On The Accelerated Approval Path](https://www.merlintrader.com/uniqure-reversal-path/): The AMT-130 story has moved from enthusiasm, to regulatory shock, to a sudden reopening of the U.S. accelerated approval path. The key issue now is whether uniQure can convert today’s FDA reversal into a credible Q3 2026 BLA submission and, eventually, a first disease-modifying therapy for Huntington’s disease. - [Jazz Pharmaceuticals + AbCelleraT-Cell Engager Partnership: Up to ~$4.0 Billion Multi-Program Deal Analysis](https://www.merlintrader.com/jazz-pharmaceuticals-abcellera-partnership/): $JAZZ $ABCL Official Partnership Deal T-Cell Engagers Jazz Pharmaceuticals + AbCellera ($JAZZ $ABCL): T-Cell Engager Partnership and Competitive Oncology Landscape A complete deep dive into Jazz Pharmaceuticals’ collaboration with AbCellera to discover next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors — including the official deal structure, strategic logic, company fundamentals, direct […] - [Micropolis Robotics (NYSE American: $MCRP): Physical AI Moves From Hype To City Streets](https://www.merlintrader.com/micropolis-robotics-abu-dhabi-agreement/): Micropolis AI Robotics announced a five-year Abu Dhabi agreement for autonomous urban cleaning systems, giving traders a fresh Physical AI and smart-city robotics catalyst. The news is attention-grabbing, but the stock remains a highly speculative early-stage robotics name with filing, financing and execution risks that should not be ignored. - [Defence AI Watch #1: Grok, Iran and the Defence-AI Supercycle — PLTR, KTOS, BBAI and PDYN](https://www.merlintrader.com/defence-ai-watch-june2026/): The news hook is today’s new disclosure on Grok’s role in U.S. Iran operations: it does not just change the defence-AI narrative, it reinforces the central theme of this column — data, targeting, drones, intelligence and tactical autonomy are entering the real operational chain. - [Moderna (Nasdaq: $MRNA): From FDA Refusal to AdCom Reversal — Why MFLUSIVA Is Now the New mRNA Sentiment Test](https://www.merlintrader.com/moderna-adcom-reversal-june2026/): Moderna’s seasonal flu vaccine story has changed sharply. The previous setup was built around a refusal-to-file shock and a PDUFA clock that never started. Now the same asset is heading into a public FDA advisory committee, with a formal August decision date, a reorganized commercial leadership structure, and a stock narrative that has moved from “regulatory roadblock” to “high-stakes execution window.” - [Airlines and Travel Stocks Rebound as Peace Deal Hopes Drag Oil Lower: Why $AAL, $UAL, $DAL and $CCL Are Back on the Radar](https://www.merlintrader.com/airlines-travel-stocks-rebound-june2026/): The travel trade is suddenly alive again. A preliminary U.S.-Iran agreement has pushed crude prices sharply lower, lifted risk appetite and brought airlines, cruise lines and tourism-linked stocks back into focus. The setup is not risk-free: the deal still has political loose ends, jet fuel remains volatile, and the airline industry is still working through one of the harshest cost shocks since the pandemic era. But the market has a simple reason to pay attention: lower oil can quickly change the narrative for every company that moves people. - [Fed, Inflation and Oil: Why SPY Is Trading the Energy Shock Before the June FOMC](https://www.merlintrader.com/fed-inflation-oil-june16fomc/): The market is not only reacting to lower crude prices. It is repricing the inflation path, the Federal Reserve’s room for patience, and the durability of the equity rally just as the June 16–17 FOMC meeting begins. - [The Truce That Changes the Tape: the U.S.-Iran Deal Reopens the Hormuz Question](https://www.merlintrader.com/truce-usa-iran-june2026/): To understand the weight of the diplomatic turn announced between June 14 and June 15, it is necessary to go back to late February 2026, when the United States and Israel launched a military campaign against Iran. From that point, the conflict turned the Strait of Hormuz from a latent geopolitical risk into a central variable for oil, gas, inflation, interest rates and global equity markets. - [Celldex Therapeutics — Barzolvolimab, Mast Cells and the Revolution in Chronic Urticaria Treatmen](https://www.merlintrader.com/celldex-therapeutics-revolution-urticaria/): Phase 3 enrollment completed with 1,939 patients across 43 countries, topline data expected Q4 2026: barzolvolimab has the potential to redefine the standard of care in a disease affecting more than 1.8 million patients in the United States according to Celldex, with a narrower biologic-eligible subpopulation. - [Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215](https://www.merlintrader.com/neumora-therapeutics-june2026-deepdive/): Neumora’s June 15, 2026 update turns the $NMRA story into a cleaner but more unforgiving special situation: the former lead depression asset has now failed across the Phase 3 KOASTAL program, the company is discontinuing navacaprant, cutting approximately 35% of its workforce and trying to preserve enough runway to prove whether the remaining neuroscience pipeline can still justify investor attention. - [Amylyx Pharmaceuticals (Nasdaq: $AMLX) — Avexitide, Post-Bariatric Hypoglycemia and the LUCIDITY Phase 3 Trial](https://www.merlintrader.com/amylyx-pharmaceuticals-june2026-deepdive/): After the collapse of Relyvrio in ALS, Amylyx is rebuilding its equity story around avexitide, a GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia, a serious complication after bariatric surgery with no FDA-approved therapy. The pivotal LUCIDITY Phase 3 readout is expected in Q3 2026. - [The Week Ahead: Fed Pressure, Trump Risk, SpaceX Aftershock and Small-Cap Catalysts to Watch — $SPRO $RKLB $PL](https://www.merlintrader.com/the-week-ahead-june15/): The week of June 15–19, 2026 arrives with an unusually dense mix of market-moving forces. It is not only a Federal Reserve week. It is not only a SpaceX aftershock week. It is not only a geopolitical oil-risk week. It is all of those things at once, compressed into four U.S. trading sessions because U.S. stock and bond markets are scheduled to close on Friday, June 19, for Juneteenth - [Short Squeeze Watch: three crowded short-interest stocks, but not the same setup](https://www.merlintrader.com/short-squeeze-watch-june15/): A short squeeze does not happen just because a stock is “heavily shorted.” It happens when many short sellers need to exit at the same time, on a tight float, with volume accelerating and a catalyst strong enough to change the story. INR, SNSE and WOLF show three different versions of the same risk. - [FDA Pressure Builds Into Summer: Unicycive, Spero and Capricor Move Toward High-Stakes Decisions](https://www.merlintrader.com/fda-into-summer-unicycive-spero-capricor/): Unicycive, Spero and Capricor are approaching three very different regulatory moments: a phosphate-binder resubmission for dialysis patients, a partnered oral carbapenem opportunity in complicated urinary tract infection, and a rare-disease cell therapy review in Duchenne muscular dystrophy. The common thread is simple: each story now has a dated FDA catalyst, a defined risk window and a market setup that demands precision rather than hype. - [SpaceX (Nasdaq: $SPCX): The Real “X Day” for Public Markets and the New Space Trade](https://www.merlintrader.com/spacex-ipo-xday/): SpaceX’s historic public-market debut is more than an IPO. It is the moment Wall Street gets a direct, liquid benchmark for reusable launch, Starlink, Starship, satellite infrastructure, space-enabled communications and the broader commercial space economy. - [Outlook Therapeutics (OTLK) — The Crash, the Fight, and the FDA Appeal Win](https://www.merlintrader.com/outlook-therapeutics-june2026/): From the $0.23 post-CRL low to an FDA Formal Dispute Resolution victory — a narrative deep dive into how OTLK collapsed, survived, and what comes next with the LYTENAVA US BLA and the expected late July / early August 2026 FDA decision window. - [Biotech Tape in Focus: $MBX Strengthens Phase 3 Setup, $JAZZ Hits Oncology Trial Risk, $KYMR Adds Platform Momentum](https://www.merlintrader.com/biotech-tape-mbx-jazz-kymr/): A fresh biotech tape with three very different clinical and regulatory signals: durable endocrine data from MBX Biosciences, a Phase 3 oncology setback for Jazz Pharmaceuticals, and a platform-supportive STAT6 degrader update from Kymera Therapeutics. - [Cogent Biosciences (Nasdaq: $COGT) Deep Dive: Bezuclastinib, Three FDA Paths, and the EHA APEX Catalyst](https://www.merlintrader.com/cogent-biosciences-june2026-deepdive/): A full Merlintrader research report on Cogent’s transition from late-stage precision-medicine developer to potential commercial biotech, with focus on bezuclastinib in systemic mastocytosis and GIST, the June 2026 EHA catalyst, dual 2026 PDUFA dates, management, ownership, balance sheet, dilution risk, and the bull/bear setup. - [MDA Space Ltd. (TSX: $MDA / NYSE: $MDA): Canada’s Space Champion Enters the Global Defense-Orbit Race](https://www.merlintrader.com/mda-space-ltd-june2026-deepdive/): MDA Space is not a typical speculative space stock. It is a Canadian space and defense technology company with real revenue, a large backlog, positive adjusted EBITDA, and growing exposure to satellite constellations, space robotics, missile warning, and sovereign orbital infrastructure. - [SpaceX IPO: Why $SPCX Could Reprice the Public Space Stock Narrative](https://www.merlintrader.com/spacex-ipo-reprice-sector/): SpaceX is not just another listing. A record IPO at a reported $1.75 trillion valuation would turn Elon Musk’s rocket, Starlink and AI platform into the first true public-market benchmark for the modern space economy, with possible indirect read-through effects for $RKLB, $LUNR, $PL and $SATL. - [LILA $107M, HOOD $55M, NCLH $25M, IFF $20M and more: the 20 largest insider purchases of the last two weeks](https://www.merlintrader.com/insider-buys-mayjune2026/): Insider purchases — cash buys at market prices by those who know the company from the inside — are among the most closely watched signals by professional investors. They are not a guarantee, but when a CEO, a board member, or a 10% shareholder buys millions of dollars with their own money, something is worth examining. - [Market Crossroads: SPY, Inflation, War Risk, Fed Rates and the Trump Factor](https://www.merlintrader.com/market-crossroads-june2026/): The U.S. market is no longer trading a single story. SPY is now sitting at the intersection of an oil shock, sticky inflation, a cautious Federal Reserve, geopolitical escalation and a tariff-heavy policy backdrop. - [Disc Medicine (Nasdaq: $IRON): FDA Type A Meeting Keeps Bitopertin Alive After CRL](https://www.merlintrader.com/disc-medicine-june2026-deepdive/): Disc Medicine has moved from regulatory disappointment to a defined late-2026 readout path. The FDA Type A meeting does not erase the Complete Response Letter, but it gives investors a clearer framework: APOLLO must deliver clinically and statistically, and if it does, bitopertin may still have a path toward a traditional approval decision around mid-2027. - [RedHill Biopharma (Nasdaq: $RDHL): Opaganib Gets a Rare Pediatric Disease Designation, but the Bigger Story Is a High-Risk Pipeline Rebuild](https://www.merlintrader.com/redhill-biopharma-june2026-deepdive/): RedHill Biopharma gained renewed attention after the FDA granted Rare Pediatric Disease designation to opaganib for neuroblastoma, adding a potential Priority Review Voucher angle. But the full RDHL story involves far more than a single designation. With limited cash, going-concern risk, Nasdaq compliance pressure, and a pipeline requiring external funding, this remains a high-risk, high-volatility catalyst watch demanding strict risk discipline. - [Parabilis Medicines IPO Deep Dive: Helicon Peptides, Regeneron Validation, Zolucatetide Catalysts and the Real Risk Behind a Hot Biotech Debut: $PBLS](https://www.merlintrader.com/parabilis-medicines-ipo-june2026-deepdive/): Parabilis Medicines enters Nasdaq after an upsized IPO with a rare mix of platform ambition, heavyweight private investors, Regeneron validation and a first-in-class oncology lead program. The opportunity is real, but so are the risks: early-stage clinical proof, no commercial revenue, post-IPO valuation pressure, and the challenge of turning a hard-to-drug biology platform into approved medicines. - [$IDYA, $STTK, $ELOX: Biotech Funding Window Reopens, But Not All Dilution Looks the Same](https://www.merlintrader.com/biotech-funding-window-reopens/): Three biotech financing headlines crossed the market within the same short window: IDEAYA Biosciences (Nasdaq: $IDYA) priced a roughly $300 million public offering, Shattuck Labs (Nasdaq: $STTK) priced a roughly $75 million public offering, and Eloxx Pharmaceuticals (Nasdaq: $ELOX) announced a roughly $66 million public offering alongside an uplisting to the Nasdaq Capital Market. - [AI Drones and Counter-Drone Radar Are Back in Focus: $JFB and $MPTI Put the Defense Tech Trade on Watch](https://www.merlintrader.com/ai-drones-counter-drones-in-focus-june2026/): Fresh contract news from XTEND, the pending merger target of JFB Construction Holdings, and M-tron’s growing RF exposure to counter-drone radar programs highlight a broader trader theme: autonomous defense systems are no longer a futuristic niche, but an increasingly active procurement lane. - [Humacyte (Nasdaq: $HUMA): V012 Phase 3 Win Strengthens the Dialysis Access Story, While $50M Offering Defines the Near-Term Tape](https://www.merlintrader.com/humacyte-june2026/): V012 Phase 3 interim readout expected on June 11, 2026 Humacyte has said that top-line interim results from the Phase 3 V012 study in hemodialysis vascular access are expected to be available for reporting on June 11, 2026 at the SVS Vascular Annual Meeting in Boston. If the data are supportive, the company expects to pursue a supplemental BLA submission in the second half of 2026 for the AV access indication in hemodialysis patients. - [Citius Oncology (Nasdaq: $CTOR): LYMPHIR Revenue Is Real Now, But the Commercial Launch Still Sits Inside a High-Risk Small-Cap Biotech Setup](https://www.merlintrader.com/citius-oncology-june2026-deepdive/): Citius Oncology has moved beyond the old “approved asset waiting for launch” phase. LYMPHIR is now on the U.S. market, revenue has started, and payer/formulary access appears to be building. The same story, however, still carries serious small-cap biotech risks: dilution, limited runway, Nasdaq bid-price pressure, manufacturing transition, and extreme price volatility. - [Brand Engagement Network (Nasdaq: $BNAI): From January Spike to a Broader AI Execution Story](https://www.merlintrader.com/brand-engagement-networdk-june2026-deepdive/): BNAI has added new corporate events since the January squeeze — a pending Cataneo acquisition, an Accelevate investment, Q1 liquidity improvements and continued international AI expansion. The story is more developed, but the stock remains speculative, thin, headline-sensitive and vulnerable to violent swings. - [Nuvalent ($NUVL) Acquired by GSKfor $10.6 Billion](https://www.merlintrader.com/nuvalent-gsk-acquisition/): All-cash deal at $124 per share — 40% premium to prior close. GSK’s largest oncology acquisition in over a decade. Two NDAs under FDA review, one PDUFA in September 202 - [Oculis Holding AG (Nasdaq: $OCS): PREDICT-1 Starts as Licaminlimab Becomes the Next Test After the DIAMOND Phase 3 Miss](https://www.merlintrader.com/oculis-holding-predict/): The first patient randomized in PREDICT-1 does not erase the DIAMOND disappointment, but it gives Oculis a fresh late-stage catalyst path. The equity story is now less about OCS-01 in DME and more about whether Licaminlimab and Privosegtor can rebuild confidence from a funded pipeline reset. - [Tango Therapeutics (Nasdaq: $TNGX): 92% ORR Pancreatic Cancer Data and the $500M Offering](https://www.merlintrader.com/tango-therapeutics-june2026-deepdive/): A full deep dive into the June 2026 vopimetostat + daraxonrasib readout, the PRMT5/RAS(ON) combination thesis, the role of Revolution Medicines, Tango's cash runway, pipeline optionality, ownership structure, key catalysts and the risks behind one of the strongest biotech moves of the year. - [BioCardia ($BCDA) – CardiAMP Cell Therapy and the Road to FDA Premarket Approval](https://www.merlintrader.com/biocardia-bcda-june2026-deepdive/): BCDA BioCardia deep dive — CardiAMP cell therapy, FDA PMA path confirmed June 2026, Japan PMDA Q4 2026. Educational content only. - [Nurix Therapeutics (Nasdaq: $NRIX): Roche Deal Puts BTK Degradation Back in the Spotlight](https://www.merlintrader.com/nurix-therapeutics-junr2026-deepdive/): A full trader-focused deep dive on Nurix Therapeutics, the Roche collaboration for bexobrutideg, the company’s targeted protein degradation platform, its clinical and partnered pipeline, financial runway, ownership profile, catalysts, risks and the scenarios that matter after the June 8 announcement. - [Enliven Therapeutics (Nasdaq: $ELVN): ELVN-001 Faces the EHA 2026 Test](https://www.merlintrader.com/enliven-therapeutics-june2026-deepdive/): The June 11, 2026 catalyst is days away: oral presentation at EHA in Stockholm, updated Phase 1 data on ELVN-001 in chronic myeloid leukemia, and the pivotal Phase 3 ENABLE-2 trial launch expected in H2 2026. Cash of $452M, no near-term financing pressure, a new CEO with commercial ambitions. - [Senseonics Holdings (Nasdaq: $SENS): ADA 2026 Real-World Data Puts the One-Year CGM Story Back in Focus](https://www.merlintrader.com/senseonics-holdings-jun2026-deepdive/): A deep-dive report on Senseonics after fresh ADA 2026 real-world evidence for Eversense 365, the first and only one-year implantable continuous glucose monitoring system, with new open-loop and closed-loop data, twiist AID integration, commercial momentum, European expansion, financing risk and the next execution test. - [Weekly Market Recap · June 6, 2026](https://www.merlintrader.com/weekly-market-recap-june6-2026/): After a nine-week winning streak, the S&P 500 finally broke lower as strong labor data pushed yields higher and forced traders to reprice the “easy money plus AI growth” narrative. Next week, inflation data, Treasury auctions and major software earnings will decide whether this was only a reset — or the beginning of a deeper rotation. - [$ZBIO $VSTM $EDSA On the Move](https://www.merlintrader.com/biotech-on-the-move-jun5/): Three biotechnology and healthcare names are standing out this morning for very different reasons. Zenas BioPharma (Nasdaq: $ZBIO) is the highest-quality fundamental setup among the group because the latest news is tied to a registrational Phase 3 dataset, a peer-reviewed medical publication, a major rheumatology conference and a recently submitted Biologics License Application. Verastem Oncology (Nasdaq: $VSTM) offers the cleanest oncology headline because the company has expanded the regulatory visibility of its KRAS G12D program through an FDA Fast Track designation in non-small cell lung cancer. Edesa Biotech (Nasdaq: $EDSA) is the most speculative of the three, but it has a timely conference catalyst in acute kidney injury, an area with high mortality, limited pharmacological options and a plausible inflammatory biology angle. - [Oculis Holding AG (Nasdaq: $OCS): DIAMOND Phase 3 miss resets the story toward Privosegtor and Licaminlimab](https://www.merlintrader.com/oculis-holding-ag-diamond-phase-3-miss/): After OCS-01 failed to meet the primary visual acuity endpoint in both DIAMOND Phase 3 trials for diabetic macular edema, Oculis is no longer a clean near-term DME filing story. The new setup is a cash-rich ophthalmology and neuro-ophthalmology pipeline reset, with Privosegtor and Licaminlimab now carrying the next real tests. Primary endp - [Fulcrum Therapeutics (Nasdaq: $FULC): Pociredir Discontinued, Strategic Review Begins After FDA Safety Concerns](https://www.merlintrader.com/fulcrum-therapeutics-strategic-review-june2026/): Fulcrum was previously framed on Merlintrader as a cleaner but harsher one-asset biotech setup: pociredir had shown real fetal hemoglobin movement, but the next value bridge depended on FDA alignment, trial design and long-term safety confidence. The June 2026 update did not merely delay that bridge. It broke it. - [Veru Inc. (Nasdaq: $VERU): Novo Nordisk Supply Agreement Puts Enobosarm Back on the Obesity Map](https://www.merlintrader.com/veru-inc-deepdive-june2026/): A single-stock deep dive on the Phase 2b PLATEAU trial, Wegovy supply, enobosarm’s GLP-1 adjunct thesis, FDA pathway, cash runway, dilution risk, catalysts, and the real bull-bear setup behind Veru. - [June 2026 PDUFA Watchlist: Small and Mid-Cap Biotech Catalysts Beyond Big Pharma](https://www.merlintrader.com/june-pdufa-watchlist/): A focused regulatory calendar screen for June, excluding major pharmaceutical companies and highlighting the smaller names where an FDA decision may still matter for valuation, narrative, liquidity, and trading behavior. - [Spero Therapeutics (Nasdaq: $SPRO): FDA Approval Turns the Tebipenem PDUFA Story Into a GSK Commercial Launch Watch](https://www.merlintrader.com/spero-therapeutics-june2026-deepdive/): A deep dive into tebipenem HBr, the GSK partnership, the PIVOT-PO data package, Spero’s financial position, and the key regulatory risks heading into the June 18, 2026 PDUFA date. - [ASCO 2026 News Watch · June 2 Data](https://www.merlintrader.com/asco-oncology-updates-jun2/): Cardiff Oncology, BeyondSpring and Lantern Pharma each used the final day of ASCO 2026 to push a different small-cap oncology story: a randomized colorectal cancer signal moving toward a registrational program, a post-checkpoint lung cancer combination with long follow-up, and a biomarker-focused NSCLC dataset tied to an FDA-cleared protocol amendment. - [Apogee Therapeutics (Nasdaq: $APGE)](https://www.merlintrader.com/apogee-therapeutics-jun2026-deepdive/): Apogee Therapeutics (NASDAQ: APGE) is a clinical-stage biopharmaceutical company developing a pipeline of next-generation, extended half-life (HLE) antibodies engineered to treat immunological and inflammatory diseases — with atopic dermatitis (AD) and asthma as its primary targets. The company's thesis is direct and compelling: take validated biological targets, engineer antibodies with dramatically longer half-lives, and deliver comparable or superior efficacy with a fraction of the injections required by existing therapies. - [Marvell Technology (Nasdaq: $MRVL): Why the AI Infrastructure Trade Suddenly Has a New Star](https://www.merlintrader.com/marvell-technology-ai-june2026-deepdive/): After Nvidia CEO Jensen Huang pushed Marvell into the center of the AI conversation, $MRVL has become one of the most watched semiconductor stocks in the market. The real story is not only the headline. It is custom silicon, high-speed switching, optical connectivity, data-center power limits, and whether Marvell can grow into a valuation that now prices in a much larger future. - [Laser Photonics Corporation (Nasdaq: $LASE): Anti-Drone Laser Deep Dive After MEIA Vulcan Selection](https://www.merlintrader.com/laser-photonics-corporation-june2026-deepdive/): Nasdaq: $LASE Defense Technology Published June 3, 2026 Laser Photonics Corporation (Nasdaq: $LASE): Anti-Drone Laser Deep Dive After MEIA Vulcan Selection Laser Photonics has moved back into the speculative small-cap spotlight after its Laser Shield Anti-Drone system was selected under the MEIA Vulcan Call for Solutions. The story now combines counter-drone optionality, directed-energy ambition, government […] - [UroGen Pharma (Nasdaq: $URGN) & Teva Pharmaceutical (NYSE: $TEVA): The JELMYTO Settlement, the 2030 Generic Window and a Two-Company Biotech Story](https://www.merlintrader.com/urogen-teva-litigation-june2026/): UroGen and Teva resolved the patent litigation around JELMYTO. The headline is legal, but the real investor story is broader: UroGen gets a clearer commercial window while ZUSDURI scales, and Teva secures future generic optionality while its larger turnaround story continues to shift toward innovative medicines, biosimilars and disciplined execution. - [Cingulate Inc. (Nasdaq: $CING): The CTx-1301 CRL, What Went Wrong And What Comes Next](https://www.merlintrader.com/cingulate-inc-jun26-crl/): Cingulate’s ADHD catalyst did not resolve with approval. The FDA issued a Complete Response Letter for CTx-1301, shifting the story from a near-term launch setup to a post-CRL resubmission and manufacturing-execution test. - [$PMI $QTTB $ICCM: Three Small-Cap Healthcare Stories Beyond the Tape](https://www.merlintrader.com/healthcare-stories-pmi-qttb-iccm/): Small-cap healthcare is not one market. It is several markets stacked on top of each other: commercial medtech, clinical-stage biotech, regulatory-transition stories, reimbursement stories, capital-structure stories, and pure volatility. That is why Picard Medical, Inc. ($PMI), Q32 Bio Inc. ($QTTB), and IceCure Medical Ltd. ($ICCM) make an interesting three-company group. They all sit in the healthcare small-cap universe, but they do not ask the same investment question. - [Three Small-Cap Stories Worth Reading Beyond the Tape: Sunshine Biopharma, Jin Medical International and Cognition Therapeutics](https://www.merlintrader.com/small-cap-stories-sbfm-zjyl-cgtx/): A compact but detailed Merlintrader deep dive on three very different small-cap stories: a revenue-generating pharma platform with dilution risk, a profitable China-based mobility-products manufacturer with margin and concentration questions, and a clinical-stage neuroscience biotech approaching a potentially important regulatory checkpoint. - [ASCO 2026 Oncology Signals, Part Three: $TLX, $FLGT and $GLSI Show Three Different Ways to Read Mid-Stage and Late-Stage Cancer Data](https://www.merlintrader.com/asco-2026-part-three-tlx-flgt-glsi/): ASCO 2026 did not only deliver obvious late-stage winners or high-beta small-cap oncology stories. It also produced a third layer of updates where the data are meaningful, but the interpretation requires discipline. Telix Pharmaceuticals, Fulgent Genetics and Greenwich LifeSciences each presented oncology data tied to active development programs, but the nature of the data differs sharply across the three names. - [ASCO 2026 Oncology Signals, Part Two: $IMTX, $ACTU and $BCTX Highlight Three Higher-Risk Cancer Stories Beyond the Headline Data](https://www.merlintrader.com/asco-2026-oncology-signals-part2-imtx-actu-bctx/): ASCO 2026 did not only produce clean late-stage regulatory stories. It also produced a second layer of oncology updates that are highly relevant for biotech investors precisely because they are more complex. Immatics, Actuate Therapeutics and BriaCell each presented data that can support investor attention, but each case requires a careful distinction between clinical promise and actual development derisking. - [ASCO 2026 Oncology Signals: $IDYA, $IMRX and $NXTC Put Three Very Different Cancer Stories in Focus](https://www.merlintrader.com/asco-2026-oncology-signals-idya-imrx-nxtc/): ASCO 2026 delivered exactly the kind of oncology tape that serious biotech investors look for: not one single story, but a cluster of very different clinical readouts that force the market to separate late-stage validation from promising Phase 2 signals and early Phase 1 excitement. In the same ASCO window, IDEAYA Biosciences, Immuneering and NextCure each brought forward data that could matter for their respective development paths, but the quality, maturity and investment meaning of those data are not the same. - [Exelixis (Nasdaq: $EXEL): Cabozantinib Cash Engine, ASCO 2026 NET Data and the Zanzalintinib Transition](https://www.merlintrader.com/exelixis-asco2026-deepdive/): Exelixis is not a fragile pre-revenue biotech waiting for one binary trial to decide whether the company survives. It is a profitable oncology business with a large commercial base, a long-running kinase inhibitor franchise, significant cash generation, and a management team trying to build a second growth engine before the market starts treating CABOMETYX as a mature asset. That makes EXEL a very different type of biotech setup: less dramatic than a PDUFA microcap, but potentially more important for investors who follow oncology platforms, lifecycle management, buybacks, and the transition from one flagship product to the next. - [ASCO 2026 Watch: Replimune, Cogent and Immunome Bring Three High-Intensity Biotech Catalysts — $REPL $COGT $IMNM](https://www.merlintrader.com/asco-2026-watch-biotech-catalysts-repl-cogt-imnm/): ASCO 2026: why these three stories matter to the market ASCO 2026 is producing many important oncology updates, but for traders the key question is not simply which dataset is scientifically interesting. The more useful question is: which dataset can change a regulatory path, reduce or increase perceived risk, alter the probability of approval, move commercial timing or change how the market values a biotech company? Through that lens, three st - [Virgin Galactic (NYSE: $SPCE): From Space Tourism Dream to the May 2026 Repricing](https://www.merlintrader.com/virgin-galactic-space-tourism/): An editorial deep dive tracing Virgin Galactic’s story from the original commercial-space dream to the latest high-volume rally, the Delta-class restart narrative, and the risks that still define one of the market’s most emotional space stocks. - [Cannabis Stocks on Nasdaq: Cronos, Canopy Growth and Tilray Rebuild the Global Cannabis Trade Around Medical Markets, Europe and Balance Sheet Discipline $CRON $CGC $TLRY](https://www.merlintrader.com/cannabis-stocks-cronos-canopy-tilray-jun2026/): The cannabis trade is no longer the same speculative legalization trade that dominated the previous cycle. Cronos, Canopy Growth and Tilray now represent three different Nasdaq-listed cannabis reset stories: one balance-sheet name, one turnaround catalyst name, and one diversified global medical and consumer platform. - [Okta Inc. (Nasdaq: $OKTA): Identity Security, AI Agents And The Cash-Flow Re-Rating Test](https://www.merlintrader.com/okta-identity-security-june2026-deepdive/): Merlintrader Deep Dive Cybersecurity AI Agents Cash Flow Re-Rating Microsoft Competition Risk “` Okta Inc. (Nasdaq: $OKTA): Identity Security, AI Agents And The Cash-Flow Re-Rating Test Okta is no longer a pure hypergrowth SaaS story. After Q1 FY2027, the cleaner question is whether the market is willing to re-rate a mature identity-security platform with moderate […] - [Replimune Group (Nasdaq: $REPL): RP1 Gets A Third FDA Opening After The Second CRL](https://www.merlintrader.com/replimune-gets-third-fda-opening/): Replimune’s May 29, 2026 announcement reopens one of the most controversial oncology regulatory stories of the year. RP1 is not approved, and a new PDUFA date has not yet been announced, but the company says FDA has aligned on a path for resubmission and urgent reconsideration of the BLA for RP1 plus nivolumab in advanced melanoma. - [U.S. Drone Funding Talks: What the Rumor Really Means for $UMAC, $RCAT, $ONDS, $KTOS and $AVAV](https://www.merlintrader.com/drone-funding-talks-june2026/): Clean read: the rumor is not the same for every ticker. Unusual Machines appears closest to the specific reported funding discussion among the listed public names. Red Cat, Ondas, Kratos and AeroVironment are better understood as sector beneficiaries unless direct funding, contracts or Office of Strategic Capital support are confirmed by filings, official releases or named government awards. - [USA–Israel–Iran: the war enters the most dangerous phase, the armed ceasefire](https://www.merlintrader.com/usa-israel-iran-may2026-dangerous-war/): Fresh U.S. strikes against Iranian targets, Tehran’s retaliation, tankers leaving Hormuz with transponders off and renewed pressure on oil prices: de-escalation remains possible, but markets are pricing a fragile, opaque and highly vulnerable ceasefire. - [ASCO 2026 Investor Calendar: 25 Key Oncology Presentations, Dates, Times and Webcasts to Track](https://www.merlintrader.com/asco-2026-investor-calendar/): ASCO 2026 runs from May 29 to June 2, 2026 in Chicago and online. Regular abstract text was released before the meeting, while ASCO states that late-breaking abstracts, including plenary LBAs, are released at 7:00 AM CT / 8:00 AM ET on the day of their presentation. That timing matters because some of the most important market reactions may begin before the actual oral presentation if the abstract text contains enough clinical detail. - [Three Biotech Data Presentations to Watch: Precision BioSciences, Lipocine and Citius Oncology $DTIL $LPCN $CTOR](https://www.merlintrader.com/biotech-data-presentations-may2026/): Biotech traders do not need every conference appearance. They need the few events where a company is putting clinical data in front of a specialized audience, where the data may change the investor debate, and where the stock can react not only to the headline but to the details underneath it. On May 27, 2026, the cleanest U.S.-listed “data presentation” group is not a single mega-cap oncology story. It is a smaller, more speculative three-name basket: Precision BioSciences, Lipocine and Citius Oncology. - [Artiva Biotherapeutics, Inc. (Nasdaq: $ARTV): EULAR, AlloNK and the Institutional Read-Through Ahead of the Next Catalyst](https://www.merlintrader.com/artiva-biotherapeutics-inc-jun2026-deepdive/): Artiva has moved from a quiet NK-cell platform story into a high-conviction autoimmune catalyst setup. The question now is not whether the early AlloNK signal is interesting. The question is whether EULAR 2026 and the planned registrational Phase 3 path can support the level of institutional attention that arrived after the May financing. - [SpaceX IPO Filing Puts the New Space Trade Back in Motion — Why $RKLB, $RDW and $ASTS Moved Today](https://www.merlintrader.com/spacex-ipo-filling-may2026-deep/): The SpaceX IPO filing has turned into a market-wide valuation event for the space sector. The most important point is not that SpaceX is going public — that had already been widely expected — but that the filing gives investors a new, highly visible reference point for how public markets may price the combined story of reusable launch, Starlink connectivity, satellite infrastructure, defense-linked space services, orbital logistics and long-duration AI/compute ambitions. - [Biotech Catalyst Watch: Phase 2 IgAN Start, CRB-701 Cancer Data And Cullinan Autoimmune Updates $JBIO $CRBP $CGEM](https://www.merlintrader.com/biotech-catalyst-jun2026b/): Three official biotech updates from May 26, 2026 highlight different development stages: Jade Biosciences dosed the first participant in a Phase 2 IgA nephropathy study, Corbus updated Phase 1/2 data for its Nectin-4 ADC CRB-701, and Cullinan set an Immunology Day around CLN-978 and velinotamig in autoimmune diseases. - [Healthcare Catalyst Watch: RenovoRx ASCO Data, Axsome AUVELITY Updates, Olema-Bayer Trial Deal $RNXT $AXSM $OLMA](https://www.merlintrader.com/healthcare-catalyst-whatch-jun2026/): Merlintrader Healthcare Focus Published: May 26, 2026 Conference and collaboration catalysts $RNXT $AXSM $OLMA EN IT Healthcare Catalyst Watch: RenovoRx ASCO Data, Axsome AUVELITY Updates, Olema-Bayer Trial Deal $RNXT $AXSM $OLMA Three official healthcare updates from May 26, 2026 show very different kinds of market-relevant progress: a drug-delivery pharmacokinetic story in pancreatic cancer, new AUVELITY […] - [Biotech Catalyst Watch: Dyne Files BLA, NervGen Reports Neural Recovery Data, BriaCell Gets DSMB Green Light $DYN $NGEN $BCTX](https://www.merlintrader.com/biotech-catalyst-watch-amay26-2026/): The biotech tape on May 26, 2026 delivered three very different but clearly catalyst-driven updates. Dyne Therapeutics announced the submission of a Biologics License Application to the U.S. FDA for zeleciment rostudirsen, also known as z-rostudirsen or DYNE-251, in Duchenne muscular dystrophy patients amenable to exon 51 skipping. NervGen Pharma reported positive independent, blinded biomechanical gait analyses from the Phase 1b/2a CONNECT SCI study of NVG-291 in chronic spinal cord injury. BriaCell Therapeutics announced that an independent Data Safety Monitoring Board issued its sixth consecutive positive recommendation for the pivotal Phase 3 Bria-ABC study in metastatic breast cancer. - [Karyopharm’s ASCO Moment: Can a Mixed Phase 3 Still Become a Myelofibrosis Story? $KPTI](https://www.merlintrader.com/karyopharm-asco-moment-june2026/): Karyopharm is heading into ASCO 2026 with one of the more debate-friendly biotech setups of the week: a Phase 3 myelofibrosis trial that hit spleen-volume reduction, missed its symptom co-primary endpoint, showed a company-described promising survival signal, and may still feed into an FDA discussion for a possible sNDA path. - [Three Near-Term Biotech Catalysts To Watch: Nuvalent, Legend Biotech and Zenas BioPharma $NUVL $LEGN $ZBIO](https://www.merlintrader.com/three-biotech-catalysts-nuvl-legn-zbio/): ASCO and EULAR are about to put three very different clinical stories in front of investors: a registrational ALK lung-cancer dataset already used for an NDA submission, an early solid-tumor CAR-T update from a commercial cell-therapy company, and a Phase 3 autoimmune dataset that could shape an upcoming regulatory filing. - [Rental Car Sector Deep Dive — Summer Travel 2026 Outlook: Avis Budget, Hertz and Sixt ($CAR $HTZ $SIX2)](https://www.merlintrader.com/rental-car-summer2026-deepdive/): The summer travel 2026 rental-car trade is not as clean as the hotel or airline trade, but it may be even more useful for investors because it sits directly at the intersection of airports, road trips, leisure budgets, business mobility, fleet prices, used-car residual values and consumer sensitivity to gasoline. - [Hilton, Marriott and Wyndham: Hotel Sector Deep Dive for the 2026 Summer Travel Season $HLT $MAR $WH](https://www.merlintrader.com/hilton-marriott-wyndham-may2026-deepdive/): A long-form look at the lodging cycle before the peak vacation season: RevPAR, occupancy, ADR, loyalty ecosystems, bookings, destinations, pipelines, balance sheets and the different risk/reward profiles behind three major publicly traded hotel companies. - [American Airlines, Delta Air Lines and United Airlines: Summer 2026 Sector Deep Dive ($AAL $DAL $UAL)](https://www.merlintrader.com/american-airlines-delta-united-may2026-deepdive/): A complete bilingual sector report on the three U.S. listed airline majors ahead of the vacation season: demand, load factor, bookings, destinations, fuel, margins, balance sheet quality and the difference between full aircraft and profitable aircraft. - [Final Russell 2026 Reconstitution: $CRWV, $FIG, $ONDS and $UMAC Highlight the AI, Industrial and Small-Cap Flow Trade](https://www.merlintrader.com/russell-reconstitution-june2026/): Key point: FTSE Russell’s preliminary 2026 reconstitution list shows 237 companies joining the Russell 2000 Index. The list is preliminary, not final. Updates are scheduled before the final implementation after the U.S. market close on June 26, 2026, with updated membership reflected from the open on June 29, 2026. - [Hyliion Holdings Corp. (NYSE American: $HYLN): The KARNO Pivot, Navy Validation, Data Center Optionality and the Real Execution Test Ahead](https://www.merlintrader.com/hyliion-holdings-corp-may2026-deepdive/): A full single-stock deep dive on Hyliion’s transition from electric powertrains to modular fuel-agnostic power generation, with a focus on Q1 2026 results, KARNO commercialization, U.S. Navy activity, data center demand, liquidity, risks, catalysts and trading setup. - [Artelo Biosciences (Nasdaq: $ARTL) — May 2026 Deep Dive: FABP5 Pain Catalyst, ART27.13 Optionality, Balance-Sheet Reset and Dilution Reality](https://www.merlintrader.com/artelo-biosciences-may2026-deepdive/): A single-stock May 2026 review of Artelo’s story from the earlier CAReS and FABP5 setup to the latest Q1 business update, the ScienceMachine collaboration, the glaucoma expansion, the GLP-1 companion angle, the $11 million financing, the Nasdaq compliance repair and the still-visible common-equity risks. - [Weekly Market Recap & Outlook for May 25–29, 2026: Memorial Day, Iran/Hormuz, Warsh Fed, Core PCE and the AI Earnings Test](https://www.merlintrader.com/weekly-market-recap-outlook-for-may-25-29-2026/): The week ahead starts with U.S. markets closed for Memorial Day on Monday, May 25, then moves quickly into a dense calendar: Consumer Confidence, Marvell, Salesforce, Snowflake, Synopsys, Dell, Costco, GDP, durable goods and the Fed’s preferred inflation gauge. The setup is constructive but fragile: AI infrastructure remains the leadership engine, Iran/Hormuz headlines can move oil and inflation expectations, and Kevin Warsh’s first days at the Fed put rate sensitivity back at the center of the tape. - [Natera, Inc. (Nasdaq: $NTRA): A Full Deep Dive Into the cfDNA Platform, Signatera Momentum, FDA CDx Validation, Fetal Focus, Prospera and the Next Catalyst Stack](https://www.merlintrader.com/natera-inc-may2026-deepdive/): Natera has moved far beyond the simple label of a prenatal genetic-testing company. The 2026 story is now a scaled precision-diagnostics platform built around oncology MRD, women’s health, organ transplant monitoring, rare-disease genomics, data generation, reimbursement expansion, and industrial-scale sequencing infrastructure. - [Immuneering Corporation ($IMRX) Stock Hub: atebimetinib, MAPKeeper 301, Q2 cash runway and the Phase 3 test](https://www.merlintrader.com/immuneering-corporation-stock-hub/): Complete IMRX Stock Hub: Phase 2a survival signal, MAPKeeper 301 Phase 3 design, Q2 2026 cash runway, dilution, ownership, competition and catalysts. - [Ebola Preparedness Trade: $GOVX, $CODX and $RDHL Revisit Vaccines, Diagnostics and Antiviral Readiness](https://www.merlintrader.com/ebola-preparedness-trade/): The Bundibugyo Ebola outbreak is pushing public-health preparedness back into focus. GeoVax and Co-Diagnostics have fresh Ebola-linked updates, while RedHill belongs in the same theme through earlier Ebola antiviral research and BARDA-supported opaganib development, but not as a same-day outbreak catalyst. - [Rare Earth Independence Is Back: $USAR, $CRML and $MP Race to Rebuild the Western Supply Chain](https://www.merlintrader.com/rare-earth-independence/): ENIT Rare Earth Reset · May 2026 · $USAR $CRML $MP Rare Earth Independence Is Back: $USAR, $CRML and $MP Race to Rebuild the Western Supply Chain USA Rare Earth, Critical Metals and MP Materials sit at three different points of the same strategic puzzle: mine-to-magnet integration, Greenland heavy rare earth feedstock, and America’s most […] - [USA Rare Earth Inc. (Nasdaq: $USAR): from strategic promise to execution pressure](https://www.merlintrader.com/usa-rare-earth-inc-may2026-deepdive/): DOE selection, Q1 numbers, Stillwater magnet ramp, Round Top consolidation, Serra Verde, Carester and the real question for investors: can USA Rare Earth turn a heavily funded national-security story into a commercially disciplined mine-to-magnet platform? - [Quantum Cyber N.V. (Nasdaq: $QUCY): From Mainz Biomed to an Autonomous Defense Platform](https://www.merlintrader.com/quantum-cyber-may2026-deepdive/): A full deep dive on the most important issue behind QUCY: whether the market is looking at the early assembly of a defense-tech platform, or at a highly speculative micro-cap pivot that still has to turn press releases, patent filings and procurement ambition into verifiable contracts and revenue. - [Quantum Leap, One Month Later: Washington Puts Real Money Behind the Quantum Trade — $QBTS $RGTI $IONQ](https://www.merlintrader.com/quantum-leap-one-month-later/): A month after quantum computing stocks broke into the trader conversation, the setup has changed again. The sector is still early, volatile and valuation-sensitive, but the new U.S. funding headlines move the debate from pure future-tech speculation toward industrial policy, national security and strategic infrastructure. - [AI Optics 2026: The Memory-to-Fiber Rotation, Read Through $CIEN, $LITE and $POET](https://www.merlintrader.com/ai-optical-rotation-cien-lite-poet-2026/): Memory-to-optics rotation and the draft US ban on Chinese modules: Ciena at $1.57B revenue, Lumentum at a 47.9% gross margin, POET at half a million with warrants struck at $26.25. - [RKLB, ASTS, LUNR, RDW: Real Reversal or Dead Cat Bounce? Space & Defense After the Crash](https://www.merlintrader.com/rklb-asts-lunr-rdw-space-defense-reversal-2026/): Between late May and July 29, 2026, RKLB, ASTS, LUNR and RDW lost 60-75% of their value, then rallied 35-75% in seven sessions. Nine defense names beat and raised guidance. Real reversal, or dead cat bounce? The next earnings decide. - [$GERN, $NVAX and $IOVA After Q2 2026: Three Retail Favorites, Three Very Different Paths to Scale](https://www.merlintrader.com/gern-nvax-iova-q2-2026-earnings-deep-dive/): A source-verified Q2 2026 deep dive into Geron, Novavax and Iovance: revenue quality, cash, dilution, pipelines, regulation, competition, valuation and catalysts. - [$GRAL and the FDA’s Galleri Test: Can a Cancer Blood Test That Missed Its Primary Endpoint Still Change Screening Forever?](https://www.merlintrader.com/gral-galleri-fda-adcom-cancer-blood-test/): GRAIL’s Galleri faces an FDA AdCom on September 23. We examine the missed NHS endpoint, Stage IV signal, PATHFINDER 2, cash, reimbursement and risk. - [$NBIS, $MSFT, $BE and $ORCL: Nebius Vineland and the $17.4 Billion Microsoft Bet](https://www.merlintrader.com/nebius-vineland-data-center-nbis-microsoft/): The Nebius Vineland AI data center is already under construction while the amended site plan returns to a Planning Board hearing on August 17. Inside $NBIS: the $17.4 billion Microsoft contract, the Bloom Energy power redesign, Michael Burry's short, DA Davidson's cut to $175 and the August 12 earnings call. - [$IOVA vs $IMTX vs $REPL vs $IMCR: The New Battle in Advanced Melanoma](https://www.merlintrader.com/iova-the-new-battle-advanced-melanoma/): Iovance, Immatics, Replimune and Immunocore compared across development status, efficacy, durability, safety, commercialization, manufacturing, patient journey, balance-sheet strength and upcoming catalysts. At the end: the next contender, Obsidian Therapeutics. - [$ADMA: Can the Buyback Rewrite the Valuation Math? 11 Questions Investors Are Asking After Q2](https://www.merlintrader.com/adma-investors-questions/): ADMA has repurchased about 13.8 million shares in 2026 while ASCENIV keeps growing, gross margin remains near 70%, short interest stays elevated and retail discussion has shifted toward State Street, a possible squeeze, SG-001 and buyout speculation. The useful question is not whether these narratives sound bullish. It is which ones actually change per-share value — and which ones do not. - [$SENS Jumped 26% on an Earnings Miss. Here Is What the Numbers Actually Say](https://www.merlintrader.com/sens-senseonics-earnings-miss-stock-jump-explained/): Senseonics jumped 26% the day after a wider loss. The three numbers that actually moved, the dilution that already happened, the break-even arithmetic nobody ran, and where a 365-day sensor sits in a market of 7 to 15 day sensors. - [$CAPR After $REPL: Does Tudriqev’s FDA Approval Create a Real Path for Deramiocel?](https://www.merlintrader.com/capr-repl-the-path-to-aug22/): A 3–9 loss, a 10–3 win, an FDA approval one week later — and Capricor’s August 22 PDUFA is still alive. The tempting conclusion is that Replimune just created a precedent for deramiocel. The more useful conclusion is harder, narrower and much more interesting. - [$OKLO, $XE, $SMR and $IMSR: Four Advanced Nuclear Business Models, Compared](https://www.merlintrader.com/advanced-nuclear-stocks-compared-oklo-xe-smr-imsr/): Oklo, X-Energy, NuScale and Terrestrial Energy are usually traded as one theme. They are four different businesses. A comparison on business model, regulatory status, fuel enrichment, contracts and cash, with a reusable six-question triage tool. - [Biotech Radar — August 5, 2026: $OBX, $ACRV and $URGN Lead a Broad Clinical and Capital-Markets Tape](https://www.merlintrader.com/biotech-radar-august-5-2026-obx-acrv-urgn/): Biotech Radar for August 5, 2026: $OBX, $ACRV and $URGN lead, with clinical, commercial and financing news across nine additional biotech names. - [Biotech Radar July 29, 2026: PolyPid Gets Priority Review, Processa Resets Around VT-7208, TScan Starts Phase 3 — $PYPD $PCSA $TCRX](https://www.merlintrader.com/biotech-radar-july-29-2026-pypd-pcsa-tcrx/): PolyPid receives FDA Priority Review for D-PLEX100, Processa rebuilds around VT-7208 with a $200 million financing, and TScan begins pivotal Phase 3 execution. - [$OTLK After FDA Approval: The Warrant–ATM–Reverse Split Spiral Retail Cannot Fight on Equal Terms](https://www.merlintrader.com/otlk-warrant-atm-reverse-split-spiral/): LYTENAVA’s approval removed the central regulatory risk, but it also exposed a financing structure built around low-strike warrants, resale registration, a large at-the-market program, convertible debt and an already-authorized reverse split. The key question is no longer only what the drug may be worth. It is how much of that value can survive on a per-share basis. - [Biotech Radar July 28, 2026: Kiniksa Rerates, Nautilus Pushes Voyager Shipments to Mid-2027 and Alkermes Expands Its Sleep Franchise — $KNSA $NAUT $ALKS](https://www.merlintrader.com/biotech-radar-july28-2026/): Today’s Radar separates a genuine commercial-plus-clinical rerating at Kiniksa from a material commercialization-timeline reset at Nautilus Biotechnology and a strong but more complex post-acquisition quarter at Alkermes. NeoGenomics and Mirion remain on the closing-bell watchlist, with results scheduled after the market closes. - [$MSOS $TLRY $CGC $ACB: After the DEA Hearing, the Cannabis Trade Moves Into the Shadows](https://www.merlintrader.com/after-dea-hearing-cannabis-moves/): The courtroom has gone quiet, but the federal cannabis story is becoming more complicated—not less. Behind the August 17 deadline, investors are watching an unfinished tax rule, a dangerous court challenge and a Schedule II scenario that few traders appear prepared to discuss. - [Biotech Radar July 27, 2026: Entera Bio ($ENTX), Freenome ($FRNM), Sarepta Therapeutics ($SRPT) and Legend Biotech ($LEGN)](https://www.merlintrader.com/biotech-radar-july27-2026/): Four biotech stories moved onto the radar for four very different reasons: a company-changing financing at $ENTX, a first commercial FDA approval at $FRNM, a planned leadership handoff at $SRPT and a sudden CEO departure at $LEGN. - [MapLight Therapeutics ($MPLT): Why the Stock Collapsed After a “Positive” Schizophrenia Trial](https://www.merlintrader.com/maplight-therapeutics-collapsed-after-trial/): ZEPHYR met its primary endpoint with the twice-daily dose of ML-007C-MA, yet MapLight lost roughly two-thirds of its value intraday. The apparent contradiction disappears once efficacy magnitude, dosing convenience, competitive benchmarks, expectations and the remaining regulatory path are examined together. - [$DPRO, $AXON, $RCAT, $ONDS: Why Small-Town America Is the Hardest Drone Market to Sell — The Five Barriers Explained](https://www.merlintrader.com/public-safety-drones-five-barriers-dpro/): 17,541 US law enforcement agencies, nearly 70% with 24 officers or fewer. The five barriers between a department and a flying drone, with $DPRO, $AXON, $RCAT and $ONDS mapped. - [$SMMT, $MRK: Ivonescimab’s China-First Test](https://www.merlintrader.com/smmt-mrk-china-first-test/): Why $SMMT’s PD-1/VEGF bispecific is no longer just a drug story—and how its FDA review could redraw the path from Chinese discovery to global oncology markets, with $MRK’s Keytruda franchise directly in view. - [FDA Showdown Week: Capricor and Replimune Face Back-to-Back AdCom Tests — $CAPR $REPL](https://www.merlintrader.com/fda-showdown-week-capricor-replimune/): Two damaged regulatory stories return to the same FDA advisory committee on consecutive days. Capricor brings a new randomized Phase 3 dataset in Duchenne muscular dystrophy; Replimune asks the agency to reconsider accelerated approval after two Complete Response Letters in advanced melanoma. This report separates the clinical evidence, the likely pressure points, the retail narrative and the decisions that actually matter. - [Weekly Market Recap & Week Ahead: AI Cash Burn, Oil Shock, Fed Week and FDA AdComs — $SPY $QQQ $XBI](https://www.merlintrader.com/weekly-market-recap-july20-24-week-ahead-july27-31-2026/): The July 20–24 tape punished Alphabet and Tesla, pushed Brent above $100 before a late retreat, and kept rotation alive below the mega-cap surface. Next comes the Federal Reserve, GDP, PCE, Microsoft, Meta, Apple, Amazon and back-to-back FDA Advisory Committee meetings. - [Golden Dome Enters the Procurement Era: 108 Tracking Satellites, the FY2027 Funding Fight and What It Means for $LHX $RKLB $LMT $NOC](https://www.merlintrader.com/golden-dome-procurement-era/): Golden Dome is no longer only a presidential vision or a broad market narrative. Congress has begun writing oversight into law, billions are moving through missile-warning and tracking awards, and the next political battle is already forming around FY2027 funding, space-based interceptors, acquisition authority and the true cost of defending the U.S. homeland. - [Cannabis News Today: DEA Rescheduling, U.S. Hemp and $ACB $TLRY $CRON $CGC](https://www.merlintrader.com/cannabis-news-today-dea-rescheduling-july25/): A complete cannabis-sector update: the federal hearing is over, but a decision is not imminent; Congress is split between legalization and an attempt to block rescheduling; industry political donations are rising; and a parallel court fight could delay the process. Meanwhile, Aurora Cannabis, Tilray Brands, Cronos Group and Canopy Growth are looking for company-specific catalysts that do not depend entirely on Washington. - [Biotech Radar July 22, 2026: BridgeBio, Curis, Monopar and Others — $BBIO $CRIS $MNPR](https://www.merlintrader.com/biotech-radar-july22/): Six verified biotech developments published today: an accepted rare-disease NDA, updated PCNSL response data, the opening of a rolling Wilson-disease application, a positive brain-metastases imaging study, a Canadian ALS regulatory path and a $1.5 billion cell-therapy tools acquisition. - [Why The Critical-Minerals Race Is Won In The Midstream, Not The Mine ($UAMY, $MP, $USAR, $TMC)](https://www.merlintrader.com/critical-minerals-midstream-explained-uamy/): A framework for reading the critical-minerals sector: why the real bottleneck is processing (the midstream), a four-question tool to triage any headline, with $UAMY as the worked example and $MP, $USAR and $TMC on the map. - [Priority Review Vouchers Explained: How an FDA Approval Becomes $180-205 Million in Cash, With $RCKT and $DNLI as Worked Examples · $XBI $IBB](https://www.merlintrader.com/priority-review-voucher-explained-rckt-dnli-2026/): How Rare Pediatric Disease Priority Review Vouchers turn a single FDA approval into $180-205 million in non-dilutive cash - the mechanism explained, with $RCKT and $DNLI as worked examples. - [Betting on the FDA: How Kalshi's Biotech Prediction Markets Work, and What They Mean for $XBI, $IBB and the Sector](https://www.merlintrader.com/kalshi-biotech-prediction-markets-fda/): Kalshi launched a pilot program on July 16, 2026, enabling trading on clinical trial outcomes and FDA decisions linked to biotech firms. This new prediction market offers a public price reflecting the probability of drug approval, but raises ethical concerns and potential manipulation risks due to limited participant knowledge and liquidity challenges. - [The Cannabis Risk That Quietly Died in January: What It Means for $MSOS, $TLRY, $CGC and $ACB](https://www.merlintrader.com/cannabis-rescheduling-rider-january-2026/): Congress stripped the provision that would have defunded marijuana rescheduling — the House passed the clean bill 397-28 — and cannabis investors never priced it. Meanwhile the sector fell during the DEA hearing itself. - [ASRS 2026 Retina Showdown: New Data Put $FDMT, $RGNX and $KLRS Under the Spotlight](https://www.merlintrader.com/asrs-2026-retina-showdown/): Three small- and mid-cap biotechnology companies are chasing the same strategic prize—durable retinal-disease control with fewer injections—but they are using different technologies, different delivery routes and radically different levels of clinical evidence. - [Insider Trading This Week: The 20 Biggest Buys And Sells (July 13-17, 2026)](https://www.merlintrader.com/insider-trading-biggest-buys-sells-july-17-2026/): Insider trading this week (July 13-17, 2026): the 20 biggest open-market buys and 20 biggest executed sells by dollar value, with names, tickers, amounts and next catalysts. Educational, not advice. - [Weekly Market Recap & Week Ahead: AI Selloff, Oil Shock and a Catalyst-Heavy Earnings Week — $SPY $QQQ $XBI](https://www.merlintrader.com/weekly-market-recap-jul13-17-2026/): The July 13–17 tape delivered a sharp semiconductor reset, cooler inflation data, a renewed oil shock and resilient rotation below the headline indices. Next comes Alphabet, Tesla, Texas Instruments and Intel, plus AMD’s AI event, Farnborough, biotech data and a weekend FDA decision. - [Biotech Radar July 17, 2026: Kalaris, REGENXBIO and Novartis — $KLRS $RGNX $NVS](https://www.merlintrader.com/biotech-radar-july17-2026/): A full three-company edition covering an early wet-AMD durability signal, a $100 million gene-therapy financing that materially resets per-share ownership, and a traditional FDA approval that raises the evidence standard across the increasingly competitive IgA-nephropathy market. - [Why U.S. Defense Stocks Are Correcting: $LMT, $AVAV, $KTOS, $RCAT and the Full Merlintrader Stock-Hub Map](https://www.merlintrader.com/defense-stocks-correcting/): A U.S.-only defense report covering traditional primes, scaled defense-tech, high-beta drone and AI names, and national-security space companies already followed by Merlintrader. The central question is not whether military demand exists, but which companies can turn budgets and contract ceilings into funded backlog, margins and free cash flow per share. - [Why Space Stocks Keep Falling: $RKLB, $ASTS, $PL, $LUNR and the July 2026 Reversal Map](https://www.merlintrader.com/space-stocks-keep-failing/): The space economy has not stopped growing, but its public-market proxies have lost scarcity, absorbed a wave of new securities and broken key technical support. This report separates the common sector shock from each company’s own risks and identifies what would have to change before the decline can credibly reverse. - [Jasper Therapeutics–Kira Merger Rewrites $JSPR: $132M PIPE, 653.6M Shares and Why a Reverse Split Looks Increasingly Likely](https://www.merlintrader.com/jasper-therapeutics-kira-merger/): Jasper has acquired Kira Pharmaceuticals and preserved its Nasdaq ticker, but the company behind that ticker is being rebuilt around Kira’s complement pipeline. The financing solves an immediate liquidity crisis; the ownership math leaves legacy Jasper holders with only 6.68% of the combined company and creates a capital structure that will almost certainly require further corporate action. - [Why Advanced Reactors Are a Fuel Problem First: The HALEU Bottleneck, With $OKLO, $LEU and $CCJ](https://www.merlintrader.com/haleu-enrichment-bottleneck-oklo-leu-ccj/): How the HALEU enrichment bottleneck decides the advanced-reactor race: the fuel-cycle map, a reusable triage tool, and $OKLO, $LEU and $CCJ as worked examples. - [Biotech Radar July 16, 2026: Gain Therapeutics, aTyr Pharma and Medicus Pharma — $GANX $ATYR $MDCX](https://www.merlintrader.com/biotech-radar-july16-2026/): Three biotech updates, three very different evidence problems: an early Parkinson’s disease signal moving toward Phase 2, a post hoc attempt to rescue a pulmonary sarcoidosis program after a missed Phase 3 endpoint, and an FDA-guided protocol optimization that may make a urology study faster and less expensive without yet proving efficacy. - [Beyond Nvidia: The Physical AI Infrastructure Chain Behind Defense, Power and Critical Minerals — $BBAI $BE $MP](https://www.merlintrader.com/physical-ai-infrastructure-chain-defense-power-minerals/): The AI boom is no longer only a semiconductor and cloud-computing story. It is becoming a race for mission-ready software, deployable electricity and secure magnet supply. This report separates the common narrative from the very different financial realities of BigBear.ai, Bloom Energy and MP Materials. - [AtaiBeckley $ATAI Agrees to Eli Lilly $LLY Deal: $6.75 Cash, $2.50 CVR and Potential $3.8B Value](https://www.merlintrader.com/ataibeckley-soars-on-rumor-takeover-jul16/): Eli Lilly and AtaiBeckley signed a definitive merger agreement. ATAI holders are entitled to $6.75 per share in cash at closing plus a non-transferable CVR worth up to $2.50 per share tied to VLS-01 Phase 3 initiation and U.S. approval plus DEA rescheduling milestones for BPL-003 and VLS-01. The transaction carries approximately $2.8 billion of upfront equity value and up to $1.0 billion of contingent value. - [Cannabis Rescheduling Hearing Final Wrap: What the Record Says for $ACB , $MSOS , $TLRY and $CGC](https://www.merlintrader.com/cannabis-rescheduling-hearing-final-wrap/): The July 15 testimony is over. There is no verdict, no vote and no broad Schedule III final rule yet. The hearing nevertheless clarified which parts of the government’s case survived, where the opposition created real legal risk and what investors should watch next. - [Biotech Radar — July 15, 2026: Biogen and Ionis — Diranersen Lowers Tau, but CELIA Leaves Clinical Risk Unresolved ($BIIB, $IONS)](https://www.merlintrader.com/biotech-radar-july15-biogen-and-ionis/): Phase 2 CELIA produced one of the most intriguing tau signals yet seen in Alzheimer’s disease, but it did not settle the key issue: why did the lowest dose show the most persuasive cognitive benefit while higher doses failed to produce a stronger response? $BIIB · $IONS Alzheimer’s · Tau · Antisense - [Biotech Radar July 14, 2026: Biogen ($BIIB), AstraZeneca ($AZN), GSK ($GSK) and Evotec ($EVO)](https://www.merlintrader.com/biotech-radar-july14-2026/): Merlintrader Biotech Radar Biotech Radar July 14, 2026: Biogen, AstraZeneca, GSK and Evotec — $BIIB, $AZN, $GSK, $EVO A deeper four-company edition covering an FDA delivery breakthrough in Alzheimer’s disease, a $1.5 billion lung-cancer licensing deal, a potentially treatment-changing organ-preservation strategy in rectal cancer, and a severe guidance reset that puts partnership economics under the […] - [Gravity ($GRVY) Deep Dive 2026: The Ragnarok Cash Machine — One Franchise, 91 Regions, And A Cash Pile Near Its Market Cap](https://www.merlintrader.com/gravity-grvy-ragnarok-cash-machine/): Gravity ($GRVY) deep dive: verified Q1 2026 and FY2025 numbers, ~$400M cash and no debt against a ~$440M market cap, the Ragnarok launch engine, GungHo control, and the bull vs bear case. Educational, not advice. - [FDA U-Turns: Moderna $MRNA, Sarepta $SRPT and uniQure $QURE Lead a Year of Regulatory Reversals](https://www.merlintrader.com/fda-u-turns-july2026/): Merlintrader Regulatory Deep Dive · July 13, 2026 FDA U-Turns: Moderna $MRNA, Sarepta $SRPT and uniQure $QURE Lead a Year of Regulatory Reversals Six major cases — including Regenxbio, Replimune and Valneva — show how quickly a drug review, safety restriction or approval pathway can change when new evidence, a formal appeal, patient urgency and […] - [Outlook Therapeutics ($OTLK): A Story — The World's Most-Used Eye Drug Is Not Approved for the Eye](https://www.merlintrader.com/otlk-outlook-a-story/): Off-label economics explained with Outlook Therapeutics ($OTLK): why the most-used wet AMD treatment costs $50 and is not approved, while approved alternatives cost twenty times more. FDA PDUFA July 29, 2026. - [ImmunityBio ($IBRX): A Story — Why FDA Approval Is Only the Starting Line](https://www.merlintrader.com/ibrx-immunitybio-a-story/): An accessible three-act explainer using ImmunityBio ($IBRX) and its bladder-cancer drug Anktiva to show why FDA approval is only the starting line: the human stakes, the commercial launch curve, and who controls the company. - [Oil Shock Returns: Trump, Iran and the Fed Put Wall Street’s Summer Rally Under Pressure $SPY](https://www.merlintrader.com/oil-shock-returns-july2026/): Macro & Markets Editorial Oil Shock Returns: Trump, Iran and the Fed Put Wall Street’s Summer Rally Under Pressure The renewed battle over the Strait of Hormuz is no longer only a geopolitical story. It is an inflation story, a bond-market story, a valuation story and—perhaps most importantly—a test of whether Washington can simultaneously pursue […] - [Beyond ReWalk: The Public Companies Competing for the Future of Exoskeletons and Neurorehabilitation — $LFWD $MYO $CHRN $APLD](https://www.merlintrader.com/beyond-rewalk-future-exoskeletons/): Merlintrader Sector Deep Dive · Medical Robotics · Wearable Technology · Neurorehabilitation Beyond ReWalk: The Public Companies Competing for the Future of Exoskeletons and Neurorehabilitation — $LFWD $MYO $CHRN $APLD From the engineers who first turned robotic walking into a medical reality to the public companies now competing for patients, rehabilitation budgets, reimbursement and clinical […] - [Biotech Radar July 13, 2026: Sanofi, Guardant Health and Pharvaris](https://www.merlintrader.com/biotech-radar-july13-2026/): Biotech Radar July 13, 2026 $SNY $GH $PHVS Three-name biotech watch Biotech Radar July 13, 2026: Sanofi ($SNY), Guardant Health ($GH) and Pharvaris ($PHVS) Three distinct healthcare setups define today’s watch: a first-of-its-kind oncology delivery approval, a competitive read-through in blood-based colorectal-cancer screening, and an oral hereditary-angioedema program that has entered formal FDA review while […] - [$MSOS $TLRY $CGC $ACB Cannabis Rescheduling Hearing Week 2 Wrap: Finn, the TBI and the July 15 Schedule III Deadline](https://www.merlintrader.com/cannabis-rescheduling-hearing-week2-wrap-july12/): Week two of the DEA marijuana rescheduling hearing: Dr. Kenneth Finn's testimony, the Tennessee Bureau of Investigation, the July 13-15 final stretch, and the non-binding path to a Schedule III Final Rule - and what it means for $MSOS, $TLRY, $CGC and $ACB. - [Reusable Rockets Explained: The Launch Economics, $RKLB as the Worked Example, and What China's First Booster Catch Changes](https://www.merlintrader.com/reusable-rockets-launch-economics-explained/): A plain-English guide to the economics of reusable rockets: why refurbishing beats rebuilding, how cost-per-kg collapsed, where SpaceX ($SPCX), Blue Origin, China's Long March 10B and Rocket Lab ($RKLB) sit on the reuse ladder, a reusable triage for launch news, and what China's first booster catch does and doesn't change. Educational, not investment advice. - [Why AI Needs Optics: The Optical Interconnect Stack Explained, With POET as the Worked Example](https://www.merlintrader.com/ai-optical-interconnect-explained-poet/): An educational guide to the AI optical interconnect stack - switch silicon, lasers, modulators, optical engines and modules - using POET Technologies (POET) as the highlighted optical-engine example. - [Space stocks weakness: the SpaceX rotation, insider selling and the Planet Labs case](https://www.merlintrader.com/space-stocks-weakness-july-2026/): Why space stocks pulled back in July 2026: profit-taking after a huge run, capital rotating to the newly public SpaceX, insider selling at Rocket Lab, the Rocket Lab-Iridium deal and the company-specific Planet Labs case. Educational, no recommendations. - [Insider Trading This Week: The 20 Biggest Buys And Sells](https://www.merlintrader.com/insider-trading-biggest-buys-sells-july-10-2026/): Insider trading this week (July 6-10, 2026): the 20 biggest open-market buys and 20 biggest sells by dollar value, with names, tickers, amounts and next catalysts. Educational, no recommendations. - [Biotech Radar — July 11, 2026: Chemomab, CervoMed and AtaiBeckley — $CMMB $CRVO $ATAI](https://www.merlintrader.com/biotech-radar-jul11-2026/): Today’s radar compares three very different catalyst structures: Chemomab’s proposed merger with Scipher Medicine and shift toward AI-guided rheumatoid arthritis development, CervoMed’s completed Phase 2a enrollment in nonfluent variant primary progressive aphasia, and AtaiBeckley’s completion of dosing in the VLS-01 Phase 2b Elumina trial ahead of a Q4 2026 topline readout. - [$VKTX, $GPCR, $SKYE: Next-Generation Obesity Drug Stocks to Watch](https://www.merlintrader.com/obesity-drug-stocks-vktx-gpcr-skye-2026/): Obesity drugs radar: Viking ($VKTX), Structure ($GPCR) and Skye ($SKYE) — three clinical-stage weight-loss stocks, their trials, cash positions and 2026 catalysts, with the Novo/Lilly landscape as context. - [Mesoblast ($MESO) Deep Dive: Ryoncil Hits $36M in Q4 and $115M in FY2026](https://www.merlintrader.com/mesoblast-july2026-deepdive/): Merlintrader Deep Dive Published / updated: July 10, 2026 Biotech / Cell Therapy / Commercial Launch Analysis Mesoblast ($MESO) Deep Dive: Ryoncil Hits $36M in Q4 and $115M in FY2026 A full trader-focused analysis of Mesoblast’s first full fiscal year of commercialization, Ryoncil’s accelerating launch, cash and debt position, adult GvHD, Duchenne, LVAD, chronic low […] - [$IONS / $AZN ATTR-CM Setback: Eplontersen Misses Phase 3 Endpoint, While $ALNY and $BBIO Gain a Cleaner Competitive Read-Through](https://www.merlintrader.com/ions-azn-setback-july2026/): Ionis and AstraZeneca’s CARDIO-TTRansform trial did not meet its primary endpoint in transthyretin-mediated amyloid cardiomyopathy. The result does not erase Wainua’s existing polyneuropathy franchise, but it changes the near-term ATTR-CM competitive map and puts Alnylam and BridgeBio back at the center of investor attention. - [Immunome (Nasdaq: IMNM) Deep Dive: Varegacestat FDA Review and April 2027 PDUFA](https://www.merlintrader.com/immunome-imnm-varegacestat-fda-pdufa-2027/): Immunome (Nasdaq: IMNM) deep dive: the FDA accepted the varegacestat NDA for desmoid tumors with an April 28, 2027 PDUFA date, backed by strong Phase 3 RINGSIDE data, 82.7M cash and a broader ADC pipeline. - [Penguin Solutions Stock Deep Dive: The AI Factory Platform Company Behind Memory, HPC and Full-Stack Infrastructure](https://www.merlintrader.com/penguin-solutions-july2026-deepdive/): Penguin Solutions has moved from the old SMART Global Holdings identity into a more focused AI infrastructure story. The market is no longer looking at PENG as a simple memory-cycle name. It is looking at a company trying to sit at the intersection of accelerated compute, advanced memory, AI cluster software, deployment services and enterprise-scale AI factory buildouts. - [Biotech Radar — July 8, 2026: Vertex’s $10B Crinetics Deal, Seres’ Microbiome Signal and OKYO’s FDA Phase 3 Pathway ($CRNX, $MCRB, $OKYO)](https://www.merlintrader.com/biotech-radar-crnx-mcrb-okyo-july-2026/): Biotech radar: Vertex to acquire Crinetics ($CRNX) for ~$10B, Seres ($MCRB) posts an early 80% Day 15 SER-155 signal in checkpoint-inhibitor enterocolitis, and OKYO ($OKYO) moves urcosimod to Phase 3 NEPTUNE after FDA Type D feedback. - [Oil Shock and the Hormuz Premium: Why $CVX, $XOM and $OXY Are Back in Focus](https://www.merlintrader.com/oil-shock-hormuz-premium-cvx-xom-oxy/): Oil surged over 6% and energy stocks jumped after the U.S.-Iran framework broke down and Iranian oil sanctions returned. The Strait of Hormuz premium puts Chevron ($CVX), Exxon Mobil ($XOM) and Occidental ($OXY) back in focus. - [$MSOS $TLRY $CGC $ACB: Cannabis Rescheduling Hearing Update After DEA Recess Order Shifts the July 9 Schedule](https://www.merlintrader.com/cannabis-hearing-coverage-july7/): The July cannabis trade is no longer about a simple “rescheduling soon” headline. It is about the administrative record being built inside the DEA hearing room: medical use, abuse potential, dependence profile, public-safety arguments, product-standardization attacks, impaired-driving concerns and the litigation path that may follow any final Schedule III decision. - [Biotech Radar: $VANI, $PHVS, $TOVX — Three Catalyst Stories From GLP-1 Implants to HAE and Pancreatic Cancer](https://www.merlintrader.com/biotech-radar-july7-deepdive/): Today’s radar is not built around one single theme. It is built around three very different biotech catalyst profiles: a small-cap GLP-1 implant narrative, a cleaner late-stage rare-disease regulatory story, and a highly speculative oncology microcap with a real but very early dosing question. - [Trump Media & Technology Group ($DJT) Deep Dive: Truth Social, Crypto Treasury, Truth.Fi and the TAE Fusion Merger](https://www.merlintrader.com/trump-media-technology-group-djt-deep-dive-2026/): Deep dive on Trump Media ($DJT) after Q1 2026: $871K revenue, -$405.9M net loss driven by crypto marks, 9,542 BTC treasury, the CEO change, the paused Truth Social spin-off and the pending ~$6B TAE Technologies fusion merger. - [$WULF, $AVGO, $MU: AI Infrastructure Back in Focus as Data Centers Replace the Old Crypto-Mining Story](https://www.merlintrader.com/wulf-avgo-mu-ai-infrastructure-2026/): Deep dive on the July 2026 AI infrastructure trade: TeraWulf's $19B Anthropic data-center lease, Broadcom's Apple custom-chip extension through 2031, and Micron's AI-driven memory super-cycle. $WULF, $AVGO, $MU. - [Uranium Energy Corp. (NYSE American: $UEC): America's ISR Uranium Restart, Burke Hollow, Christensen Ranch and the Nuclear Fuel Chain Bet](https://www.merlintrader.com/uranium-energy-corp-uec-deep-dive-2026/): Deep dive on Uranium Energy Corp. ($UEC): fiscal Q3 2026, U.S. ISR restart at Christensen Ranch and Burke Hollow, 1.456M lbs uranium inventory, $794M liquidity, no debt, Roughrider, UR&C conversion, catalysts and risks. - [Lithium Americas Corp. (NYSE: $LAC): The Thacker Pass Bet After Q1 2026, DOE/GM Funding and the Lithium Downcycle](https://www.merlintrader.com/lithium-americas-lac-deep-dive-2026/): Deep dive on Lithium Americas ($LAC): Thacker Pass Phase 1 construction after Q1 2026, ~$1.2B cash, $2.93B capex, GM/DOE funding, dilution, lithium market risks, catalysts and red flags. - [Biotech Radar — July 6, 2026: $PHVS, $AGEN, $IONS (FDA NDA Acceptance, MSS Colorectal Survival Data, Phase 3 Angelman Milestone)](https://www.merlintrader.com/biotech-radar-phvs-agen-ions-july-2026/): Biotech radar for July 6, 2026: Pharvaris ($PHVS) FDA NDA acceptance with an April 2027 PDUFA date, Agenus ($AGEN) three-year BOT+BAL survival data in MSS colorectal cancer, and Ionis ($IONS) Phase 3 pivotal enrollment complete in Angelman syndrome. - [Biotech & Trading Glossary: PDUFA, FDA & Small Caps](https://www.merlintrader.com/biotech-trading-glossary/): 70+ biotech, small-cap, FDA and trading terms explained clearly: PDUFA date, CRL, cash runway, short squeeze, surrogate endpoint and more. - [Cannabis Rescheduling Watch: Why the Anti-Schedule III Case Matters Before the DEA’s July 15 Deadline](https://www.merlintrader.com/cannabis-rescheduling-watch-july5/): The cannabis trade is not waiting for a simple headline. It is watching an administrative record being built in real time. The key question is not only whether marijuana can move from Schedule I to Schedule III, but whether the evidence supporting that move is strong enough to survive opposition, procedural scrutiny and possible litigation. - [Critical Metals, Rare Earths and the Western Supply Chain Race: From CRML’s Tanbreez Update to the Mine-to-Magnet Economy](https://www.merlintrader.com/critical-metals-western-supply-chain/): Critical Metals Corp. ($CRML) is the starting point, but the full map reaches across MP Materials ($MP), USA Rare Earth ($USAR), Energy Fuels ($UUUU), NioCorp ($NB), Lithium Americas ($LAC), Albemarle ($ALB), Sigma Lithium ($SGML), Nouveau Monde Graphite ($NMG) and Westwater Resources ($WWR): heavy rare earths, lithium, graphite, niobium, scandium, magnet manufacturing, defense procurement, EV motors, wind turbines, robotics, electronics and the geopolitical race to rebuild strategic supply chains outside China. - [Insider Trading This Week: The 20 Biggest Buys and Sells](https://www.merlintrader.com/insider-trading-biggest-buys-sells-july-3-2026/): Insider trading this week (June 29-July 3, 2026): the 20 biggest buys and 20 biggest sells by dollar value, with names, tickers, amounts and next catalysts. - [AI: the 10 hottest stocks of July 2026](https://www.merlintrader.com/ai-hottest-stocks-july2026/): Ten artificial-intelligence names, screened for momentum, chart position and base, with the genuine small/mid caps up top. For each one: a mini chart, a short explainer, the AI niche and the real analyst price targets with sources. - [Defense: the 10 hottest stocks of July 2026](https://www.merlintrader.com/defense-10-hottest-stockst-july26/): Watchlist 2026 · Defense & Defense-Tech Drones Space Counter-UAS Momentum AVAV · KTOS · RKLB · LUNR · PL · DRS · KRMN · RCAT · UMAC · ONDS Defense: the 10 hottest stocks of July 2026 Ten small and mid-cap names across defense and defense-tech, screened for momentum, chart position and base. For each […] - [Atlas Lithium ($ATLX) Deep Dive 2026](https://www.merlintrader.com/atlas-lithium-july2026-deepdive/): The junior developer aiming to bring the Neves hard-rock lithium project into production in Minas Gerais' "Lithium Valley": a fully paid processing plant already shipped to Brazil, offtake deals with Mitsui, Chengxin and Yahua — but also years of delays, heavy dilution and a CEO who controls 51% of the vote. - [NANO Nuclear Energy ($NNE) Deep Dive 2026](https://www.merlintrader.com/nano-nuclear-energy-july2026-deepdive/): The microreactor developer aiming to become a fully integrated nuclear supply chain for the AI data-center era: pre-commercial technology, a large cash pile and a calendar of regulatory and test milestones. - [$MVIS MicroVision: Small-Cap LiDAR Reawakens as Defense, Security and AI Robotics Become the New Battleground](https://www.merlintrader.com/microvision-defense-security-robotics/): MicroVision’s new Southeast Asia partnership adds another piece to a busy 2026 commercial reset, but the story remains a high-risk execution trade: stronger customer activity, broader LiDAR portfolio, still-small revenue, meaningful cash burn and visible financing risk. - [Biotech Radar July 1, 2026: $CANF, $ABVX, $SXTP and $MODD Lead Today’s Catalyst Watch](https://www.merlintrader.com/biotech-radar-july1/): Today’s biotech tape is not built around one single mega-cap headline. It is a classic catalyst radar session: one small oncology name with a fresh Phase 2a survival signal, one late-stage inflammatory disease story with a major Phase 3/NDA setup but financing pressure, one infectious-disease micro-cap tied to babesiosis development, and one diabetes medtech name moving from clearance into real-world use. - [Abivax (NASDAQ: $ABVX): Obefazimod, the ABTECT Phase 3 Safety Reset and the Q4 2026 NDA Path](https://www.merlintrader.com/abivax-artect-phase3-safety-reset/): Abivax has moved from a speculative French biotech story to one of the most closely watched late-stage ulcerative colitis names in global healthcare. The June 29 ABTECT Maintenance Part 2 update did not simply add another dataset. It directly addressed the safety debate that had pressured the stock after the June 1 maintenance readout and pushed investors to reassess the risk/reward profile ahead of the planned U.S. NDA submission in Q4 2026. - [VisionWave Holdings (Nasdaq: $VWAV): Meteor Aerospace Deal](https://www.merlintrader.com/visionwave-holdings-meteor-deal/): Deep Dive · Defense Autonomy · $VWAV VisionWave Holdings (Nasdaq: $VWAV): Meteor Aerospace Deal Turns the Pre-Market Spike Into a Real Defense-Autonomy Test VisionWave announced a definitive binding agreement to acquire a 51% controlling interest in Meteor Aerospace, an Israeli aerospace and defense company with unmanned air, ground and maritime systems, electronic warfare, SIGINT, C4ISR […] - [DEA Cannabis Hearing Begins: Why Schedule III Still Matters for $TLRY, $CGC and $MSOS](https://www.merlintrader.com/dea-cannabis-hearing-begins-june29/): The market did not get a final ruling today. What it got is the start of a federal process that could decide whether the cannabis trade remains a narrow medical-only tax story or becomes a broader sector repricing catalyst. - [Analyst Price Targets in Biotech: Why the Most Quoted Number Is Often the Least Useful One](https://www.merlintrader.com/analyst-price-targets-in-biotech/): A deeper, U.S.-focused Merlintrader editorial on how to read sell-side price targets in small and mid-cap biotech, why 12-month targets often fail as forecasts, and why binary events such as PDUFA dates, Phase 3 readouts and FDA advisory committees can turn the “average target” into a misleading comfort number. - [Three Space Stories That Matter Now: $RKLB’s Iridium Shock, $ASTS’s August Launch Window, and Rocket Lab’s NASA Credibility Trade. $IRDM](https://www.merlintrader.com/space-stories-matter-now-jun29/): The public space sector just received a concentrated set of catalysts: Rocket Lab is trying to buy an operating satellite communications network, AST SpaceMobile has placed its next BlueBird batch on the launch calendar, and NASA has selected Rocket Lab for dedicated Sun/Earth science missions. Together, these updates show how the investable space trade is moving beyond launch hype and into infrastructure, networks, services, and execution. - [Biotech Radar — June 29, 2026: Ipsen-Kartos M&A, $CAPR’s FDA AdCom and $REPL’s RP1 Resubmission](https://www.merlintrader.com/biotech-radar-jun29/): The biotech calendar is entering a dense FDA-driven window, with three Nasdaq-listed names standing out for very different reasons: a renal-disease PDUFA decision watch, a rare-disease cell therapy advisory committee, and an oncology BLA resubmission that has put accelerated approval back in focus. - [Space Economy 2026: $ASTS vs $RKLB vs $SPCE vs $FJET — Four Business Models Compared](https://www.merlintrader.com/space-economy-2026/): Space Economy · $ASTS · $RKLB · $SPCE · $FJET Space Economy 2026: $ASTS vs $RKLB vs $SPCE vs $FJET — Four Business Models Compared A focused comparison of four publicly traded US space-economy names: satellite-to-phone connectivity ($ASTS), launch and space systems ($RKLB), suborbital tourism ($SPCE), and supersonic flight-testing / air-launch infrastructure ($FJET), after the […] - [Russell 2026 Final Rebalance Radar: Best Post-Upgrade Stocks to Watch by Sector](https://www.merlintrader.com/russell-2026-final-rebalance-radar-best-post-upgrade-stocks-to-watch-by-sector/): A sector-by-sector operational screen of the June 2026 Russell reconstitution, focused on stocks that deserve attention after the index event because chart structure, post-rebalance volume, fundamentals, catalysts and analyst target references overlap. - [Space Stocks Selloff: Why $PL, $LUNR, $SATL, $ASTS and RKLB Are Falling Together After June’s Rally](https://www.merlintrader.com/space-selloff-june2026/): The June space trade is no longer being priced stock by stock. Planet Labs, Intuitive Machines, Satellogic, AST SpaceMobile and Rocket Lab are being traded as one high-beta space basket — and the unwind has exposed the same pressure points across the sector: SpaceX gravity, ETF outflows, valuation resets, execution risk, launch cadence, defense-contract timing and profit-taking after a crowded rally. - [Russell 2026 Biotech Watchlist: $UNCY, $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch](https://www.merlintrader.com/russell-2026-biotech-watchlist/): RUSSELL 2026 PRELIMINARY LIST 87 HEALTH CARE ADDITIONS BIOTECH FOCUS Russell 2026 Biotech Watchlist: $UNCY, $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch The June 2026 Russell reconstitution becomes effective after the U.S. market close on June 26, with the new index membership active from the June 29 open. Among the Health […] - [4 FDA PDUFA Dates — Week of June 29–30, 2026](https://www.merlintrader.com/4-fda-pdufa-dates-week-of-june-29-30-2026/): ARQT, LNTH and UNCY face FDA target action dates on June 29, while VRDN follows on June 30. The setup spans pediatric dermatology, nuclear medicine imaging, dialysis-related nephrology and thyroid eye disease — four very different regulatory events with very different trading profiles. Report date: June 25, 2026 Financial data: latest Q1 2026 updates where available - [$PLSM $ICCM $SLN: Remote Care, Cryoablation and siRNA Catalysts Move Back Into Focus](https://www.merlintrader.com/back-in-focus-jun25-biotech/): Three healthcare small caps enter the morning radar for different reasons: Pulsenmore is pushing FDA-authorized home ultrasound into U.S. virtual maternity care, IceCure is building the clinical-validation story around ProSense cryoablation, and Silence Therapeutics is moving closer to a Phase 2 SANRECO readout for divesiran in polycythemia vera. - [$SPCX, $RKLB, $LMT: Space Defense Is Moving From Launch Hype to Military Infrastructure](https://www.merlintrader.com/space-defense-military-infrastructure/): SpaceX’s massive financing push, Rocket Lab’s record-setting rapid-response U.S. Space Force mission, and the SB-AMTI sensing architecture point toward a bigger market theme: the next phase of the space trade may be less about launch spectacle and more about military infrastructure, orbital resilience, sensor networks, and defense procurement. - [Ionis Pharmaceuticals (Nasdaq: $IONS): TRYNGOLZA Wins FDA Approval in Severe Hypertriglyceridemia](https://www.merlintrader.com/ions-pharmaceuticals-june2026-approval/): The FDA approval of TRYNGOLZA in adults with severe hypertriglyceridemia turns olezarsen from a rare-disease FCS launch into a broader cardiometabolic commercial story. The key issue now is not simply whether the drug works, but how quickly Ionis can convert a stronger label, a larger addressable population and pancreatitis-risk messaging into real prescribing momentum. - [Biotech Radar – $DFTX $ABSI $NVCT – June 24, 2026](https://www.merlintrader.com/biotech-radar-june24-dftx-absi-nvct/): Phase 3 clinical data, analyst coverage and an international licensing deal: three real, verified catalysts across DFTX, ABSI and NVCT. - [FuelCell Energy (Nasdaq: $FCEL) – Deep Dive 2026](https://www.merlintrader.com/fuelcell-energy-june2026-deepdive/): From overlooked micro-cap to AI data center power story: MCFC fuel-cell technology, the gigawatt-scale commercial pivot, and the Russell 2000 watch into Friday, June 26, 2026. - [Moleculin Biotech (Nasdaq: $MBRX) — MIRACLE Trial Countdown Ahead of the June 30 Interim Unblinding](https://www.merlintrader.com/moleculin-biotech-june2026-deepdive/): A verified deep dive on Annamycin, the MIRACLE Phase 2b/3 trial, the latest cardiac-safety package, the company’s fragile cash position, and the binary scenarios surrounding the first 45-subject interim unblinding expected by June 30, 2026. - [SpaceX (Nasdaq: $SPCX): The Party Lasted Four Days. Then Came the Bill.](https://www.merlintrader.com/spacex-party-lasted-four-days/): NASDAQ: SPCX Market Analysis IPO / Space / AI SpaceX (Nasdaq: $SPCX): The Party Lasted Four Days. Then Came the Bill. The largest IPO in market history pushed SpaceX into the center of the global tape: $135 pricing, roughly $75 billion in base proceeds, a greenshoe that brought the deal to about $85.7 billion, an […] - [Taysha, Entera Bio and Scholar Rock Put Rare Disease, Oral Peptides and Neuromuscular Catalysts Back on the Tape — $TSHA / $ENTX / $SRRK](https://www.merlintrader.com/taysha-entera-scholar-catalysts-back/): Three biotech updates hit the tape today with very different market meanings: Taysha delivered the strongest clinical/regulatory signal, Entera Bio reduced Phase 3 design uncertainty around EB613, and Scholar Rock added a near-term neuromuscular conference watch around SMA and FSHD - [HIVE Digital Technologies (Nasdaq/TSX: $HIVE): Bitcoin Mining, AI Infrastructure, Paraguay, Canada and the New Compute Trade](https://www.merlintrader.com/hive-digital-technologies-june2026-deepdive/): HIVE is no longer just a public Bitcoin miner. The company is trying to become a dual-engine digital infrastructure platform, using renewable-powered mining scale, GPU infrastructure and BUZZ HPC to participate in the AI compute boom. The opportunity is real enough to monitor closely, but the equity remains exposed to Bitcoin volatility, dilution, capex intensity and major execution risk. - [Definium Therapeutics (Nasdaq: $DFTX): DT120 Phase 3 Emerge Deep Dive After Positive MDD Data](https://www.merlintrader.com/definium-therapeutics-jun22-deepdive/): Definium has moved from a speculative late-stage psychedelic psychiatry story into a much more serious Phase 3 data story. The positive Emerge readout in major depressive disorder changes the market conversation around DT120 ODT, but it does not remove the key risks: replication, regulatory execution, controlled-substance scheduling, commercial infrastructure, reimbursement and future capital strategy. ## Pages - [Agios Pharmaceuticals ($AGIO) Stock Hub 2026: From Mitapivat Launch Story To Broader Rare-Disease Hematology Platform](https://www.merlintrader.com/agios-pharmaceuticals-stock-hub/): An evergreen, source-backed view of Agios Pharmaceuticals after the U.S. thalassemia approval, the AQVESME launch, the sickle cell sNDA submission, and the next-generation pipeline inflection points that can define the company’s next phase. - [Outlook Therapeutics (Nasdaq: $OTLK): FDA-approved LYTENAVA opens a new U.S. commercial chapter](https://www.merlintrader.com/outlook-therapeutics-stock-hub/): Outlook Therapeutics is not a simple “approval or no approval” biotech story anymore. It is a long regulatory case study around ophthalmic bevacizumab, multiple FDA Complete Response Letters, an approved European/UK product, repeated financing pressure, management resets, and a retail shareholder base trying to understand whether the U.S. file is still alive or structurally blocked. - [Newsletter](https://www.merlintrader.com/newsletter/): [newsletter] - [Manage Consent Preferences](https://www.merlintrader.com/manage-consent-preferences/): [cmplz_preferences] - [CorMedix Therapeutics (Nasdaq: $CRMD) Stock Hub](https://www.merlintrader.com/cormedix-therapeutics-stock-hub/): CorMedix Therapeutics is no longer the same equity story that long-time CRMD followers remember from the pre-commercial DefenCath years. For a long time, the company traded like a classic single-asset biotech with all the usual emotional baggage: regulatory delays, manufacturing questions, financing risk, retail frustration, and a shareholder base waiting for one product to finally cross the line. That chapter is over. It did not end quietly. It ended through an FDA approval, a live commercial launch, a major reimbursement framework, the Melinta acquisition, a broader anti-infective platform, a buyback authorization, positive Phase III REZZAYO data, and a Q1 2026 update that confirmed CorMedix now has real revenue, real profit, and real cash generation. - [SeaStar Medical Holding Corporation (Nasdaq: $ICU): QUELIMMUNE Adoption, Adult AKI Pivotal Execution and the Funding Equation](https://www.merlintrader.com/seastar-medical-holding-stock-hub/): A fully refreshed research hub on SeaStar Medical’s Selective Cytopheretic Device platform, pediatric QUELIMMUNE commercialization, SAVE Registry evidence, NEUTRALIZE-AKI and NEUTRALIZE-CRS execution, reimbursement infrastructure, Q1 financials, equity-plan dilution and scenario analysis. - [Intuitive Machines (Nasdaq: $LUNR) Stock Hub 2026: Q2 Earnings on August 13, the Lanteris-Powered Revenue Step-Up and the Backlog That Follows It](https://www.merlintrader.com/intuitive-machines-stock-hub/): Intuitive Machines ($LUNR) hub updated August 4, 2026: Q2 results and call on August 13, the Lanteris revenue step-up, a $1.06 billion backlog, the 2026 outlook of $900 million to $1 billion and the ceiling-versus-funded question. - [Protalix BioTherapeutics (NYSE American: $PLX) Stock Hub](https://www.merlintrader.com/protalix-biotherapeutics-stock-hub/): Protalix BioTherapeutics is one of the more unusual small-cap biotech stories because it does not fit neatly into the common pre-PDUFA, cash-burning, single-readout template. The company has already developed and manufactured approved enzyme replacement therapies, it operates through significant commercial partnerships, and it owns a differentiated plant cell-based protein expression platform called ProCellEx. That makes PLX a hybrid story: part commercial rare-disease company, part manufacturing platform, part pipeline optionality, and part underfollowed small-cap biotech with a valuation still heavily shaped by execution risk. - [Capricor Therapeutics ($CAPR): The FDA Fight, the BioSpace Interview and Every Path to August 22](https://www.merlintrader.com/capricor-therapeutics-stock-hub/): Capricor Therapeutics enters the final weeks before its August 22 PDUFA after a 3–9 negative FDA advisory vote. This fully updated hub explains Linda Marbán’s BioSpace interview, the SAP dispute, possible legal action, a Europe-first route, the company’s cash position and the scenarios that now control $CAPR. - [Ocugen ($OCGN) Stock Hub: Q2 2026, FDA-Cleared OCU410 Phase 3, OCU400 Data-Linked BLA and 2027 Catalysts](https://www.merlintrader.com/ocugen-inc-stock-hub/): Ocugen Q2 2026 Stock Hub: FDA-cleared OCU410 ArMaDa3, OCU400 BLA timing tied to Q1 2027 topline, $100.4 million cash, $24.9 million net loss, convertible-note risks and the 2026-2028 catalyst map. - [Fate Therapeutics (Nasdaq: $FATE): RECLAIM-LN Recruitment, FT819 Lupus Data, FT839, and the Next Autoimmune CAR-T Tests](https://www.merlintrader.com/fate-therapeutics-stock-hub/): A complete Merlintrader Stock Hub covering Fate Therapeutics’ platform history, FT819 autoimmune reset strategy, oncology optionality, collaborations, regulatory path, financing profile, dilution risk, catalysts, timeline, bull case, bear case and key red flags. - [Ocular Therapeutix ($OCUL): AXPAXLI’s FDA-Aligned NDA Path, SOL-1 Durability and the Retina-Franchise Test](https://www.merlintrader.com/ocular-therapeuthix-stock-hu/): Breaking update · August 3, 2026: Ocular reported that the finalized FDA Type C meeting minutes are consistent with management’s plan to use SOL-1 Week 52 efficacy and safety, interim SOL-R safety and confirmatory evidence for the AXPAXLI wet-AMD NDA. The company kept the Q4 2026 submission target, said the pre-NDA meeting is scheduled for Q3, and introduced a post-hoc analysis estimating a 72% reduction in injection burden excluding loading doses, or 56% including loading doses, versus a projected on-label aflibercept 2 mg every-eight-week schedule through Week 52. The comparison is modeled and post hoc—not a randomized head-to-head result against continuous on-label aflibercept. Q2 net revenue was $13.5 million, net loss was $78.8 million and cash ended June at $598.6 million, with runway guidance maintained into 2028 but still excluding the full anticipated cost of near-term AXPAXLI commercialization. - [$SLS SELLAS Update: REGAL Is Still Officially 78/80, 3D Medicines Wins Arbitration and Vanguard Files a Passive Warrant Position](https://www.merlintrader.com/sellas-life-sciences/): Next confirmed catalyst: SELLAS has not announced event 80, database lock, unblinding or topline results; the latest official count remains 78 of 80 events as of May 11, 2026. Management later said the company was approaching the threshold and had entered a quiet period. This update also adds the 3D Medicines arbitration award, Vanguard’s passive warrant-based Schedule 13G and the latest analyst changes. Claims that event 80 has already occurred or that a buyer or bidding war exists remain unverified speculation and are classified in the rumor monitor below. - [Omeros confirms YARTEMLEA’s FY2027 NTAP: up to $287,079 in additional Medicare reimbursement per eligible inpatient from October 1](https://www.merlintrader.com/omeros-corporation-stock-hub/): A long-form evergreen hub on Omeros, YARTEMLEA in TA-TMA, the long regulatory road from the first FDA complete response letter to approval, the Novo Nordisk zaltenibart transaction, the remaining complement pipeline, commercial launch milestones, bull and bear scenarios, analyst context and retail sentiment. - [BlackSky Technology (NYSE: $BKSY) Stock Hub 2026: Q2 Revenue Up 50%, the Gen-3 Fleet and the Backlog Arithmetic](https://www.merlintrader.com/blacksky-technology-stock-hub/): BlackSky ($BKSY) hub updated August 4, 2026: Q2 results and call on August 6, the four-satellite Gen-3 fleet, $351.6 million of backlog and its timing, raised 2026 guidance, the $250 million ATM and the share count question. - [Rocket Lab Corporation (Nasdaq: $RKLB) Stock Hub 2026: Q2 Earnings on August 10, the Iridium Collar, Neutron and the Backlog Math](https://www.merlintrader.com/rocket-lab-stock-hub/): Rocket Lab ($RKLB) hub updated August 5, 2026: the $397 million SB-AMTI Flatellite contract awarded on August 4, Q2 results and call on August 10, the $54.00 per share Iridium acquisition, Neutron and the backlog math. - [Geron Corporation (Nasdaq: $GERN) Stock Hub: RYTELO Q2 2026, IMpactMF and the Execution Test](https://www.merlintrader.com/geron-corporation-stock-hub/): Advanced Geron ($GERN) Stock Hub updated for Q2 2026: RYTELO revenue, demand, ordering accounts, guidance, cash, IMpactMF catalysts and risks. - [Lexicon Pharmaceuticals (Nasdaq: $LXRX) Stock Hub: ZYNQUISTA, INPEFA, SONATA-HCM, Novo Nordisk and the 2026 comeback setup](https://www.merlintrader.com/lexicon-pharmaceuticals-stock-hub/): A complete evergreen stock hub on Lexicon Pharmaceuticals after the Q1 2026 update: the ZYNQUISTA resubmission path, the SONATA-HCM Phase 3 window, the Novo Nordisk LX9851 economics, pilavapadin optionality, cash runway, dilution risk, bull/bear scenarios and the real catalysts that can define the next phase of the story. - [Redwire Corporation (NYSE: $RDW) Stock Hub 2026: Record Q2 Revenue, 27.8% Gross Margin, a $542M Backlog and the Dilution Arithmetic](https://www.merlintrader.com/redwire-corporation-stock-hub/): Redwire ($RDW) stock hub updated August 4, 2026: Q2 2026 results due August 5 after the close with the call on August 6, the reaffirmed $450-500M full-year forecast, record $498.1M backlog, the $981M NITE-STAR selection and the ATM dilution math. - [BioCryst Pharmaceuticals (Nasdaq: $BCRX) Stock Hub: ORLADEYO, Navenibart, EAACI 2026 Data and the HAE Franchise Transition](https://www.merlintrader.com/biocryst-pharmaceuticals-stock-hub/): BioCryst Pharmaceuticals is one of those rare biotechnology stories that has lived several lives. It started as a long-duration drug-discovery company, survived years of clinical uncertainty, built credibility through antiviral work, achieved its first U.S. approval with RAPIVAB, absorbed the boom-and-bust psychology that often surrounds small-cap biotech, and then finally reached a more durable commercial phase through ORLADEYO, the once-daily oral prophylactic therapy for hereditary angioedema. That evolution matters because the market still tends to treat BCRX as if it were merely another pre-catalyst biotech trade. The more complete picture is different: BioCryst is now a commercial rare-disease company with one scaled flagship product, a newly acquired late-stage injectable HAE asset, an early rare-dermatology program, a management transition, a cleaner profitability narrative than in the past, and still a meaningful list of risks that cannot be ignored. - [Novavax, Inc. (Nasdaq: $NVAX) Stock Hub: Complete Timeline, Matrix-M Turnaround and Post-COVID Vaccine Story](https://www.merlintrader.com/novavax-inc-stock-hub/): Novavax is one of the most dramatic vaccine stories in modern public markets. It is not a simple COVID stock, even if the COVID trade made it famous to a much broader audience. The company existed for decades before the pandemic, built a reputation around recombinant vaccine technology, suffered painful late-stage RSV disappointments, briefly recovered credibility with NanoFlu, became a pandemic-era market star, then collapsed when the commercial window for COVID vaccination shifted faster than Novavax could execute. Today, the stock sits in a very different chapter: a partner-led turnaround built around Matrix-M, its proprietary saponin-based adjuvant. - [Palladyne AI Corp. (Nasdaq: $PDYN) Stock Hub 2026: Q2 Revenue of $5.8 Million, a Widening Operating Loss and the Cash Runway Question](https://www.merlintrader.com/palladyne-ai-corp-stock-hub/): Palladyne AI ($PDYN) Q2 2026 Stock Hub update: $5.783 million revenue, $24.6 million backlog, $43.746 million liquidity, reaffirmed guidance, cash burn, dilution and the second-half execution test. - [BigBear.ai Holdings (NYSE: $BBAI) Stock Hub 2026: the New 100 Million Share Programme, Backlog Quality and the Revenue That Has Not Grown](https://www.merlintrader.com/bigbear-ai-stock-hub/): BigBear.ai ($BBAI) hub updated August 4, 2026: the July 30 second quarter results, the new 100 million share ATM, backlog quality, $36.3 million of cash and $409.8 million including investments, and the dilution arithmetic. - [Viridian Therapeutics (Nasdaq: $VRDN): Complete Stock Hub for FDA-Approved Lumvoa, Elegrobart and the TED Franchise](https://www.merlintrader.com/viridian-therapeutics-stock-hub/): Viridian Therapeutics is one of the cleaner late-stage biotech stories on the 2026 catalyst board because the narrative is both simple and demanding: the company is trying to move from development-stage biotech to commercial rare-disease player in thyroid eye disease, a market validated by Amgen’s Tepezza but still underpenetrated, expensive, payer-sensitive and clinically nuanced. VRDN is not a one-binary company anymore. It now has veligrotug, an IV anti-IGF‑1R antibody under FDA Priority Review, and elegrobart, a subcutaneous anti-IGF‑1R candidate with positive phase 3 data in both active and chronic TED. That gives the story depth. It also raises the bar: the stock is increasingly being judged not only on statistical success, but on whether the data look commercially good enough to compete. - [NRx Pharmaceuticals (Nasdaq: $NRXP) Stock Hub: KETAFREE™ FDA First-Cycle Review, NRX-100, NRX-101/TMS and HOPE Therapeutics](https://www.merlintrader.com/nrx-pharmaceuticals-stock-hub/): NRx Pharmaceuticals ($NRXP): FDA found no drug-related Major Deficiency in KETAFREE, but one formal container-closure Major Deficiency remains. Full August 7, 2026 update on the response path, capital structure, catalysts and risks. - [Travere Therapeutics ($TVTX) Q2 2026 Stock Hub: FILSPARI Revenue, FSGS Launch and Capital Structure](https://www.merlintrader.com/travere-therapeutics-stock-hub/): Travere Therapeutics reported Q2 2026 revenue of $169.6 million and $141.1 million of FILSPARI sales. The business generated positive operating income before a large convertible-note charge drove a $0.37 GAAP loss per share. - [Cytokinetics ($CYTK) Stock Hub 2026: MYQORZO, Aficamten and the Hypertrophic Cardiomyopathy Franchise Expansion](https://www.merlintrader.com/cytokinetics-incorporated-stock-hub/): Cytokinetics is no longer only a long-duration R&D story. After more than two decades focused on muscle biology, the company entered a new phase in December 2025 when the FDA approved MYQORZO, formerly aficamten, for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. That approval transformed Cytokinetics from a clinical-stage biotech into a commercial cardiovascular company. - [Alpha Tau Medical Ltd. (Nasdaq: $DRTS) Stock Hub: Alpha DaRT, Recurrent GBM, Pancreatic Cancer, ReSTART, Tolmar and the 2026 Catalyst Map](https://www.merlintrader.com/alpha-tau-stock-hub/): Alpha Tau Medical is not a classic drug-development biotech. It is an Israeli oncology company trying to build a new category around Alpha DaRT, a localized intratumoral alpha-radiation platform designed to deliver highly potent alpha-particle radiation directly inside solid tumors while limiting exposure to surrounding healthy tissue. The stock story is therefore a hybrid: part medtech/device, part radiopharmaceutical oncology, part regulatory execution, and part early commercial launch risk. - [ADMA Biologics (Nasdaq: $ADMA): Q2 2026 Results, ASCENIV Growth, BIVIGAM Stabilization, Margins and the Revenue-Quality Test](https://www.merlintrader.com/adma-biologics-stock-hub/): ADMA Biologics is not a classic binary biotech story anymore. It is a commercial, vertically integrated plasma-derived biologics company with three FDA-approved marketed products, a U.S. manufacturing base in Boca Raton, Florida, a plasma collection network, and a financial profile that has moved from survival-stage biotech to profitable specialty biologics platform. That shift is exactly why ADMA deserves an evergreen page rather than only a stream of short news notes. - [Iovance Biotherapeutics (Nasdaq: $IOVA): AMTAGVI, TIL Therapy and the Commercial Execution Story](https://www.merlintrader.com/iovance-biotherapeutics-stock-hub/): Iovance has moved beyond the old binary approval setup. The company now sits in a more demanding phase: AMTAGVI revenue, authorized treatment-center productivity, manufacturing reliability, gross-margin recovery, international expansion and pipeline conversion beyond advanced melanoma. - [ImmunityBio, Inc. (Nasdaq: $IBRX) Stock Hub](https://www.merlintrader.com/immunitybio-inc-nasdaq-ibrx-stock-hub/): ImmunityBio is one of the more unusual biotech stories in the U.S. small-to-mid cap universe because it sits at the intersection of three narratives that rarely move in a straight line: a real commercial oncology product, a broad immunotherapy platform with ambitious expansion plans, and a regulatory history that has forced the market to constantly reassess how much execution risk should be attached to the company. The heart of the story is ANKTIVA, also known as nogapendekin alfa inbakicept-pmln or N-803, an IL-15 receptor agonist designed to activate natural killer cells and CD8+ T cells while supporting immune memory. The first major commercial validation came in April 2024, when the FDA approved ANKTIVA in combination with Bacillus Calmette-Guérin for adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. This is not an abstract platform milestone. It is a marketed drug in a defined oncology indication, with product revenue that has moved from early launch levels into a much more visible commercial ramp. - [Satellogic Inc. (Nasdaq: $SATL) Stock Hub 2026: the Q2 Print, First Positive Operating Income and Where the Revenue Actually Came From](https://www.merlintrader.com/satellogic-inc-stock-hub/): Satellogic ($SATL) hub updated August 5, 2026: Q2 revenue up 259% to $15.9 million, the first positive operating income and adjusted EBITDA in company history, the $20.0 million net loss and the non-cash charge behind it, cash of $112.8 million, RPO of $80.7 million and the Merlin schedule. - [Corcept Therapeutics ($CORT): Lifyorli’s launch changes the scale of the story](https://www.merlintrader.com/corcept-therapeutics-cort-stock-hub-2026/): Corcept Therapeutics has become one of the more complex revenue-generating biotech stories in the Merlintrader universe. It is not a small pre-revenue binary biotech. It has a commercial base through Korlym and its authorized generic, a newly approved oncology product with Lifyorli, an unresolved but still strategically important Cushing relacorilant program, and a pipeline that now includes ovarian cancer expansion studies, MASH and a planned pivotal ALS program. - [Planet Labs PBC (NYSE: $PL) Stock Hub 2026: the January Fiscal Year, a $906 Million Backlog and the $1.5 Billion Shelf](https://www.merlintrader.com/planet-labs-stock-hub/): Planet Labs ($PL) hub updated August 4, 2026: the fiscal Q2 2027 print that has not been dated yet, a backlog above $906 million, fiscal 2027 guidance of $425 to $441 million, the German and Swedish contracts, the convertible notes and the $1.5 billion ATM. - [Red Cat Holdings (Nasdaq: $RCAT) Stock Hub 2026: the Army SRR Funded Orders, Lumpy Deliveries and the Cost of the Ramp](https://www.merlintrader.com/red-cat-holdings-nasdaq-stock-hub-2026/): Red Cat Holdings ($RCAT) hub updated August 4, 2026: Q2 2026 results and webinar on August 6, the Army SRR funded-order question, Black Widow and Blue Ops, gross margin, cash and the dilution arithmetic. - [Biotech Stocks Hub: catalysts, clinical data, FDA events and high-volatility healthcare setups](https://www.merlintrader.com/biotech-stocks-hub-catalyst-2026/): Browse Biotech Stock Hubs 84 $ABCLAbCellera BiologicsUpdated Aug 9, 2026 $ADMAADMA BiologicsUpdated Aug 9, 2026 $AGENAgenus Inc.Updated Aug 6, 2026 $AGIOAgios PharmaceuticalsUpdated Aug 9, 2026 $ALDXAldeyra TherapeuticsUpdated Aug 9, 2026 $ALLOAllogene TherapeuticsUpdated Aug 9, 2026 $ALTAltimmuneUpdated Aug 9, 2026 $AQSTAquestive TherapeuticsUpdated Aug 6, 2026 $ARDXArdelyxUpdated Aug 9, 2026 $ARQTArcutis BiotherapeuticsUpdated Aug 9, 2026 $ARTVArtiva BiotherapeuticsUpdated […] - [POET Technologies (Nasdaq: $POET) Stock Hub 2026: Q2 Results Due by August 14, the Lumilens Order and What Is Actually Funded](https://www.merlintrader.com/poet-technologies-company-hub/): POET Technologies ($POET) hub updated August 4, 2026: Q2 results due by August 14, the Lumilens order and its conditions, the Marvell cancellation, $830 million raised, the share count and what is actually a purchase order rather than an intention. - [Ondas Inc. (Nasdaq: $ONDS) Stock Hub 2026: Q2 Results on August 13, the $875.8 Million DZYNE Acquisition and the $525 Million Target](https://www.merlintrader.com/ondas-holdings-hub-2026-coverage/): Ondas ($ONDS) hub updated August 4, 2026: Q2 results and call on August 13, the $875.8 million DZYNE acquisition, the raised revenue target above $525 million, the acquisition spree of 2026 and the dilution arithmetic. - [Space, Defense & AI Stocks Hub 2026: The New Infrastructure Race](https://www.merlintrader.com/space-defense-ai-stocks-hub-2026-the-new-infrastructure-race/): What this hub will cover Major space, defense and AI infrastructure themes Public companies exposed to launch, satellites, drones, autonomy and defense software The difference between mature contractors and speculative emerging players Government spending, geopolitical risk, earnings quality and commercial execution - [Altimmune Inc. (Nasdaq: $ALT) Stock Hub](https://www.merlintrader.com/altimmune-inc/): Altimmune Stock Hub: pemvidutide, IMPACT Phase 2b data, PERFORMA Phase 3 in MASH, RECLAIM AUD, RESTORE ALD, cash runway, share-equivalent dilution, warrant risks and the 2026 catalyst map. - [Cannabis Stocks HUB 2026: A Possible Reset for a Broken Sector $MSOS, $TLRY, $CGC, $CRON, $ACB](https://www.merlintrader.com/cannabis-stocks-hub/): The intention is to make this hub a neutral, objective, and continuously useful information point on the cannabis sector and the stock tickers most directly involved in it. That means following both policy and fundamentals, both opportunity and risk, and both the legacy names that came to define the sector and the emerging stories that may matter in the next cycle. - [Daily Briefing](https://www.merlintrader.com/daily-briefing/): Sunday, August 9, 2026: China inflation cools, Hormuz remains unresolved, Berkshire deploys capital and Monday opens with $BRK.B, energy risk and the $NRXP call. - [Intelligence Hub](https://www.merlintrader.com/intelligence-hub-dashboard/): This page is the Merlintrader Intelligence Hub – a fast dashboard to see everything that matters at a glance: daily notes (morning/afternoon), personal board, imminent catalysts, focused watchlist and the latest reports by category. It’s built for speed and clarity, so you can quickly scan catalysts, ideas and fresh analysis without jumping between multiple pages. - [Master Tracker Mobile Pwa](https://www.merlintrader.com/master-tracker-mobile-pwa/): Merlintrader PWA MERLINTRADER Caricamento eventi… - [Small-Cap and Mid-Cap Stocks to Watch](https://www.merlintrader.com/small-medium-caps/): Explore undercovered small- and mid-cap stocks across space, defense, AI, energy and emerging technology, with research on earnings, catalysts, capital structure, risks and volatility. - [BIOTECH STOCKS SAGA](https://www.merlintrader.com/biotech-stocks-saga/): Biotech is not just “tech with a lab coat”. If you dive in without a framework, you do not just risk a normal −20% correction – you risk waking up to a −70% gap after a failed trial or a nasty FDA letter. Before you even consider buying a biotech stock, it helps to slow down and ask yourself a few important questions. Not magic questions that guarantee the perfect stock (that does not exist), but a mental filter that keeps you from going in blind. - [Encyclopedia of Social Trader Myths (Read This as Soon as "To-da-moon" Appears)](https://www.merlintrader.com/encyclopedia-of-social-trader-myths/): A curated – and slightly mean – list of the legends that keep circulating on Stocktwits, Reddit, X and every other corner of “social trading land”. Not a guide on how to make money, but a manual on how to not donate your account every time a ticker starts trending. Written with biotech, small caps and catalyst traders in mind, but applicable to almost any stock that ends up in the social media meat grinder. - [Biotech Due Diligence: Red Flags, Green Flags and a Repeatable Checklist](https://www.merlintrader.com/red-green-flags-in-biotech-stocks-2025/): A complete biotech due-diligence framework covering clinical evidence, regulation, CMC, cash, dilution, management, competition, intellectual property, SEC filings and market structure. - [Biotech Valuation Framework](https://www.merlintrader.com/biotech-valuation-framework-2025/): A practical biotech valuation framework covering enterprise value, patient-based peak sales, rNPV, cash runway, SEC financing instruments, partnerships and fully diluted per-share outcomes. - [PDUFA Date Meaning: FDA Reviews, Timelines and Complete Response Letters](https://www.merlintrader.com/pdufa-decisions-explained-2025/): What does a PDUFA date mean? A detailed guide to FDA target action dates, NDA and BLA reviews, standard and priority review, inspections, approval outcomes and Complete Response Letters. - [How to Read Clinical Trial Results](https://www.merlintrader.com/read-clinical-trial-results-2025/): A practical guide to trial phases, study design, endpoints, effect size, statistics, safety, topline releases and the difference between statistical and clinical significance. - [Biotech Catalyst Trading Guide](https://www.merlintrader.com/day-1-catalyst-trading-guide/): A detailed framework for identifying, verifying and analyzing biotech catalysts through evidence, expectations, valuation, financing risk and market structure. - [RunUP Biotech Masterclass](https://www.merlintrader.com/run-up-biotech-masterclass/): A structured five-chapter course on biotech catalysts, clinical trial data, FDA decisions, valuation, dilution risk and due diligence. - [Biotech Tools Hub](https://www.merlintrader.com/biotech-tools-hub/): Biotech Tools Hub – Merlintrader Biotech Tools Hub All core Merlintrader tools in one place: catalyst calendar, spreadsheet view, Total Tracker, Tracker v2 and the daily dashboard with a fully customizable watchlist. This page is the base for the TOOLS menu. Scope Biotech catalysts Tools Calendar, Spreadsheet, Trackers Access Free, no login EN IT TOOLS […] - [CRL 101 – Understanding FDA Complete Response Letters in Biotech](https://www.merlintrader.com/crl-101-complete-response-letters/): Not every FDA “no” is the same. Some Complete Response Letters mean the story is over for years; others are mainly about manufacturing or paperwork. For investors and traders, understanding the difference is critical. - [Biotech Trading Without the Fairy Tales: Risks, Catalysts and Reality](https://www.merlintrader.com/biotech-trading-without-the-fairy-tales-risks-catalysts-and-reality/): If trading biotech stocks were just about knowing FDA dates, everyone on Reddit would be rich. They are not. Most traders lose money for a simpler reason: they completely misread what actually moves price. - [RunUp Energy 2026](https://www.merlintrader.com/runup-energy/): RunUp Energy tries to make this readable: instead of one giant “biotech calendar”, we build lanes of events for a select group of utilities, each tied to specific dockets (ACC, BPU, CPUC, RRC, OPUC, MPUC, etc.) and to the company’s own strategic steps (M&A, divestitures, capital plans). The goal is not to guess outcomes, but to know when the market is most likely to care. - [Merlintrader Blog](https://www.merlintrader.com/merlintrader-blog-2/): Welcome to Merlintrader Blog – Your comprehensive resource for biotech stock analysis, FDA PDUFA catalysts, and trading insights for small-cap pharmaceutical companies. What You’ll Find on Merlintrader Blog Start Your Trading Journey Today Explore our comprehensive stock analysis, join weekly reports, and stay updated with the latest biotech catalyst tracking. Sign up to get real-time […] - [Disclaimer](https://www.merlintrader.com/disclaimer/): IMPORTANT: This is a personal blog, NOT a financial services company or registered investment advisor. Read this disclaimer in its entirety before using content from Merlintrader Trading Pub. This applies to ALL articles, analysis, commentary, charts, and research published here. - [Merlintrader Blog](https://www.merlintrader.com/merlintrader-blog/): Welcome to Merlintrader Blog – Your comprehensive resource for biotech stock analysis, FDA PDUFA catalysts, and trading insights for small-cap pharmaceutical companies. What You’ll Find on Merlintrader Blog Start Your Trading Journey Today Explore our comprehensive stock analysis, join weekly reports, and stay updated with the latest biotech catalyst tracking. Sign up to get real-time […] - [CHARTSWATCHER 10% OFF !](https://www.merlintrader.com/chartswatcher/): Guide · Trader tools ChartsWatcher: the complete guide to the real-time market scanner How ChartsWatcher works, how to build scanners, alerts, toplists and watchlists on a multi-window dashboard, and how to start from the free version up to the paid plans. A practical, step-by-step guide with links to the official sources. What ChartsWatcher is ChartsWatcher […] - [Cookie and Privacy Policies](https://www.merlintrader.com/condizioni-duso-e-info-privacy/): Merlintrader Trading Pub · Legal Documents Terms and Conditions These Terms and Conditions govern the use of Merlintrader Trading Pub, an independent personal research and educational blog. This version updates the legal links and cookie-management references for the current CookieYes setup. Last updated: 06/04/2026 Owner: Horacio Fabian Greco Jurisdiction: Italy CMP: CookieYes Important: Merlintrader Trading […] - [Merlintrader | Biotech Catalysts & U.S. Small-Mid Cap Research](https://www.merlintrader.com/): Daily U.S. market briefings, biotech catalyst tracking and independent research on small- and mid-cap stocks across biotech, space, defense, AI, energy and cannabis. - [Catalyst Total Tracker](https://www.merlintrader.com/catalyst-total-tracker/): New: added a Google Sheet data view of the Biotech Catalyst Calendar, useful for filtering events by phase, status, and date. Data & Risk Disclaimer EN IT Data source. All entries in this tracker are compiled from public and third-party sources (company press releases, FDA/EMA calendars, clinicaltrials.gov, SEC filings and market data providers). Accuracy. Despite […] - [Daily Watchlist](https://www.merlintrader.com/daily-dashboard-con-tracker/): Daily Dasboard per Biorunup - [RunUP Biotech Strategy Guide](https://www.merlintrader.com/run-up-biotech/): A complete practical guide to the RunUP Biotech strategy, covering catalyst research, clinical and FDA risk, expectations, valuation, dilution, liquidity, entry and exit frameworks, and risk management. - [Latest News](https://www.merlintrader.com/ultime-news/): Latest News - [STRATEGIA RUN UP BIOTECH](https://www.merlintrader.com/strategia-run-up-biotech/): he Run-Up Biotech strategy focuses on observing and tracking how biotech stocks behave in the weeks leading up to key clinical or regulatory events, such as PDUFA decisions, top-line readouts from trials, or presentations at major medical conferences. The objective is not to predict the outcome of the event, but to identify speculative interest and market accumulation that often appear before those dates. The core focus remains on pre-event momentum and on risk management in a sector that is structurally volatile. - [Biotech Catalyst Calendar 2026](https://www.merlintrader.com/free-catalyst-calendar/): Track upcoming biotech catalysts, FDA decisions, PDUFA dates, advisory committee meetings and clinical-trial readouts for U.S.-listed biotech stocks, with dates, sources and risk context. - [Merlintrader](https://www.merlintrader.com/menu/) - [About Merlintrader](https://www.merlintrader.com/aboutme/): Merlintrader trading Blog is an independent project focused mainly on biotech and small-cap stocks, with occasional deep dives into selected mid and large caps when the story really matters. The goal is simple: understand what is happening, not sell you a dream. - [Silence Therapeutics ($SLN) Stock Hub 2026: The August SANRECO Readout, A Zerlasiran Asset Waiting For A Partner And US$70 Million Of Cash](https://www.merlintrader.com/silence-therapeutics-sln-stock-hub/): Stock Hub 2026 · siRNA / Haematology / Cardiovascular siRNA PlatformSingle CatalystPhase 2 ReadoutCash Into 2028Pre-Revenue Nasdaq: $SLN Silence Therapeutics ($SLN) Stock Hub 2026: The August SANRECO Readout, A Zerlasiran Asset Waiting For A Partner And US$70 Million Of Cash Silence halved its loss by finishing one programme and parking another. What is left is […] - [Telix Pharmaceuticals ($TLX) Stock Hub 2026: The September 11 Pixclara Decision, The Unclosed Zircaix CRL And A US$1 Billion Revenue Year](https://www.merlintrader.com/telix-pharmaceuticals-tlx-stock-hub/): Stock Hub 2026 · Radiopharmaceuticals / Oncology Imaging RadiopharmaCommercial StageSeptember PDUFAOpen CRLASX / Nasdaq Dual Listing Nasdaq: $TLX · ASX: TLX Telix Pharmaceuticals ($TLX) Stock Hub 2026: The September 11 Pixclara Decision, The Unclosed Zircaix CRL And A US$1 Billion Revenue Year Telix already sells more than US$800 million of radiopharmaceutical product a year. What […] - [USA Rare Earth ($USAR) Stock Hub 2026: The Stillwater Magnet Ramp, Round Top And The $1.6 Billion Federal Package](https://www.merlintrader.com/usa-rare-earth-usar-stock-hub/): USA Rare Earth stock hub: verified numbers on the Stillwater magnet ramp, the Round Top deposit, the $1.6 billion Department of Commerce package, and the two dated catalysts ahead - Q2 results on August 10 and the August 28 vote on issuing 126.8 million new shares. - [Intellia Therapeutics ($NTLA) Stock Hub: Rolling BLA, HAELO Data and In Vivo CRISPR](https://www.merlintrader.com/intellia-therapeutics-ntla-stock-hub/): Intellia Therapeutics ($NTLA) stock hub: the rolling BLA for lonvo-z, the Phase 3 HAELO dataset, the nex-z liver signal and the HLA finding, cash into 2028 and a share count up 29% year on year. - [SoundHound AI (Nasdaq: $SOUN) Stock Hub 2026: Record Q2 Revenue of $61.9 Million, the Narrow Guidance Raise and the LivePerson Arithmetic](https://www.merlintrader.com/soundhound-ai-stock-hub/): SoundHound AI $SOUN stock hub: Q2 2026 revenue of $61.9 million up 45%, the guidance raise that moved only the floor, and the LivePerson merger that means 42.6 million new shares, not $42.8 million. Vote August 20, 2026. - [Kratos Defense & Security Solutions (Nasdaq: $KTOS) Stock Hub: Drones, Hypersonics, Engines and the Cost of Scaling](https://www.merlintrader.com/kratos-defense-ktos-stock-hub/): Kratos ($KTOS) Stock Hub updated August 5, 2026: Q2 earnings, segment economics, $2.08 billion backlog, Valkyrie, hypersonics, jet engines, guidance, cash flow, dilution, catalysts and risks. - [SpaceX (Nasdaq: $SPCX) Stock Hub 2026: the First Quarter as a Public Company, $18.4 Billion of Capex and the Lock-Up Calendar](https://www.merlintrader.com/spacex-stock-hub/): SpaceX ($SPCX) stock hub, August 4, 2026: the first Form 10-Q as a listed company, Q2 revenue of $7,814M up 91.9%, $18,369M of quarterly capex with 86% in the AI segment, Starlink at 12.0 million subscribers with ARPU down to $66, a $47,461M backlog, the $25 billion bond and the dated lock-up release calendar against a 4.9% float. - [Senseonics Holdings ($SENS) Stock Hub: Eversense 365, Q2 Earnings, Gemini Pipeline and Dilution Risk](https://www.merlintrader.com/senseonics-holdings-stock-hub/): Management will hold the conference call at 4:30 p.m. ET. This is the first major financial checkpoint after the ADA 2026 data, the Welldoc app partnership, the European launch, the $92 million equity financing and the expansion of the Hercules debt facility. - [Educational](https://www.merlintrader.com/educational/): MerlinTrader Learning Library Educational Guides, Courses and Trading Frameworks This library brings together MerlinTrader’s educational material on biotech catalysts, FDA regulation, clinical data, valuation, dilution, exchange compliance, market structure and trading psychology. Use the search field to find a topic, course chapter or practical guide. The material is educational only and is designed to help […] - [PDS Biotechnology ($PDSB): the clinical signal is real, but financing controls the clock](https://www.merlintrader.com/pds-biotechnology-stock-hub/): A complete research hub on Versamune HPV, the VERSATILE-003 Phase 3 program, the potential accelerated-approval pathway, PDS01ADC, cash runway, debt, ATM dilution, Nasdaq risk, management execution, catalysts and the bull-versus-bear debate. - [Zymeworks ($ZYME) Stock Hub: the $250 Million FDA Milestone, Ziihera PDUFA, Theravance Deal and the New Royalty-R&D Model](https://www.merlintrader.com/zymeworks-stock-hub/): Jazz Pharmaceuticals holds the application, but Zymeworks holds a direct economic trigger: a U.S. approval of Ziihera in gastroesophageal adenocarcinoma would generate a $250 million regulatory milestone. This is an indication expansion, not Ziihera’s first approval; the medicine has been approved in the United States for previously treated HER2-positive biliary tract cancer since November 20, 2024. - [Karyopharm Therapeutics Stock Hub: The $KPTI Story After SENTRY, the FDA Path and the Endometrial Phase 3 Miss](https://www.merlintrader.com/karyopharm-therapeutics-stock-hub/): Karyopharm is no longer a three-readout 2026 story. It is now a concentrated regulatory and financing case built around selinexor in frontline myelofibrosis, a still-commercial XPOVIO franchise in multiple myeloma, and a capital structure that may determine how much of the clinical upside ultimately reaches common shareholders. - [Weekly Market Pulse: US Payrolls Miss, Record S&P 500 Close and the July CPI Week Ahead](https://www.merlintrader.com/weekly-market-pulse/): Extended weekly edition. July payrolls fell 23,000 and the S&P 500 closed at a record: the full cross-asset map, earnings review, verified macro calendar for August 10-14 and the biotech catalyst pulse into the August PDUFA dates. - [Definium Therapeutics (Nasdaq: $DFTX) Stock Hub](https://www.merlintrader.com/definium-therapeutics-stock-hub/): DT120 ODT has delivered a powerful first Phase 3 result in major depressive disorder. The investment story now moves into a tightly packed confirmation sequence spanning Voyage, Panorama, DT402 and Ascend—backed by one of the strongest cash positions in development-stage neuropsychiatry. - [Hims & Hers Health $HIMS Stock Hub: Digital Health, GLP-1s, Peptides and Global Expansion](https://www.merlintrader.com/hims-hers-health-stock-hub/): A complete evergreen research hub on Hims & Hers: the consumer-health platform model, telemedicine, online pharmacy, compounded and branded medicines, GLP-1 strategy, peptide optionality, Eucalyptus integration, international expansion, financials, debt, dilution, regulatory risk, competition, valuation and bull/base/bear scenarios. - [C3.ai, Inc. (NYSE: $AI) Stock Hub 2026: Fiscal Q1 2027 Results Due in September, the Fiscal 2026 Revenue Break and the Cost Base Behind It](https://www.merlintrader.com/c3-ai-stock-hub/): C3.ai ($AI) hub updated August 4, 2026: fiscal Q1 2027 results due in early September, the fiscal 2026 revenue decline to $250.3 million, stock-based compensation above 100% of revenue, Siebel back as CEO and short interest above 32%. - [Virgin Galactic Holdings (NYSE: $SPCE) Stock Hub 2026: Q2 Results on August 12, the Going-Concern Flag and the Road to Delta-Class Flights](https://www.merlintrader.com/virgin-galactic-spce-stock-hub-2026/): Virgin Galactic ($SPCE) hub updated August 4, 2026: Q2 results and call on August 12, the going-concern flag, convertible debt converting into shares, cash and free cash flow, and the Q3 glide-flight window. - [Bloom Energy ($BE) Stock Hub: Record Q2, AI Power Demand, Concentration and the Valuation Test](https://www.merlintrader.com/bloom-energy-stock-hub/): A complete post-earnings investor guide to Bloom Energy: record Q2 2026 results, raised guidance, AI data-center power demand, Oracle and Brookfield structures, customer concentration, cash conversion, valuation, technical levels, catalysts and risks. - [Insider Trading Weekly: The Biggest Insider Buys And Sells](https://www.merlintrader.com/insider-trading-weekly/): Updated every Saturday: the biggest executed insider buys and sells of the week from SEC Form 4 filings, ranked by dollar value and checked one by one against the original filing. Week of July 27-31, 2026. - [Pharvaris ($PHVS) Stock Hub: Deucrictibant, CHAPTER-3 and the HAE Franchise Thesis](https://www.merlintrader.com/pharvaris-stock-hub/): A complete investor guide to Pharvaris, its oral bradykinin B2 receptor antagonist deucrictibant, the imminent CHAPTER-3 Phase 3 prophylaxis readout, the accepted U.S. NDA for on-demand treatment, the April 23, 2027 PDUFA date, commercial competition, cash runway, dilution and the evidence that could confirm or break the investment thesis. - [EyePoint (EYPT) Stock Hub: Two Phase 3 Wet AMD Readouts Could Redefine the Company](https://www.merlintrader.com/eyepoint-stock-hub/): A complete investor-focused review of DURAVYU, the LUGANO and LUCIA pivotal trials, diabetic macular edema expansion, manufacturing readiness, cash runway, dilution, ownership, short positioning and the evidence that will determine whether EyePoint can become a commercial retina company. - [Zevra Therapeutics Stock Hub ($ZVRA): MIPLYFFA Launch, EMA Rejection and Celiprolol Phase 3](https://www.merlintrader.com/zevra-therapeutics-stock-hub/): A complete English research hub on Zevra’s rare-disease portfolio, the U.S. MIPLYFFA commercial launch, the FDA–EMA divergence over arimoclomol, the event-driven DiSCOVER Phase 3 trial in vascular Ehlers-Danlos syndrome, OLPRUVA’s limited contribution, balance-sheet strength, dilution capacity and the catalyst path after the July 2026 regulatory setback. - [Cingulate Inc. Stock Hub: CTx-1301 Phase 3 Publication, the FDA CRL, Resubmission Timeline and Risks](https://www.merlintrader.com/cingulate-inc-stock-hub/): A complete, evidence-based guide to Cingulate’s newly published peer-reviewed pediatric data, its Precision Timed Release platform, the manufacturing problem that blocked approval, and the milestones that now determine whether the company can convert a clinically credible ADHD product into an approved and commercially viable medicine. - [Plug Power Inc. (Nasdaq: $PLUG) Stock Hub: $80M Near-Term Liquidity, a 50MW Australia Order and the Q2 Turnaround Test](https://www.merlintrader.com/plug-power-stock-hub/): Plug Power is no longer only a hydrogen-hype story, but it is not yet a proven profitable platform. The July setup combines a real 50 MW electrolyzer order at an Australian project that reached final investment decision, a completed 5 MW commissioning in Denmark, asset monetization intended to deliver more than $80 million of near-term liquidity, and a Q1 margin recovery that still left the company with negative gross margin, a $150 million quarterly operating cash outflow and only about $162 million of unrestricted cash at June 30 before the expected Stream proceeds. - [Incyte ($INCY) Stock Hub 2026: A Cash-Rich Jakafi Machine Racing Its 2028 Patent Cliff](https://www.merlintrader.com/incyte-incy-stock-hub/): Incyte ($INCY) stock hub: verified financials, the Jakafi franchise and 2028 patent cliff, full portfolio and pipeline, the Halozyme deal, Health Score, analysts, risks and scenarios. - [The Top Ten Biotech Stocks Right Now](https://www.merlintrader.com/top-ten-biotech-stocks-right-now/): Merlintrader’s ranking of ten listed biotech companies with the strongest current combination of near-term catalysts, scientific credibility, financial resilience and clearly identifiable risk. - [Nektar Therapeutics (Nasdaq: $NKTR) Stock Hub: Rezpegaldesleukin Enters Phase 3, but the Market Must Separate AD Strength from AA Uncertainty](https://www.merlintrader.com/nektar-therapeutics-stock-hub/): Nektar has transformed from a damaged legacy biotech into a well-financed late-stage immunology story. The central question is no longer whether rezpegaldesleukin can produce an interesting Phase 2 signal. It is whether a first-in-class regulatory T-cell biologic can reproduce that signal in a 1,530-patient global Phase 3 program while management controls execution, manufacturing and dilution risk. - [United States Antimony ($UAMY) Stock Hub 2026: The Only US Antimony Smelter, a $245M Defense-Stockpile Contract, and the China Supply-Chain Trade](https://www.merlintrader.com/united-states-antimony-uamy-stock-hub/): United States Antimony ($UAMY) runs the only significant US antimony smelter and holds a $245M DLA defense-stockpile contract plus a $27M federal grant. Verified deep dive: DLA orders, financials, dilution, the antimony market and China supply chain. - [AbCellera Biologics (Nasdaq: $ABCL) Stock Hub: ABCL635 Data, Jazz Deal, Cash Runway, Pipeline and 2026 Catalysts](https://www.merlintrader.com/abcellera-biologics-stock-hub/): AbCellera ($ABCL) hub updated August 5, 2026: Q2 revenue of $4.1 million, net loss of $55.4 million, the Jazz and Vertex upfronts worth over $100 million, liquidity above $675 million, and ABCL635 Phase 2 top-line data now expected in August 2026. - [Neuronetics ($STIM): Q2 Earnings Can Reprice the Story or Reconfirm the Financing Trap](https://www.merlintrader.com/neuronetics-stock-hub/): Neuronetics, following its acquisition of Greenbrook, operates as a vertically integrated mental-health platform with significant revenue growth in 2025. However, the company faces serious financial risks, notably a projected revenue shortfall under a debt covenant by March 2027. Investors must monitor cash flow, clinic expansion, and treatment-session stability for clearer insights into its financial health. - [Oncolytics Biotech ($ONCY) Stock Hub: Pelareorep Pipeline, FDA Fast Track and Catalysts](https://www.merlintrader.com/oncolytics-biotech-stock-hub/): Pelareorep’s full history, mechanism, clinical evidence, FDA Fast Track designations, colorectal and anal cancer registration strategy, pancreatic and breast cancer optionality, financial position, dilution risk and future catalysts - [Quantum BioPharma (QNTM) Stock Hub](https://www.merlintrader.com/quantum-biopharma-stock-hub/): May 28, 2026 is the confirmed date on which Quantum received FDA correspondence stating that the Lucid-MS IND had been placed on clinical hold. Quantum disclosed the event on June 1 and filed it with the SEC on June 2. The company withdrew its former targets for FDA review, Phase 2 initiation and interim data. The previously promoted Q2 2026 trial start and Q4 2026 interim-data target are obsolete and must not be used. - [Oklo Inc. ($OKLO): Aurora, Nuclear Fuel, Isotopes and the Road to First Power](https://www.merlintrader.com/oklo-inc-stock-hub/): One company, four intertwined options: build-own-operate advanced reactors, secure scarce fuel, recycle nuclear material and produce radioisotopes. The opportunity is unusually large; so is the distance between today's milestones and commercial cash flow. - [Satellos Bioscience ($MSLE): SAT-3247, BASECAMP, TRAILHEAD and the Q4 2026 Readouts](https://www.merlintrader.com/satellos-bioscience-stock-hub/): An evidence-first investor hub on a high-risk, single-asset Duchenne story: what the AAK1 mechanism is designed to do, what the four-adult TRAILHEAD dataset does and does not show, why BASECAMP is the real proof-of-concept test, and which dates are confirmed, guided, registered or conditional. - [Cardiol Therapeutics ($CRDL) Stock Hub: Phase III MAVERIC, CardiolRx Data, Cash Runway and the 2027 Catalyst](https://www.merlintrader.com/cardiol-therapeutics-stock-hub/): An evidence-first deep dive into Cardiol’s pivotal recurrent-pericarditis program, the real strengths and limitations of the Phase II evidence, the mixed ARCHER myocarditis readout, CRD-38 optionality, capital structure, dilution risk and what must happen for the story to graduate from a speculative catalyst setup to a credible late-stage cardiovascular franchise. - [IDEAYA Biosciences: the darovasertib approval trade — and the pipeline the market may still be underpricing](https://www.merlintrader.com/ideaya-biosciences-stock-hub/): IDEAYA has crossed the line from diversified clinical biotech to potential commercial oncology company. The pivotal OptimUM-02 result is real, the FDA process has started, and a heavily financed pipeline now offers several additional shots on goal. The debate is no longer whether the company can produce a positive trial. It is how much regulatory, commercial and pipeline success is already embedded in the stock. - [Arrowhead Pharmaceuticals ($ARWR) Stock Hub 2026: REDEMPLO Launch, Positive SHASTA Phase 3 Data, YOSEMITE Enrollment And A $1.78B Liquidity Base](https://www.merlintrader.com/arrowhead-pharmaceuticals-stock-hub/): Arrowhead crossed the line from clinical to commercial in November 2025 with the FDA approval of REDEMPLO (plozasiran) for familial chylomicronemia syndrome. Behind that first launch sits one of the broadest RNAi pipelines in the industry — a wholly-owned cardiometabolic franchise plus partnered programs with Amgen, Takeda, Sarepta, Novartis and others — funded by roughly $1.78 billion in cash and investments. Here is the verified picture as of July 2026. - [Fractyl Health $GUTS Stock Hub: Revita, REMAIN-1, Rejuva and 2026 Catalysts](https://www.merlintrader.com/fractyl-health-guts-stock-hub/): Fractyl Health enters the decisive phase of the Revita story after new one-year randomized REMAIN-1 data. This Stock Hub reviews the complete clinical evidence, pivotal design, De Novo path, Rejuva gene therapy, financial position, dilution risk and the catalysts that could reshape $GUTS through the end of 2026. - [BridgeBio Oncology Therapeutics ($BBOT) Stock Hub 2026: Three KRAS Shots On Goal, A 2028 Runway, And The 2H26 Data That Could Decide The Story](https://www.merlintrader.com/bridgebio-oncology-bbot-stock-hub/): BridgeBio Oncology ($BBOT) stock hub: verified pipeline (KRAS G12C BBO-8520, pan-KRAS BBO-11818, RAS:PI3Ka BBO-10203), ~$389M cash into 2028, the 2H26 binary catalysts, Merlintrader Health Score, competition (RVMD, BMY) and key risks. Educational, not advice. - [MetaVia Inc. (Nasdaq: $MTVA) Stock Hub: DA-1726 Obesity Data, Q4 2026 Catalyst, Dong-A ST Link and the Dilution Equation](https://www.merlintrader.com/metavia-inc-stock-hub/): MetaVia Inc. (Nasdaq: $MTVA) focuses on developing obesity treatments, primarily with its lead program, DA-1726, a dual GLP-1/glucagon receptor agonist. The company has reported encouraging early-phase data but faces significant financial challenges, including a need for further capital. Q4 2026 is critical for evaluating DA-1726's efficacy and market potential. - [WEBTOON Entertainment ($WBTN) Stock Hub 2026: The Disney Bet, NAVER Anchor And A Profitability Turn](https://www.merlintrader.com/webtoon-wbtn-stock-hub/): WEBTOON Entertainment ($WBTN) stock hub: verified Q1 2026 numbers, ~$595M cash and no debt, the Disney comics-platform catalyst, NAVER control, bull vs bear case and key risks. Educational, not advice. - [Artiva Biotherapeutics Stock Hub: $ARTV, AlloNK, FDA RMAT and the Phase 3 Rheumatoid Arthritis Path](https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/): A complete, source-backed overview of Artiva’s off-the-shelf natural killer cell platform, the post-EULAR clinical case, the FDA-aligned registrational strategy, the $300 million financing, the company’s deep South Korean ties through GC Cell, institutional ownership, dilution, catalysts and the evidence that could strengthen—or break—the investment narrative. - [Q32 Bio ($QTTB) Stock Hub: SIGNAL-AA Data, $200M Financing and the 2027 Registrational Path](https://www.merlintrader.com/q32-bio-qttb-stock-hub/): Q32 Bio ($QTTB) stock hub: positive Part B SIGNAL-AA 36-week topline for bempikibart in alopecia areata, plus cash, dilution, Health Score and next catalysts. - [FuelCell Energy (Nasdaq: $FCEL): AI Data Center Power, Carbon Capture, Hydrogen and the Execution Test Behind the Rally](https://www.merlintrader.com/fuelcell-energy-stock-hub/): FuelCell Energy Stock Hub covering FCEL’s AI data-center power strategy, carbonate fuel cells, Fit Energy, EXIM financing, South Korea, carbon capture, financial position, dilution, technical analysis, catalysts and risks. Updated July 12, 2026. - [Energy, Critical Minerals & Rare Earths Stock Hubs](https://www.merlintrader.com/energy-critical-minerals-stock-hubs/): Explore Merlintrader Stock Hubs across clean energy, fuel cells, hydrogen, nuclear power, uranium, critical minerals, rare earths, battery materials, industrial metals, carbon capture, grid infrastructure and energy storage. - [MDA Space Ltd. (NYSE and TSX: $MDA) Stock Hub 2026: Q2 Bookings Reverse the Backlog Slide, Guidance Raised and Two Acquisitions to Absorb](https://www.merlintrader.com/mda-space-mda-stock-hub/): MDA Space ($MDA) hub updated August 4, 2026: Q2 results and call on August 7, the Blue Canyon and CLS acquisitions, the US$819 million bought deal, the C$600 million notes and a C$3.69 billion backlog. - [Draganfly Inc. (Nasdaq: $DPRO) Stock Hub 2026: Q2 Results Due by August 14, C$147.3 Million of Cash and the Runway Arithmetic](https://www.merlintrader.com/draganfly-dpro-stock-hub/): Draganfly ($DPRO) hub updated August 4, 2026: Q2 results due by August 14 with no date announced, C$147.3 million of cash and no debt, the February 2026 US$50 million raise, revenue trend and the dilution behind the balance sheet. - [Firefly Aerospace (Nasdaq: $FLY) Stock Hub 2026: Q2 Results on August 11, the Lock-Up That Expires the Same Day and the Two Backlog Numbers](https://www.merlintrader.com/firefly-aerospace-stock-hub/): Firefly Aerospace ($FLY) hub updated August 4, 2026: Q2 results and call on August 11, the follow-on lock-up expiring the same day, backlog and remaining performance obligations, cash burn and the NITE-STAR vendor pool. - [Agenus Inc. Stock Hub: Q2 2026, ROBBIN Phase 3, BOT+BAL Revenue and Dilution](https://www.merlintrader.com/agenus-inc-stock-hub/): Updated August 6, 2026: Q2 revenue mix, $6.4 million of BOT+BAL access-program revenue, formal BATTMAN termination, ROBBIN milestones, the September 10 strategy webcast, July PIPE financing and dilution. - [Aurinia Pharmaceuticals ($AUPH) Stock Hub: Q2 2026, LUPKYNIS Growth, PRESERVE and Aritinercept](https://www.merlintrader.com/aurinia-pharmaceuticals-stock-hub/): AUPH Stock Hub updated for Q2 2026: LUPKYNIS growth, earnings quality, reiterated guidance, $443.1M liquidity, buybacks, PRESERVE, aritinercept, Kezar, patent risk and catalysts. - [Lifeward Ltd. (Nasdaq: $LFWD): From ReWalk's Bionic Walking Pioneer to a High-Risk Neurorehabilitation and Biomedical Platform](https://www.merlintrader.com/lifeward-ltd-stock-hub/): Lifeward ($LFWD) hub updated August 5, 2026: the six-month Ottobock Care pilot across more than 50 U.S. clinics, the July convertible financing and its equity shadow, the reimbursement history and what has to change for ReWalk economics to work. - [Compass Pathways ($CMPS) Stock Hub: Q2 2026 Results, COMP360, Rolling NDA and the 2027 Launch Path](https://www.merlintrader.com/compass-pathways-stock-hub/): Compass Pathways has moved beyond the “does Phase 3 work?” stage. The central debate is now whether two positive pivotal trials, durable six-month data, an FDA rolling review and a Commissioner’s National Priority Voucher can translate into approval, rescheduling, reimbursement and a commercially workable treatment network. - [uniQure (Nasdaq: $QURE) Stock Hub: AMT-130, the FDA Reversal and the Q3 2026 BLA Path](https://www.merlintrader.com/uniqure-stock-hub/): A complete evergreen research hub on uniQure after the extraordinary regulatory reversal that moved AMT-130 from a likely new sham-controlled trial back to a potential accelerated-approval filing in Huntington’s disease, while AMT-260, AMT-191 and the HEMGENIX legacy define the broader platform. - [Rocket Pharmaceuticals (Nasdaq: $RCKT) Stock Hub: Positive RP-A501 Danon Safety Update, FDA Path and the 2026 Catalyst Map](https://www.merlintrader.com/rocket-pharmaceuticals-stock-hub/): A fully updated research hub on Rocket Pharmaceuticals after KRESLADI’s accelerated approval, the completed $180 million Priority Review Voucher sale, the planned Q4 2026 phased launch, the lower-dose restart of RP-A501 in Danon disease, and the current clinical status of RP-A601 and RP-A701. The balance sheet is stronger; the valuation case still turns primarily on cardiovascular safety, biological activity and FDA alignment. - [Forte Biosciences ($FBRX) Stock Hub: argenx to Acquire FBRX for $77 Per Share in Cash](https://www.merlintrader.com/forte-biosciences-stock-hub/): An evergreen, source-based stock hub for Forte Biosciences, focused on FB102, celiac disease, vitiligo, alopecia areata, cash runway, dilution risk, competitive context and the 2026 catalyst map. - [Vanda Pharmaceuticals ($VNDA) Stock Hub: Q2 2026 Results, Fanapt Growth, NEREUS Launch and December PDUFA](https://www.merlintrader.com/vanda-pharmaceuticals-vnda-stock-hub/): Vanda Pharmaceuticals (VNDA) reports Q2 2026 results on August 5 after market close. Updated hub tracks NEREUS launch traction, BYSANTI rollout, cash burn, VQW-765 Phase 3 status and the December 12 imsidolimab PDUFA. - [Ultragenyx ($RARE) Q2 2026 Stock Hub: Record $214M Revenue, Two PDUFAs and the GTX-102 Readout](https://www.merlintrader.com/ultragenyx-pharmaceuticals-rare-stock-hub/): Ultragenyx reported record Q2 2026 revenue of $214 million, a narrower $92 million net loss, $436 million in liquidity and reaffirmed guidance. The RARE thesis now turns to DTX401 and UX111 PDUFAs and GTX-102 Phase 3 data expected in September or October. - [Kodiak Sciences (Nasdaq: $KOD) Stock Hub: PEAK First Cohort Fully Enrolled, Zenkuda, DAYBREAK and the 2026 Retina Catalyst Map](https://www.merlintrader.com/kodiak-sciences-stock-hub/): Kodiak Sciences (KOD) stock hub: Zenkuda/tarcocimab, the GLOW2 diabetic retinopathy win, the September 2026 DAYBREAK wet AMD readout, KSI-501 and KSI-101 (PEAK/PINNACLE), cash runway, dilution risk, catalysts and key risks. - [Fortress Biotech (Nasdaq: $FBIO) Stock Hub: ZYCUBO, the $205M PRV Sale, Journey/Emrosi and the Portfolio-Model Test](https://www.merlintrader.com/fortress-biotech-fbio-stock-hub/): Complete Merlintrader stock hub on Fortress Biotech ($FBIO): ZYCUBO Menkes approval, the $205M Priority Review Voucher sale, Journey Medical/Emrosi royalties, Q1 2026 results, balance sheet, catalysts, Merlintrader Health Score and future outlook. - [Sidus Space, Inc. (Nasdaq: $SIDU) Stock Hub 2026: an Unscheduled Q2 Print, the LizzieSat-4 Launch Window and a Balance Sheet Without Debt](https://www.merlintrader.com/sidus-space-stock-hub/): Sidus Space ($SIDU) hub updated August 4, 2026: no Q2 date announced yet with a 10-Q deadline of August 14, the LizzieSat-4 launch window, Fortis Maxima, revenue concentration and a share count that has risen about 100 times since 2023. - [Vera Therapeutics (Nasdaq: $VERA) Stock Hub: TRUTAKNA Approved in IgAN](https://www.merlintrader.com/vera-therapeutics-stock-hub/): Vera Therapeutics (VERA) stock hub: the FDA accelerated approval of TRUTAKNA (atacicept) in IgA nephropathy, the launch, the competition from Vertex, and the Q3 2026 confirmatory eGFR catalyst. - [Vicore Pharma (Nasdaq: $VCRE) Stock Hub: The AT2 Agonist Betting on Disease Modification in IPF](https://www.merlintrader.com/vicore-pharma-stock-hub/): Vicore Pharma (VCRE) stock hub: first-in-class oral AT2 receptor agonist buloxibutid, the +216 mL Phase 2a AIR signal, the 52-week Phase 2b ASPIRE trial in IPF (topline mid-2027), the July 2026 Nasdaq US dual listing, financials and catalysts. - [BriaCell Therapeutics ($BCTX) Stock Hub: FDA Clears Bria-PROS+ IND, Bria-IMT Phase 3 and Platform Expansion](https://www.merlintrader.com/briacell-therapeutics-stock-hub/): BriaCell ($BCTX) receives FDA IND clearance for Bria-PROS+ to begin a Phase 1/2a prostate-cancer study, while Bria-IMT remains the central Phase 3 catalyst. - [Viking Therapeutics ($VKTX) Stock Hub: The Obesity Pure-Play With Oral, Injectable and Amylin Optionality](https://www.merlintrader.com/viking-therapeutics-stock-hub/): Viking Therapeutics has become one of the most watched independent obesity and metabolic-disease biotech names on Nasdaq. The stock story is built around VK2735, a dual GLP-1/GIP agonist being developed in both injectable and oral forms, with additional optionality from MASH candidate VK2809, the early amylin/DACRA program VK3019, and rare-disease asset VK0214. - [Vertex Pharmaceuticals ($VRTX) Stock Hub: The Cystic Fibrosis Fortress, the Pain Launch, the Kidney Catalyst and the Crinetics Endocrinology Bet](https://www.merlintrader.com/vertex-pharmaceuticals-stock-hub/): Vertex Pharmaceuticals is no longer only the dominant cystic fibrosis company. It is now trying to convert one of biotech’s strongest cash engines into a broader rare disease platform spanning cystic fibrosis, hematology, pain, renal disease, cell therapy and — after the planned Crinetics acquisition — endocrinology. - [IREN Limited (Nasdaq: $IREN) Stock Hub 2026: Fiscal 2026 Results Due Late August, 480MW of AI Cloud Capacity and the ARR Ladder](https://www.merlintrader.com/iren-limited-stock-hub/): IREN ($IREN) hub updated August 4, 2026: fiscal 2026 results due late August with no date announced, 4,510MW of secured capacity, the Microsoft and NVIDIA contracts, the AI cloud revenue ramp, convertible notes and the dilution math. - [Karman Holdings (NYSE: $KRMN) Stock Hub 2026: the $1.03 Billion Backlog, Leverage After the Acquisitions and What the Next Print Has to Show](https://www.merlintrader.com/karman-holdings-stock-hub/): Karman Holdings ($KRMN) hub updated August 4, 2026: Q2 results and call on August 6, backlog of $1.03 billion, 2026 guidance of $720 to $735 million, leverage after the refinancing, the July lock-up expiry and the peer multiple. - [Aurora Cannabis ($ACB) Q1 FY2027 Stock Hub: Revenue Down 9%, International Medical Up 17%](https://www.merlintrader.com/aurora-cannabis-stock-hub/): Aurora Cannabis ($ACB) hub updated August 5, 2026: Q1 FY2027 net revenue of C$67.6 million down 9%, international medical up 17%, adjusted EBITDA of C$3.4 million, the fair-value gain that flatters gross profit, negative free cash flow and C$149.1 million of cash with no debt. - [LightPath Technologies (Nasdaq: $LPTH) Stock Hub 2026: Fiscal Year-End Results, the BlackDiamond Germanium Substitution and the Balance Sheet After the Offering](https://www.merlintrader.com/lightpath-technologies-stock-hub/): LightPath ($LPTH) hub updated August 4, 2026: fiscal 2026 year-end results not yet dated, record backlog of $110.6 million, the BlackDiamond germanium substitution story, the China divestiture and the share count up 54%. - [Lipocine ($LPCN): The Oral Brexanolone Rescue Thesis After a Failed Phase 3](https://www.merlintrader.com/lipocine-stock-hub/): Lipocine is no longer a clean “Phase 3 success into NDA” story. After the April 2026 failure in the full analysis set, the investment case has shifted into a more complicated, higher-risk regulatory recovery setup built around an outlier clinical site, post-hoc subgroup analyses, FDA feedback, a possible validation study and the value of an oral, at-home brexanolone profile in postpartum depression. - [ProKidney ($PROK): Rilparencel, PROACT 1 and the Unconfirmed Mid-2026 Enrollment Checkpoint](https://www.merlintrader.com/prokidney-stock-hub/): A complete evergreen hub on ProKidney Corp. (NASDAQ: PROK), the late clinical-stage company developing rilparencel, also known as REACT, for advanced chronic kidney disease in patients with type 2 diabetes. The central question is not whether the story is exciting. It is whether a promising Phase 2 eGFR-slope signal can survive a larger, sham-controlled Phase 3 trial before cash, dilution risk and manufacturing complexity become the dominant variables. - [TENX Stock Hub: Tenax Therapeutics, Oral Levosimendan and the August 2026 Phase 3 Moment](https://www.merlintrader.com/tenax-therapeutics-stock-hub/): Tenax Therapeutics is approaching the first major Phase 3 readout for TNX-103 in PH-HFpEF, a difficult cardiopulmonary condition with a large unmet need and no approved product specifically addressing the disease. The stock now sits at the intersection of a near-term binary catalyst, a strengthened balance sheet, a more ambitious global Phase 3 program and a capital structure that still needs to be understood carefully. - [Replimune (Nasdaq: $REPL) Stock Hub — FDA Grants Accelerated Approval to TUDRIQEV](https://www.merlintrader.com/replimune-group-stock-hub/): Replimune (Nasdaq: $REPL) stock hub, updated July 28, 2026: the FDA has published the April 10 Complete Response Letter in full - a unanimous determination, and the finding that 53% of responders had no uninjected lesion. Plus the July 30 CTGTAC advisory committee, the August 2 goal date, the going-concern language, the 55% workforce cut, and the 61% four-session collapse. - [Canopy Growth (Nasdaq: $CGC) Stock Hub: Q1 FY2027 Margins Improve as Cash Burn Doubles, MTL Cannabis, the Share Consolidation Vote](https://www.merlintrader.com/canopy-growth-stock-hub/): Canopy Growth is no longer the old cannabis boom story. The current $CGC setup is a turnaround test built around Canadian medical cannabis, selected adult-use brands, Storz & Bickel devices, the newly acquired MTL Cannabis platform, a repaired but still dilution-sensitive balance sheet, and a policy-sensitive U.S. THC option through Canopy USA. - [$ALDX Aldeyra Therapeutics Stock Hub: The Full Reproxalap FDA Saga, Type A Meeting Watch, AbbVie Optionality and the Post-CRL Pipeline Reset](https://www.merlintrader.com/aldeyra-therapeutics-stock-hub/): Aldeyra Therapeutics has become one of the cleanest examples of a small-cap biotech story that changed shape without disappearing. The March 2026 third Complete Response Letter damaged the reproxalap dry-eye thesis, but the scheduled FDA Type A meeting, the still-unexercised AbbVie option, a funded balance sheet and a broader RASP/retinal pipeline keep $ALDX alive as a high-risk regulatory clarification watch. - [Can-Fite BioPharma Stock Hub: Namodenoson, Pancreatic Cancer, HCC, MASH and the Nano-Cap Dilution Puzzle](https://www.merlintrader.com/can-fite-biopharma-stock-hub/): Can-Fite BioPharma is no longer just another tiny biotech with a distant pipeline. The July 2026 pancreatic cancer update gives Namodenoson a cleaner near-term story, but the stock remains a classic high-volatility nano-cap: real clinical programs, real regulatory designations, real financing pressure, and very little room for investors to ignore dilution risk. - [The Government-Spending Supercycle: Space, Defense-AI and Nuclear-for-AI $VSAT $OKLO $AVAV](https://www.merlintrader.com/government-spending-supercycle/): Stock Hub 2026 · Space / Defense-AI / Nuclear-for-AI Space / SATCOM Defense · AI Drones Nuclear-for-AI Gov Spending NASDAQ: $VSAT NASDAQ: $AVAV NYSE: $OKLO The Government-Spending Supercycle: Space, Defense-AI and Nuclear-for-AI Three sectors, one engine: public and institutional money flowing into military satellites, AI-enabled drones and nuclear reactors to power AI data centers. Three […] - [AeroVironment, Inc. (Nasdaq: $AVAV) Stock Hub 2026: Fiscal Q1 2027 Results Due in September, the BlueHalo Integration and the Accounting Questions](https://www.merlintrader.com/aerovironment-stock-hub/): AeroVironment ($AVAV) hub updated August 4, 2026: fiscal Q1 2027 results due in September, fiscal 2026 revenue of $1.98 billion, the BlueHalo integration and purchase accounting, $2.6 billion of backlog, two material weaknesses and fiscal 2027 guidance. - [Rezolve AI PLC (Nasdaq: $RZLV) Stock Hub 2026: Half-Year Results Due in September, and the Gap Between Audited, Unaudited and Guided](https://www.merlintrader.com/rezolve-ai-stock-hub/): Rezolve AI ($RZLV) hub updated August 4, 2026: half-year results expected in September, the gap between management revenue claims and audited figures, the going-concern disclosure, the Microsoft and Google Cloud partnerships and the dilution history. - [Unicycive Therapeutics (Nasdaq: $UNCY) Stock Hub: OLC, the Second FDA CRL, Manufacturing Risk and the Road Back](https://www.merlintrader.com/unicycive-therapeutics-stock-hub/): Unicycive is no longer just a near-term PDUFA story. After the June 30, 2026 Complete Response Letter, $UNCY has become a cleaner but harder case study: a kidney-disease biotech with a clinically credible phosphate-binder asset, a repeated manufacturing-vendor bottleneck, an open FDA inspection path, a still-relevant commercial opportunity and a much tougher execution test. - [Allogene Therapeutics ($ALLO) Stock Hub: Off-the-Shelf CAR-T After the ALPHA3 Interim Readout](https://www.merlintrader.com/allogene-therapeutics-stock-hub/): Allogene has moved from a beaten-down allogeneic CAR-T story into a 2026 execution test. The April ALPHA3 interim analysis gave cema-cel a clear MRD signal and clean early safety profile, but the real investment question is still open: can that MRD clearance translate into event-free survival, regulatory leverage, and a commercially credible outpatient CAR-T model? - [Arcutis Biotherapeutics (Nasdaq: $ARQT): ZORYVE’s Commercial Franchise, Pediatric Label Expansion and the Next FDA Catalyst](https://www.merlintrader.com/arcutis-biotherapeutics-stock-hub/): Arcutis has moved beyond the classic binary biotech profile. The company is now a commercial-stage immuno-dermatology story built around ZORYVE, a topical roflumilast franchise with multiple FDA-approved indications, nine-figure quarterly product revenue, positive operating cash flow in the latest reported quarter, and a new pediatric atopic dermatitis PDUFA now set for February 23, 2027. - [REGENXBIO ($RGNX) Stock Hub: Q2 2026 Results, $313M Pro Forma Cash and Two Q3 BLA Paths](https://www.merlintrader.com/regenxbio-stock-hub/): REGENXBIO Q2 2026: $108.0M revenue, $22.7M GAAP net income, a positive NAVSUNLI Type A meeting, approximately $313M pro forma liquidity and runway into Q4 2027. RGX-202 and NAVSUNLI remain on Q3 BLA timelines; pivotal sura-vec wet-AMD data are expected in Q4. - [Index Reconstitution Explained: Why ETF Rebalancing Creates Volume, Volatility and Forced Flows](https://www.merlintrader.com/index-reconstitution-explained/): When a stock enters or exits a major index, the story is not just about prestige. The real mechanism sits underneath the surface: ETFs, index funds and benchmarked portfolios must adjust their holdings. That adjustment can create mechanical buying, mechanical selling, abnormal volume and short-term volatility — especially in small and mid-cap stocks. - [Vistagen Therapeutics (Nasdaq: $VTGN) Stock Hub: PALISADE-4 Failure, Repeat-Dose Topline and the FDA Reset](https://www.merlintrader.com/vistagen-therapeutics-stock-hub/): Updated Vistagen Therapeutics stock hub covering the PALISADE-4 Phase 3 failure, the post-hoc very-severe-SAD signal, the proposed FDA reset toward an LSAS-based multi-dose Phase 3 trial, the Q3 2026 repeat-dose catalyst, refisolone, itruvone, cash runway, dilution and governance. - [AST SpaceMobile (Nasdaq: $ASTS) Stock Hub 2026: the August 10 Business Update, Twelve BlueBirds in Orbit, $4.17 Billion of Debt and What Is Actually Contracted](https://www.merlintrader.com/ast-spacemobile-stock-hub/): AST SpaceMobile ($ASTS) hub updated August 5, 2026: BlueBirds 11, 12 and 13 launched on a Falcon 9, twelve commercial BlueBirds now in orbit, the August 10 business update, the $1.15 billion convertible and what is actually contracted. - [Humacyte ($HUMA) Advanced Stock Hub: Dialysis sBLA Execution, Symvess Launch, CTEV Option Value and Dilution Risk](https://www.merlintrader.com/humacyte-presentation-june2026-deepdive/): Humacyte now combines an FDA-approved vascular-trauma product, a positive Phase 3 dialysis-access dataset, a planned second-half 2026 supplemental BLA and a newly cleared first-in-human coronary bypass study. The science has become broader; the equity case still depends on commercial proof, regulatory execution, manufacturing economics and capital discipline. - [Dilution, ATM Offerings, PIPE Deals and Reverse Splits: A Practical Guide for Small-Cap and Biotech Investors](https://www.merlintrader.com/dilution-atm-pipe-guide/): Merlintrader Educational Guide Dilution, ATM Offerings, PIPE Deals and Reverse Splits: A Practical Guide for Small-Cap and Biotech Investors Understanding how a company raises capital is often as important as understanding its product, pipeline or next catalyst. This guide explains what to check before the market prices the risk into the stock. Merlintrader June 12, […] - [Tilray Brands (Nasdaq: $TLRY): Record FY2026 Revenue, FY2027 Guidance and Cannabis / Beverage Stock Hub](https://www.merlintrader.com/tilray-brands-stock-hub/): Tilray Brands $TLRY stock hub updated July 29, 2026: record FY2026 net revenue of $915.5 million, adjusted EBITDA of $61.1 million, FY2027 guidance of $68-75 million, $234.6 million of cash, net debt of $0.7 million, $70 million of 2027 convertible notes left, BrewDog and the post-hearing DEA process. - [Microbot Medical Inc. (Nasdaq: $MBOT): LIBERTY, Endovascular Robotics and the Commercialization Test](https://www.merlintrader.com/microbot-medical-stock-hub/): Microbot Medical has moved from a regulatory-clearance story into a commercial execution story. LIBERTY is FDA-cleared, first revenue has appeared, hospital adoption is expanding, Israel has granted the first international marketing clearance, and the next proof point is whether early adoption becomes repeatable revenue. - [MannKind Corporation ($MNKD) Stock Hub: Q2 2026 Earnings, Afrezza, FUROSCIX and Nintedanib DPI](https://www.merlintrader.com/mannkind-corporation-stock-hub/): MannKind Q2 2026 Stock Hub: $109.4M revenue, Furoscix growth, pediatric Afrezza launch, positive INFLO-1 safety data, cash, debt, dilution and catalysts. - [Summit Therapeutics (Nasdaq: $SMMT): Ivonescimab, the FDA OS Hurdle, HARMONi-3 and the New $380M ATM](https://www.merlintrader.com/summit-therapeutics-stock-hub/): Summit Therapeutics ($SMMT) hub updated August 5, 2026: the HARMONi-GU1 Phase II/III bladder-cancer study, the FDA overall-survival hurdle, the November 14 PDUFA, HARMONi-3 timing, the 797.75M share count and the new $380M ATM. - [Moleculin Biotech (Nasdaq: $MBRX): Annamycin, MIRACLE AML and the ASCO 2026 Cardiac Safety Update](https://www.merlintrader.com/moleculin-biotech-stock-hub/): An evergreen deep dive on a nano-cap oncology story built around one high-risk, high-impact question: can a redesigned anthracycline produce meaningful relapsed/refractory AML activity while avoiding the cardiotoxicity that has historically limited the drug class? - [Privacy Policy Cookieyes](https://www.merlintrader.com/privacy-policy-cookieyes/): EN IT GDPR Addendum — Additional Rights for Users in the EU/EEA and UK This addendum supplements our Privacy Policy and applies to data subjects located in the European Union, the European Economic Area, and the United Kingdom. In addition to the rights already described in our Privacy Policy, you have the following rights under […] - [Cookie Policy - Cookieyes](https://www.merlintrader.com/cookie-policy-cookieyes/) - [Ardelyx, Inc. (Nasdaq: $ARDX) Stock Hub: Record Q2 Revenue With the IBSRELA Guidance Cut, XPHOZAH Access and ACCEL Phase 3](https://www.merlintrader.com/ardelyx-inc-stock-hub/): A long-form evergreen research page on Ardelyx: the long tenapanor story, the FDA path from IBSRELA to XPHOZAH, the transition from binary biotech to commercial execution, the 2026 guidance framework, the ACCEL Phase 3 expansion opportunity and the risks traders should keep watching. - [Aquestive Therapeutics Stock Hub: Anaphylm, Libervant and the 2026–2027 Regulatory Story](https://www.merlintrader.com/aquestive-therapeutics-stock-hub/): Aquestive Therapeutics stock hub covering Anaphylm, the January 2026 CRL, Q3 2026 resubmission guidance, Type A meeting feedback, Oaktree refinancing, Libervant, AQST-108 and key regulatory risks. - [Castellum, Inc. (NYSE American: $CTM) Stock Hub 2026: Q2 Revenue Holds Flat, Margins Compress and the Market Reaction on August 7](https://www.merlintrader.com/castellum-inc-stock-hub/): Castellum ($CTM) Stock Hub updated August 6, 2026: Q2 revenue $13.865 million, gross margin 34.0%, cash $16.865 million, debt-free balance sheet, $271.7 million backlog and $953.5 million qualified pipeline. - [Merlintrader Travel Pub](https://www.merlintrader.com/merlintrader-travel-pub/): TP Merlintrader Travel Pub A colorful travel space for destinations, practical advice and selected travel-market stories. EN IT Travel ideas • Practical advice • Tourism trends Merlintrader Travel Pub A colorful travel corner inside Merlintrader, built around destinations, real-world travel advice, seasonal tourism trends, personal experience and selected market stories from the global travel economy. […] - [Terms and Conditions](https://www.merlintrader.com/terms-and-conditions/) ## Optional - [Agent (MCP protocol)](websites-agents.hostinger.com/www.merlintrader.com/mcp) [comment]: # (Generated by Hostinger Tools Plugin)